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Patients with advanced gastric cancer have limited therapeutic options to which response rates 
are low. Very few targeted therapies are available. There is an urgent need for novel targeted 
inhibitors for patients who are either ineligible for the existing targeted therapies or have 
developed resistance. Several studies have supported the importance of the IGF signal 
transduction pathway in cancer cell survival and proliferation and inhibitors of the type I IGF 
and insulin receptors have reached clinical trials in various cancer types. To date, the role of 
the IGF signal transduction pathway in gastric cancer has not been investigated thoroughly.        
The aim of the present study is to investigate the importance of the IGF signal transduction 
pathway in gastric cancer cells and the effect of inhibition of IGF signal transduction in cell 
survival and proliferation.  
IGF-1 was protective against gastric cancer cell death induced by protein kinase inhibition 
and disruption of cell attachment to the extracellular matrix. The survival effect was mediated 
by the PI3K/Akt pathway. The survival effect of IGF-1 was even more prominent in ex vivo 
cultures of gastric cancer cells established from patient ascites. IGF-1 stimulated proliferation 
of gastric cancer cells, which was mediated by activation of the Ras/Raf/ERK pathway. IGF-2 
and insulin induced also gastric cancer cell survival and proliferation.  
Inhibition of the type I IGF receptor by siRNA knockdown reduced proliferation of gastric 
cancer cells and ex vivo cultures by inhibition of cell mitosis and DNA synthesis. Inhibition of 
the insulin receptor by siRNA knockdown resulted in the induction of apoptosis. Combined 
inhibition of the two receptors with a small molecule tyrosine kinase inhibitor reduced 
effectively cell growth and induced apoptosis. 
Our results suggest that inhibition of the type I IGF and insulin receptors could be a valid 
therapeutic strategy for advanced gastric cancer patients who are not eligible for the currently 
available targeted treatments.     
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Chapter 1.  Introduction 
 
1.1 Cancer 
Cancer is a disease that involves abnormal cell growth and has the potential to invade or 
spread to other parts of the body. The transformation of normal cells into cancer cells involves 
the acquisition of specific characteristics that give them malignant behaviour. In 2000, 
Hanahan and Weinberg described six traits that are shared by the majority of cancer cells, 
irrespective of the tumour type from which they originate (Hanahan and Weinberg, 2000). 
These characteristics include sustained proliferative signalling, resistance to cell death, 
evasion of growth suppressors, ability to invade and metastasise, replicative immortality and 
ability to induce angiogenesis (Figure 1.1). 
 
 
Figure 1.1. Acquired capabilities of cancer cells. Cancer cells tend to be self-sufficient in growth signals, 
insensitive to growth-inhibitory signals, capable of evading programmed cell death, have limitless replicative 
potential, sustained angiogenesis, and are able to invade and metastasise (Hanahan and Weinberg, 2000). 
 
In 2011, the same authors described four additional hallmarks and enabling characteristics 
involved in the pathogenesis of cancer: the ability to modify cellular metabolism in order to 
support neoplastic proliferation, the ability to evade immunological destruction, genomic 
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instability and mutability and tumour-induced inflammation (Figure 1.2) (Hanahan and 
Weinberg, 2011). The acquisition of some of the above 10 hallmarks of cancer results from 
accumulation of loss-of-function mutations in oncosuppressor genes involved in apoptosis 
and suppression of proliferation or gain-of-function mutations in oncogenic genes involved in 
induction of survival and proliferation.   
 
Figure 1.2. Emerging hallmarks and enabling characteristics. Cancer cells are able to deregulate cellular 
metabolism and evade immunological destruction. Cancer cells are enabled by genomic instability and tumour-
promoting consequences of inflammatory responses (Hanahan and Weinberg, 2011).  
 
In normal cells, growth-promoting signals are conveyed mostly by growth factors that bind to 
cell-surface receptors, which often contain intracellular tyrosine kinase domains. The 
receptors emit signals via branched intracellular signal transduction pathways that regulate 
progression through the cell cycle and, thus, growth. Cancer cells can acquire the capability to 
sustain proliferative signalling in various ways: they may produce growth factor ligands 
themselves, which bind to their cognate receptors, and act as autocrine stimulators of 
proliferation. Alternatively, signal transduction may be deregulated by elevation of the levels 
of receptor proteins, which makes the cells hyper-responsive to the normal amounts of growth 
factor-ligand. Finally, growth factor independence may derive from the constitutive activation 
of components of signal transduction pathways that operate downstream of these receptors, 
which obviates the need to stimulate these pathways by ligand-mediated receptor activation 
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(Hanahan and Weinberg, 2011). The mitogen-activated protein (MAP)-kinase and the 
PI3K/Akt pathways are important pathways that are often deregulated in tumour cells. 
 
1.1 Gastric Cancer 
 
1.1.1 Epidemiology 
Despite a marked decrease in the incidence and mortality rates of gastric cancer over the past 
50 years, it remains the fifth most common malignancy and the third leading cause of cancer-
related deaths worldwide. There were approximately 723,000 deaths from gastric cancer in 
2012, 8.8 % of the total number of cancer-related deaths. Approximately 70% of cases occur 
in developing countries and 50% of the cases, worldwide, occur in Eastern Asia, mainly 
China. Mortality rates are highest in Eastern Asia, followed by Central and Eastern Europe. 
Incidence rates, standardised for age, are twofold greater in men than women (Ferlay et al., 
2015). The chances of a patient surviving 5 years after diagnosis of gastric cancer are 
approximately 20%. This is remarkably low compared to more common cancer types, such as 
breast cancer, which has a 5-year survival rate of 80% and prostate cancer, with a 10-year 
survival rate of approximately 80%.  
 
1.1.2 Risk factors 
The main risk factor for the development of gastric cancer is infection with Helicobacter 
pylori (Xue et al., 2001). Approximately 90% of patients with gastric cancer have previous or 
current H. pylori infection (Kato et al., 2007; Yoon et al., 2011). High consumption of salt 
and salt preserved foods has also been associated with increased risk of gastric cancer, 
however, the absolute increase was not very high (high salt intake group compared with low 
salt intake group, relative risk [RR], 1.68; 95% confidence interval, 1.17 to 2.41) (D'Elia et 
al., 2012). Smoking and heavy alcohol intake have been linked to increased risk for gastric 
cancer. The odds ratio (OR) for gastric cancer in current smokers was 1.69 (95% confidence 
interval, 1.35 to 2.11) (La Torre et al., 2009). A meta-analysis including a total of 34,557 
gastric cancer cases reported an association between the risk of gastric cancer and heavy 
alcohol intake (four or more drinks per day) (Tramacere et al., 2012). Obesity has been 
associated with increased risk of gastric cardiac cancer, which occurs in the top portion of the 
stomach near the junction of the oesophagus, but not non-cardiac cancer, which may be found 
in all other areas of the stomach (Chen et al., 2013). Previously, development of gastric 
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cancer was attributed to the appearance of precancerous lesions, such as chronic superficial 
gastritis, atrophic gastritis, intestinal metaplasia and dysplasia, following infection with H. 
pylori (Correa, 1992). A more recent study showed that the risk of gastric cancer increased 
according to the severity of premalignant cancer lesions (de Vries et al., 2008).  
 
1.1.3 Histopathological classification 
The inner lining of the stomach wall comprises four main layers. The mucosa is the first main 
layer that consists of the epithelium and the lamina propria, a thin layer of loose connective 
tissue. The submucosa lies under the mucosa and consists of fibrous connective tissue that 
joins the mucosa to the overlying smooth muscle. Muscularis is a thin layer of muscle, which 
is responsible for the digestion of food. The serosa is a smooth membrane which encloses the 
abdominal cavity and consists of layers of connective tissue continuous with the peritoneum 
(Figure 1.3). 
 
Figure 1.3. Structures of the human stomach. The stomach has three layers of muscle: an inner oblique layer, 
a middle circular layer and an outer longitudinal layer. The inner-lining consists of four layers: the mucosa, the 
submucosa, the muscularis and the serosa. The mucosa is densely packed with gastric glands, which contain cells 
that produce digestive enzymes, hydrochloric acid, and mucus (Encyclopaedia Britannica). 
 
Malignant cells are confined initially to the mucosal layer and are called intra-mucosal 
cancers. As they develop, they infiltrate the other layers of the gastric wall and penetrate 
progressively through the submucosa, muscularis and serosa (Figure 1.4). When a cancer is 
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confined to the mucosa or submucosal layer, it is defined as early gastric cancer, whereas if it 
has invaded into the muscularis mucosae or beyond, at diagnosis, it is defined as advanced 
gastric cancer (Roukos et al., 2002). 
 
 
Figure 1.4. Schematic representation of pathological staging of tumour for gastric carcinoma. When the 
tumour invades the lamina propria or the muscularis mucosae it is staged as T1a. Cancer invasion in the 
submucosa is staged as T1b, in the serosa T4a, and invasion into adjacent organs is staged as T4b (Taken from 
Han and Lauwers, 2010). 
 
Histologically, gastric malignancies are classified into five categories: adenocarcinomas, 
squamous cell cancers, lymphomas, gastrointestinal stromal tumours and neuroendocrine 
tumours. Adenocarcinomas are the most common form of gastric cancer and account for 90-
95% of all malignant gastric tumours. They are malignant epithelial tumours which originate 
from the glandular epithelium of the gastric mucosa. Around 5% of gastric malignancies are 
lymphomas, whereas gastrointestinal stromal tumours and neuroendocrine tumours are 
extremely rare (Kumar et al., 2010). 
 
The most successful and widely used classification of gastric adenocarcinoma has been 
described by Lauren in 1965. Lauren divided gastric adenocarcinomas into intestinal and 
diffuse types. Intestinal type adenocarcinomas are usually well-differentiated, associated with 
or developed from intestinal-type metaplastic epithelium and are characterised by cohesive 
neoplastic cells that form gland-like tubular structures. Diffuse-type adenocarcinomas are 
usually poorly differentiated or undifferentiated. In these tumours, cells are discohesive and 
secrete mucus which is delivered into the interstitium. When the mucus remains inside the 
tumour cells, it pushes the nucleus to the periphery and creates a "signet-ring cell" 






Figure 1.5. Gastric adenocarcinoma of diffuse (a) and intestinal (b) subtype. The most typical feature of the 
diffuse type is the appearance of a mass of “mucocellular” cells, some of which may resemble “signet-ring 
cells”, which grow in the mucosa and in the gastric wall with poor or no glandular differentiation. The intestinal 
type is characterised by the appearance of gland-like tubular structures  (Vauhkonen et al., 2006).  
 
Several studies have supported the idea that the development of intestinal-type gastric 
adenocarcinomas is a gradual, stepwise de-differentiation of the gastric epithelium into 
autonomously growing tumours that form glandular structures. Intestinal-type tumours may 
contain well-matured goblet cells and express enzymes typical of mature small bowel 
epithelium. These characteristics, however, can disappear gradually due to de-differentiation 
of tumours into more anaplastic forms of cancer. Atrophic gastritis and intestinal metaplasia 
are common lesions that underlie or accompany intestinal-type gastric cancer. Unlike 
intestinal-type tumours, there is little or no association between diffuse-type gastric tumours 
and intestinal-type epithelium. Infection with H. Pylori has been shown to be the only 
universal precursor for diffuse-type gastric cancer. These tumours lack glandular 
differentiation and grow as groups of single muco-cellular cells. In the best differentiated 
tumours, those muco-cellular cells have a singet-ring-cell type morphology (Vauhkonen et al., 
2006).   
 
Epidemiologically, intestinal-type gastric cancer accounts for approximately 50% of all 
gastric adenocarcinomas diagnosed and that of the diffuse-type 35%. The remainder are 
characterised as ''unclassified'' or mixed-type cancers. In younger people, the diffuse-type is 
more prevalent than the intestinal-type. The intestinal-type is more common in patients older 
than 50 years of age (Munoz and Connelly, 1971; Roukos et al., 1989; Lauren and 
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Nevalainen, 1993). Furthermore, patients with intestinal-type gastric cancer have significantly 
better survival than those with diffuse-type gastric cancer (Lee et al., 2001). 
 
1.1.4 Molecular classification 
In a recent study, gastric adenocarcinomas have been classified molecularly, as part of The 
Cancer Genome Atlas (TCGA) project. Four subtypes of gastric adenocarcinoma have been 
described. The first subtype comprises tumours which are positive for Epstein-Barr virus and 
are characterised by recurrent mutations of the gene that encodes phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), extreme DNA hypermethylation and 
amplification of the genes that encode Janus kinase 2 (JAK2), programmed death-ligand 1 
(PD-L1) and programmed cell death 1 ligand 2 (PDCD1LG2). The second subtype comprises 
microsatellite unstable tumours with elevated mutation rates of genes that encode oncogenic 
signal transduction proteins. The third subtype includes genomically stable tumours enriched 
for the diffuse histological variant and with mutations of the Ras homologue gene family 
member A (RHOA) or fusions involving RHO-family GTPase-activating proteins. The last 
group consists of tumours with chromosomal instability and marked aneuploidy, and is 
characterised by amplification of receptor tyrosine kinases (Cancer Genome Atlas Research, 





Gastric cancer may be asymptomatic in its early stages, which is why it is often diagnosed at 
an advanced stage. Inevitably, therapeutic options are limited. The most common symptoms 
of gastric cancer are unspecific e.g. abdominal pain, early satiety, reduced apetite or loss of 
weight. Clinical diagnosis requires upper gastrointestinal endoscopy and biopsy (Schwarz, 
2015).  
 
1.1.5.2 Surgical resection  
Total or subtotal gastrectomy is the gold standard of gastric cancer management worldwide 
because complete surgical removal of macroscopic and microscopic tumour tissue will cure 
the disease. In Eastern Asia, the accepted standard treatment includes radical gastrectomy 
with a D2 lymphadenectomy, during which, distant perigastric nodes and the nodes along the 
8 
 
main arteries that supply the stomach are removed. In Western countries, radical gastrectomy 
with limited D1 lymphadenectomy of the perigastric nodes closest to the primary lesion, in 
combination with chemoradiotherapy, is more frequent (Figure 1.6) (Macdonald et al., 2001). 
For advanced gastric cancers, surgical resection is palliative to relieve symptoms and, in some 
cases, prolong survival.  
 
 
Figure 1.6. Surgical lymphadenectomy. The groups of lymph node in red, green and blue should be dissected 
in a D2 lymphadenectomy; the groups of lymph node in red and green should be dissected in a D1 
lymphadenectomy (Cui et al., 2012). 
 
1.1.5.3 Chemotherapy 
Approximately 40-60% of patients with advanced gastric cancer have recurrent disease after 
surgery (Gunderson, 2002). A number of phase III clinical trials have investigated the 
potential benefits of administering chemotherapy post-operatively or peri-operatively, to 
prolong disease-free survival. 
 
1.1.5.3.1 Adjuvant chemotherapy 
S-1 is an oral fluorouracil anticancer product that combines 3 pharmacological agents: 
tegafur, which is a pro-drug of 5 fluorouracil; gimeracil [5-chloro-2,4 dihydropyridine 
(CDHP)] which inhibits dihydropyrimidine dehydrogenase (DPD) enzyme activity; and 
oteracil [potassium oxonate (Oxo)] a gastrointestinal side effects corrector. During the 
Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC), a total of 1059 patients 
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with stage II or III gastric cancer, who underwent total  gastrectomy with D2 
lymphadenectomy, were randomized to either observation or one-year of oral S-1 adjuvant 
therapy. The 3-year overall survival was improved in the S-1 group (80.1% vs 70.1%) 
(Sakuramoto et al., 2007). The positive results of this trial have made adjuvant S-1 therapy 
the standard treatment of choice for patients with advanced gastric cancer after radical 
resections with D2 lymphadenectomy in Japan. 
A large meta-analysis of 3,838 individual patients from 17 clinical trials (Gastric Group), 
reported a small but significant benefit of adjuvant chemotherapy after curative resection of 
gastric cancer. According to the authors, postoperative adjuvant chemotherapy based on 
fluorouracil derivatives was associated with a statistically significant benefit in terms of 
overall survival and an increase from 49.6% to 55.3% in five-year overall survival (Group et 
al., 2010). 
An analysis of international (Korea, China, and Taiwan), multicentre, randomized, phase III 
trials (CLASSIC), compared a group of 520 patients, with locally advanced cancer, that 
received capecitabine plus oxaliplatin (CapOX) following gastrectomy with D2 
lymphadenectomy, with an observation group of 515 patients that received surgery alone. 
Three-year disease-free survival increased significantly from 59% to 74% in the group that 
received a combination of capecitabine and oxaliplatin treatment compared to the surgery 
only group (Bang et al., 2012).  
 
1.1.5.3.2 Adjuvant radiochemotherapy 
The intergroup 0116 trial (INT-0116) by the Southwest Oncology Group 9008, tested the 
application of adjuvant radiotherapy in combination with adjuvant 5-fluorouracil plus 
leucovorin after curative resection in 556 patients. The median overall survival in the surgery-
only group was 27 months, as compared with 36 months in the chemoradiotherapy group 
(Smalley et al., 2012). 
The ARTIST trial (Adjuvant Chemoradiation Therapy in Stomach Cancer) tested the 
administration of postoperative treatment with capecitabine plus cisplatin (XP) versus 
capecitabine plus cisplatin (XP) plus radiotherapy with capecitabine (XP/XRT/XP). The 
addition of radiotherapy with capecitabine (XRT) to capecitabine plus cisplatin (XP) 
chemotherapy did not significantly prolong disease-free survival (p = 0.0862). However, in 
patients with lymph node metastasis at the time of surgery (n = 396), the addition of XRT 
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significantly increased three-year disease-free survival from 74 to 78% (p=0.0365) (Lee et al., 
2012). 
 
1.1.5.3.3 Neoadjuvant therapy  
The MAGIC trial in patients with gastric and gastroesophageal junctional cancer was 
designed to test the effect of perioperative chemotherapy consisting of epirubicin, cisplatin 
and 5-fluorouracil and surgery, compared to surgery alone. The resected tumours were 
significantly smaller and less advanced in the perioperative-chemotherapy group. As 
compared with the surgery alone group, the perioperative-chemotherapy group had a better 
pregression-free survival and overall survival; five-year survival rate was 36 percent vs. 23 
percent (Cunningham et al., 2006).  
A phase III randomised trial by the Fédération Nationale des Centres de Luttecontre le Cancer 
(FNCLLCC) and the Fédération Francophone de Cancérologie Digestive (FFCD) in 28 
French centres (ACCORD 07 trial) was also designed to evaluate the benefit in overall 
survival of perioperative fluorouracil plus cisplatin in resectable gastroesophageal 
adenocarcinoma. Compared with the surgery-alone group, the chemotherapy plus surgery 
group had a better 5-year overall survival rate of 38% vs 24% and a better 5-year disease-free 
survival rate of 34% vs 19% (Ychou et al., 2011).  
A summary of the clinical trials and the outcomes is shown in  








Treatment Outcomes p value 
INT-0116
 
2001 Gastric 556 postop. FL-RT vs 
S 











2012 Gastric 1035 postop. CapOx vs 
S 





2011 Gastric 458 postop. XP-RT vs 
XP 














224 periop. CF vs S 34 vs 24 % 5 years 
OS 
0.02 




Table 1.1. Randomised phase III trials of therapies for resected gastric cancer (Modified from (Schwarz, 
2015)). HR hazard ratio, RFS recurrence-free survival, OS overall survival, DFS disease-free survival, S surgical 
resection, FL 5-fluorouracil (5FU)/leukovorin, RT radiation therapy, CapOx capecitabine/oxaliplatin, XP 
capecitabine/cisplatin, ECF epirubicin/cisplatin/5FU, CF cisplatin/5FU.  
 
As a result of the above clinical trials, a combination of a fluorouracil-based regimen, such as 
capecitabine or 5-fluorouracil, with cisplatin or oxaliplatin and epirubicin has become the 
standard of treatment for patients with advanced gastric cancer in the UK.     
 
1.1.5.3.4 Mechanism of action of 5-florouracil and oxaliplatin 
The fluoropyrimidine 5-fluorouracil (5-FU) is a uracil analogue with a fluorine atom at the C-
5 position in place of hydrogen. It enters the cell using the same mechanism as uracil and is 
converted to active metabolites such as fluorodeoxyuridine monophosphate (FdUMP), 
fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate (FUTP). The above 
active metabolites disrupt RNA synthesis as well as the action of thymidylate synthase. 
Thymidylate synthase catalyses the reductive methylation of deoxyuridine monophosphate 
(dUMP) to deoxythymidine monophosphate (dTMP), with the reduced folate 5,10-
methylenetetrahydrofolate (CH2THF) as the methyl donor (Longley et al., 2003). This 
reaction is necessary for the production of thymidylate, which is essential for DNA replication 
and repair. Depletion of dTMP levels, affects the levels of the other deoxynucleotides (dATP, 
dGTP, dCTP) through feedback mechanisms (Jackson et al., 1984). Disruption of the balance 
of the deoxynucleotide pool affects severely DNA synthesis and repair and results in lethal 
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DNA damage (Yoshioka et al., 1987; Houghton et al., 1995). Thymidylate synthase inhibition 
also causes accumulation of deoxyuridine monophosphate (dUMP), which leads to increased 
levels of deoxyuridine triphosphate (dUTP) (Mitrovski et al., 1994; Aherne et al., 1996). Both 
dUTP and the metabolite fluorodeoxyuridine triphosphate (FdUTP) can be misincorporated 
into DNA. High (F)dUTP/dTTP ratios cause ineffective repair of uracil and 5-FU-containing 
DNA by the nucleotide excision repair enzyme uracil-DNA-glycosylase (UDG), which results 
in additional false nucleotide incorporation (Lindahl, 1974). Repeated cycles of 
misincorporation, excision and repair lead to DNA strand breaks and, eventually, cell death.   
Oxaliplatin (eloxatin; Sanofi-Synthelabo) is a third-generation platinum-based drug which 
was first approved for the treatment of colorectal cancer but is now used in several cancers, 
including gastric cancer. Similarly to cisplatin, oxaliplatin acts as an alkylating agent on DNA 
by forming platinated intrastrand cross-links between two adjacent guanine bases d(GpG) or 
two adjacent guanine-adenine bases d(GpA) (Misset et al., 2000). The DACH-platinum DNA 
adducts formed by oxaliplatin are more bulky and hydrophobic than platinum adducts formed 
by cisplatin or carboplatin. Consequently, oxaliplatin inhibits DNA synthesis more effectively 
and is more cytotoxic than cisplatin or carboplatin (Schmidt and Chaney, 1993; Rixe et al., 
1996). Furthermore, damage recognition proteins e.g. the mismatch repair (MMR) enzyme 
complex can possibly be prevented from binding to oxaliplatin adducts because of the steric 
hindrance presented by the DACH ring. As a result, oxaliplatin causes primary and secondary 
DNA lesions that eventually lead to apoptosis in cancer cells (Faivre et al., 2003).   
 
1.1.5.3.5 Targeted therapy for advanced gastric cancer 
In gastric cancer, the best studied molecular targets, so far, include human epidermal growth 
factor receptor-2 (HER-2), vascular endothelial growth factor (VEGF) and its receptors, 
fibroblast growth factor receptor 2 (FGFR2), hepatocyte growth factor receptor (c-Met) and 
mammalian target of rapamycin (mTOR). 
HER2 is a transmembrane tyrosine kinase receptor and the preferred heterodimerization 
partner of the other HER family members, HER1 or EGFR, HER3 and HER4. The HER2-
HER3 heterodimer plays a central role in oncogenic transformation in HER2-driven tumours 
(Hsieh and Moasser, 2007). Trastuzumab (Herceptin®) is a humanized monoclonal antibody 
that interacts with HER-2. The trastuzumab for Gastric Cancer (ToGA) trial, a pivotal 
randomised clinical trial of 594 patients with HER-2 positive, advanced, mostly metastatic, 
gastric cancer tested the efficacy of trastuzumab in combination with chemotherapy compared 
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to chemotherapy alone. Median overall survival was 13.8 months in those assigned to 
trastuzumab plus chemotherapy compared with 11.1 months in those assigned to 
chemotherapy alone (Bang et al., 2010). After the above trial trastuzumab was the first 
targeted agent approved for patients with advanced gastric cancer. 
VEGF is an endothelial cell-specific mitogen and the most potent driver of angiogenesis in 
tumourigenesis (Ferrara et al., 2003). Bevacizumab (Avastin®) is a humanized monoclonal 
antibody against VEGF. AVAGAST was a multinational, randomised, placebo-controlled 
phase III clinical trial designed to evaluate bevacizumab in combination with standard 
chemotherapy with capecitabine plus cisplatin, as first-line therapy in patients diagnosed with 
inoperable, advanced gastric carcinoma. Fluorouracil was administered to patients unable to 
take oral medications. Median overall survival was 12.1 months with bevacizumab plus 
fluoropyrimidine-cisplatin and 10.1 months with placebo plus fluoropyrimidine-cisplatin. 
Median progression-free survival was longer at 6.7 versus 5.3 months and overall response 
rate was higher at 46.0% versus 37.4% with bevacizumab versus placebo. However, this trial 
did not reach its primary endpoint, which was to achieve a significant difference in overall 
survival (Ohtsu et al., 2011). 
Ramucirumab (IMC-1121B) is a fully human immunoglobulin G1 monoclonal antibody that 
binds with high affinity to the extracellular VEGF-binding domain of VEGF receptor-2 
(VEGFR-2). REGARD study is a phase III, randomized, double-blinded trial of ramucirumab 
for the treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma. 
Patients received ramucirumab plus best supportive care or placebo plus best supportive care 
until progressive disease, unacceptable toxicity, or death. Ramucirumab conferred a 
statistically significant benefit in overall survival, 5.2 months vs 3.8 months, and progression-
free survival, 2.1 months vs 1 month, compared to placebo in advanced gastric cancer and had 
an acceptable safety profile (Fuchs et al., 2014). 
Fibroblast growth factor receptor family members (FGFR1–4) are transmembrane receptor 
tyrosine kinases which activate both the phosphoinositide 3-kinase (PI3K-AKT) and the 
mitogen-activated protein kinase–extracellular signal-regulated kinase (MAPK-ERK) 
pathways (Matsumoto et al., 2012). Preclinical work has suggested that FGFR2 amplified 
gastric cancer is sensitive to FGFR/VEGFR inhibition (Xie et al., 2013). An ongoing phase II 
trial aims to test the FGFR inhibitor dovitinib as monotherapy in patients with metastatic or 
unresectable gastric cancer harbouring FGFR2 amplification (NCT01719549). Moreover, the 
efficacy of the FGFR1-3 inhibitor AZD4547 monotherapy is compared to paclitaxel in the 
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phase II randomised SHINE trial, in patients with advanced gastric adenocarcinoma with 
FGFR2 polysomy or gene amplification (NCT01457846). 
MET is a proto-oncogene that encodes a protein known as hepatocyte growth factor receptor 
(HGFR). The receptor possesses tyrosine kinase activity and after binding with its ligand, 
hepatocyte growth factor, it activates signal transduction pathways involved in proliferation, 
motility, migration and invasion (Organ and Tsao, 2011). Rilotumumab (AMG 102) is a 
monoclonal antibody against hepatocyte growth factor (HGF), which binds c-Met. A phase II 
trial of rilotumumab in combination with epirubicin, cisplatin and capecitabine (ECX) in 
patients with advanced gastric or gastroesophageal junction cancers with high c-Met 
expression showed a trend toward improved progression-free survival and overall survival 
(Wadhwa et al., 2013). A phase III, randomized, double-blind, placebo controlled trial of 
rilotumumab with cisplatin and capecitabine (CX) for untreated advanced c-Met-positive 
gastric or gastroesophageal junctional adenocarcinoma is currently ongoing (NCT02137343). 
The results from this trial will shed more light into the efficacy of rilotumumab in increasing 
progression-free and overall survival in advanced gastric cancer.  
Mammalian target of rapamycin (m-TOR) is a serine/threonine protein kinase important for 
cell growth and proliferation, cellular metabolism and angiogenesis (Bjornsti and Houghton, 
2004). Everolimus (RAD001) is an oral inhibitor of m-TOR. GRANITE-1 was a phase III 
trial of everolimus in 656 patients with advanced gastric cancer who had undergone 
gastrectomy received prior chemotherapy. Everolimus monotherapy did not improve 
significantly overall survival compared to placebo (5.39 months vs 4.34 months) (p=0.1244) 
(Ohtsu et al., 2013). 
 
1.1.5.3.6 Challenges 
Despite the treatments available, the 5-year survival rate for gastric cancer remains dismal. 
Approximately 13 to 20% of patients with advanced gastric cancers have HER2 amplification 
or overexpression, 4-8% have FGFR2 amplification and 1.5-10% have MET amplification 
(Gravalos and Jimeno, 2008; Kawakami et al., 2013; Xie et al., 2013; Su et al., 2014). There 
remain, therefore, a large proportion of patients whose tumour cells are not driven by one of 
these three tyrosine kinase receptors. Furthermore, approximately 50% of patients with HER-
2 positive advanced gastric cancer did not respond to trastuzumab treatment and 
approximately 12% developed progressive disease (Bang et al., 2010). It is, therefore, 
required to investigate alternative targeted therapies that might allow the introduction of 
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effective therapeutic regimens for patients who are ineligible or who have developed 
resistance to the above treatments. 
 
1.2 The Insulin-Like Growth Factor (IGF) Signal Transduction Pathway  
The insulin-like growth factor (IGF) signal transduction pathway comprises three ligands, 
insulin-like growth factors 1 and 2 (IGF-1 and IGF-2) and insulin, which transduce their 
signals through two receptors, the type I IGF receptor (IGF-IR) and the insulin receptor (IR). 
The type I IGF and insulin receptors are heterotetrameric and contain two extracellular α-
subunits and two transmembrane β-subunits, with intrinsic tyrosine kinase activity. The two 
receptors are transported to the membrane fully assembled in the heterotetrameric form 
(Ullrich et al., 1986; Adams et al., 2000). A third transmembrane protein, the type II IGF 
receptor (IGF-IIR), binds IGF-1 and IGF-2 but lacks tyrosine kinase activity and does not 
transduce a signal (MacDonald et al., 1988). In the circulation, insulin-like growth factors 
(IGFs) bind to IGF-binding proteins (IGFBPs). 
The insulin-like growth factor (IGF) system involves complex regulatory networks that 
operate at the whole organism, cellular and subcellular levels. IGF-1 acts both as a circulating 
hormone and as a tissue growth factor and is produced mainly in the liver. Hepatic IGF-1 
production is regulated by hormonal and nutritional factors. Growth hormone (GH) is 
produced in the pituitary gland under control of the hypothalamic factors growth-hormone-
releasing hormone (GHRH) and somatostatin (SMS) and stimulates IGF-1 production. IGF-2 
production is not regulated by growth hormone. Several IGF-binding proteins (IGFBPs) are 
also produced in the liver. IGFs and IGFBPs can be delivered from the liver through the 
circulation to IGF-responsive tissues in an endocrine manner. IGFs and IGFBPs can also be 
locally produced in other organs in an autocrine and paracrine manner, often involving 
interactions between stromal and epithelial cells (Pollak et al., 2004).  
 
1.2.1 Signalling through the type I IGF receptor (IGF-IR) 
Ligand binding of IGF-1 or IGF-2 to IGF-IR results in a conformational change that leads to 
transphosphorylation of one β subunit by the other. These phosphorylations create docking 
sites for receptor adaptor proteins, including Src homology 2 domain containing protein (Shc) 
and insulin receptor substrate proteins (IRS 1, 2 and 4). The adaptor proteins are able to 
initiate intracellular signalling by activating several pathways (Chitnis et al., 2008) 
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Phosphorylation of IRS-1 in tyrosine residues recruits the regulatory (p85) and catalytic 
(p110) subunits of PI3K. Phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3) 
production activates PDK-1, which in turn phosphorylates the enzyme protein kinase B (Akt) 
on threonine 308.  The mTORC2 complex, activated by an unknown mechanism by the IGF-
IR, phosphorylates Akt on serine 473. Activated Akt promotes cell survival by negatively 
regulating the expression or function of Bcl-2 homology domain 3 (BH3)-only proteins, 
which exert their pro-apoptotic effects by binding to and inactivating pro-survival Bcl-2 
family members. For example, Akt phosphorylates and inhibits the BH3-only protein BAD on 
S136 and this creates a binding site for 14-3-3 proteins, which causes release of BAD from its 
target proteins (Datta et al., 2000). Another way of inhibiting BH3-only proteins by Akt is 
through effects on transcription factors, such as FOXO and p53. The BH3-only protein BIM 
is an important pro-apoptotic target of FOXO proteins which stimulates cell death in 
hematopoietic lineages following cytokine withdrawal (Dijkers et al., 2002). MDM2 (or 
HDM2 in humans) is a third target of Akt, which promotes survival by inhibiting BH3-only 
proteins. It is an E3 ubiquitin ligase that triggers p53 degradation (Mayo and Donner, 2001). 
Also, Akt phosphorylates GSK3 isoforms on a N-terminal regulatory site (GSK3a-S21, 
GSK3β-S9), and inactivates the kinase (Cross et al., 1995). A schematic summary of the 
interactions and activation of the downstream pathways is shown in Figure 1.7.   
Concomitantly, phosphorylation of Shc or IRS proteins by IGF-IR leads to sequential 
activation of Ras and the mitogen-activated-protein-kinase (MAPK) pathway. There are 4 
separate MAPK pathways: the classical pathway or MAPK/ERK pathway, the Big MAP 
kinase-1 (BMK-1) pathway, the c-Jun N-terminal kinase (JNK) pathway and the p38 
signalling pathway (Cossa et al., 2013). The above pathways share a similar organisation of 2 
serine/threonine kinases and 1 dual specificity threonine/tyrosine kinase (Dhanasekaran and 
Premkumar Reddy, 1998). From upstream to downstream these kinases include a MAPK 
kinase-kinase (MAPKKK), e.g. Raf/MKKK/MEKK1, a MAPK kinase and a MAPK, e.g. 
ERK1/ERK5/p38 (De Luca et al., 2012). The classical MAPK/ERK pathway comprises 3 
types of MAPKKK: A-RAF, B-RAF and RAF-1 or c-RAF kinases. One level downstream are 
the MAPKKs, which are specified as MEK1 and MEK2. Finally, further downstream are the 
ERK1 and ERK2, which are the final effectors of the canonical MAPK pathway (Robinson 
and Cobb, 1997). ERK phosphorylation activates multiple substrates which are responsible 




Figure 1.7. The insulin-like growth factor signal transduction pathway. Ligand binding to IGF-IR causes 
autophosphorylation of one β subunit by the other and creates docking sites for adaptor proteins (IRS1, 2 and 4, 
Shc). Phosphorylation of adaptor proteins results in the activation of two main pathways, the 
RAS/RAF/MEK/MAPK and the PI3K/Akt pathway. Both IR isoforms can transduce signal but the type II IGF 
receptor does not contain a tyrosine kinase domain. Hybrid receptors formed by insulin receptor isoforms and 
type I IGF receptor also contribute to downstream signalling. When in the circulation, IGFs are bound to IGF 
binding proteins, IGFBPs.        
                                                                                                                                                                                                                                                                             
1.2.2 Type 2 IGF receptor (IGF-2R) 
The type II IGF receptor (IGF-2R) or the cation-independent mannose-6-phosphate receptor 
binds IGF-1 and IGF-2 but lacks tyrosine kinase activity and does not transduce downstream 
signals. It has a higher affinity for IGF-2 compared to IGF-1 (Nissley et al., 1985). IGF-2 
binding to the type II IGF receptor results in IGF-2 downregulation via internalisation and 
degradation at lysosomes. IGF-2 binding to the type I IGF receptor is, consequently, 
precluded (Oates et al., 1998). The type II IGF receptor is, therefore, considered a tumour 
suppressor, as it has antagonistic effects on cell growth. This is further supported by the loss-
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of-heterozygosity and loss-of-function mutations in the type II IGF receptor detected in 
several cancers (Chappell et al., 1997).  
 
1.2.3 Insulin receptor (IR) and IGF-IR/IR hybrids 
IGF-IR shares a high degree of homology to IR especially in the kinase domains which are 
84% homologous (De Meyts, 1994). Two isoforms of IR are generated by alternative splicing 
of exon 11.The form that contains 12 amino acids encoded by exon 11 is called the B-isoform 
(IR-B) and the form that lacks the 12 amino acids encoded by exon 11 is called the A-isoform 
(IR-A). The two isoforms are expressed in a developmentally specific manner with IR-A 
expressed highly in foetal tissue and IR-B found predominantly in adult tissues. 
Overexpression of IR-A is observed in several human malignancies and is proposed to be a 
major mechanism of IGF system over-activation in cancer (Belfiore, 2007). 
IR-A binds insulin with the highest affinity (Kd=0.25 nM), followed by IGF-2 (Kd=2 nM) and 
IGF-1 (Kd=10 nM) (Frasca et al., 1999; Westley and May, 2013). Activation of IR also leads 
to phosphorylation of IRS adaptor proteins and activation of downstream phosphatidylinositol 
3’-kinase and MAPK pathways. Evidence from gene deletion studies suggests that the 
functions of IR and IGF-IR, although physiologically distinct, overlap partially, with IR 
capable of stimulating growth and IGF-IR able to regulate a metabolic response (Ludwig et 
al., 1996; Di Cola et al., 1997).  
Many cells and tissues have hybrid receptors assembled with one α and β chain of the IGF-IR 
and one α and β chain of the IR-A or IR-B (Pandini et al., 1999; Frasca et al., 2003). Both 
IGF-IR/IR-A and IGF-IR/IR-B hybrids have been described. It has been shown that IGF-
IR/IR-A and IGF-IR/IR-B hybrids bind insulin with comparable and relatively low affinity, 
intermediate between that of homodimeric IR and homodimeric IGF-IR (Benyoucef et al., 
2007). The same group has also shown that both IGF-IR/IR-A and IGF-IR/IR-B hybrids bind 
IGF-1 and IGF-2 with high affinity, which is comparable to that of homodimeric IGF-IR. The 
existence of these hybrid receptors adds another level of complexity to the insulin and IGF 
signal transduction system. A representation of all the different receptor and possible 




1.2.4 IGF binding proteins 
The family of IGF binding proteins (IGFBPs) comprises six homologous multifunctional 
proteins, IGFBP1 to IGFBP6. IGF-binding proteins modulate the bioactivities of circulating 
IGFs (Clemmons, 1998). The IGFBPs may inhibit the signalling pathway by binding 
circulating IGFs, thus preventing their binding to the receptors, but they may also maintain 
IGFs in circulation and lengthen their circulating half-life (Jones and Clemmons, 1995). In 
this sense, they perform dual but opposing roles in regulating IGF bioavailability. 
The IGFBPs bind to IGF-1 and IGF-2 with similar affinities, with the exception of IGFBP-6, 
which has a stronger affinity for IGF-2 (Headey et al., 2004; Beattie et al., 2008). The IGFs 
bind to the type I IGF receptor with similar affinities as their binding to IGFBPs. Therefore, 
pericellular IGFBPs can competitively inhibit IGF-IR binding and activation by IGFs. The 
above competition results from the fact that some IGF residues involved in IGFBP binding 
are also involved in the interaction with the type I IGF receptor (Sitar et al., 2006; Forbes et 
al., 2012).   
 
1.2.5 The IGF pathway in normal development 
Mouse models and other studies in animals have provided striking data regarding the role of 
IGFs in the development of somatic tissues. IGF-1 or IGF-2 null mice are viable, but 
approximately 40% smaller than littermates. Conversely, IGF-IR signalling is necessary for 
viability in mice; IGF-IR null mice die at birth and are approximately 55% smaller than 
littermates. Interestingly, IGF-1-IGF-2 doubly deficient mice remain viable, but 70% smaller 
than normal littermates (Liu et al., 1993).  
Data implicate IGF-1 signal transduction in variations in human growth and development. 
Rare IGF-1 deficient humans have been identified, who demonstrate short stature, delayed 
bone age, and low IGF-1 levels in the setting of increased levels of growth hormone. In the 
above syndrome called Laron syndrome, the growth hormone receptor is mutated or otherwise 
inactive (Savage et al., 2006). A girl who was a compound heterozygote for point mutations 
in exon 2 of the IGF-IR gene, resulting in an alteration of the amino acid sequence of the α 
subunit of the receptor and in reduced binding of IGF-1 to the IGF-IR in fibroblasts, has been 
identified. The same group has also identified a boy with a nonsense mutation in exon 2 of the 
IGF-IR gene, that reduced the number of type I IGF receptors expressed by fibroblasts. Both 




1.2.6 Role of the IGF signal transduction pathway in tumourigenicity 
Many tumours show altered expression of the type I IGF receptor, its ligands IGF-1 and IGF-
2 and/or the IGFBPs. Alterations in IGF signal transduction pathway components might be 
early, possibly initiating, events in tumourigenesis; examples include loss of imprinting for 
IGF-2 expression and inactivation of the type 2 IGF receptor (Hebert, 2006; Cui, 2007). 
Furthermore, people with higher IGF-1 circulating levels are at increased risk of developing 
common solid tumours compared with those with levels at the lower end of the normal range, 
possibly because IGFs favour the neoplastic progression of small lesions that would otherwise 
remain occult (Pollak et al., 2004). 
At a molecular level, the IGF-IR mediates key features of malignancy. It is required for 
cellular transformation by most oncogenes, including Ras (Sell et al., 1994), and mediates the 
combination of proliferation and survival signalling required for anchorage-independent 
growth (Resnicoff et al., 1994). This property enables transformed cells to form macroscopic 
tumours, and to survive the process of detachment required for metastasis (Baserga et al., 
2003). Consistent with these functions, preclinical studies indicate that IGF-IR overexpression 
induces invasive and metastatic capability in a mouse model of pancreatic islet 
tumourigenesis and IGF-IR overexpression in transgenic mice induces mammary epithelial 
hyperplasia and tumour formation (Lopez and Hanahan, 2002; Jones et al., 2007). 
 
1.2.7 IGF-IR targeted therapy 
Over the last decades preclinical data have supported the idea that inhibition of the IGF signal 
transduction pathway could be effective for cancer treatment. In a wide variety of in vitro and 
in vivo models, interruption of IGF signalling has been shown to inhibit tumour growth, block 
metastasis, and enhance the effects of other forms of cancer treatment (Baserga et al., 2003; 
Samani et al., 2007; Yuen and Macaulay, 2008). For example, IMC-A12, a monoclonal 
antibody against the type I IGF receptor, enhanced anti-tumour efficacy in combination with 
radiation in a non-small cell lung cancer model (Allen et al., 2007). Furthermore, in vivo 
studies in musculoskeletal and prostate tumours supported the idea that blockade of the IGF-
IR induced sensitisation to cytotoxic drugs (Scotlandi et al., 2005; Wu et al., 2006).  
Genetic alterations resulting in reduced levels of the ligands, as well as knockdown of IGF-1 
in mice decreased tumour incidence (Pollak et al., 2001; Wu et al., 2003). Multiple 
oncogenes, such as the simian virus 40 (SV40) large T antigen and the oncogenic ETV6-
NTRK3 (EN) chimeric tyrosine kinase, required the presence of the type I IGF receptor to 
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achieve cellular transformation (Sell et al., 1993; Martin et al., 2006). Also, IGF-1 signalling 
was found to induce resistance to tamoxifen and trastuzumab in breast cancer cells (Wiseman 
et al., 1993; Lu et al., 2001). Other studies have provided evidence that inhibition of the type I 
IGF receptor can be useful in attenuating the malignancy of EGFR-overexpressing sarcomas 
and of Kras mutant (Kras
G12D
) basal-like breast cancer (Huang et al., 2009; Klinakis et al., 
2009). All of the above data have paved the way for the development of drugs targeting the 
IGF signal transduction pathway for cancer. 
The three main classes of inhibitors of the IGF signal transduction pathway include, 
humanised monoclonal antibodies (mAb) directed specifically against the type I IGF receptor, 
small molecule inhibitors that target the tyrosine kinase domain of the IGF-IR (TKI) and 
monoclonal antibodies directed at the ligands, IGF-1 and IGF-2.  
 
1.2.7.1 Monoclonal antibodies against the type I IGF receptor 
The antibodies that have been developed are selective for the IGF-IR and do not bind the 
insulin receptor. They bind the extracellular domain of the IGF-IR, block ligand interaction 
with the receptor, then cause receptor internalisation and degradation (Gao et al., 2012; King 
and Wong, 2012). Several monoclonal antibodies targeting the IGF-IR reached clinical trials, 
such as AMG-479, AVE-1642, MK-0646, CP-751,871 (figitumumab), BIIB-022, SCH-
717454, R-1507 and IMC-A12 (cixutumumab).  Phase I and II clinical trials of such inhibitors 
showed positive results in lung cancer, Ewing’s sarcoma, breast cancer and adrenocortical 
carcinoma (Karp et al., 2009; Haluska et al., 2010; Olmos et al., 2010; Pappo et al., 2011; 
Gombos et al., 2012).  
 
1.2.7.2 Small molecule tyrosine kinase inhibitors 
There are two categories of tyrosine kinase inhibitors against the type I IGF receptor. The 
most common are ATP antagonists, which compete for the ATP binding sites on the tyrosine 
kinase domains, thereby preventing receptor autophosphorylation. ATP-competitive tyrosine 
kinase inhibitors include OSI-906, BMS754807, BMS-536924, BMS-554417, NVP-
ADW742, NVP-AEW541 and INSM-18. The second class of tyrosine kinase inhibitors 
includes non-ATP antagonists, such as BVP-51004 (picropodophyllin, PPP) and AG-1024 
(Buck and Mulvihill, 2011; Haisa, 2013). Although small molecule tyrosine kinase inhibitors 
are highly effective, receptor specificity is poorer than that of monoclonal antibodies, and 
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concurrent insulin receptor inhibition usually occurs. Interestingly, this lack of specificity 
provides added benefit in the case of hybrid IGF-IR/IR receptors, which are more abundant in 
certain tumour types. BMS754807 (Bristol-Myers-Squibb, New York, NY, US7534792) is a 
dual inhibitor of IGF-IR and IR that has been shown to inhibit [
3
H]-thymidine incorporation 
in pre-clinical studies of breast, lung, pancreatic and colon cancer cells as well as in multiple 
myeloma, leukaemia, and sarcomas (Carboni et al., 2009).  
 
1.2.7.3 Monoclonal antibodies against the ligands IGF-1 and IGF-2 
A third class of inhibitors comprises monoclonal antibodies that neutralise selectively the 
bioactivity of IGF-1 and IGF-2 but do not affect insulin. Such inhibitors have reached phase I 
clinical trials (Friedbichler et al., 2014; Haluska et al., 2014).  
 
1.2.7.4 Disappointing trials and future aims  
After the promising outcomes of phase II clinical trials with IGF-IR specific antibodies and 
tyrosine kinase inhibitors, some anti-IGF-IR antibodies reached phase III clinical trials (Gao 
et al., 2012; King et al., 2014). However, an initial randomised phase III trial of figitumumab 
in non-small cell lung cancer (NSCLC) was disappointing compared to early phase trials and 
has documented low efficacy, with a combination of metabolic toxicity and hyperglycaemia 
(Langer et al., 2014). The negative phase III results have initiated a debate, with some people 
in favour of abandoning any future attempt to investigate therapeutic targeting of the insulin 
and type I IGF receptor and others in favour of continuing the investigation but with selected 
patients or alternative IGF-IR inhibition methods.  
According to Pollak, 2012, a few points need further investigation before IGF-IR targeted 
therapy is taken forward. Firstly, predictive biomarkers should be used to define a subset of 
patients that are most likely to benefit from IGF targeted therapy. For example, high IGF-1 
circulating levels in some patients could indicate tumour dependency or addiction to IGF-IR 
activation, in which case it would be more likely for the tumour cells to respond to 
interruption of IGF signalling. Secondly, resistance mechanisms can often be observed as 
some cancers have evolved to such an extent that their behaviour is uninfluenced by growth 
signals. Furthermore, some cancers are driven by other receptors, e.g EGFR or HER-2, and 
any attempt to target the IGF pathway would be ineffective. Another possible resistance 
mechanism is observed when inhibition of IGF-IR leads to increased expression and 
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phosphorylation of another tyrorine kinase receptor, e.g HER-2 or EGFR. Likewise, EGFR 
inhibition with erlotinib results in increased IGF-IR expression and phosphorylation in 
ovarian and head and neck squamous cell carcinoma cells (Barr et al., 2007). Thirdly, 
combination therapies used so far have not been selected on the basis of a specific synergy 
demonstrated in preclinical studies but on the basis of an approach involving the addition of a 
drug to an already standard regimen that has some activity but requires improved efficacy. It 
is, therefore, essential to establish appropriate combination therapies in a preclinical setting 
before bringing them to the clinic (Pollak, 2012).  
 
1.2.8 Epidemiologic studies of IGF-IR expression in gastric cancer 
Several epidemiologic studies support a link between IGF-IR expression and increased gastric 
cancer risk. Positive IGF-IR expression was detected in 87.5% gastric carcinoma tissues, 55% 
atypical hyperplasia tissues and 17.86% normal gastric mucosal membrane tissues, suggesting 
that IGF-IR expression might be related to the development of gastric carcinoma (Liu et al., 
2009). IGF-IR expression in gastric cancer has been associated with lymph node metastasis, 
worse prognosis and high histological malignancy grade (Gryko et al., 2014). In particular, 
positive IGF-IR expression was found mostly in patients with moderately and poorly 
differentiated carcinoma and in 95.23% of patients with lymph node involvement, suggesting 
that the IGF signal transduction pathway might be important for gastric cancer progression. 
An additional study has demonstrated a correlation between IGF-IR overexpression and poor 
prognosis for gastric cancer (Ge et al., 2009). Specifically, IGF-IR expression was associated 
with tumour size, stroma quantity, depth of invasion, lymph node involvement and stage of 
gastric cancer. The above suggest that IGF-IR expression in gastric cancer is more common in 
advanced stages and it is possibly involved in disease progression. 
 
1.2.9 Preclinical studies of IGF-targeted therapeutic intervention in gastric cancer 
Inhibition of IGF signal transduction has been investigated extensively in other cancer types, 
in which monoclonal antibodies that target the IGF-IR or tyrosine kinase inhibitors that target 
the IGF-IR and IR have reached phase III clinical trials. However, there have been limited 
studies in gastric cancer. In 2003, Pavelic et al., studied the expression of components of the 
IGF signal transduction pathway in primary gastric tumours. High stage diffuse-type tumours 
overexpressed IGF-2 but were moderately positive for the type 2 IGF receptor. IGF-IR 
mRNA expression correlated well with cell proliferation,  assessed by thymidine 
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incorporation, in 12 diffuse-type gastric cancer samples, whereas aIR3, a monoclonal 
antibody against the IGF-IR, inhibited thymidine incorporation and decreased the number of 
colonies that formed in soft agar (Pavelic et al., 2003).    
In 2005, Min et al., showed that IGF-1 and IGF-2 induced cell proliferation in MKN45 gastric 
cancer cells and cell survival in MKN45 and MKN74 gastric cancer cells. IGF-1 induced Akt 
phosphorylation and transduction with an adenovirus that led to expression of a dominant 
negative type I IGF receptor, reduced this phosphorylation. Experiments with dominant 
negative receptors showed reduced proliferation, assessed by trypan blue staining, of MKN45, 
NUGC4 and MKN74 cells, compared to cells expressing the type I IGF receptor. Expression 
of the dominant negative receptor induced caspase-3 activity in MKN45 and MKN74 cells, 
which supported a role for IGF-IR on cell survival. Furthermore, expression of dominant 
negative IGF-IR enhanced the effects of radiotherapy and 5-fluorouracil-based chemotherapy 
both in vitro, in MKN45 cells and in vivo in gastric cancer xenografts (Min et al., 2005). In 
2010, Wang et al., showed that a shRNA against the type I IGF receptor increased cell death 
in a tunnel assay and decreased colony formation in soft agar of MKN45 gastric cancer cells 
(Wang et al., 2010a). 
Despite the above encouraging results, there have been limited studies on the effectiveness of 
IGF targeted therapy combined with other agents in gastric cancer and only in 2011 Li 
investigated the potential of combining IGF-IR and VEGF inhibition in subcutaneous 
xenografts in mice. Transduction of MKN45 cells with adenovirus expressing dominant 
negative IGF-IR in combination with bevacizumab, a human VEGF targeted monoclonal 
antibody was more effective than either monotherapy and resulted in complete regression of 3 
out of 7 subcutaneous MKN45 tumours in nude mice. Expression of dominant negative IGF-
IR also reduced in vitro vascular formation and lymphangiogenesis (Li et al., 2011). 
The above studies provided encouraging data regarding the importance of the IGF pathway in 
gastric cancer progression and the potential of targeting IGF-IR. However, the number of 
studies is limited and further investigation into the importance of activation of the IGF-IR and 
downstream pathways in gastric cancer cell survival and proliferation is required. Also, most 
of the results obtained from the previous studies were based on the use of one particular cell 
line, MKN45 cells, as a model of gastric cancer. It is, therefore, important to test the response 
of different types of gastric cancer cells to increase the chances of getting positive results with 





Apoptosis is a type of programmed cell death that occurs in multicellular organisms to 
preserve their homeostasis or as part of their normal developmental programme. It is a tightly 
regulated process that results in the self-destruction of a particular unwanted or damaged cell, 
without harming its neighbouring cells. Apoptosis can be triggered after exposure to factors 
that induce different types of stress, such as nutrient deprivation, osmotic stress, cytotoxic 
agents and others. 
Apoptosis is characterised by rounding-up of the cell, reduction of the cell volume, chromatin 
condensation, nuclear fragmentation, little or no ultrastructural modification of cytoplasmic 
organelles, pseudopode retraction, blebbing of the plasma membrane and engulfment of the 
cell by phagocytes (Kerr et al., 1972).  
Apoptosis can be regulated by an extrinsic and an intrinsic pathway. The extrinsic pathway is 
initiated by the activation of transmembrane death receptors by ligands released by other 
cells. Death receptors often include members of the tumour necrosis factor family (TNF). 
TNF receptors have a cysteine-rich extracellular subdomain that is responsible for recognising 
the ligands and a cytoplasmic domain, called the ‘death domain’, which is responsible for 
transmitting the death signal from the cell surface to intracellular pathways. Once the 
intracellular domain is activated it binds to the adaptor protein Fas-associated death domain 
(FADD) or TRADD (TNFR1-associated death domain protein) and forms the death inducing 
complex (DISC). The above complex recruits pro-caspase 8, which is cleaved proteolytically 
and acts as the ‘initiator caspase’, to activate downstream proteins such as caspases 3 and 7, 
which, in turn, initiate cell degradation resulting in apoptosis (Burz et al., 2009).      
The intrinsic or mitochondrial pathway is often activated by loss of growth factor signals or in 
response to death stimuli within the cell, e.g. DNA damage, oxidative stress, hypoxia or 
chemotherapeutic drugs. Lethal stimuli cause changes to the mitochondrial membrane and 
cause release of pro-apoptotic proteins, such as cytochrome C from the mitochondria to the 
cytoplasm. Cytochrome C stimulates formation of the apoptosome, a complex that includes 
apoptotic protease-activating factor [Apaf-1], dATP, cytochrome c and caspase 9. The 
apoptosome activates ‘initiator’ caspase 9, which, in turn, activates the ‘executioner’ caspases 
3, 6 and 7. The ‘executioner’ caspases cleave vital proteins, such as the poly (ADP-ribose) 
polymerase (PARP), resulting in cell death (Burz et al., 2009). 
Interactions between proapoptotic and antiapoptotic proteins of the Bcl-2 protein family are 
important for controlling the intrinsic pathway. The members of the Bcl-2 family contain 
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conserved sequence motifs known as Bcl-2 homology domains (BH1 to BH4). Antiapoptotic 
Bcl-2 proteins contain all Bcl-2 homology domains and include Bcl-2, Mcl-1, Bcl-xL, and 
A1. Proapoptotic proteins are divided into two groups, the BH3-only group which comprises 
Bid, Bim, Bik, Bad, Bmf, Noxa, Puma, and Hrk and the BH1-3 group which comprises Bax, 
Bak and Bcl-xs. Antiapoptotic Bcl-2 proteins bind the proapototic proteins Bax and Bak and 
prevent mitochondrial damage (Scorrano and Korsmeyer, 2003). A schematic representation 




Figure 1.8. Intrinsic and extrinsic pathway of apoptosis. Apoptosis can be induced by the extrinsic pathway 
and the intrinsic pathway. The intrinsic pathway starts with induction of BH3-only proteins, which inactivates 
some BCL-2 family members. This activates BAX and BAK, which in turn results in apoptosis. Some BH3-only 
proteins, such as BIM and PUMA, also activate BAX and BAK. BAX and BAK promote cytochrome c release 
and mitochondrial fragmentation, which activates APAF1 into an apoptosome and activates caspase-9 to activate 
caspase-3. Caspase-3 then cleaves various substrates and leads to destruction of the cells. The extrinsic pathway 
bypasses the mitochondrial step by activating caspase-8 directly, resulting in caspase-3 activation and cell 
destruction. The BCL-2 family regulates the intrinsic pathway and modulates the extrinsic pathway when BID 
cleavage communicates between the two pathways (Youle and Strasser, 2008).    
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1.4 Cell Cycle 
The cell cycle comprises four sequential phases. The most important are S phase, during 
which DNA is replicated and mitosis (M), during which the cell divides into two daughter 
cells. The two gap phases separating S phase and mitosis are called G1 and G2. G1 follows 
mitosis and precedes S phase. During G1 the cells are sensitive to positive or negative signals 
from growth signalling pathways. G2 is the phase after S phase during which cells prepare for 
entry into mitosis (Murray et al., 1993). G0 is a phase into which cells enter when they have 
withdrawn reversibly from the cell division cycle due to high cell density or absence of 
mitogens (Zetterberg and Larsson, 1985). Cells may also withdraw from the cell cycle 
irreversibly into terminally differentiated or senescent states.    
Progression through the cell cycle and transition from one phase to the following are 
controlled by sensor mechanisms or checkpoints, which ensure the appropriate conditions and 
order of events (Hartwell and Weinert, 1989). When abnormal or incomplete cell cycle 
events, e.g. DNA damage, are detected by the sensor mechanisms, checkpoint pathways 
transmit the signal to effector proteins, which can induce cell cycle arrest until the 
abnormality is resolved (Bartek et al., 2004; Musacchio and Salmon, 2007). Proteins 
responsible for regulating progression through the cell cycle comprise the cyclin-dependent 
kinase (CDK) family of serine/threonine kinases and the cyclins (Malumbres and Barbacid, 
2006). Cyclin D-CDK4, cyclin D-CDK6 and cyclin E-CDK2 are responsible for driving G1 
progression through the restriction point, making the cell commit to the cycle (Planas-Silva 
and Weinberg, 1997). Cyclin A-CDK2 drives initiation of the S phase and cyclin B-CDK1 
drives progression through G2 and initiation of mitosis (Nigg, 2001). Effector proteins, which 
can reversibly stop cell cycle progression include the CDK inhibitors (CDKIs). G1 arrest can 
be induced by the Ink4 family of CDKIs (p16, p15, p18 and p19), which inhibit CDK4 and 
CDK6 or by the Cip/Kip family of CDKIs (p21, p27 and p57), which inhibit CDK2 activity 
(Malumbres and Barbacid, 2009; Hanahan and Weinberg, 2011). 
The malignant phenotype is characterised by deregulation of the cell cycle engine resulting in 
uncontrolled proliferation. Mitogens stimulate G1-S CDK activities triggering 
phosphorylation of retinoblastoma proteins (pRB) proteins, which stops their interaction with 
the E2F family of transcription factors. In cancer cells, phosphorylation of pRB is often 
prevented, thus, causing E2F-induced G1-S gene expression even in the absence of mitogens 
(Harbour and Dean, 2000). This can be caused by activating mutations in the mitogenic 
signalling pathways either in ligands and receptors, such as HER2/ErbB2/neu receptor 
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mutations or HER2 gene amplification, or in downstream signalling networks such as Ras-
Raf-MAPK or PI3K/Akt signalling pathways.       
    
1.5 Summary and Aims 
The majority of gastric cancers are diagnosed at advanced stages, by which therapy has to be 
palliative rather than curative. Chemotherapy combined with targeted agents, such as 
trastuzumab for HER-2 positive cancers, is the standard of palliative therapy for patients with 
advanced inoperable gastric cancer. However, a large number of patients are ineligible or 
develop secondary resistance to the above agents. It is, therefore, essential to identify and 
validate alternative targets for patients with advanced gastric cancer, to establish the 
appropriate drug combinations. The utilisation of positive and negative predictive biomarkers 
could increase the likelihood for a particular targeted therapy to being effective.  
Implication of the IGF signal transduction pathway in the progression of several cancer types 
and in the development of therapeutic resistance has been reported repeatedly. Monoclonal 
antibodies and tyrosine kinase inhibitors against the type I IGF receptor have reached clinical 
trials in various cancers. To date, the importance of the IGF signal transduction pathway in 
gastric cancer progression has not been investigated extensively. The selection of gastric 
cancer cell lines as models for demonstrating the importance of the IGF signal transduction 
pathway has not been based on a specific rational.  
We hypothesise that activation of the IGF signal transduction pathway has important survival 
and proliferative effects in a subset of gastric cancer cells. Therefore, inhibition of IGF 
signalling could possibly confer a significant benefit in the growth and survival of the above 
gastric cancers. 
The aim of this study is to test the effects of IGFs and insulin on survival and proliferation of 
gastric cancer cell lines and patient samples. The benefits of inhibiting the type I IGF and 
insulin receptors in gastric cancer cells will be examined by RNA interference methods and 
by the use of inhibitors which target the two receptors. The effect of combining IGF-IR/IR 




Chapter 2. Materials and Methods 
2.1 Cell Culture 
 
2.1.1 Cell lines 
The human gastric cancer cell lines NCI-N87, KATO III, SNU-16, SNU-5, SNU-1, MKN74, 
NUGC3 and AGS were used in this study. Breast cancer cell lines SKBR3, MCF7 and MDA-
MB-231 were used for comparative purposes. The origins of all cell lines and available 











Age Sex Race 












Poorly differ. ? FGFR2 55 M Asian 
SNU-16 Park et al 
1990 
Ascites Poorly differ. None FGFR2 33 F Korea 
SNU-5 Park et al 
1990 




MET 33 F Korea 
SNU-1 Park et al 
1990 
Primary GA Poorly differ. None - 44 M Korea 
MKN74 Motoyama 






? - ? ? ? 





Poorly differ. ? - ? ? ? 
AGS Barranco et 
al 1983 
Primary GA Not known None - 54 F Caucasian 








HER2 43 F Caucasian 













? ? - 51 F Caucasian 
Table 2.1. Gastric and breast adenocarcinoma cell lines used. GA; gastric adenocarcinoma, BA; breast 
adenocarcinoma  
 
2.1.2 Routine cell culture 
NCI-N87, MKN74, NUGC3 and AGS were cultured as adherent monolayers. SNU-1, SNU-5 
and SNU-16 cells were cultured in suspension and KATO III cells were cultured in mixed 
conditions, adherent and suspension. All cell lines except SNU-5 cells were sub-cultured in 
tissue culture flasks (Corning) in Dulbecco’s modified Eagle’s medium (DMEM) with 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) modification (Sigma-Aldrich, 
Dorset, United Kingdom), supplemented with 10% foetal bovine serum (FBS), whereas SNU-
5 cells were supplemented with 20% foetal bovine serum (FBS). When adherent cells reached 
70-80% confluence they were washed twice with phosphate buffered saline (PBS) and 
detached from the flasks by incubation in trypsin-EDTA solution (Sigma-Aldrich, Dorset, 
United Kingdom). Cells were then collected by centrifugation at 300 x g for 3 minutes 
(Beckman Allegra X-12 R, rotor SX 4750) at room temperature and reseeded into fresh flasks 
at dilutions ranging from 1:5 to 1:20. Cells in suspension were collected by centrifugation at 
300 x g for 3 minutes and reseeded into fresh flasks at dilutions ranging from 1:5 to 1:20. Cell 
lines were tested every 6 months to confirm the absence of Mycoplasma contamination. Long 
term storage of cells was in DMEM, 20% FBS and 10% dimethyl sulphoxide (DMSO) in 0.5 
ml aliquots at -70 
o 
C or in liquid nitrogen.  
 
2.1.3 Establishment of primary cultures of gastric cancer cells from ascites 
Ascites was collected from the peritoneal cavity of patients that were previously diagnosed 
with gastric adenocarcinoma. Ascites was diluted inside tissue culture flasks in a 1:1 ratio 
with Dulbecco’s modified Eagle’s medium (DMEM) with 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) modification (Sigma), supplemented with 20% foetal 
bovine serum (FBS) and 1% penicillin/streptomycin (Sigma). The ascitic fluid was left inside 
the flasks for 5-7 days in order to enhance attachment of the epithelial cells. Subsequently, the 
supernatant was removed and the remaining adherent cells were supplemented with fresh 
medium supplemented with 20% FBS. Upon reaching 70-80% confluence, cells were 
trypsinised in a manner similar to the one described in section 2.1.2. Long term storage of 
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cells was in 90% FBS and 10% dimethyl sulphoxide (DMSO). Passage number 6 or lower 
was used for experiments as most primary cultures enter senescence around that stage.  
 
2.1.4 Preparation of dextran-coated charcoal stripped serum (DCCS) 
Dextran-coated charcoal was prepared by addition of 0.2 g dextran T70 (Pharmacia, Kent, 
United Kingdom) to 20 g charcoal (Sigma-Aldrich, Dorset, United Kingdom). The above was 
resuspended in 250 ml deionised water in 250 ml centrifuge bottles (Beckman Coulter).  The 
suspension was allowed to stand for 10 minutes and then centrifuged at 7,000 rpm (Beckman 
Avanti J-26 XP centrifuge, JA 16.250 rotor) for 15 minutes at 4
o
C. The supernatant was 
discarded and charcoal was resuspended in 250 ml of deionised water. After an additional 
centrifugation at 7,000 rpm for 15 minutes at 4
o
C, the supernatant was discarded again and 
charcoal resuspended in 200 ml newborn calf serum (Invitrogen, Paisley, United Kingdom). 
The serum was transferred to a 500 ml conical flask and agitated rigorously in a shaking 
waterbath for 40 minutes at 55
o
C. The serum was then transferred to new 250 ml centrifuge 
bottles and centrifuged twice at 10,000 rpm (JA 16.250 rotor) for 30 minutes at 4
o
C. Finally, 
the supernatant was collected and filtered into sterile tissue culture glassware through a 0.45 
µm filter (Corning). The serum was then aliquoted into 50 ml Falcon tubes and stored at -
20
o
C.   
 
2.1.5 Withdrawal of cells from steroid hormones and growth factors 
Withdrawal of cells from the effects of growth factors was achieved by culture in withdrawal 
medium which comprised phenol red-free DMEM (Sigma-Aldrich, Dorset, United Kingdom) 
supplemented with 10% dextran-coated charcoal treated calf serum (DCCS). During 
withdrawal, routine culture medium was removed by a pulled glass Pasteur pipette and cells 
were washed in phosphate buffered saline (PBS) before the addition of withdrawal medium. 
Medium was changed once or twice daily for 2 days, unless otherwise specified.   
 
2.2 Stimulation of Protein Phosphorylation 
Adherent cells were grown until ~70% confluence and detached from cell culture flasks by 
incubation with trypsin:EDTA. Cells were then resuspended in maintenance medium and 
counted using a haemocytometer. Cells were seeded into 12-well tissue culture plates in 1 ml 
maintenance medium at a concentration of 100,000 to 150,000 cells/well. Cells were left to 
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attach for ~24 hours and were withdrawn from growth factors by culturing in withdrawal 
medium for 2 days, as described above. Cells in suspension were grown until ~70% 
confluence and centrifuged at 300 x g for 3 minutes and resuspended in PBS. Cells were 
centrifuged again at 300 x g for 3 minutes and resuspended in DCCS medium. The above was 
repeated for 2 days. On the day of the assay, withdrawal medium was replaced with phenol-
red free DMEM supplemented with 0.1% bovine serum albumin (BSA, Sigma-Aldrich, 
Dorset, United Kingdom) and cells were incubated at 37
o
C for 2 hours. Then, medium was 
changed to phenol-red free DMEM with 0.1% bovine serum albumin and various 
concentrations of IGF-1, IGF-2 or insulin. Cells were incubated for 15 minutes prior to 
protein extraction with RIPA buffer plus inhibitors. The extent of phosphorylation of proteins 
in the IGF signal transduction pathway was analysed by Western transfer. 
For experiments designed to investigate the effect of the BMS754807 tyrosine kinase 
inhibitor on the inhibition of receptor activation, the cells were plated and withdrawn as 
described above and were incubated with the appropriate concentrations of the BMS754807 
for at least 30 minutes before the addition of IGF-1.  
 
2.3 Apoptosis Assay 
Adherent cells were grown until ~70% confluence and detached from cell culture flasks by 
incubation with trypsin:EDTA. Cells were resuspended in maintenance medium and counted 
using a haemocytometer. Cells were seeded into 12-well tissue culture plates in 1 ml 
maintenance medium at a concentration of 100,000 to 150,000 cells/well. Cells were left to 
attach for ~24 hours and were withdrawn from growth factors by culturing in withdrawal 
medium for 2 days, as described above. Cells in suspension were grown until ~70% 
confluence and centrifuged at 300 x g for 3 minutes and resuspended in PBS. Cells were 
centrifuged again at 300 x g for 3 minutes and resuspended in DCCS medium. The above was 
repeated for 2 days. In order to investigate the effect of IGF-1, IGF-2 or insulin on apoptosis, 
cells were incubated with various concentrations of the above growth factors for 15 minutes. 
Then, the medium was replaced with DCCS medium supplemented with 0.5-1 μM 
staurosporine (Sigma-Aldrich, Dorset, United Kingdom) with or without the growth factors. 
Cells were incubated in staurosporine for various times. At the end of each time point, protein 
extracts were prepared from the cells with RIPA buffer plus inhibitors. For experiments 
designed to investigate the effect of inhibiting the IGF-IR on the ability to induce apoptosis 
with staurosporine, cells were incubated with various concentrations of the BMS754807 
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inhibitor for 30 minutes prior to treatment with IGF-1. For experiments designed to test the 
effect of the LY294002 (New England Biolabs, Hitchin, United Kingdom) or U0126 inhibitor 
(Calbiochem) on the protective effect of IGF-1 against apoptosis, the cells were detached as 
before and incubated with the appropriate concentrations of the inhibitors for at least 30 
minutes before the addition of IGF-1 and staurosporine. 
 
2.4 Anoikis Assay 
 
2.4.1 Preparation of poly (2-hydroxyethylmethacrylate) (poly-hema) coated plates 
Poly (2-hydroxyethylmethacrylate) or poly-HEMA (Sigma-Aldrich, Dorset, United Kingdom) 
was dissolved in 97% ethanol at a concentration of 10 mg/ml and placed at 37
o
C to prevent 
precipitation. Twelve-well tissue culture plates were coated with 0.5 ml of poly-HEMA 
solution per well, in a tissue culture hood. The plates were then incubated at 37
o
C with gentle 
agitation, until dry. The procedure was repeated with the same amount of poly-HEMA 
solution and the plates were stored at 4
o
C until use. 
 
2.4.2 Anoikis assay 
Adherent cells were grown until ~70% confluence and withdrawn from the effects of growth 
factors by culture in withdrawal medium for two days. Cells were detached from cell culture 
flasks by incubation with trypsin:EDTA. Cells were counted using a haemocytometer and 
diluted to the required density in the experimental medium. For experiments designed to 
investigate the effect of IGF-1 on cell survival, cells were resuspended in phenol red-free 
DMEM without serum (SFM), or SFM supplemented with various concentrations of IGF-1. 
The cell suspension was diluted to 100,000 cells/ml and wells were seeded with 2 ml/well. 
Cells were incubated in the poly-HEMA coated plates for 2-24 hours before lysis with RIPA 
buffer plus inhibitors. 
 
2.5 Proliferation Assay 
Adherent cells grown until ~70% confluence were detached from cell culture flasks by 
incubation with trypsin:EDTA. Cells were resuspended in maintenance medium and counted 
using a haemocytometer. Cells were seeded into 24-well plates at a density of 5,000 to 10,000 
cells/well in 0.5 ml maintenance medium. After a 24-hour incubation, in order to allow 
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attachment, medium was removed gently using a pulled glass Pasteur pipette and replaced 
with DCCS or serum-free medium (SFM). Cells were cultured in withdrawal medium or 
serum-free medium for 24 hours. The next day the medium was replaced with DCCS medium 
containing 50 ng/ml IGF-1, IGF-2 or insulin. Withdrawal or serum-free medium with growth 
factors was replaced every 3 days. After 3, 6, and 9 days the medium was removed, cells were 
washed in cold PBS once and stored at -20
o
C until analysis. The amount of DNA in each well 
was measured using a dsDNA quantification assay, as described in section 2.8. 
For experiments which investigated the effect of the U0126 inhibitor on the proliferative 
effect of IGF-1, the cells were seeded into 24-well plates, as described above, and cultured in 
serum-free medium for 24 hours. The cells were then treated with the appropriate amounts of 
DMSO or the inhibitors for at least 30 minutes before the addition of the ligands. The medium 
containing the ligands and the inhibitors was replenished every 3 days and the experiments 
were stopped after 9 days of treatment. 
For experiments designed to investigate the effect of the BMS754807 inhibitor on cell 
proliferation, adherent cells grown until ~70% confluence were detached from cell culture 
flasks by incubation with trypsin:EDTA. Cells were resuspended in maintenance medium and 
counted using a haemocytometer. Cells were seeded into 24-well plates at a density of 5,000 
to 10,000 cells/well in 0.5 ml maintenance medium. The next day the medium was 
replenished with maintenance medium containing different concentrations of the BMS754807 
inhibitor or DMSO. The medium was changed daily for up to 5 days and cells were stored at -
20
o
C for further analysis. 
 
2.6 Protein Extraction and Quantification 
 
2.6.1 Protein extraction 
To extract proteins from attached cells, the medium was aspirated and cells were washed with 
cold PBS. The lysis buffer was radioimmunoprecipitation assay buffer (RIPA), which 
contained 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40 (v/v) and 0.25% 
sodium deoxycholate (w/v). Protease inhibitors were added at a final concentration of 1 μg/ml 
pepstatin, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 2 mM sodium orthovanadate, 2 mM sodium 
fluoride and 2 mM phenyl methyl sulphonyl fluoride. For 12-well plates, 80-100 μl of RIPA 
buffer plus inhibitors were added to each well and for 75 cm
2
 cell culture flasks, 1 ml of RIPA 
buffer plus inhibitors was added per flask. Addition of the lysis buffer was followed by gentle 
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agitation on ice for 30 minutes. The lysis buffer was then pipetted repeatedly over the cell 
culture surface or the cell pellet and the lysate was transferred into 1.5 ml centrifuge tubes 
(Anachem). Cell lysates were centrifuged at 14,000 rpm (Thermo-scientific MicroCL 21R) 
for 10 minutes at 4
o




To extract proteins from non-attached cells cultured in poly-HEMA or cells that grow 
naturally in suspension, the medium containing the cells was collected into 15 ml Falcon 
tubes (Greiner Bio-one, Stroudwater, United Kingdom). The remaining cells were washed 
with cold PBS which was pipetted repeatedly over the flask or well surface. PBS was then 
collected and added to the cell suspension. Cells were centrifuged at 300 x g for 5 minutes at 
room temperature. The supernatant was removed and the cells were lysed with RIPA buffer 
plus inhibitors. Samples were agitated gently on ice for 30 minutes and then vortexed in order 
to ensure complete lysis. Samples were then transferred to 1.5 ml centrifuge tubes and 
centrifuged at 14,000 rpm for 10 minutes at 4
o
C. The supernatant was transferred to fresh 




2.6.2 Protein quantification 
A binchinchonic acid assay (BCA, Pierce) was used for the measurement of protein 
concentrations of the cell lysates. Aliquots of 0.5 µl of each cell lysate were diluted in 4.5 µl 
sterile deionized water. Protein standards were prepared from bovine serum albumin (Sigma-
Aldrich, Dorset, United Kingdom) in a 1:10 dilution of RIPA buffer in sterile deionized 
water. Standard concentrations ranged between 0.025 and 2 mg/ml. The assay reagents were 
mixed at a ratio of 50:1. For each standard and sample, 5 µl were mixed with 95 µl of BCA 
assay reagent mixture and incubated for 30 minutes at 37
o
C. Samples were then transferred to 
ice and the absorbance at 562 nm was measured with a spectrophotometer (Beckman DU 
640). The protein standards were used to generate a curve, with a correlation coefficient, R
2
, 





2.7 Western Transfer Analysis 
 
2.7.1 Polyacrylamide gel electrophoresis   
Proteins were separated in sodium dodecyl sulphate (SDS) polyacrylamide gels. Separating 
gels comprised acrylamide and bisacrylamide in a 200:1 ratio, 0.5 M Tris-HCl pH 8.8, 0.1% 
sodium dodecyl sulphate (w/v), 0.05% ammonium persulphate (w/v) and 0.1% N, N, N’, N’-
tetramethylethylenediamine (TEMED) (v/v). Separating gels containing 20% acrylamide were 
used when the required proteins were smaller than 30 kDa, and gels containing 12% 
acrylamide were used for proteins larger than 30 kDa. Stacking gels contained 3% acrylamide 
and 0.15% bisacrylamide, 125 mM Tris-HCl pH 6.8, 0.1% SDS (w/v), 0.1% ammonium 
persulphate (w/v) and 0.5% TEMED. Both separating and stacking gels were poured in a 
vertical minigel apparatus (Hoeffer) and allowed to polymerise for 45 and 15 minutes, 
respectively.  
Aliquots of the protein lysates containing equal amounts of protein were mixed with 124 mM 
Tris-HCl, 25 mM Na2EDTA, 4% SDS (w/v), 20% glycerol (w/v), 0.01% bromophenol blue 
(w/v) and 10% β-mercaptoethanol (v/v) (pH 6.8)  and heated at 95oC for 10 minutes. Protein 
markers of known molecular mass were included in each polyacrylamide gel (Full Range 
Rainbow Marker: GE Life Sciences). Proteins were electrophoresed in a running buffer which 
comprised 0.5 M Tris-HCl, 0.38 M glycine and 0.1% SDS (w/v), at a constant current of 10 
mA, in Mighty Small II electrophoresis chambers (Amersham Pharmacia). 
 
2.7.2 Western transfer 
After electrophoresis, proteins were transferred to a Westran 0.45 µM nitrocellulose 
membrane (VWR) in a semi-dry transfer apparatus (S&S CarboGlas, Peqlab PerfectBlue). 
The transfer sandwich comprised (from anode to cathode) two sheets of Whatman 3mm 
chromatography paper soaked in 0.3 M Tris, 20% methanol (Anode buffer 1), one sheet 
soaked in 25 mM Tris, 20% methanol (Anode buffer 2), the nitrocellulose membrane soaked 
in Anode buffer 2, the polyacrylamide gel, and three sheets of chromatography paper soaked 
in 25 mM Tris, 40 mM 6-amonicaproic acid, 20% methanol (Cathode buffer). Proteins were 
transferred at 100 mA for 10 to 30 minutes when the target proteins were smaller than 30 
kDa, or for 45 to 60 minutes for proteins larger than 30 kDa. Following transfer, the 
membranes were dried overnight. The next day, the membranes were blocked in 5% milk 
(v/v) in 20 mM Tris-HCl, 140 mM NaCl, 0.1% Tween 20 (v/v) (TBS-Tween solution) for one 
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hour at room temperature. After three washes in TBS-Tween the membranes were incubated 
with primary antibody diluted in 5 ml of 5% milk in TBS-Tween, in 50 ml Falcon tubes and 
agitated on rollers overnight at 4
o
C. Membranes were washed thrice in TBS-Tween before 
incubation in horse-radish peroxidase conjugated secondary antibody. The secondary 
antibody was diluted in 5 ml of 5% milk in TBS-Tween in 50 ml Falcon tubes and the 
membranes were incubated for 60 minutes agitated on rollers at room temperature. They were 
then washed again in TBS-Tween thrice and in TBS once. The membranes were incubated in 
a 1:1 mix of Supersignal West Dura extended duration substrate chemiluminescent solutions 
Luminol/Enhancer and Peroxide buffer, for 5 minutes at room temperature and exposed to X-
ray film (Fuji, SuperRX). 
A list of all the antibodies used and their origin is shown in Table 2.2. 
Antibody Source Concentration Species Antibody 
type 
Cleaved PARP (Asp 214) Cell signaling 
technologies #9541 
1:2000 Rabbit Polyclonal 




1:1000 Rabbit Polyclonal 
IGF-IR-β Cell signaling 
technologies #3027 
1:2000 Rabbit Polyclonal 
IR-β Cell signaling 
technologies #3025 
1:1000 Rabbit Monoclonal 





1:1000 Rabbit Monoclonal 
HER-2 Cell signaling 
technologies #2165 
1:1000 Rabbit Monoclonal 
Met Cell signaling 
technologies #4560 
1:2000 Rabbit Polyclonal 
FGFR-2 Fisher scientific- PA5-
29426 
1:1000 Rabbit Polyclonal 
Phosphorylated IGF-
IR/IR (Tyr 1135/1136) 
Cell signaling 
technologies #3024 
1:1000 Rabbit Monoclonal 
IRS-1 Cell signaling 
technologies #3407 
1:2000 Rabbit Monoclonal 








1:2000 Rabbit Monoclonal 
ERK1/ERK2 Cell signaling 
technologies #9102 











1:1000 Rabbit Monoclonal 
GAPDH-HRP Santa Cruz-25778 1:10000 Rabbit Polyclonal 
β-Tubulin (9F3) Cell signaling 
technologies #5346 
1:5000 Rabbit Monoclonal 
Anti-rabbit HRP Cell signaling 
technologies #7074 
1:5000 Goat - 
Anti-mouse HRP Cell signaling 
technologies #7076 
1:5000 Horse - 
Table 2.2. Origin of antibodies for western transfer analyses and dilutions used.  
 
2.8 DNA Quantification 
DNA was quantified using the Quanti-iT picogreen fluorimetric assay (Invitrogen). Prior to 
analysis, cells were frozen at -20
o
C overnight. Cells were lysed in 0.15 M NaCl, 17 nM 
sodium citrate adjusted to pH 7.0, with 0.02% SDS (saline sodium citrate solution SSC:SDS) 
and incubated at 37
o
C for 30 minutes with gentle agitation. DNA was sheared and 
homogenised by repeated pipetting of the lysis buffer through a 25g needle with a 2 ml 
syringe. DNA standards were prepared from calf thymus DNA (Invitrogen) in 0.02% SSC 
/SDS solution at a concentration range of 0.005-2 μg/ml. A volume of 50 μl of each sample 
and DNA standard were pipetted into a black 96-well plate (Greiner). Samples with high 
DNA concentration were diluted at a range of 1:2 to 1:10. The PicoGreen reagent was diluted 
1:200 in 10 mM Tris-HCl, 1 mM Na2EDTA adjusted to pH 7.5 (Tris-EDTA buffer) and 50 μl 
added to each well. The plates were covered in foil until measurement. The samples were 
excited at 485 nm and fluorescence emission intensity was measured at 520 nm, within 5 
minutes of addition of the PicoGreen reagent. A standard curve was created from the DNA 
standards and the DNA concentrations of the samples were interpolated from the standard 





Adherent cells grown on coverslips inside 6-well plates were fixed in methanol at -20
o
C for 
30 minutes, in 4% paraformaldehyde at room temperature for 20 minutes or in 70 % ethanol 
at room temperature for 20 minutes, depending on the protein of interest. Cells were blocked 
in 5% goat serum (Invitrogen, Paisley, United Kingdom), PBS, 0.3 % Triton-X for 1 hour and 
incubated with the appropriate concentration of primary antibody diluted in PBS with 0.3% 
Triton-X, at 4
o
C overnight. The antibodies used and the different fixation methods 
corresponding to each antibody are shown in Table 2.3. Proteins were visualised by 
incubation in Alexa Fluorochrome-labelled antibodies (New England Biolabs, Hitchin, United 
Kingdom), followed by nuclear staining/mounting in Vectashield Mounting Medium with 
DAPI (Vector laboratories). A fluorescent microscope was used to take pictures of the cells 
(Leica). For quantification, five fields of view were analysed for each treatment.  
For cells grown in suspension all incubations were in a 1.5 ml eppendorf tube, with repeated 
centrifugation steps at 500xg for 5 minutes. At the end of the procedure, the cells were 
resuspended in Vectashield Mounting Medium with DAPI, placed on top of microscope slides 




Antibody Source Fixation method Species Antibody 
type 
Cleaved PARP 
(Asp 214)  
Cell signaling 
technologies #6894 
Methanol Rabbit Monoclonal 




Methanol Rabbit Monoclonal 
Phospho-Akt Cell signaling 
technologies #4060 
Methanol Rabbit Monoclonal 
Phospho-Histone 
H3 (Ser 10) 
Cell signaling 
technologies #9701 
4% paraformaldehyde Rabbit Polyclonal 
BrdU Cell signaling 
technologies #5292 
70% ethanol, 1.5M HCl Mouse Monoclonal 







Invitrogen #A-11034 - Goat - 
Anti-mouse (AF 
488) 
Invitrogen #A-11001 - Goat - 
Table 2.3. Antibodies for immunofluorescence analyses, their dilutions and the initial fixation conditions. 
 
2.10 RNA Extraction 
RNA was extracted with the Direct-zol™ RNA MiniPrep from Zymo Research. Cells were 
grown in 25 cm
2
 tissue culture flasks until they were 80% confluent. They were washed in 
PBS once before the addition of 700 μl TRIzol (Invitrogen, Paisley, United Kingdom). TRIzol 
was pipetted repeatedly on top of the cell surface until cells were completely lysed. Lysed 
cells were transferred to an Eppendorf tube, vortexed vigorously and left to stand for 5 
minutes at room temperature. After centrifugation at 12,000 x g for 1 minute, the supernatant 
was transferred to a fresh tube containing an equal volume of ethanol (95-100%). After 
vigorous vortexing, the lysate was loaded onto a Zymo-Spin™ IIC Column in a collection 
tube and centrifuged for 1 minute at 16,000 x g. The column was transferred into a new 
collection tube and 400 μl Direct-zol™ RNA PreWash buffer were added to the column, 
before centrifugation at 16,000 x g for 1 minute. This step was repeated once. Then, 700 μl 
RNA Wash Buffer
 
were added to the column before another centrifugation at 16,000 x g for 1 
minute. The flow-through was discarded and 25 μl of DNase/RNase-Free water were added 
directly to the column matrix. After a final step of centrifugation at 21,000 x g for 1 minute 





RNA was quantified by UV spectroscopy (Beckman DU 640). RNA samples were diluted 
1:100 in 10 mM Tris, pH 8, 1 mM EDTA and the absorbance was measured at 260 and 280 
nM. The A260/A280 ratio was used to assess the RNA purity.   
 
2.11 Reverse Transcription and Polymerase Chain Reaction 
Complementary DNA was synthesised from total RNA with the Moloney Murine Leukaemia 
Virus Reverse Transcriptase (M-MLV RT) (Usb) in a 20 μl reaction. RNA aliquots of 1 µg 
were mixed with 0.5 μM Random Hexamers (Invitrogen) and sterile deionised water in a 0.5 
ml Eppendorf tube and incubated at 70
o
C for 10 minutes. The buffer was adjusted to pH 8.3 
with Tris-HCl, 75 mm KCl, 3 mM MgCl2 and 10 mM DTT and 4mM dNTPs and 60 units of 
M-MLV RT were added. After vortexing, the sample was incubated at 25
o
C for 10 minutes 
and at 37
o
C for 60 minutes. To inactivate the enzyme, 7 mM EDTA pH 8 were added and the 
sample was incubated at 75
o
C for 15 minutes. The sample was placed on ice to chill for 5 
minutes and the evaporated liquid was recovered by centrifugation. Complementary DNA 
was stored at -20
o
C.  
Complementary DNA was amplified with the Red Hot DNA polymerase (Thermo-scientific) 
in a 10 μl PCR reaction. The standard protocol comprised 75 mM Tris-HCl (pH 8.8 at 25oC), 
20 mM (NH4)2SO4, 0.01% (v/v) Tween 20, 0.2 mM dNTPs, 0.5 μM forward primer, 0.5 μM 
reverse primer, 0.8 mg/ml bovine serum albumin, 1.5 mM MgCl2, 0.625 units Red Hot DNA 
polymerase (Life technologies Ltd, Paisley, United Kingdom), 10 ng cDNA and sterile 
deionised water up to 10μl. The primers were obtained from Sigma-Aldrich and their 
sequences are shown in Table 2.4. 
Polymerase chain reaction was in a thermocycler using the following conditions: initial 
denaturation for 2 minutes at 94
o
C, two cycles of 90 seconds at 94
o
C, 30 seconds at the 
annealing temperature and 60 seconds at 72
o
C, 28-33 cycles of 20 seconds at 94
o
C, 30 
seconds at the annealing temperature and 60 seconds at 72
o
C and final extension for 5 minutes 
at 72
o
C. The annealing temperatures used for each pair of primers and the number of cycles 








No of cycles 





31 Insulin receptor (reverse) TCACATTCCCAACATCGCCA 








Insulin receptor isoform 
A (reverse) 
GATGCGATAGCCCGTGAAGT 








Insulin receptor isoform 
B (reverse) 
GACCAGCGACTCCTTGTTCA 





35 IRS-1 (reverse) ACTGAAATGGATGCATCGTACC 





35 IRS-2 (reverse) AGCCCTCCAATCAAGTGTCG 





35 IRS-4 (reverse) ACTGTAGACTGTAGCGCATCG 





30 18s rRNA (reverse) GGGACTTAATCAACGCAAGC 
  Table 2.4. Primer sequences and PCR conditions 
 
2.12 DNA Agarose Gels  
DNA was electrophoresed in 3% agarose gels, which comprised 2% Nusieve agarose (FMC 
Bioproducts) and 1% Type I agarose (Sigma-Aldrich, Dorset, United Kingdom) in 89 mM 
Tris base, 89 mM Boric acid and 2 mM EDTA (pH 8.3) (TBE buffer). The agarose was 
stained with GelRed (Cambridge bioscience, Cambridge, United Kingdom) before casting the 
gels. Agarose gels were poured into a DNA gel chamber (Bioscience Services) and left to 
polymerise for 60 minutes. The PCR products were mixed with 0.2% Ficoll (w/v), 100 mM 
EDTA, 0.04% bromophenol blue (w/v) in TBE buffer. DNA was electrophoresed in TBE 
buffer, at 60 volts. DNA was visualised with Gel Doc (Bio-Rad).  
 
2.13 Gene Silencing With Small Interfering RNA 
Short interfering RNA sequences designed to target the type I IGF receptor and matched 
scrambled sequences were purchased from Sigma-Aldrich. The siRNA and scrambled 
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sequences are shown in Table 2.5. Cells were transfected with a reverse transfection 
procedure. The transfection medium was prepared by mixing serum-free DMEM with siRNA 
or scrambled oligonucleotides and lipofectamine (Invitrogen, Paisley, United Kingdom). 
Scaling of the transfection reagents according to the surface of tissue culture plasticware is 
shown in Table 2.6. The different concentrations of siRNAs used for each cell line are shown 
in Table 2.7. The transfection medium was incubated for 30 minutes at room temperature 
before the addition of cell suspension. Cells were incubated for 24 hours in 37
o
C and were 
used in experiments, thereafter. 
Oligonucleotide  Sequence (5’-3’) 
Scrambled 1 sense UUCUCCGAACGUGUCACGU[dT][dT] 
Scrambled 1 antisense ACGUGACACGUUCGGAGAA[dT][dT] 
Scrambled 2 sense GCGCGAUAGCGCGAAUAUA[dT][dT] 
Scrambled 2 antisense UAUAUUCGCGCUAUCGCGC[dT][dT] 
siRNA 2 (IGF-IR) sense CUGACUACAGGGAUCUCAU[dT][dT] 
siRNA 2 (IGF-IR) antisense AUGAGAUCCCUGUAGUCAG[dT][dT] 
siRNA 3 (IGF-IR) sense GGAAUUGCAUGGUAGCCGA[dT][dT] 
siRNA 3 (IGF-IR) antisense UCGGCUACCAUGCAAUUCC[dT][dT] 
siRNA 2 (IR) sense GAAACUGCAUGGUCGCCCA[dT][dT] 
siRNA 2 (IR) antisense UGGGCGACCAUGCAGUUUC[dT][dT] 
siRNA 3 (IR) sense GAAACUCUUCUUCCACUAU[dT][dT] 
siRNA 3 (IR) antisense AUAGUGGAAGAAGAGUUUC[dT][dT] 
































1.25 250 100.000 20-50 2.5 ul 
24-well 
plate 
1.9  500 100 50.000 20-50 1 ul 










siRNA 2 (IR) 
(nM) 
siRNA 3 (IR) 
(nM) 
SNU-1 50 50 20 50 
MKN74 40 20 - - 
NUGC3 40 20 20 50 
AGS 40 20 - - 
GC 40 20 - - 
HC 20 20 - - 
NC 40 20 - - 
JW 40 20 - - 
Table 2.7. SiRNA concentration for each cell line. 
 
2.14 Treatment of Cells with Drugs 
Adherent cells were grown until ~70% confluence and detached from cell culture flasks by 
incubation with trypsin:EDTA. Cells were resuspended in maintenance medium and counted 
using a haemocytometer. For experiments designed to investigate the cytotoxic effect of 
oxaliplatin on gastric cancer cells, cells were seeded in 12-well tissue culture plates, in 1 ml 
maintenance medium at a concentration of 100,000 to 150,000 cells/well. Cells were left to 
attach for ~24 hours and the medium was changed to medium containing the appropriate 
amounts of oxaliplatin. Protein extracts were prepared after 1 to 3 days of incubation with the 
cytotoxic agents.  
For experiments designed to investigate the effect of oxaliplatin, 5-fluorouracil (Sigma-
Aldrich, Dorset, United Kingdom), lapatinib (LC laboratories, United States), AZD4547 (LC 
laboratories, United States), crizotinib (LC laboratories, United States) and BMS754807 
(Bristol-Myers Squibb, Middlesex, United Kingdom) on cell number, cells were plated in 24-
well plates at a concentration of 50000 cells/well or in 48-well plates at a concentration of 
25000 cells/ well and treated with a range of concentrations for 3 days. Cells were then 
washed with PBS once and kept in -20
o
C overnight before analysis with Quanti-iT picogreen 
fluorimetric assay (Invitrogen, Paisley, United Kingdom).   
For the establishment of lapatinib resistant NCI-N87 cells, NCI-N87 cells were treated for a 
period of 6 months with gradually increasing concentrations of lapatinib ranging from 0.05 to 




2.15 Statistical analysis 
Experiments were replicated at least thrice. Differences between groups were tested by one-
way or two-way analysis of variance (ANOVA) and paired or unpaired t test. P values < 0.05 




Chapter 3. Expression and Activation of Components of the IGF Signal 
Transduction Pathway in Gastric Cancer Cells 
 
3.1 Introduction 
In advanced gastric cancer, trastuzumab is the first targeted agent approved for the treatment 
of HER-2-overexpressing tumours (Bang et al., 2010). Inhibitors that target vascular 
endothelial growth factor, mammalian target of rapamycin, c-Met and FGFR2 are also under 
investigation (Qiu and Xu, 2013) (Su et al., 2014). Approximately 13-22% of advanced 
gastric cancers have HER-2 amplification or overexpression, 2-10% have c-Met amplification 
and 4-8% have FGFR2 amplification (Gravalos and Jimeno, 2008) (Kawakami et al., 2013) 
(Xie et al., 2013) (Su et al., 2014). There is, therefore, a large remaining population of 
patients that require alternative targeted treatments. 
In order to identify tumours that are most likely to benefit from IGF-targeted therapies it is 
necessary to measure the expression of components of molecular pathways which are already 
targeted in advanced gastric cancer, in combination with components of the IGF-signal 
transduction pathway. Detection of a receptor amplification in a growth factor pathway 
different to the IGF-signal transduction pathway would automatically exclude the possibility 
of administering IGF-targeted monotherapy for this tumour type.  
Unlike other growth factor pathways, it is quite uncommon for components of the IGF-signal 
transduction pathway to be amplified in cancer. However, detection of expression and 
activation of receptors and downstream molecules of the IGF-signal transduction pathway is 
of particular importance for elucidating the implication of the pathway in tumour progression.  
 
3.1.1 Aim 
The aim of the results reported in this chapter is to determine the expression of receptors and 
downstream molecules of the IGF-signal transduction pathway and other important growth 
factor pathways, in gastric cancer cells. Activation of the receptors and downstream 
molecules by IGF-1 was investigated in the same panel of gastric cancer cell lines. The 
effectiveness of a small molecule tyrosine kinase inhibitor in elimination of signal 






3.2.1 The relative expression of IGF-signal transduction pathway proteins in gastric cancer 
cells 
The responsiveness of a particular cell type to IGFs might depend on the expression levels of 
the receptors and downstream signal transduction molecules. The type I IGF receptor binds 
both IGF-1 and IGF-2 with high affinity and is the main receptor that mediates activation of 
downstream signal transduction pathways. The ligands IGF-1 and IGF-2 bind also to the type 
II IGF receptor, which lacks a tyrosine kinase domain and cannot transduce a downstream 
signal. However, the type II IGF receptor is of particular importance in regulating the 
bioavailability of IGF-1 and IGF-2. For example, high expression levels of the type II IGF 
receptor result in reduced availability of IGF-1 and IGF-2. Insulin receptor binds insulin with 
the highest affinity but it also binds IGF-1 and IGF-2 with lower affinity. In particular, the 
foetal splice variant of the insulin receptor, IR-A, is highly expressed in many cancer types 
and has a high affinity for IGF-2 (Frasca et al., 1999). Furthermore, the formation of hybrids 
between the type I IGF receptor and the insulin receptor attracts IGF-1 with high affinity and 
adds more complexity to the ligand-receptor interaction.  
Activation of the type I IGF and insulin receptors attracts adaptor proteins such as the insulin 
receptor substrate proteins 1, 2 and 4 (IRS 1, 2 and 4). Activation and phosphorylation of the 
IRS proteins result in activation of the downstream PI3K/Akt and Ras/Raf/MAPK pathways. 
Expression of the three receptors of the IGF-signal transduction pathway and of downstream 
molecules was investigated in a panel of gastric cancer cells lines. NCI-N87, KATO III, SNU-
16, SNU-5, SNU-1, MKN74, NUGC3 and AGS cells were cultured until 80% confluence and 
protein extracts were prepared. The expression of the three receptors and downstream 
molecules in each cell line was determined by western transfer analysis or by RT-PCR.    
NCI-N87 and AGS cells expressed the type I IGF and insulin receptors at lower levels 
compared to the other cells lines (Figure 3.1). KATO III and SNU-16 cells expressed higher 
levels of insulin receptor and type I IGF receptor and SNU-16 cells did not express the type II 
IGF receptor. SNU-5 cells expressed the insulin receptor and had much lower levels of the 
type I IGF receptor compared to the other cell lines. On the contrary, MKN74 cells expressed 
the highest levels of the type I IGF receptor among the cell lines, comparable with MCF7 
breast cancer cells and SNU-16 cells, but had extremely lower levels of the insulin receptor in 
comparison with the remaining cell lines. Expression of the type I IGF and insulin receptors 
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was similar in SNU-1 and NUGC3 cells, with SNU-1 cells expressing slightly higher levels of 
type II IGF receptor.  
 
Figure 3.1. Expression of IGF-signal transduction pathway proteins in gastric cancer cells. NCI-N87, 
KATO III, SNU-16, SNU-5, SNU-1, MKN74, NUGC3 and AGS cells were cultured in 75 cm
2  
tissue culture 
flasks in maintenance medium to ~80% confluence. Proteins were extracted with 1 ml per flask of RIPA buffer 
plus inhibitors, as described in the Materials and Methods section. Aliquots containing 10-20 µg of protein were 
electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 
minutes. Membranes were incubated with antibodies against the IGF-IR-β (1:2000), IR-β (1:1000), IGF-IIR 
(1:1000) and GAPDH (1:10000). All secondary antibodies were horseradish-peroxidase bound. Bands were 
visualised on Fuji X-ray film following incubation of membranes with Supersignal chemiluminescent solutions, 
as described in the Methods section. The images shown are representative of results from three separate 
experiments. The molecular masses of the proteins are indicated on the right hand side of the panels (A). 
Densitometric analysis of the bands for IGF-IR and IR was by Labworks 4.0 software. Measurements were 
adjusted for the background optical density of the X-ray film. Expression was not normalised to GAPDH, due to 
variation in GAPDH expression across different cell lines. Bars are the mean ±SEM (B).  
 
Expression of IRS-1 was variable among the cell lines, with SNU-1 cells expressing the 
highest levels, followed by NCI-N87, MKN74 and AGS cells (Figure 3.2). IRS-1 was not 
detected in SNU-16 cells. The mRNA of IRS-1 was detected by PCR in all gastric cancer cell 
lines (Figure 3.3). The highest levels of IRS-1 mRNA were detected in SNU-1, SNU-5 and 
AGS cells, followed by NCI-N87, MKN74, KATO III, SNU-16 and NUGC3. Due to the lack 
of high quality commercially available antibodies for IRS-2 and IRS-4, their expression was 
detected only by PCR. IRS-2 was expressed in all the cell lines, with lowest expression 
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detected in KATO III, AGS and SNU-1 cells. IRS-4 was not expressed in NUGC3 cells and 
was detected at highest levels in SNU-5 and SNU-16 cells (Figure 3.3). All cell lines 
expressed Akt, with KATO III, MKN74 and AGS cells having the lowest levels of 
expression. Similarly, ERK1 and 2 were expressed in all of the cell lines and SNU-5 cells 
expressed the lowest levels (Figure 3.2).  
 
Figure 3.2. Expression of IGF-signal transduction pathway proteins in gastric cancer cells. NCI-N87, 
KATO III, SNU-16, SNU-5, SNU-1, MKN74, NUGC3 and AGS cells were cultured in 75 cm
2  
tissue culture 
flasks in maintenance medium to ~80% confluence. Proteins were extracted with 1 ml per flask of RIPA buffer 
plus inhibitors, as described in the Materials and Methods section. Aliquots containing 10-20 µg of protein were 
electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 
minutes. Membranes were incubated with antibodies against IRS-1 (1:2000), Akt (1:3000) ERK1/2 (1:5000) and 
GAPDH (1:10000). All secondary antibodies were horseradish-peroxidase bound. Bands were visualised on Fuji 
X-ray film following incubation of membranes with Supersignal chemiluminescent solutions, as described in the 
Methods section. The images shown are representative of results from three separate experiments. The molecular 





Figure 3.3. Expression of genes that encode for IGF-signal transduction pathway proteins in gastric 
cancer cells. NCI-N87, KATO III, SNU-16, SNU-5, SNU-1, MKN74, NUGC3 and AGS cells were cultured in 
25 cm
2 
tissue culture flasks in maintenance medium to ~80% confluence. Total RNA was extracted from the 
cells with the Direct-zol™ RNA MiniPrep, as described in the Materials and Methods section. Complementary 
DNA was synthesised from total RNA with the Moloney Murine Leukaemia Virus Reverse Transcriptase. 
Specific primer sequences were used to amplify IRS-1, IRS-2, IRS-4 and 18S rRNA. The amplified DNA was 
electrophoresed in a 3% agarose gel and bands were visualised with a UV transilluminator. 
 
The level of IGF-IR expression in the gastric cancer cell lines was comparable to the level of 
expression in the breast cancer cell line MCF-7. MCF-7 cells are known to express high levels 
of the type I IGF receptor and IRS-1 and are particularly responsive to IGFs (Stewart et al., 
1990). SNU-1 cells, which also have relatively high levels of the type I IGF receptor and IRS-
1, are expected to be highly responsive to stimulation with IGF-1 and IGF-2. SNU-5 cells are 
expected to be the least responsive to IGFs, since they express the type I IGF receptor and 
IRS-1 at extremely low levels.   
 
3.2.2 The relative expression of HER-2, c-Met and FGFR2 in gastric cancer cells 
Inhibition of the dependence of malignant cells on amplified or overexpressed tyrosine kinase 
receptors has proven an effective therapeutic strategy. The genes that encode the three 
tyrosine kinase receptors, HER-2, FGFR-2 and c-Met are known to be amplified in gastric 
cancer. As mentioned previously, approximately 13-22% of advanced gastric cancers have 
HER-2 amplification or overexpression, 2-10% have c-Met amplification and 4-8% have 
FGFR2 amplification (Gravalos and Jimeno, 2008; Kawakami et al., 2013; Xie et al., 2013; 
Su et al., 2014).  
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In order to extend the expression profile of the gastric cancer cell lines, expression of the 
above three receptors was measured by western transfer (Figure 3.4). HER-2 was expressed at 
extremely high levels in NCI-N87 cells. Expression was even higher than in the HER-2 
amplified breast cancer SKBR3 cells. No HER-2 expression was detected in the remaining 
cell lines by western transfer. Similarly, KATO III and SNU-16 were the only two cell lines 
that overexpressed FGFR2. SNU-5 cells expressed the highest levels of the hepatocyte growth 
factor receptor (c-Met), followed by KATO III, SNU-16 and NUGC3 cells (Figure 3.4).  
 
Figure 3.4. Expression of HER-2, FGFR2 and c-Met in gastric cancer cells. NCI-N87, KATO III, SNU-16, 
SNU-5, SNU-1, MKN74, NUGC3 and AGS cells were cultured in 75 cm
2  
tissue culture flasks in maintenance 
medium to ~80% confluence. Proteins were extracted with 1 ml per flask of RIPA buffer plus inhibitors, as 
described in the Materials and Methods section. Aliquots containing 10-20 µg of protein were electrophoresed 
on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes 
were incubated with antibodies against the HER-2 (1:2000), FGFR2 (1:1000) and Met (1:1000). All secondary 
antibodies were horseradish-peroxidase bound. Bands were visualised on Fuji X-ray film following incubation of 
membranes with Supersignal chemiluminescent solutions, as described in the Methods section. The molecular 
masses of the proteins are indicated on the right hand side of the panels.  
 
Overexpression and/or amplification of a receptor which is not a member of the IGF-signal 
transduction pathway could affect the responsiveness of a particular cell type to IGFs. Cells 
with such amplification are expected to depend primarily on their amplified receptors, for 
activation of downstream pathways and induction of cell survival and proliferation. It is, 
therefore, likely that those cells will not be very sensitive to ligands from other pathways, 
such as IGF-1, IGF-2 and insulin. Consequently, NCI-N87, KATO III, SNU-16 and SNU-5 
cells might not be as responsive to IGF stimulation as the remaining four cell lines, which 
don’t have HER-2, FGFR2 or c-Met amplification.  
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3.2.3 The effect of IGF-1 stimulation on the activity of IGF-signal transduction pathway 
proteins 
The effect of stimulation with IGF-1 on activation and phosphorylation of components of the 
IGF signal transduction pathway was tested in NCI-N87, KATO III, SNU-16, SNU-5, SNU-
1, MKN74, NUGC3 and AGS cells. The cells were withdrawn from the effects of growth 
factors present in the serum by culture in medium containing dextran-coated charcoal stripped 
serum (DCCS). Phosphorylation of proteins of the IGF-signal transduction pathway in cells 
that had been treated with 50 ng/ml IGF-1 was determined by western transfer.  
Phosphorylation of the type I IGF receptor and insulin receptor was not detected in any of the 
cell lines after culture in growth factor-depleted medium for 48 hours (Figure 3.5). 
Stimulation with IGF-1 resulted in the induction of phosphorylated IGF-IR and/or IR in all 
cell lines. The highest amount of phosphorylation was detected in MKN74 cells, which also 
expressed the highest levels of total IGF-IR. The lowest amount of phosphorylation was 
observed in SNU-5 cells, which expressed the lowest levels of total IGF-IR. The amount of 
total IGF-IR was not altered by stimulation with IGF-1 in any of the cell lines.  
There were baseline levels of Akt phosphorylation in NCI-N87, MKN74, NUGC3 and AGS 
cells after withdrawal of growth factors from the culture medium. However, stimulation with 
IGF-1 increased Akt phosphorylation in all four cell lines. KATO III, SNU-16, SNU-5 and 
SNU-1 cells had no detectable baseline levels of Akt phosphorylation. IGF-1 stimulation 
induced Akt phosphorylation in all of these cell lines. Most effective induction of Akt 
phosphorylation in response to IGF-1 stimulation was observed in SNU-1 cells, which had no 
baseline levels of phosphorylated Akt and had the highest amount of phosphorylated Akt after 
stimulation with IGF-1. This suggests that activation of the Akt pathway might be highly 
dependent on IGF-1-induced phosphorylation of the type I IGF receptor in those cells. Total 
Akt levels were not affected by stimulation with IGF-1 in any of the cell lines (Figure 3.5).   
Phosphorylated ERK2 was detected in the absence of IGF-1 in all the cell lines used here. 
There was no increase in ERK1 and ERK2 phosphorylation after stimulation with IGF-1 in 
KATO III and SNU-5 cells. Most effective induction of ERK2 phosphorylation was observed 
in MKN74, NUGC3, AGS and SNU-16 cells, followed by a smaller induction in NCI-N87 
and SNU-1 cells. ERK1 phosphorylation was induced after stimulation with IGF-1 in NCI-
N87, SNU-16, SNU-1 and MKN74 cells. The levels of total ERK1 and ERK2 remained 
unchanged after stimulation with IGF-1 in all cell lines, except NCI-N87 cells, where a small 




Figure 3.5. The effect of stimulation with IGF-1 on phosphorylation of IGF signal transduction pathway 
proteins in gastric cancer cell lines. SNU-16, SNU-5 and SNU-1 cells were centrifuged and resuspended in 
withdrawal medium and seeded into a 75 cm
2 
flask at a concentration of 0.6x10
6 
cells per flask. After 24 hours, 
medium was replaced with 12 ml fresh withdrawal medium for another 24 hours. Cells were centrifuged and 
resuspended in serum-free medium with 0.1% BSA for 2 hours. Cells were then centrifuged and resuspended in 
serum-free medium with or without 50 ng/ml IGF-1 for 15 minutes. Cells were collected in a 15 ml Falcon tube 
and proteins were lysed with 50 µl RIPA buffer plus inhibitors. NCI-N87, KATO III, MKN74, NUGC3 and 
AGS cells were seeded into 12 well tissue culture plates at 15x10
4 
cells/well, in 1ml maintenance medium. Cells 
were incubated for 24 hours to allow attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. 
Medium was replaced daily with 1 ml withdrawal medium for two days. Cells were incubated with serum-free 
medium which contained 0.1% BSA for two hours. Cells were incubated with 50 ng/ml IGF-1 for 15 minutes. 
Proteins were extracted with 80 µl per well RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein 
were electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 
minutes. Membranes were incubated with antibodies against phosphorylated IGF-IR/IR (1:1000 dilution), IGF-
IR (1:2000 dilution), phosphorylated Akt (1:3000 dilution), Akt (1:3000 dilution), phosphorylated ERK1/2 
(1:5000 dilution), ERK1/2 (1:5000 dilution) and GAPDH (1:10000 dilution). Images obtained after incubation 
with antibodies against the total proteins are shown beneath those of the phosphorylated proteins. The images 
shown are representative of results from three separate triplicate experiments. 
 
To investigate the concentration dependence of the IGF-1 activation effect of signal 
transduction proteins SNU-1 and NUGC3 cells were incubated with different IGF-1 
concentrations up to 200 ng/ml. SNU-1 and NUGC3 were chosen as representative triple-
negative gastric cancer cell lines that express relatively high levels of both the type I IGF and 
insulin receptors compared to other cell lines and that respond well to IGF-1 stimulation 
(Figure 3.5). Induction of IGF receptor phosphorylation was detected in SNU-1 cells, after 
stimulation with 5 ng/ml IGF-1 or higher (Figure 3.6). Maximal phosphorylation was 
achieved with 50 ng/ml IGF-1. Treatment with 200 ng/ml IGF-1 did not increase the amount 
of phosphorylated IGF-IR/IR, suggesting that the receptor(s) were saturated. Phosphorylated 
IGF-IR/IR was detected in NUGC3 cells after treatment with 2 ng/ml IGF-1 or higher. Again 




Figure 3.6. The effect of stimulation with different concentrations of IGF-1 on phosphorylation of IGF 
signal transduction proteins in gastric cancer cell lines. SNU-1 cells were centrifuged and resuspended in 
withdrawal medium and seeded into a 75 cm
2 
flask at a concentration of 0.9x10
6 
cells per flask. After 24 hours, 
medium was replaced with 12 ml fresh withdrawal medium for another 24 hours. Cells were centrifuged and 
resuspended in serum-free medium with 0.1% BSA for 2 hours. Cells were then centrifuged and resuspended in 
serum-free medium with 0.1% BSA and 0, 0.5, 2, 5, 20, 50 ng/ml IGF-1 for 15 minutes. Cells were collected in a 
15 ml Falcon tube and proteins were lysed with 50 µl RIPA buffer plus inhibitors. NUGC3 cells were seeded 
into 12-well tissue culture plates at 15x10
4 
cells/well, in 1 ml maintenance medium. Cells were incubated for 24 
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hours to allow attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. Medium was replaced 
daily with 1 ml withdrawal medium for two days. Cells were incubated with serum-free medium which 
contained 0.1% BSA for two hours. Medium was changed to include IGF- 1 at final concentrations of 0, 0.5, 2, 
5, 20, 50, 200 ng/ml. After incubation for 15 minutes proteins were extracted with 80 µl per well RIPA buffer 
plus inhibitors. Aliquots containing 10 µg of protein were electrophoresed on denaturing 12 % polyacrylamide 
gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with antibodies 
against phosphorylated IGF-IR/IR (1:1000 dilution), IGF-IR (1:2000 dilution), phosphorylated Akt (1:3000 
dilution), Akt (1:3000 dilution), phosphorylated ERK1/2 (1:5000 dilution), ERK1/2 (1:5000 dilution) and 
GAPDH (1:10000 dilution). Images obtained after incubation with antibodies against the total proteins are 
shown beneath those of the phosphorylated proteins. Images shown are representative of results from one 
triplicate experiment (A). Densitometric analysis of the bands was by Labworks 4.0 software. Measurements 
were adjusted for the background optical density of the X-ray film and normalised to the total proteins (B). 
Results are expressed as a percentage of the maximum observed phosphorylation in each case. Bars are the mean 
±SEM.   
 
Akt stimulation was detected in SNU-1 cells after treatment with 2 ng/ml IGF-1, whereas 
maximal Akt phosphorylation was achieved with 20 and 50 ng/ml IGF-1. In NUGC3 cells 
some levels of Akt phosphorylation were detected in the absence of IGF-1, but increased after 
IGF-1 stimulation in a concentration dependent manner. Again, maximal Akt phosphorylation 
was reached with 20 and 50 ng/ml IGF-1. Phosphorylated ERK1 and ERK2 were detected in 
both cell lines in the absence of IGF-1 but there was a concentration dependent increase after 
stimulation with IGF-1. Maximal phosphorylation was achieved with 5 ng/ml and above in 
SNU-1 cells and 20 ng/ml in NUGC3 cells (Figure 3.6). 
Stimulation of most gastric cancer cell lines with IGF-1 resulted in phosphorylation of the 
type I IGF and/or insulin receptor and activation of downstream pathways, suggesting that 
signalling through the two receptors is functional in those cells. Detectable phosphorylation of 
IGF-IR/IR was achieved with a slightly lower IGF-1 concentration in NUGC3 cells compared 
to SNU-1 cells. Expression of the type II IGF receptor is slightly higher in SNU-1 cells 
compared to NUGC3 cells, which could contribute to reduced IGF-1 availability to the type I 
IGF receptor and result in a higher threshold for IGF-IR phosphorylation. Lower 
concentrations of IGF-1 were required to induce phosphorylation of Akt, ERK1 and ERK2 
compared to phosphorylation of the type I IGF and insulin receptors in both SNU-1 and 
NUGC3 cells. Possibly, the sensitivity of the antibodies that detect phosphorylated Akt and 
ERK1 and 2 is higher compared to the antibody that detects phosphorylated IGF-IR/IR.  
 
3.2.4 The effect of IGF-IR/IR inhibition with a small molecule tyrosine kinase inhibitor on 
activation of IGF-signal transduction pathway proteins in response to IGF-1 
BMS754807 (Bristol-Myers-Squibb, New York, NY, US7534792) has been shown to inhibit 
[
3
H]-thymidine incorporation in pre-clinical studies of breast, lung, pancreatic and colon 
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cancer cells as well as in multiple myeloma, leukaemia, and sarcomas (Carboni et al., 2009). 
It prevents ATP interaction with the tyrosine kinase domain of the type I IGF receptor, which 
results in reduced receptor phosphorylation. Due to the high homology of the tyrosine kinase 
domain of the type I IGF receptor and the insulin receptor, BMS754807 inhibits both 
receptors. Phase I studies have investigated the safety and tolerability of BMS754807 alone in 
patients with advanced or metastatic solid tumours (NCT00569036 and NCT00898716) and 
the safety and tolerability of BMS754807 in combination with paclitaxel and carboplatin 
(NCT00793897). Phase I/II studies have investigated combinations of BMS754807 with 
cetuximab (EGFR inhibitor) in advanced or metastatic solid tumours (NCT00908024), with 
trastuzumab in advanced or metastatic HER-2 positive breast cancer (NCT00788333) and 
with letrozole in hormone receptor-positive breast cancer with resistance to non-steroidal 
aromatase inhibitors (NCT01225172). Results of the above trials are yet to be published.  
The effectiveness of BMS754807 on the inhibition of activation of downstream pathways in 
response to IGF-1 was tested in NUGC3 and SNU-1 cells. The cells were withdrawn from the 
effects of growth factors present in the medium by culture in medium containing dextran-
coated charcoal stripped serum (DCCS). Phosphorylation of proteins of the IGF-signal 
transduction pathway in cells that had been treated with different concentrations of 
BMS754807 prior to treatment with 50 ng/ml IGF-1 was determined by western transfer.  
As mentioned previously, treatment of both SNU 1 and NUGC3 cells with 50 ng/ml IGF-1 
resulted in maximal phosphorylation of the type I IGF and insulin receptors. Partial inhibition 
of IGF-IR/IR phosphorylation was achieved with 5 nM BMS754807 in SNU-1 cells and 5 and 
50 nM in NUGC3 cells (Figure 3.7). Complete inhibition of IGF-IR/IR phosphorylation was 
achieved with 50 nM BMS754807 in SNU-1 cells and 500 nM in NUGC3 cells. The levels of 
total IGF-IR were not altered after treatment with BMS754807. 
Akt phosphorylation was completely inhibited with 500 nM BMS754807 in SNU-1 cells. In 
NUGC3 cells phosphorylated Akt was detected in the absence of IGF-1 but increased after 
IGF-1 treatment. Complete restoration of phosphorylated Akt to baseline levels was achieved 
with 500 nM BMS754807. In SNU-1 cells there was some stimulation of ERK2 
phosphorylation in response to IGF-1 but BMS754807 did not inhibit ERK2 phosphorylation 
at any concentration tested. In NUGC3 cells, stimulation of ERK1 and 2 phosphorylation in 
response to IGF-1 was much better compared to SNU-1 cells but BMS754807 reduced the 
levels of ERK1 and 2 phosphorylation to a very small extent (Figure 3.7).  
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BMS754807 inhibited effectively phosphorylation of the type I IGF and insulin receptor and 
Akt in response to IGF-1 at a concentration of 500 nM both in SNU-1 and NUGC3 cells. 
However, it was not equally effective in the inhibition of IGF-1-induced ERK1 and ERK2 
phosphorylation.  
 
Figure 3.7. The effect of inhibition of IGF-IR/IR with BMS754807 on stimulation of SNU-1 and NUGC3 
cells with IGF-1. SNU-1 cells were centrifuged and resuspended in withdrawal medium and seeded into a 75 
cm
2 
flask at a concentration of 0.9x10
6 
cells per flask. After 24 hours, medium was replaced with 12 ml fresh 
withdrawal medium for another 24 hours. Cells were centrifuged and resuspended in withdrawal medium 
containing 0, 5, 50, 500 or 5000 nM BMS754807 for 30 minutes. Cells were centrifuged and medium was 
changed to include 50ng/ml IGF-1. After incubation for 15 minutes cells were collected in a 15 ml Falcon tube 
and proteins were lysed with 50 µl RIPA buffer plus inhibitors. NUGC3 cells were seeded into 12 well tissue 
culture plates at 15x10
4 
cells/well, in 1 ml maintenance medium. Cells were incubated for 24 hours to allow 
attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. Medium was replaced daily with 1 ml 
withdrawal medium for two days. Cells were incubated with withdrawal medium with 0, 5, 50, 500 and 5000 nM 
BMS754807 for 30 minutes. Medium was then changed to include 50 ng/ml IGF-1. After incubation for 15 
minutes proteins were extracted with 80 µl per well RIPA buffer plus inhibitors. Aliquots containing 10 µg of 
protein were electrophoresed on denaturing 12 % polyacrylamide gels and transferred to nitrocellulose at 100 
mA for 45 minutes. Membranes were incubated with antibodies against phosphorylated IGF-IR/IR (1:1000 
dilution), IGF-IR (1:2000 dilution), phosphorylated Akt (1:3000 dilution), Akt (1:3000 dilution), phosphorylated 
ERK1/2 (1:5000 dilution), ERK1/2 (1:5000 dilution) and GAPDH (1:10000 dilution). Images obtained after 
incubation with antibodies against the total proteins are shown beneath those of the phosphorylated proteins.   
 
3.3 Discussion 
Liu et al., have investigated the correlation between IGF-IR expression and gastric cancer 
risk. Positive IGF-IR expression was detected in 87.5% of gastric carcinoma tissues, 55% of 
atypical hyperplasia tissues and 17.86% of normal gastric mucosal membrane tissues, 
suggesting that IGF-IR expression might be related to the development of gastric carcinoma 
(Liu et al., 2009). An additional study has shown that IGF-IR expression in gastric cancer is 
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associated with lymph node metastasis, worse prognosis and high histological malignancy 
grade and is an independent predictor of survival (Gryko et al., 2014). In a separate study, 
IGF-IR expression was associated with tumour size, stroma quantity, depth of invasion, 
lymph node involvement and stage of gastric cancer (Ge et al., 2009). 
Despite the above information linking IGF-IR expression to gastric cancer progression, it is 
known that IGF-IR expression alone is not a sufficient predictor of the responsiveness of a 
particular cell type to IGF-targeted treatment. Other proteins such as insulin receptor, type II 
IGF receptor or insulin receptor substrate proteins 1, 2 and 4 are also implicated and can 
affect the response of cells to IGFs, as well as the response to IGF-IR-targeted drugs. For 
example, SNU-1 and NUGC3 cells express similar amounts of the type I IGF receptor but 
SNU-1 cells express higher levels of IRS-1, which suggests that activation of the type I IGF 
receptor in those cells could have a more powerful biological effect. The above should be 
taken into consideration when designing targeted treatments.     
Out of the eight gastric cancer cell lines used here, seven expressed IGF-IR and IR, one 
expressed HER-2, two expressed FGFR2 and four expressed c-Met. Despite the small sample 
size used, it seems that IGF-IR and IR expression is quite common in gastric cancer. This is 
also supported by the study of Liu et al., (2009), in which 87.5% of 56 gastric carcinomas 
were positive for IGF-IR and it suggests that a large proportion of gastric adenocarcinomas 
use the IGF signal transduction pathway for their growth and survival mechanisms. 
Stimulation of all gastric cancer cell lines with IGF-1 resulted in phosphorylation of the type I 
IGF and insulin receptor and Akt, which demonstrates that the IGF signal transduction 
pathway is active in cells driven by overexpression of amplified HER2, FGFR2 or MET. 
However, the level of response varied amongst the cell lines. In general, cells without a 
known amplification, such as SNU-1, MKN74, NUGC3 and AGS responded well to IGF-1 
stimulation. Best stimulation of ERK2 was achieved in MKN74, NUGC3, AGS and SNU-16 
cells. Interestingly, NCI-N87 and SNU-16 cells, which overexpress HER-2 and FGFR2, 
respectively, responded quite well to IGF-1 stimulation by concomitant increase of Akt and 
ERK1 and ERK2 phosphorylation. Our results suggest that the IGF signal transduction 
pathway might be more important than previously appreciated in gastric cancer cells that are 
driven by amplification of other tyrosine kinase receptors and that consideration should be 
given to dual targeting to limit the onset of resistance. 
BMS754807 is a small molecule tyrosine kinase inhibitor that inhibits activation of the type I 
IGF receptor and, due to the high homology of the two receptors, the insulin receptor. 
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Treatment of SNU-1 and NUGC3 cells, which express both receptors, with the BMS754807 
inhibited completely phosphorylation of the two receptors in response to IGF-1. Furthermore, 
IGF-1-induced Akt phosphorylation was inhibited also by BMS754807 in both cell lines. 
However, the inhibitor did not reduce IGF-1-induced ERK1 and ERK2 phosphorylation in 
NUGC3 cells. This is in contrast with a study in which BMS754807 inhibited activation of 
both Akt and ERK1/2 phosphorylation by IGF-1 in mouse embryonic fibroblasts (Dinchuk et 
al., 2010). In another study, IGF-1-induced Akt but not ERK1/2 phosphorylation, was 
inhibited by BMS754807 in rhabdomyosarcoma and colon cancer cells (Carboni et al., 2009).  
In summary, the above findings suggest that the IGF signal transduction pathway is active in 
the vast majority of gastric cancer cell lines used here. Importantly, the IGF signal 
transduction pathway can be activated even in cell lines with amplification of HER-2, FGFR2 
and c-Met. It remains to be seen whether and how the biological effect of IGF-1 varies from 
one cell line to the other.       
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Chapter 4. The Effect of IGF-1 on Cell Survival in Gastric Cancer Cells 
 
4.1 Introduction 
Caspase-dependent programmed cell death has been evolved by multicellular organisms to 
eliminate unwanted or unhealthy cells, either as a part of normal development or following 
stress. It consists of multiple cellular events which lead to activation of a family of cysteine 
proteases called caspases. ‘Initiator’ caspases 2, 8, 9, and 10, which are activated in response 
to apoptotic stimuli, cleave and activate the ‘executioner’ caspases 3 and 7 (Fernald and 
Kurokawa, 2013).  It has been proposed that apoptosis, serves as a natural barrier to cancer 
development. Unlike normal cells, cancer cells are constantly under stress, including 
oncogenic stress, genomic instability, and cellular hypoxia. In response to such stress, the 
intrinsic pathway of apoptosis would normally be activated. However, cancer cells can often 
establish the appropriate molecular machinery that will help them to evade apoptosis. This 
evasion may involve alteration of the balance between pro- and anti-apoptotic members of the 
Bcl-2 family of regulatory proteins (Adams and Cory, 2007). 
Involvement of the IGF signal transduction pathway in evasion of apoptosis induced by 
chemotherapeutic agents and serum withdrawal has been reported in cancer cells. IGF-1 
protected against apoptosis induced by 5-fluorouracil, methotrexate, tamoxifen and 
camptothecin in HBL-100 breast cancer cells (Dunn et al., 1997), against doxorubicin-
induced apoptosis in MCF-7 breast cancer cells (Gooch et al., 1999), and against apoptosis 
induced by serum deficiency and doxorubicin in neuroblastoma cells (Gil-Ad et al., 1999). 
IGF-1 inhibited apoptosis induced by IL-3 withdrawal in myeloid progenitors by maintaining 
high levels of Bcl-2 protein (Minshall et al., 1997) and apoptosis induced by serum 
withdrawal in pheochromocytoma PC12 cells by increasing Bcl-XL levels (Parrizas and 
LeRoith, 1997). The importance of the type I IGF receptor in cell survival has also been 
reported. Inhibition of endogenous levels of IGF-IR increased sensitivity to UV radiation and 
proteasome inhibitors in A549 lung carcinoma cells (Jiang et al., 1999), whereas insulin-
induced IGF-IR activation protected against apoptosis caused by ultraviolet B irradiation in 
primary human keratinocytes (Kuhn et al., 1999).  
When displaced from the extracellular matrix, epithelial cells undergo a type of apoptosis, 
called anoikis (Folkman and Moscona, 1978). Anoikis prevents cells from surviving and 
colonising elsewhere when detached. Anoikis can be regulated by both the intrinsic and 
extrinsic pathways. In the intrinsic pathway, the Bcl-2 family of proteins controls the 
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formation of pores in the outer mitochondrial membrane, releasing pro-apoptotic factors, such 
as cytochrome C, which activate caspases. The extrinsic pathway consists of ligation of death 
receptors on the cell surface, resulting in the assembly of a death-inducing signalling complex 
(Gilmore, 2005).  
IGF-1 has been reported to protect fibroblasts that overexpress IGF-IR from anoikis 
(Valentinis et al., 1998), and Ewing’s sarcoma cells carrying antisense IGF-IR had a 
significant increase in apoptosis induced by prevention of cell attachment (Scotlandi et al., 
2002).    
One of the most common problems in cancer therapy involves the acquisition of resistance to 
apoptosis by cancer cells. Given the reported importance of the IGF signal transduction 
pathway in apoptosis evasion, it is possible that targeting this pathway could confer a 
significant benefit in gastric cancer patients.  
 
4.1.1 Aim 
The results presented in this chapter aim to elucidate the role of IGF-1 on survival of gastric 
cancer cells. Two cell survival assays were established, the apoptosis assay and the anoikis 
assay. The protective effect of IGF-1 against both apoptosis and anoikis was investigated. The 
role of the type I IGF and insulin receptors and of downstream molecules of the IGF-signal 
transduction pathway in the IGF-1 survival effect was investigated with a small molecule 
tyrosine kinase inhibitor that targets the type I IGF receptor and the insulin receptor and with 




4.2.1 The effect of IGF-1 on staurosporine-induced apoptosis in gastric cancer cells 
During apoptosis, caspase 3 is activated by proteolytic processing of its inactive zymogen into 
a 17 and a 12 kDa fragment (Nicholson et al., 1995). Cleaved caspase 3 is responsible for the 
proteolytic cleavage of many key proteins, such as the nuclear enzyme poly (ADP-ribose) 
polymerase (PARP) (Fernandes-Alnemri et al., 1994).  Cleavage of PARP from 113 to 89 
kDa results in loss of its DNA binding domain. Staurosporine is an inhibitor of protein kinase 
C that prevents interaction of ATP with the active site on the kinase. At micromolar 
concentrations, staturosporine is broader-spectrum protein kinase inhibitor that induces 
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apoptosis in a wide variety of cells via activation of the caspase cascade (Meggio et al., 1995; 
Omura et al., 1995). The protective effect of IGF-1 against staurosporine-induced apoptosis 
has been demonstrated previously in triple-negative breast cancer cells (Davison et al., 2011). 
To investigate whether IGF-1 can promote survival in gastric cancer cells, the ability of IGF-1 
to inhibit staurosporine-induced cell death was assessed.   
 
4.2.1.1 The effect of IGF-1 on staurosporine-induced apoptosis overtime 
The protective effect of IGF-1 on gastric cancer cells was investigated over time. In SNU-1 
cells, the 89 kDa PARP fragment was detected by western transfer analysis at very low levels 
after culture in withdrawal medium for two days. The amount of the 89 kDa PARP fragment 
increased 2, 4, 6 and 24 hours after the addition of staurosporine (Figure 4.1). Treatment with 
IGF-1 reduced significantly the amount of cleaved PARP in all time points tested. In NUGC3 
cells, no cell death was detected after culture in withdrawal medium. Cell death was induced 
progressively after the addition of staurosporine for 2, 4, 6 and 24 hours. IGF-1 reduced the 
amount of cleaved PARP induced by staurosporine to 70% of the amount detected in the 





Figure 4.1. The effect of IGF-1 on staurosporine-induced apoptosis in SNU-1 cells. SNU-1 cells were 
centrifuged and resuspended in withdrawal medium and seeded into a 175 cm
2 
flask at a concentration of 4.5x10
6 
cells per flask. After 24 hours, medium was replaced with 24 ml fresh withdrawal medium for another 24 hours. 
Cells were centrifuged and resuspended in withdrawal medium supplemented or not with 50 ng/ml IGF-1 for 15 
minutes. Cells were then incubated with 0.5 µM staurosporine in the presence and absence of IGF-1 for different 
lengths of time. At the end of each time point, cells were collected in 15 ml Falcon tubes and lysed in 50 µl 
RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% 
polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with 
antibodies against cleaved PARP (1:2000 dilution) and GAPDH (1:10000 dilution). The images shown are 
representative of samples from triplicate experiments which have been repeated at least twice (A). Densitometry 
was with Labworks 4.0 software, adjusted for the background optical density of the X-ray film and normalised to 
GAPDH. Results are expressed as a percentage of the intensity of the cleaved PARP band observed in the 
absence of IGF-1. Bars represent the standard error of the mean (SEM). Asterisks show cleaved PARP levels 






Figure 4.2. The effect of IGF-1 on staurosporine-induced apoptosis in NUGC3 cells. NUGC3 cells were 
seeded into 12 well tissue culture plates at 15 x 10
4 
cells per well, in 1 ml maintenance medium. Cells were 
incubated for 24 hours to allow attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. 
Medium was replaced daily with 1 ml withdrawal medium for two days. Cells were incubated with withdrawal 
medium supplemented or not with 50 ng/ml IGF-1 for 15 minutes. Cells were then incubated with 0.5 µM 
staurosporine in the presence and absence of 50 ng/ml IGF-1 for different lengths of time. At the end of each 
time point, proteins were extracted with 80 µl of RIPA buffer plus inhibitors. Aliquots containing 10 µg of 
protein were electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA 
for 45 minutes. Membranes were incubated with antibodies against cleaved PARP (1:2000 dilution) and GAPDH 
(1:10000 dilution). The images shown are representative of samples from triplicate experiments which have been 
repeated at least twice (A). Densitometry was with Labworks 4.0 software, adjusted for the background optical 
density of the X-ray film and normalised to GAPDH. Results are expressed as a percentage of the intensity of the 
cleaved PARP band observed in the absence of IGF-1. Bars represent the standard error of the mean (SEM). 
Asterisks show cleaved PARP levels that are statistically significantly lower in the presence of IGF-1 than in its 
absence (Two-way ANOVA; p<0.0001) (B). 
 
A protective effect of IGF-1 against apoptosis was also observed in AGS and NCI-N87 cells, 
after treatment with staurosporine for 2 and 5 hours, respectively. IGF-1 reduced the amount 
of the 89 kDa fragment of PARP to 30% in AGS cells and to 20% in NCI-N87 cells (Figure 
4.3). No protective effect of IGF-1 against apoptosis was detected in KATO III cells after 
treatment with staurosporine at all the time points tested (Figure 4.4). A higher concentration 
of staurosporine (1µM) was required in order to induce cleavage of PARP in MKN74 cells. 
However, no protection was achieved in the presence of IGF-1 (Figure 4.4). The amount of 
cleaved PARP detected in SNU-16 and SNU-5 cells was relatively high, even in the absence 
65 
 
of staurosporine (Figure 4.4). Addition of staurosporine increased slightly the amount of 
cleaved PARP in SNU-16 cells but did not affect the amount of cleaved PARP in SNU-5 
cells. Neither cell line was protected by IGF-1 at the time points tested.  
 
Figure 4.3. The effect of IGF-1 on staurosporine-induced apoptosis in AGS and NCI-N87 cells. AGS and 
NCI-N87 cells were seeded into 12 well tissue culture plates at 15 x 10
4 
cells per well, in 1 ml maintenance 
medium. Cells were incubated for 24 hours to allow attachment. Medium was aspirated and the cells washed 
with 0.5 ml PBS. Medium was replaced daily with 1 ml withdrawal medium for two days. Cells were incubated 
with withdrawal medium supplemented or not with 50 ng/ml IGF-1 for 15 minutes. Cells were then incubated 
with 0.5 µM staurosporine in the presence and absence of 50 ng/ml IGF-1 for different lengths of time. After two 
hours, proteins were extracted with 80 µl of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein 
were electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 
minutes. Membranes were incubated with antibodies against cleaved PARP (1:2000 dilution) and GAPDH 
(1:10000 dilution). The images shown are representative of samples from triplicate experiments which have been 
repeated at least twice (A). Densitometry was with Labworks 4.0 software, adjusted for the background optical 
density of the X-ray film and normalised to GAPDH. Results are expressed as a percentage of the intensity of the 
cleaved PARP band observed in the absence of IGF-1. Bars represent the standard error of the mean (SEM). 
Asterisks show cleaved PARP levels that are statistically significantly lower in the presence of IGF-1 than in its 





Figure 4.4. The effect of IGF-1 on staurosporine-induced apoptosis in KATO III, SNU-16, SNU-5 and 
MKN74 cells. SNU-16 and SNU-5 cells were centrifuged and resuspended in withdrawal medium and seeded 
into a 175 cm
2 
flask at a concentration of 4.5x10
6 
cells per flask. After 24 hours, medium was replaced with 24 
ml fresh withdrawal medium for another 24 hours. Cells were centrifuged and resuspended in withdrawal 
medium supplemented or not with different concentrations of IGF-1 for 15 minutes. Cells were then incubated 
with 0.5 µM staurosporine in the presence and absence of different concentrations of IGF-1 for 5 hours. Cells 
were collected in 15 ml Falcon tubes and lysed in 50 µl RIPA buffer plus inhibitors. KATO-III and MKN74 cells 
were seeded into 12 well tissue culture plates at 15x10
4 
cells per well, in 1 ml maintenance medium. Cells were 
incubated for 24 hours to allow attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. 
Medium was replaced daily with 1 ml withdrawal medium for two days. Cells were incubated with withdrawal 
medium supplemented or not with 50 ng/ml IGF-1 for 15 minutes. Cells were then incubated with 0.5 and 1 µM 
staurosporine, respectively, in the presence and absence of 50 ng/ml IGF-1 for 5 hours. Proteins were extracted 
with 80 µl of RIPA buffer plus inhibitors per well. Aliquots containing 10 µg of protein were electrophoresed on 
denaturing 12 % polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes 
were incubated with antibodies against cleaved PARP (1:2000 dilution) and GAPDH (1:10000 dilution).  
 
4.2.1.2 The effect of IGF-1 on caspase-dependent apoptosis in gastric cancer cells   
To confirm that staurosporine activates caspase-dependent apoptosis and that IGF-1 is able to 
inhibit this activation, SNU-1 and NUGC3 cells were cultured in withdrawal medium and 
treated with STS in the presence or absence of 50 ng/ml IGF-1. The cells were then incubated 
with a fluorescent antibody that detects the activated cleaved form of caspase 3.  
No cleavage of caspase 3 and PARP was detected in SNU-1 cells after culture in withdrawal 
medium for two days (Figure 4.5). Cleavage of caspase 3 was induced after 5 hours of 
treatment with staurosporine in 45% cells. When the cells were treated with staurosporine and 
IGF-1 combined, the above percentage was reduced to 15.6%. Treatment with staurosporine 
for 24 hours also resulted in detectable PARP cleavage in 52% cells. In cells that had been 
treated both with IGF-1 and staurosporine the above percentage was reduced to 25.3%. 
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Similarly, in NUGC3 cells there was no detectable cleavage of caspase 3 or PARP after 
culture in withdrawal medium for two days (Figure 4.5). Treatment with staurosporine for 24 
hours resulted in cleavage of caspase 3 in 47.7% cells, whereas concomitant treatment with 
IGF-1 resulted in reduction of the number of cleaved caspase 3 positive cells to 27.1%. 
Cleavage of PARP was induced in 39.7% NUGC3 cells that had been treated with 
staurosporine for 24 hours, whereas IGF-1 reduced this percentage to 12.9%. These results 
indicate that IGF-1 can inhibit caspase-dependent cell death induced by staurosporine.  
 
Figure 4.5. The effect of IGF-1 on caspase-dependent apoptosis induced by staurosporine in SNU-1 and 
NUGC3 cells. SNU-1 cells were centrifuged and resuspended in withdrawal medium and seeded into a 75 cm
2 
flask at a concentration of 1.5x10
6 
cells per flask. After 24 hours, medium was replaced with 12 ml fresh 
withdrawal medium for another 24 hours. Cells were centrifuged and resuspended in withdrawal medium 
supplemented or not with 50 ng/ml IGF-1 for 15 minutes. Cells were then incubated with 0.5 µM staurosporine 
in the presence and absence of 50 ng/ml IGF-1 for 4 hours. Cells were collected in 1.5 ml Eppendorf tubes and 
fixed in 1 ml 4% paraformaldehyde. NUGC3 cells were seeded on top of coverslips in 6 well tissue culture 
plates at 30 x 10
4 
cells per well, in 2.5 ml maintenance medium. Cells were incubated for 24 hours to allow 
attachment. Medium was aspirated and the cells washed with 2 ml PBS. Medium was replaced daily with 2 ml 
withdrawal medium for two days. Cells were incubated in withdrawal medium supplemented or not with 50 
ng/ml IGF-1 for 15 minutes. Cells were then incubated with 0.5 µM staurosporine in the presence and absence of 
50 ng/ml IGF-1 for 24 hours. Cells were washed with 2 ml PBS and fixed in 2 ml ice-cold methano . Fixed cells 
were incubated with fluorescent antibodies against cleaved caspase 3 (1:50 dilution) and cleaved PARP (1:150 
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dilution). All secondary antibodies were Alexa-Fluor conjugated. Cells were mounted on top of slides in 20 µl 
DAPI X mounting medium. Pictures of the cells were taken in a Leica fluorescent microscope (A). 
Quantification of the number of cells with positive staining was done in five fields of view for each treatment. 
The results are shown as a percentage of the total number of cells. Bars, SEM. Asterisks show the number of 
apoptotic cells that is significantly smaller in the presence of IGF-1 than in its absence. (One-way ANOVA; 
SNU-1, cleaved caspase 3, p<0.0001; cleaved PARP, p=0.0002; NUGC3, cleaved caspase 3, p<0.0001; cleaved 
PARP, p<0.0001) (B). 
 
4.2.1.3 The effect of different concentrations of IGF-1 on staurosporine-induced apoptosis 
As mentioned previously, PARP cleavage induced by staurosporine is inhibited significantly 
after treatment with 50 ng/ml IGF-1 in SNU-1 and NUGC3 cells. To investigate the effect of 
different concentrations of IGF-1 on cell survival, SNU-1 and NUGC3 cells were withdrawn 
from the effects of growth factors and treated with staurosporine in the presence of IGF-1 
concentrations ranging from 2 to 200 ng/ml. 
Treatment with staurosporine resulted in the appearance of cleaved PARP in SNU-1 cells 
(Figure 4.6). The amount of cleaved PARP was reduced by IGF-1 in a concentration 
dependent manner. Best protection against cell death was achieved with 200 ng/ml IGF-1, 
which suggests that the receptor mediating the IGF-1 survival effect was not saturated even at 
relatively high IGF-1 concentrations. In NUGC3 cells, treatment with staurosporine also 
resulted in cleavage of PARP into its 89 kDa fragment (Figure 4.6). IGF-1 reduced the 
amount of cleaved PARP in a concentration dependent manner with maximum protection 
achieved with 50 and 200 ng/ml IGF-1. Treatment with 200 ng/ml IGF-1 did not reduce 
further the amount of cleaved PARP, suggesting that the receptor which mediates the IGF-1 
survival effect was saturated. 
 
Figure 4.6. The protective effect of different concentrations of IGF-1 against staurosporine-induced 
apoptosis in SNU-1 and NUGC3 cells. SNU-1 cells were centrifuged and resuspended in withdrawal medium 
and seeded into a 75 cm
2 
flask at a concentration of 0.9 x 10
6 
cells per flask. After 24 hours, medium was 
replaced with 12 ml fresh withdrawal medium for another 24 hours. Cells were centrifuged and resuspended in 
withdrawal medium supplemented or not with different concentrations of IGF-1 for 15 minutes. Cells were then 
incubated with 0.5 µM staurosporine in the presence and absence of IGF-1 for 4 hours. Cells were collected in 
15 ml Falcon tubes and lysed in 50 µl RIPA buffer plus inhibitors. NUGC3 cells were seeded into 12 well tissue 
culture plates at 15x10
4 
cells per well, in 1 ml maintenance medium. Cells were incubated for 24 hours to allow 
attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. Medium was replaced daily with 1 ml 
withdrawal medium for two days. Cells were incubated with withdrawal medium supplemented or not with 
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different concentrations of IGF-1 for 15 minutes. Cells were then incubated with 0.5 µM staurosporine in the 
presence and absence of IGF-1 for 5 hours. Proteins were extracted with 80 µl of RIPA buffer plus inhibitors per 
well. Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% polyacrylamide gels and 
transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with antibodies against 
cleaved PARP (1:2000 dilution) and GAPDH (1:10000 dilution).  
 
4.2.2 The effect of IGF-1 on cell death induced by anoikis 
Frisch and Francis (1994) described anoikis as apoptosis induced by disruption of the 
interactions between normal epithelial cells and extracellular matrix. Disruption of the 
interactions may be achieved in vitro by culture of cells in plates coated with 
polyhydroxyethylmethacrylate (poly-HEMA). It has been suggested that circumvention of 
anoikis accompanies the acquisition of anchorage independence and cell motility (Frisch and 
Francis, 1994).  
 
4.2.2.1 The effect of culture on poly-hema coated plates on cell attachment 
Tissue culture plates were coated with poly-HEMA, as described in the Materials and 
Methods section. NUGC3 and AGS cells were seeded into poly-HEMA coated plates and 
cultured in serum-free medium for 24 hours. Photomicrographs of cells cultured in serum-free 
medium in poly-HEMA coated plates are shown in Figure 4.7. In comparison, cells that are 
cultured in medium supplemented with growth factors in attached conditions are shown. 
Inhibition of cell attachment by poly-HEMA resulted in the acquisition of a round shape in 




Figure 4.7. Morphological appearance of NUGC3 and AGS cells cultured in poly-HEMA coated plates. 
NUGC3 and AGS cells were seeded either into normal 12 well plates or into poly-HEMA coated 12 well plates 
at 20x10
4 
cells per well in 1 ml serum-free medium. After incubation for 4 hours, pictures were taken under the 
microscope. 
 
4.2.2.2 The effect of IGF-1 on anoikis in gastric cancer cells 
To test the hypothesis that IGF-1 is important for resistance to anoikis, NUGC3 and AGS 
cells were cultured in non-attached conditions in the presence or in the absence of IGF-1. No 
cleaved PARP was detected in NUGC3 cells before culture in poly-HEMA coated plates. 
Cleaved PARP was induced after 4 hours and progressively increased 8 and 24 hours after 
culture in non-attached conditions. IGF-1 reduced effectively the amount of cleaved PARP 
induced by anoikis approximately four fold (Figure 4.8). The amount of cleaved PARP 





Figure 4.8. The effect of IGF-1 on PARP cleavage in non-attached conditions in NUGC3 cells. NUGC3 
cells were withdrawn from the effects of growth factors by culture in withdrawal medium for 2 days. Cells were 
seeded into poly-HEMA coated 12 well plates at 20x10
4 
cells per well in 1 ml serum-free medium, in the 
presence or not of 50 ng/ml IGF-1. After incubation for various times, proteins were extracted with 50 µl per 
well of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein were electrophoresed on denaturing 
12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated 
with antibodies against cleaved PARP (1:2000 dilution) and GAPDH (1:10000 dilution). The images shown are 
representative of samples from triplicate experiments which have been repeated at least twice (A). Densitometry 
was with Labworks 4.0 software, adjusted for the background optical density of the X-ray film and normalised to 
GAPDH. Results are expressed as a percentage of the intensity of the cleaved PARP band observed in the 
absence of IGF-1. Bars are the mean ±SEM, * denotes statistically significantly less cleaved PARP in the 
presence of IGF-1 compared with in the absence of IGF-1 (Two-way ANOVA; p<0.0001) (B). 
 
A significant effect of IGF-1 was observed also in AGS cells (Figure 4.9). Induction of 
cleaved PARP was detected 2 hours after culture in poly-HEMA and increased after 24 hours. 
In cells that had been treated with IGF-1 the amount of cleaved PARP remained unchanged 
from 2 to 24 hours to approximately 20% of the amount detected in cells that had not been 
treated with IGF-1. In KATO III cells, PARP cleavage was increased after culture in non-





Figure 4.9. The effect of IGF-1 on PARP cleavage in non-attached conditions in AGS cells. AGS cells were 
withdrawn from the effects of growth factors by culture in withdrawal medium for 2 days. Cells were seeded into 
poly-HEMA coated 12 well plates at 20x10
4 
cells per well in 1 ml serum-free medium, in the presence or not of 
50 ng/ml IGF-1. After incubation for various times, proteins were extracted with 50 µl per well of RIPA buffer 
plus inhibitors. Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% polyacrylamide 
gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with antibodies 
against cleaved PARP (1:2000 dilution) and GAPDH (1:10000 dilution). The images shown are representative of 
samples from triplicate experiments which have been repeated at least twice (A). Densitometry was with 
Labworks 4.0 software, adjusted for the background optical density of the X-ray film and normalised to 
GAPDH. Results are expressed as a percentage of the intensity of the cleaved PARP band observed in the 
absence of IGF-1. Bars are the mean ±SEM, * denotes statistically significantly less cleaved PARP in the 
presence of IGF-1 compared with in the absence of IGF-1 (Two-way ANOVA, p<0.0001) (B). 
 
Figure 4.10. The effect of IGF-1 on PARP cleavage in non-attached conditions in KATO III cells. KATO 
III cells were withdrawn from the effects of growth factors by culture in withdrawal medium for 2 days. Cells 
were seeded into poly-HEMA coated 12 well plates at 20x10
4 
cells per well in 1 ml serum-free medium, in the 
presence or not of 50 ng/ml IGF-1. After incubation for various times, proteins were extracted with 50 µl per 
well of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein were electrophoresed on denaturing 
12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated 
with antibodies against cleaved PARP (1:2000 dilution) and GAPDH (1:10000 dilution).  
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Cell lines that grow in suspension, e.g. SNU-1, SNU-5 and SNU-16 are inherently resistant to 
anoikis. No PARP cleavage was detected in MKN74 cells cultured in non-attached conditions 
(data not shown).  
To investigate whether cell death induced by anoikis is caspase-dependent and whether IGF-1 
can inhibit caspase activation, NUGC3 cells were cultured in the presence or absence of 
different concentrations of IGF-1 for 24 hours and the extent of caspase and PARP cleavage 
was analysed by western transfer. Cleaved caspase 3 was detected by western transfer 
analysis in cells that had been cultured in non-attached conditions in the absence of IGF-1. 
The amount of cleaved caspase 3 was reduced with IGF-1 in a concentration dependent 
manner. A similar effect was detected for cleaved PARP (Figure 4.11).   
 
Figure 4.11. The protective effect of different concentrations of IGF-1 against caspase-dependent cell 
death induced by anoikis in NUGC3 cells. NUGC3 cells were withdrawn from the effects of growth factors by 
culture in withdrawal medium for 2 days. Cells were seeded into poly-HEMA coated 12 well plates at 20x10
4 
cells per well in 1 ml serum-free medium, in the presence or not of different concentrations of IGF-1. After 
incubation for various times, proteins were extracted with 50 µl per well of RIPA buffer plus inhibitors. Aliquots 
containing 10 µg of protein were electrophoresed on denaturing 12% polyacrylamide gels and transferred to 
nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with antibodies against cleaved caspase 3 
(1:1000 dilution), cleaved PARP (1:2000 dilution) and GAPDH (1:10000 dilution).  
 
4.2.3 The effect of inhibiting IGF-IR/IR with BMS754807 on the IGF-1 survival effect in 
controlled conditions 
The ability of the small molecule tyrosine kinase inhibitor BMS754807 to inhibit the survival 
effect of IGF-1, was investigated in SNU-1 and NUGC3 cells. As mentioned previously, 
BMS754807 prevents ATP interaction with the tyrosine kinase domain of the type I IGF 
receptor, resulting in reduced receptor phosphorylation. Due to the high homology of the 
tyrosine kinase domain of the type I IGF receptor and the insulin receptor, BMS754807 
inhibits both receptors. 
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SNU-1 cells were withdrawn from the effects of growth factors by culture in withdrawal 
medium for two days and treated with staurosporine in the presence or absence of IGF-1 and 
in the presence or absence of BMS754807. The concentration of BMS754807 used abolishes 
completely phosphorylation of the type I IGF and insulin receptors and of Akt (Figure 3.7). 
Cleaved PARP was detected after treatment of SNU-1 cells with staurosporine for 4 hours. 
Treatment with IGF-1 reduced significantly the amount of cleaved PARP, as previously. 
Treatment of SNU-1 cells with BMS754807 did not induce additional cell death compared to 
untreated cells. In cells that were treated with the BMS754807 inhibitor, the survival effect of 
IGF-1 was abrogated (Figure 4.12).   
The ability of BMS754807 to inhibit the IGF-1 survival effect was investigated in NUGC3 
cells in the context of anoikis. NUGC3 cells were cultured in withdrawal medium for 2 days 
in order to withdraw them from the effect of growth factors. The cells were seeded into poly-
HEMA coated plates in the presence or absence of BMS754807 and in the presence or 
absence of IGF-1. The cells were cultured in non-attached conditions for 24 hours before 
protein lysis. Culture in poly-HEMA coated plates induced anoikis and resulted in PARP 
cleavage. IGF-1 protected NUGC3 cells significantly from the effects of anoikis, as 
previously (Figure 4.12). Treatment with BMS754807 for 24 hours increased the amount of 
cleaved PARP in NUGC3 cells. Treatment with the BMS754807 inhibitor obliterated the 
survival effect of IGF-1 against anoikis.  
The above results suggest that treatment with BMS754807, which inhibits both the type I IGF 
receptor and the insulin receptor, abolishes the survival effect of IGF-1, both in the context of 
apoptosis and anoikis. This further suggests that either or both the type I IGF and insulin 




Figure 4.12. The effect of inhibition of IGF-IR/IR with BMS754807 on the survival effect of IGF-1 in 
SNU-1 and NUGC3 cells. SNU-1 cells were centrifuged and resuspended in withdrawal medium and seeded 
into a 75 cm
2 
flask at a concentration of 1.8x10
6 
cells per flask. After 24 hours, medium was replaced with 12 ml 
fresh withdrawal medium for another 24 hours. Cells were centrifuged and resuspended in withdrawal medium 
containing DMSO or 500 nM BMS754807 for 30 minutes. Cells were centrifuged and medium was changed to 
include 50 ng/ml IGF-1 for 15 minutes. Medium was then changed to include 0.5 µM staurosporine for 4 hours. 
Cells were collected in a 15 ml Flacon tube and proteins were lysed with 50 µl RIPA buffer plus inhibitors. 
NUGC3 cells were detached from tissue culture flasks and resuspended in serum free medium at a concentration 
of 200000 cells/ml. Six ml of the cell suspension were incubated in DMSO or 500 nM BMS754807 for 30 
minutes. The cells were then seeded into poly-HEMA coated 12 well plates at 20x10
4 
cells per well in 1 ml 
serum-free medium, in the presence or not of 50 ng/ml IGF-1. After incubation for 24 hours, proteins were 
extracted with 50 µl per well of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein were 
electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 
minutes. Membranes were incubated with antibodies against cleaved PARP (1:2000 dilution) and GAPDH 
(1:10000 dilution) (A). Densitometry was with Labworks 4.0 software, adjusted for the background optical 
density of the X-ray film and normalised to GAPDH. The images shown are representative of samples from 
triplicate experiments which have been repeated at least twice. Bars are the mean ±SEM, * denotes statistically 
significantly less cleaved PARP in the presence of IGF-1 compared with in the absence of IGF-1 (One-way 




4.2.4 The importance of the PI3K/Akt and RAS/RAF/ERK signal transduction pathways in 
the IGF-1 survival effect 
The PI3K/Akt pathway is important for transmission of the effects of external growth factor 
stimuli through tyrosine kinase receptors. The PI3K family consists of a number of lipid and 
serine/threonine kinases, which, upon activation, phosphorylate phosphatidylinositol-4,5-
bisphosphate PtdIns(4,5)P2 to produce PtdIns(3,4,5)P3, a second messenger that binds and 
recruits a subset of pleckstrin-homology (PH), FYVE, Phox (PX), C1, C2 and other lipid-
binding domains in downstream targets. Akt is the primary downstream mediator of the 
effects of PI3K. Akt signalling inhibits several pro-apoptotic factors such as BAD, 
procaspase-9 and Forkhead (FKHR) transcription factors (Hennessy et al., 2005). 
The Ras/Raf/ERK pathway is activated preferentially by mitogenic factors, differentiation 
stimuli and cytokines. Ligand binding to the respective cell surface receptor induces the 
activation of the small GTPase Ras, which recruits the MAP kinase kinase kinase Raf to the 
membrane. Activated Raf phosphorylates and activates the MAP kinase kinases MEK1 and 
MEK2, which in turn activate the effector MAP kinases ERK1 and ERK2. ERK1 and ERK2 
are multifunctional serine/threonine kinases that phosphorylate a vast array of substrates, such 
as protein kinases, signalling effectors, receptors, cytoskeletal proteins and nuclear 
transcriptional regulators (Meloche and Pouyssegur, 2007).  
 
4.2.4.1 The effect of IGF-1 on activation of the PI3K/Akt and RAS/RAF/ERK signal 
transduction pathways in the context of apoptosis and anoikis 
Activation of downstream signal transduction pathways in response to IGF-1 was investigated 
both in the apoptosis and in the anoikis assay. SNU-1 and NUGC3 cells were withdrawn from 
the effects of growth factors by culture in withdrawal medium for 2 days. The cells were then 
treated with staurosporine in the presence or absence of different concentrations of IGF-1.  
No activated Akt was detected in SNU-1 cells treated with staurosporine, in the absence of 
IGF-1 (Figure 4.13). Treatment with increasing concentrations of IGF-1 resulted in a 
concentration dependent increase in Akt phosphorylation, whereas total Akt levels were 
slightly reduced in a concentration dependent manner. ERK2 phosphorylation was detected in 
SNU-1 cells treated with staurosporine and addition of IGF-1 did not increase those levels. 
Total ERK1 and ERK2 levels also remained unchanged.  
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Similar results were obtained with NUGC3 cells. Low levels of Akt phosphorylation were 
detected in the absence of IGF-1. In response to IGF-1, Akt phosphorylation was increased in 
a concentration dependent manner, while total Akt levels decreased in a concentration 
dependent manner. ERK1 and ERK2 activation was detected in the absence of IGF-1 and did 
not increase with any concentration of IGF-1. Total ERK1 and ERK2 levels were not affected 
by different concentrations of IGF-1.  
 
Figure 4.13. The effect of IGF-1 stimulation on activation of the PI3K/Akt and RAS/RAF/ERK signal 
transduction pathways in apoptosis. SNU-1 cells were centrifuged and resuspended in withdrawal medium 
and seeded into a 175 cm
2 
flask at a concentration of 4.5x10
6 
cells per flask. After 24 hours, medium was 
replaced with 24 ml fresh withdrawal medium for another 24 hours. Cells were centrifuged and resuspended in 
withdrawal medium supplemented or not with different concentrations of IGF-1 for 15 minutes. Cells were then 
incubated with 0.5 µM staurosporine in the presence and absence of different concentrations of IGF-1 for 4 
hours. Cells were collected in 15 ml Falcon tubes and lysed in 50 µl RIPA buffer plus inhibitors. NUGC3 cells 
were seeded into 12 well tissue culture plates at 15 x 10
4 
cells per well, in 1 ml maintenance medium. Cells were 
incubated for 24 hours to allow attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. 
Medium was replaced daily with 1 ml withdrawal medium for two days. Cells were incubated with withdrawal 
medium supplemented or not with 50 ng/ml IGF-1 for 15 minutes. Cells were then incubated with 0.5 µM 
staurosporine in the presence and absence of different concentrations of IGF-1 for 4 hours. Proteins were 
extracted with 80 µl of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein were electrophoresed 
on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes 
were incubated with antibodies against phosphorylated Akt (1:3000 dilution), total Akt (1:3000 dilution), 
phosphorylated ERK1/ERK2 (1:5000 dilution), total ERK1/ERK2 (1:5000 dilution) and GAPDH (1:10000 
dilution). Densitometry was with Labworks 4.0 software, adjusted for the background optical density of the X-
ray film and normalised to GAPDH. The images shown are representative of samples from triplicate experiments 
which have been repeated at least twice. Images obtained after incubation with antibodies against the total 
proteins are shown beneath those of the phosphorylated proteins.   
 
In the context of anoikis, there was no activated Akt in NUGC3 cells, when cultured in poly-
HEMA coated plates in the absence of IGF-1 (Figure 4.14). Akt phosphorylation was induced 
by IGF-1 and increased in a concentration dependent manner. Total Akt levels decreased 
inversely proportional to phosphorylated levels. Activated ERK1 and ERK2 were detected in 
the context of anoikis even in the absence of IGF-1, and a very small induction was seen 
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when the cells were treated with 5 ng/ml and higher IGF-1 concentrations. Total ERK1 and 
ERK2 levels were not altered.  
 
Figure 4.14. The effect of IGF-1 stimulation on activation of the PI3K/Akt and MAPK signal transduction 
pathways in anoikis. NUGC3 cells were withdrawn from the effects of growth factors by culture in withdrawal 
medium for 2 days. Cells were seeded into poly-HEMA coated 12 well plates at 20x10
4 
cells per well in 1 ml 
serum-free medium, in the presence or not of 50 ng/ml IGF-1. After incubation for various times, proteins were 
extracted with 50 µl per well of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein were 
electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 
minutes. Membranes were incubated with antibodies against phosphorylated Akt (1:2000 dilution), Akt (1:2000 
dilution), phospho-ERK1/2 (1:5000 dilution), ERK1/2 (1:5000 dilution) and GAPDH (1:10000 dilution).  
 
To quantify the amount of Akt phosphorylation in response to IGF-1 in the context of 
apoptosis, SNU-1 and NUGC3 cells were withdrawn from the effects of growth factors and 
cultured in the presence or absence of staurosporine and IGF-1, before incubation with an 
antibody against phosphorylated Akt and a fluorescently-labelled secondary antibody. Akt 
was not phosphorylated in SNU-1 and NUGC3 cells cultured in withdrawal medium for two 
days, or in cells treated with staurosporine (Figure 4.15). However, IGF-1 caused a 
remarkable induction of Akt phosphorylation in both cell lines. Approximately 80% of SNU-
1 cells and 55% of NUGC3 cells treated with IGF-1 in the presence of staurosporine were 
positive for Akt phosphorylation. Phosphorylated Akt was primarily localised in the 
cytoplasm, surrounding the nuclei. 
The above results suggest that the PI3K/Akt pathway might be more involved in the IGF-1 




Figure 4.15. The effect of IGF-1 stimulation on activation of the PI3K/Akt signal transduction pathway in 
apoptosis. SNU-1 cells were centrifuged and resuspended in withdrawal medium and seeded into a 75 cm
2 
flask 
at a concentration of 1.5x10
6 
cells per flask. After 24 hours, medium was replaced with 12 ml fresh withdrawal 
medium for another 24 hours. Cells were centrifuged and resuspended in withdrawal medium supplemented or 
not with 50 ng/ml IGF-1 for 15 minutes. Cells were then incubated with 0.5 µM staurosporine in the presence 
and absence of 50 ng/ml IGF-1 for 4 hours. Cells were collected in 1.5 ml Eppendorf tubes and fixed in 1 ml 4% 
paraformaldehyde. NUGC3 cells were seeded on top of coverslips in 6 well tissue culture plates at 30 x 10
4 
cells 
per well, in 2.5 ml maintenance medium. Cells were incubated for 24 hours to allow attachment. Medium was 
aspirated and the cells washed with 2 ml PBS. Medium was replaced daily with 2 ml withdrawal medium for two 
days. Cells were incubated with withdrawal medium supplemented or not with 50 ng/ml IGF-1 for 15 minutes. 
Cells were then incubated with 0.5 µM staurosporine in the presence and absence of 50 ng/ml IGF-1 for 24 
hours. Cells were washed with 2 ml PBS and fixed in 2 ml ice-cold methanol. Fixed cells were incubated with an 
antibody against phosphorylated Akt. The secondary antibody was Alexa-Fluor conjugated. Cells were mounted 
on top of slides in 20 µl DAPI X mounting medium. Pictures of the cells were taken in a Leica fluorescent 
microscope (A). Quantification of the number of cells with positive staining was done in five fields of view for 
each treatment. The results are shown as a percentage of the total number of cells. Bars, SEM. Asterisks show 
the significant increase in the number of cells with phosphorylated Akt after treatment with IGF-1. (One-way 
ANOVA; SNU-1, p<0.0001; NUGC3, p<0.0001) (B). 
 
4.2.4.2 The effect of inhibiting the PI3K/Akt signal transduction pathway on the survival 
effect of IGF-1 
2-(4-morpholinyl)-8-phenyl-4H-l-benzopyran-4-one, also known as 2-(4-morpholinyl)-8-
phenylchromone, LY294002, is a compound that abolishes selectively PI3K activity, by 
acting as a competitive inhibitor for its ATP binding site (Vlahos et al., 1994). The 
importance of the PI3K/Akt pathway in mediation of the IGF-1 anti-apoptotic effect was 
investigated using LY294002. SNU-1 cells were withdrawn from the effects of growth factors 
for 2 days and then cultured with 0.5 µM staurosporine and in the presence or absence of 60 
µM LY294002 and 50 ng/ml IGF-1.     
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Akt is the primary downstream target of PI3K, therefore, PI3K inhibition is expected to 
reduce Akt activation. Akt was not phosphorylated in the absence of IGF-1 and LY294002 in 
SNU-1 cells (Figure 4.16). IGF-1 induced significantly Akt phosphorylation. No Akt 
phosphorylation was detected in SNU-1 cells treated with LY294002 when IGF-1 was not 
present. When IGF-1 was present, LY294002 reduced the amount of Akt phosphorylation to 
5% of the amount detected when the drug was not present. This suggests that LY294002 
inhibits effectively the activity of the PI3K/Akt pathway. 
SNU-1 cells which had been withdrawn and treated with staurosporine underwent apoptosis, 
evaluated by detection of the 89 kDa fragment of PARP (Figure 4.16). IGF-1 reduced 
significantly the amount of cleaved PARP. Inhibition of PI3K/Akt by LY294002 increased 
slightly the amount of cleaved PARP in the absence of IGF-1, confirming that inhibition of 
the pathway affects the survival of the cells. IGF-1 was ineffective at inhibiting staurosporine-
induced PARP cleavage when LY294002 was present. This result suggests that activation of 
PI3K/Akt is important for mediating the IGF-1 survival effect. 
 
Figure 4.16. The effect of PI3K inhibition with LY294002 on the anti-apoptotic effect of IGF-1 in SNU-1 
cells. SNU-1 cells were centrifuged and resuspended in withdrawal medium and seeded into a 75 cm
2 
flask at a 
concentration of 1.8x10
6 
cells per flask. After 24 hours, medium was replaced with 24 ml fresh withdrawal 
medium for another 24 hours. Cells were centrifuged and resuspended in withdrawal medium supplemented or 
not with 60 µM LY294002 for one hour and with or without 50 ng/ml IGF-1 for 15 minutes. Cells were then 
incubated with 0.5 µM staurosporine in the presence and absence of LY294002 and IGF-1 for 4 hours. Proteins 
were extracted with 80 µl of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein were 
electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 
minutes. Membranes were incubated with antibodies against phospho-Akt (1:3000), Akt (1:3000), cleaved PARP 
(1:2000 dilution) and GAPDH (1:10000 dilution). The images shown are representative of samples from 
triplicate experiments (A). Densitometry was with Labworks 4.0 software, adjusted for the background optical 
density of the X-ray film and normalised to GAPDH. Results are expressed as a percentage of the intensity of the 
cleaved PARP band observed in the absence of IGF-1 and in the presence of LY294002. Bars are the mean 
±SEM, *denotes phosphorylated Akt levels that are statistically significantly lower in the presence of LY294002 
(Two-way ANOVA; p<0.0001) and cleaved PARP levels that are statistically significantly lower in the presence 
of IGF-1 than in its absence (Two-way ANOVA; p=0.0001) (B).  
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4.2.4.3 The effect of inhibiting the Ras/Raf/ERK signal transduction pathway on the 
survival effect of IGF-1 
U0126 is a compound that inhibits selectively the mitogen-activated protein kinase kinase 
family members, MEK-1 and MEK-2 (Favata et al., 1998). The importance of the 
Ras/Raf/MAPK pathway in the survival effect of IGF-1 was investigated in SNU-1 cells. 
SNU-1 cells were withdrawn from the effects of growth factors for 2 days and then cultured 
in the presence of 0.5 µM staurosporine and in the presence or absence of 6 µM U0126 and 
50 ng/ml IGF-1.    
ERK1 and ERK2 are downstream targets of MEK-1 and MEK-2. Inhibition of MEK-1 and 
MEK-2 with the U0126 inhibitor is, therefore, expected to reduce activation of ERK1 and 
ERK2. There was ERK1 and ERK2 phosphorylation in the absence of IGF-1 and U0126 
(Figure 4.17). Addition of IGF-1 did not increase the basal levels of ERK1 and ERK2 
phosphorylation. U0126 inhibited completely ERK1 and ERK2 phosphorylation, both in the 
absence and in the presence of IGF-1.  
SNU-1 cells were treated with staurosporine and underwent apoptosis, assessed by detection 
of the 89 kDa fragment of PARP (Figure 4.17). IGF-1 reduced significantly the amount of 
cleaved PARP from 100% to less than 20%. Inhibition of MEK1 and MEK2 by U0126 did 
not increase the amount of cleaved PARP in the absence of IGF-1, suggesting that inhibition 
of the pathway does not affect cell survival, under these conditions. IGF-1 retained its ability 
to inhibit staurosporine-induced PARP cleavage with the same effectiveness as when U0126 
was not present. This suggests that an active Ras/Raf/ERK pathway is not essential for 





Figure 4.17. The effect of MEK inhibition with U0126 on the anti-apoptotic effect of IGF-1 in SNU-1 cells.  
SNU-1 cells were centrifuged and resuspended in withdrawal medium and seeded into a 75 cm
2 
flask at a 
concentration of 1.8x10
6 
cells per flask. After 24 hours, medium was replaced with 24 ml fresh withdrawal 
medium for another 24 hours. Cells were centrifuged and resuspended in withdrawal medium supplemented or 
not with 6 µM U0126 for one hour and with or without 50 ng/ml IGF-1 for 15 minutes. Cells were then 
incubated with 0.5 µM staurosporine in the presence and absence of UO06 and IGF-1 for 4 hours. Proteins were 
extracted with 80 µl of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein were electrophoresed 
on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes 
were incubated with antibodies against phospho-ERK1/2 (1:5000), ERK1/2 (1:5000), cleaved PARP (1:2000 
dilution) and GAPDH (1:10000 dilution). The images shown are representative of samples from triplicate 
experiments (A). Densitometry was with Labworks 4.0 software, adjusted for the background optical density of 
the X-ray film and normalised to GAPDH. Results are expressed as a percentage of the intensity of the cleaved 
PARP band observed in the absence of IGF-1 and in the presence of U0126. Bars are the mean ±SEM, *denotes 
phosphorylated ERK1/2 levels that are statistically significantly lower in the presence of U0126 (Two-way 
ANOVA; p=0.0006) and cleaved PARP levels that are statistically significantly lower in the presence of IGF-1 
than in its absence (Two-way ANOVA; p<0.0001) (B).  
 
4.3 Discussion  
The principal aim of the experiments presented in this chapter was to test the hypothesis that 
the IGF signal transduction pathway is important for cell survival and hence a viable 
therapeutic target in gastric cancer. For this reason, the survival effect of IGF-1 was tested in 
gastric cancer cells, using survival assays based on induction of apoptosis by staurosporine 
and by disruption of epithelial cell-matrix interaction. We demonstrated a significant 
protective effect of IGF-1 on staurosporine-induced apoptosis in gastric cancer cell lines 
SNU-1, NUGC3 and AGS. The protective effect of IGF-1 against the broad-spectrum kinase 
inhibitor staurosporine emphasises the potency of IGF-1 as a pro-survival factor. 
Interestingly, the above cell lines did not express or expressed extremely low levels of three 
tyrosine kinase receptors, HER-2, FGFR2 and c-Met, which are being inhibited in the clinic. 
This suggests that they represent patients who would be ineligible for the above treatments 
and could, possibly benefit from IGF-targeted treatment. NCI-N87 cells, which overexpress 
HER-2, were, also, protected effectively from staurosporine-induced cell death by IGF-1. This 
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is supported by a recent study which suggests that activity of the IGF signal transduction 
pathway in NCI-N87 cells provides a conduit for resistance to lapatinib, a dual EGFR/HER2 
targeted inhibitor (Zhang et al., 2014). 
A small number of studies have reported the survival effect mediated by the IGF signal 
transduction pathway in gastric cancer cells. IGF-1 protected against ethanol-induced caspase 
3 activation in MET-amplified MKN45 cells (Min et al., 2005; Smolen et al., 2006). The 
same study showed that expression of a truncated IGF-IR receptor increased cleavage of 
caspase 3 induced by ethanol, 5-fluorouracil and radiation in MKN45 cells. In a separate 
study, reduction of IGF-IR expression by recombinant adenovirus increased DNA 
fragmentation in response to apoptosis induced by UV radiation and cisplatin (Wang et al., 
2010a).  
Despite the significant protective effect of IGF-1 against staurosporine-induced apoptosis in 
SNU-1, NUGC3, AGS and NCI-N87 cells, the ligand was not as effective in KATO III and 
MKN74 cells. As mentioned in Chapter 3, KATO III cells overexpress FGFR2, and possibly 
depend on activation of this pathway in order to sustain their survival and growth potential. 
Under those circumstances, activation of the IGF signal transduction pathway might not 
suffice to promote survival. MKN74 cells have no known amplification and express the 
highest levels of the type I IGF receptor amongst all the gastric cancer cell lines tested. 
Furthermore, they respond to IGF-1 stimulation, with induction of both Akt and ERK1 and 
ERK2 phosphorylation. The lack of IGF-1 protection against apoptosis in this cell line is, 
therefore, unexpected. It is possible, though, that different experimental settings could have 
contributed to the manifestation of the IGF-1 survival effect in those cells.  
Relatively high levels of cleaved PARP were detected in SNU-16 and SNU-5 cells prior to 
staurosporine treatment. Staurosporine increased only slightly the levels of cleaved PARP in 
SNU-16 cells but IGF-1 had no protective effect. Staurosporine did not increase cleaved 
PARP levels in SNU-5 cells. The relatively high basal levels of cleaved PARP in control 
conditions suggest that the cells were not healthy and, therefore, any investigation of the IGF-
1 survival effect would be invalid.   
Activation of caspase 3 and PARP by proteolytic cleavage was detected in SNU-1 and 
NUGC3 cells after treatment with staurosporine. This result suggests that staurosporine 
induces cell death in a caspase-dependent manner. Activation of caspase 3 and 7 and cleavage 
of PARP in response to staurosporine has been reported previously in LNCaP prostate cancer 
cells (Marcelli et al., 1999). Also, staurosporine activated the caspase cascade and cleavage of 
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PARP in T47D and MCF7 breast cancer cells (Mooney et al., 2002) and in macrophages (Son 
et al., 2014). However, activation of both caspase-dependent and independent cell death by 
staurosporine has also been reported (Belmokhtar et al., 2001). 
Inhibition of cell attachment to the extracellular matrix after culture in plastic coated with 
poly-HEMA in the absence of growth factors, induced a type of apoptosis described as 
anoikis in NUGC3, AGS and KATO III cells. IGF-1 protected NUGC3 and AGS cells from 
anoikis, overtime. This protection against anoikis proposes a role for IGF-1 in promoting 
survival of anchorage-deprived gastric cancer cells and, possibly, providing a stimulus for a 
migratory and invasive phenotype. As mentioned previously, circumvention of anoikis 
accompanies the acquisition of anchorage independence and cell motility, traits necessary for 
invasion and metastasis. In agreement with the results obtained from the staurosporine assay, 
KATO III cells were not protected from anoikis by IGF-1, suggesting that those cells do not 
respond to activation of the IGF signal transduction pathway for their survival mechanisms. 
Treatment of SNU-1 and NUGC3 cells with BMS754807 abrogated the protective effect of 
IGF-1 against staurosporine-induced apoptosis. BMS754807 may inhibit both the type I IGF 
receptor and the insulin receptor due to the high similarity of their tyrosine kinase domains. It 
is, therefore, possible that either or both of the above two receptors are responsible for 
mediating the IGF-1 survival effect in those cells. Selective inhibition of the type I IGF 
receptor or the insulin receptor would clarify which of the two is involved in mediation of the 
IGF-1 survival signal.  
The marked increase of Akt but not ERK1 and ERK2 phosphorylation in response to IGF-1 in 
SNU-1 and NUGC3 cells, both in the context of apoptosis and anoikis, suggests that the Akt 
pathway might be more involved in mediating the IGF-1 survival effect. Inhibition of PI3K 
with the LY294002 inhibitor in SNU-1 cells reduced significantly the amount of 
phosphorylated Akt and abrogated partially the IGF-1 anti-apoptotic effect. In contrast, 
inhibition of MEK1 and MEK2 with the U0126 inhibitor reduced significantly the amount of 
phosphorylated ERK1 and ERK2 but did not alter the anti-apoptotic effect of IGF-1. It could 
be concluded, therefore, that in the context of staurosporine-induced apoptosis, activation of 
the PI3K/Akt pathway and not the Raf/ERK mediates the survival effect of IGF-1. 
A more prominent effect of the PI3K/Akt compared to the Raf/ERK pathway in mediation of 
the IGF-1 survival effect is supported by several studies. Inhibition of the PI3K/Akt pathway 
with the LY294002 inhibitor abrogated the protective effect of IGF-1 against apoptosis 
induced by serum deprivation in Schwann cells (Delaney et al., 1999), 3T3-L1 preadipocytes 
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(Gagnon et al., 2001) and pancreatic beta cells (Liu et al., 2002). Also, PI3K activity was 
more important for the protective effect of IGF-1 against paclitaxel and doxorubicin-induced 
apoptosis in MCF-7 breast cancer cells (Gooch et al., 1999).  
However, a dual role for the PI3K/Akt and the Raf/MAPK pathways in transduction of the 
IGF-1 survival effect has also been described. Activation of both pathways was necessary for 
the protective effect of IGF-1 against apoptosis induced by serum deprivation in immortalised 
brown adipocytes (Navarro et al., 1998), whereas IGF-1 protection against oxygen-glucose 
deprivation-induced apoptosis was blocked by PI3K/Akt and Raf/ERK signal transduction 
pathway inhibition in pheochromocytoma cells (Chung et al., 2007). Inhibition of PI3K and 
ERK1 and ERK2 activation partially inhibited the survival effect of IGF-1 in osteoblastic 
cells (Grey et al., 2003). Attenuation of the IGF-1 survival effect by inhibition of PI3K/Akt 
and ERK1 and ERK2 was also described in skeletal muscle cells subjected to oxidative stress 
and in retinal ganglion cells in hypoxic conditions (Yang et al., 2010; Yang et al., 2013).   
In summary, the findings reported in this chapter suggest that the IGF signal transduction 
pathway is important for the survival of as subset of gastric cancer cells against caspase-
dependent apoptosis induced by inhibition of kinase activity and by loss of cell-matrix 
attachment. Therefore, targeting the pathway may be useful in controlling the spread of 





Chapter 5. The Effect of IGF Signal Transduction Pathway Activation on 
Proliferation of Gastric Cancer Cells 
 
5.1 Introduction 
One of the most important traits of a cancer cell is the ability to sustain proliferation in the 
absence of appropriate external signals. This can be achieved by mutations in oncogenes or 
tumour suppressor genes or by increased expression or activation of growth factor pathways 
that stimulate cell proliferation.  
The mitogenic properties of the insulin-like growth factor signal transduction pathway have 
been described in various studies. IGF-1 and IGF-2 stimulated the growth of an oesophageal 
squamous cancer cell line (Oku et al., 1991), whereas IGF-1 enhanced the proliferation of 
acute myelogenous leukaemia blasts alone and in combination with exogenous cytokines 
(Frostad and Bruserud, 1999). In a human osteosarcoma cell line IGF-1 stimulated cyclin D1 
expression during G1 phase, cyclin B (G2 cyclin) and two cyclin-dependent kinases, cdc2 and 
cdk2 (Furlanetto et al., 1994). Stimulation of cyclin D1 synthesis, DNA synthesis and cell 
division was stimulated by IGF-1 in MCF7 cells (Dufourny et al., 1997). Increased 
proliferation of MDA-MB-231 breast cancer cells after treatment with IGF-1, IGF-2 and 
insulin has been described (Stewart et al., 1990). The involvement of IGF-2 in cell 
proliferation has been reported in human colon cancer cells, in which an anti IGF-2 antibody 
significantly retarded cell growth (Singh et al., 1996).  
The growth of prostatic cancer cell lines was inhibited by an antisense oligodeoxynucleotide 
to the type I IGF receptor or by peptide analogues of IGF-1 that compete with IGF-1 binding 
to its receptor (Pietrzkowski et al., 1993). Transfection of MCF-7 breast cancer cells with a 
construct encoding an antisense RNA complementary to the region surrounding the 
translation initiation site of the type I IGF receptor mRNA reduced both IGF-1- and serum-
stimulated proliferation (Neuenschwander et al., 1995).  Furthermore, inhibition of the 
endogenous type I insulin-like growth factor receptor by stable expression of a dominant-
negative IGF-IR repressed the tumourigenicity of a human lung carcinoma cell line (Jiang et 
al., 1999). 
Since increased proliferation is one of the main drivers of cancer progression, inhibition of the 
IGF signal transduction pathway could possibly, delay the growth of certain tumour types and 




The results reported in this chapter aim to elucidate the role of the IGF-signal transduction 
pathway in the proliferation of gastric cancer cells without receptor tyrosine kinase 
amplifications. These cells are models for gastric tumour cells of patients who would not be 
eligible for the currently available targeted treatments. The role of IGF-1 in cell proliferation 
was investigated in cells cultured in controlled conditions. The importance of the type I IGF 
receptor in the induction of cell proliferation was investigated in controlled conditions and in 
a growth factor enriched environment, by transient silencing of the type I IGF receptor with a 
short interfering RNA sequence. The effect of IGF-IR knockdown on cell cycle progression 
was also investigated. Finally, the efficiency of the small molecule tyrosine kinase inhibitor 
BMS754807 in reduction of cell proliferation was tested in a growth factor enriched 
environment.    
    
5.2 Results 
 
5.2.1 The effect of IGF-1 on cell proliferation in gastric cancer cells 
The effect of IGF-1 on gastric cancer cell growth was investigated. MKN74 and NUGC3 cells 
were cultured in withdrawal medium which is depleted from growth factors or serum-free 
medium, respectively, in the presence or absence of 50 ng/ml IGF-1. The amount of DNA in 
the presence and absence of IGF-1 was measured with the PicoGreen fluorimetric assay. 
During the cell cycle, each cell doubles its DNA content and subsequently divides into two 
new cells. Therefore, the amount of double stranded DNA in a given sample is directly 
proportional to the number of cells.  
The amount of DNA increased progressively in MKN74 cells cultured in withdrawal medium 
over the course of 9 days, when IGF-1 was not present (Figure 5.1). This suggests that the 
cells were not withdrawn completely from the effects of growth factors. When IGF-1 was 
present in the medium, the amount of DNA was higher at all times tested and this increase 
was statistically significant after 9 days. NUGC3 cells proliferated when cultured in serum-
free medium, until day 3 when they started to reach a plateau (Figure 5.1). The amount of 
DNA in cells grown in the presence of IGF-1 was increased significantly after 3 days and 
continued to increase until day 9. Interestingly, cell numbers almost doubled in the presence 
of IGF-1 compared with in the absence of IGF-1. This suggests that NUGC3 cells were more 




Figure 5.1. The effect of IGF-1 on cell proliferation in MKN74 and NUGC3 cells. MKN74 and NUGC3 cells 
were seeded into 24 well tissue culture plates at 1x10
4 
cells per well, in 0.5 ml maintenance medium. Cells were 
incubated for 24 hours to allow attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. 
Medium was replaced every 3 days with 0.5 ml serum-free medium (NUGC3 cells) or 0.5 ml withdrawal 
medium supplemented or not with 50 ng/ml IGF-1. Medium was aspirated and the cells washed with 0.5 ml ice 
cold PBS. PBS was aspirated and the cells stored in -20
o
C. The cells were lysed in SSC/SDS solution and the 
amount of DNA in each well was quantified with the Quanti-iT picogreen fluorimetric assay. Bars are the mean 
±SEM, * denotes statistically significantly increased DNA content in the presence of IGF-1 compared with in the 
absence of IGF-1 (Two-way ANOVA; MKN74, p<0.0001; NUGC3, p<0.0001).  
 
5.2.2 Effect of siRNA knockdown of the type I IGF receptor on the proliferative effect of 
IGF-1 in NUGC3 cells 
To test the hypothesis that the proliferative effect of IGF-1 in NUGC3 cells is mediated by the 
type I IGF receptor, the effect of IGF-1 on cell proliferation was tested after transient 
knockdown of the type I IGF receptor with siRNA.  
First, the efficiency of the siRNA oligonucleotide against the type I IGF receptor was tested. 
NUGC3 cells were reverse transfected with 3 siRNA sequences designed to target the type I 
IGF receptor and with a scrambled sequence, at different concentrations. Cells were incubated 
with the transfection mix, containing the siRNA sequences and lipofectamine, for 72 hours 
before protein lysis. Expression of the type I IGF receptor was analysed by western transfer. 
The type I IGF receptor was detected in NUGC3 cells that had been transfected with the 
scrambled sequence (Figure 5.2). Incubation for 72 hours with the first siRNA sequence 
designed to target the type I IGF receptor, resulted in reduced IGF-IR expression at 20, 30 and 
40 nM. The second siRNA sequence reduced IGF-IR expression at 20 and 30 nM and it 
completely counteracted IGF-IR expression at 40 nM. Finally, the third siRNA sequence 
completely inhibited IGF-IR expression at 20, 30 and 40 nM. Since siRNA duplexes 2 and 3 
were more effective, they were selected for the following experiments. A concentration of 40 
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nM was used for siRNA 2 and 20 nM for siRNA 3. SiRNA 2 was slightly more effective than 
siRNA 3 at reduction of cell proliferation (see later, Figure 5.8), and was used for the 
following experiments, unless otherwise specified. 
 
Figure 5.2. The effect of siRNA knockdown on expression of the IGF-IR in NUGC3 cells. Transfection 
medium was prepared by mixing either scrambled (scr) or IGF-IR targeted (IGF-IR) siRNA duplexes at a final 
concentration of 20, 30 and 40 nM and Lipofectamine RNAiMAX at a final concentration of 0.2% (v/v), in 0.25 
ml DMEM without serum. The transfection medium was then incubated at room temperature for 30 minutes. 
NUGC3 cells grown in maintenance medium were detached using trypsin:EDTA and resuspended in 
maintenance medium at 15 x 10
4
 cells /ml. One ml of the cell suspension was mixed with 0.25 ml of the 
transfection medium, containing scrambled or IGF-IR targeted sequences, in 12 well tissue culture plates. After 
incubation for 72 hours, protein extracts were prepared with 80 µl per well of RIPA buffer plus inhibitors. 
Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% polyacrylamide gels and 
transferred to nitrocellulose for at 100 mA for 45 minutes. Membranes were incubated with antibodies against 
the IGF-IR (1:2000 dilution) and GAPDH (1:10000 dilution).  
 
The effect of reducing the expression of the type I IGF receptor on IGF-1–stimulated cell 
proliferation was tested. NUGC3 cells were reverse transfected with siRNA 2, which targets 
the type I IGF receptor or with scrambled sequence and cultured in serum-free medium, in the 
presence or absence of IGF-1 for 9 days. In the absence of IGF-1, there was a small reduction 
in cell number after transfection with siRNA against the type I IGF receptor (Figure 5.3). This 
could be attributed to the lack of withdrawal of the cells from growth factors prior to 
transfection. The proliferative response of NUGC3 cells to IGF-1 was reduced significantly in 
cells in which endogenous expression of the type I IGF receptor had been lowered (Figure 






Figure 5.3. The effect of knockdown of the IGF-IR with siRNA on the proliferative effect of IGF-1 in 
NUGC3 cells. Transfection medium was prepared by mixing either scrambled (scr) or IGF-IR targeted (IGF-IR) 
siRNA duplexes at a final concentration of 40 nM and Lipofectamine RNAiMAX at a final concentration of 
0.2% (v/v), in 0.1 ml DMEM without serum. The transfection medium was then incubated at room temperature 
for 30 minutes. NUGC3 cells grown in maintenance medium were detached using trypsin:EDTA and 
resuspended in maintenance medium at 12.5x10
4
 cells /ml. Four hundred µl of the cell suspension were mixed 
with 0.1 ml of the transfection medium, containing scrambled or IGF-IR targeted sequences, in 24 well tissue 
culture plates. Cells were incubated for 24 hours to allow attachment. Medium was aspirated and the cells were 
washed with PBS. Medium was replaced every 3 days with serum-free medium supplemented or not with 50 
ng/ml IGF-1. After treatment with IGF-1 for 9 days, medium was aspirated and cells were washed once with ice 
cold PBS. PBS was aspirated and the cells stored in -20
o
 C. The cells were lysed in SSC/SDS solution and the 
amount of DNA present in each well was quantified with the Quanti-iT picogreen fluorimetric assay. Bars are 
the mean ±SEM. Asterisks indicate significant reduction in IGF-stimulated proliferation after reduction in type I 
IGF receptor expression (Two-way ANOVA; p<0.01). 
 
5.2.3 Effect of siRNA knockdown of the type I IGF receptor on downstream pathway 
activation in gastric cancer cells    
To test the effect of reduction of the expression of the IGF-IR by siRNA knockdown on 
activation of downstream signalling pathways, SNU-1 and MKN74 cells, which express 
relatively high levels of the type I IGF receptor compared to the other cell lines, were 
transfected with siRNA that targets the IGF-IR or with a scrambled oligonucleotide and 
proteins were extracted every day over a course of 6 days. 
In SNU-1 cells grown in full medium, expression of the IGF-IR was reduced 24 hours after 
transfection with si-IGF-IR compared with the scrambled oligonucleotide (Figure 5.4). 
Complete knockdown was achieved 48 hours after transfection and remained stable until day 
6. Very little IRS-1 expression was detected 24 and 48 hours after transfection. IRS-1 
expression was detected 72 hours after transfection. There was a clear increase in IRS-1 levels 
in cells in which IGF-IR expression had been lowered, 96 and 120 hours after transfection. 
Akt phosphorylation was detected 72 hours after transfection. IGF-IR knockdown resulted in 
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a reduction in Akt phosphorylation 72, 120 and 144 hours after transfection. In contrast, total 
Akt levels increased in cells with IGF-IR knockdown, 120 and 144 hours after transfection. 
ERK2 phosphorylation was detected in SNU-1 cells 24 hours after transfection. Reduction of 
IGF-IR expression resulted in reduced ERK2 phosphorylation at all times tested. Similarly, 
total ERK2 levels were reduced in cells transfected with siRNA against the type I IGF 
receptor. ERK1 levels were also reduced in cells with IGF-IR knockdown but to a smaller 
degree compared to ERK2.  
 
Figure 5.4. The effect of knockdown of the IGF-IR with siRNA on downstream signalling in medium 
supplemented with serum in SNU-1 cells. Transfection medium was prepared by mixing either scrambled (scr) 
or IGF-IR targeted (IGF-IR) siRNA duplexes at a final concentration of 50 nM and Lipofectamine RNAiMAX at 
a final concentration of 0.2% (v/v), in 0.2 ml DMEM without serum. The transfection medium was then 
incubated at room temperature for 30 minutes. SNU-1 cells were centrifuged and diluted in medium 
supplemented with 10% foetal calf serum at 10 x 10
4
 cells/ml. One ml of the cell suspension was mixed with 
0.25 ml of the transfection medium, containing scrambled or IGF-IR targeted sequences, in 12 well tissue culture 
plates. After 24, 48, 72, 96, 120 and 144 hours, protein extracts were prepared with 80 µl per well of RIPA 
buffer plus inhibitors. Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% 
polyacrylamide gels and transferred to nitrocellulose for at 100 mA for 45 minutes. Membranes were incubated 
with antibodies against the IGF-IR (1:2000 dilution), IRS-1 (1:2000 dilution), phosphorylated Akt (1:3000 
dilution), Akt (1:3000 dilution), phosphorylated ERK1/2 (1:5000 dilution), ERK1/2 (1:5000 dilution) and 
GAPDH (1:10000 dilution). 
 
In MKN74 cells, knockdown of the IGF-IR was achieved 24 hours after transfection and 
remained stable for 6 days after transfection (Figure 5.5). An increase in IRS-1 levels, 
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following IGF-IR knockdown was observed, 48, 72 and 96 hours after transfection. Akt 
phosphorylation was reduced after IGF-IR knockdown at all times, except 24 hours. On the 
contrary, total Akt levels increased following transfection with si IGF-IR. Both 
phosphorylated and total ERK2 levels were reduced following IGF-IR knockdown at all times 
analysed. ERK1 phosphorylation was reduced to a small extent after IGF-IR knockdown, 
whereas total ERK1 was not affected by IGF-IR knockdown. 
 
Figure 5.5. The effect of knockdown of the IGF-IR with siRNA on downstream signalling in medium 
supplemented with serum in MKN74 cells. Transfection medium was prepared by mixing either scrambled 
(scr) or IGF-IR targeted (IGF-IR) siRNA duplexes at a final concentration of 40 nM and Lipofectamine 
RNAiMAX at a final concentration of 0.2% (v/v), in 0.2 ml DMEM without serum. The transfection medium 
was then incubated at room temperature for 30 minutes. MKN74 cells grown in maintenance medium were 
detached using trypsin:EDTA and resuspended in medium supplemented with 10% foetal calf serum at 10 x 10
4
 
cells /ml. One ml of the cell suspension was mixed with 0.2 ml of the transfection medium, containing scrambled 
or IGF-IR targeted sequences, in 12 well tissue culture plates. After 24, 48, 72, 96, 120 and 144 hours, protein 
extracts were prepared with 80 µl per well of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein 
were electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose for at 100 mA for 
45 minutes. Membranes were incubated with antibodies against the IGF-IR (1:2000 dilution), IRS-1 (1:2000 
dilution), phosphorylated Akt (1:3000 dilution), Akt (1:3000 dilution), phosphorylated ERK1/2 (1:5000 
dilution), ERK1/2 (1:5000 dilution) and GAPDH (1:10000 dilution).      
 
In NUGC3 cells, complete knockdown of the IGF-IR was achieved 48 hours after transfection 
and remained stable thereafter (Figure 5.6Figure 5.5). Total IRS-1 was reduced in cells with 
reduced IGF-IR expression after 72 and 120 hours. The amount of phosphorylated and total 
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Akt was not reduced after IGF-IR knockdown at all times tested. ERK2 phosphorylation was 
reduced following IGF-IR knockdown at 72, 96, 120 and 144 hours, whereas the amount of 
phosphorylated ERK1 was not altered. Both ERK1 and ERK2 levels were reduced in cells 
with IGF-IR knockdown.  
 
Figure 5.6. The effect of knockdown of the IGF-IR with siRNA on downstream signalling in medium 
supplemented with serum in NUGC3 cells. Transfection medium was prepared by mixing either scrambled 
(scr) or IGF-IR targeted (IGF-IR) siRNA duplexes at a final concentration of 40 nM and Lipofectamine 
RNAiMAX at a final concentration of 0.2% (v/v), in 0.2 ml DMEM without serum. The transfection medium 
was then incubated at room temperature for 30 minutes. NUGC3 cells grown in maintenance medium were 
detached using trypsin:EDTA and resuspended in medium supplemented with 10% foetal calf serum at 10 x 10
4
 
cells /ml. One ml of the cell suspension was mixed with 0.2 ml of the transfection medium, containing scrambled 
or IGF-IR targeted sequences, in 12 well tissue culture plates. After 24, 48, 72, 96, 120 and 144 hours, protein 
extracts were prepared with 80 µl per well of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein 
were electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose for at 100 mA for 
45 minutes. Membranes were incubated with antibodies against the IGF-IR (1:2000 dilution), IRS-1 (1:2000 
dilution), phosphorylated Akt (1:3000 dilution), Akt (1:3000 dilution), phosphorylated ERK1/2 (1:5000 
dilution), ERK1/2 (1:5000 dilution) and GAPDH (1:10000 dilution).      
 
The above results suggest that reduction in IGF-IR expression affects directly activation of the 
RAS/RAF/ERK pathway in SNU-1, MKN74 and NUGC3 cells and of the PI3K/Akt pathway 




5.2.4 Effect of MEK1 and MEK2 inhibition on the proliferative effect of IGF-1 in NUGC3 
cells   
As mentioned previously, reduction of IGF-IR expression with siRNA transfection resulted in 
reduced phosphorylation of ERK1 and 2, as well as reduced total levels of ERK1 and 2 in 
medium supplemented with serum in SNU-1, MKN74 and NUGC3 cells. This suggests that 
an active IGF-IR is required for optimal activation of the ERK pathway. To investigate 
whether the proliferative effect of IGF-1 is mediated by ERK1 and 2 activation, NUGC3 cells 
were cultured in serum-free medium, in the presence and absence of 6µM U0126 and 50 
ng/ml IGF-1 for 9 days. U0126 inhibits MEK1 and MEK2 and, as a result, prevents 
downstream activation of ERK1 and 2. The amount of DNA in each sample was measured 
with the PicoGreen fluorimetric assay. 
In the absence of IGF-1, treatment with U0126 resulted in a small reduction in cell growth, 
compared with untreated cells (Figure 5.7). When U0126 was not present, treatment with 
IGF-1 increased significantly the number of cells by 30% after 9 days. However, in the 
presence of U0126, IGF-1 did not induce a significant increase in cell number. This suggests 
that activation of ERK1 and ERK2 is required for transmission of the proliferative effect of 
IGF-1 in NUGC3 cells.    
 
Figure 5.7. The effect of inhibition of MEK1/2 with the U0126 inhibitor on the proliferative effect of IGF-1 
in NUGC3 cells. NUGC3 cells were seeded into 24 well tissue culture plates at 1x10
4 
cells per well, in 0.5 ml 
maintenance medium. Cells were incubated for 24 hours to allow attachment. Medium was aspirated and the 
cells washed with 0.5 ml PBS. Medium was replaced every 3 days with 0.5 ml serum-free medium, 
supplemented or not with 6 µM U0126 and 50 ng/ml IGF-1. After 9 days, medium was aspirated and the cells 
washed with 0.5 ml ice cold PBS. PBS was aspirated and the cells stored in -20
o
C. The cells were lysed in 
SSC/SDS solution and the amount of DNA in each well was quantified with the Quanti-iT picogreen 
fluorimetric assay. Bars are the mean ±SEM. Asterisk indicates significant increase in cell number after 
treatment with IGF-1 (Two-way ANOVA; p=0.0007). 
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5.2.5 Effect of siRNA knockdown of the type I IGF receptor on proliferation of gastric 
cancer cells in a growth factor enriched environment 
As mentioned previously, in normal conditions, cancer cells exist in an environment enriched 
with a variety of growth factors, which may have survival and growth stimulatory effects. It 
is, therefore, of particular importance to test the effectiveness of a targeted agent in such an 
environment. For this reason, MKN74 and NUGC3 cells were transfected with siRNA 2 and 
siRNA 3, which target the type I IGF receptor or with a scrambled sequence and cultured in 
medium supplemented with 10% foetal calf serum for 3 days. The number of cells was 
measured by detecting the amount of DNA in each sample with the PicoGreen fluorimetric 
assay. 
In MKN74 cells, transfection with siRNA 2 and siRNA 3 reduced the amount of DNA after 3 
days, to 50% and 60% of the amount of DNA detected after transfection with the scrambled 
oligonucleotide (Figure 5.8). Similarly, in NUGC3 cells, siRNA 2 reduced the amount of 
DNA to 50% and siRNA 3 to 75%. Both siRNA sequences reduced significantly cell number 
in both cell lines but siRNA 2 was more effective and was used in the following experiments.      
 
Figure 5.8. The effect of knockdown of the IGF-IR with siRNA on cell number in MKN74 and NUGC3 
cells in full medium. Transfection medium was prepared by mixing either scrambled (scr) or IGF-IR targeted 
(IGF-IR) siRNA duplexes 2 and 3 at a final concentration of  40 and 20 nM, respectively, and Lipofectamine 
RNAiMAX at a final concentration of 0.2% (v/v), in 0.1 ml DMEM without serum. The transfection medium 
was then incubated at room temperature for 30 minutes. MKN74 and NUGC3 cells grown in maintenance 
medium were detached using trypsin:EDTA and resuspended in medium supplemented with 10% foetal calf 
serum at 12.5 x 10
4
 cells /ml. Four hundred µl of the cell suspension were mixed with 0.1 ml of the transfection 
medium, containing scrambled or IGF-IR targeted sequences, in 24 well tissue culture plates. After 72 hours, the 
cells were washed with 0.5 ml ice cold PBS and stored in -20
o
C. The cells were lysed in SSC/SDS solution and 
the amount of DNA present in each well was quantified with the Quanti-iT picogreen fluorimetric assay. Bars 
are the mean ±SEM. Asterisks indicate significant reduction in cell number after transfection with a siRNA 
against the type I IGF receptor compared to transfection with the scrambled oligonucleotide (One-way ANOVA; 




To investigate the effect of reducing the expression of the type I IGF receptor on cell 
proliferation over a period of time, SNU-1, MKN74, NUGC3 and AGS cells were transfected 
with siRNA 2 or with a scrambled sequence and cultured in medium supplemented with 2-
10% foetal calf serum for 1 to 4 days. The number of cells at the end of each time point was 
measured by detecting the amount of DNA in each sample with the PicoGreen fluorimetric 
assay. 
Cell proliferation was reduced significantly in SNU-1 cells after transfection with siRNA 
against the IGF-IR, compared to cells transfected with scrambled sequence (Figure 5.9). 
Interestingly, although cells with intact IGF-IR expression were actively proliferating at a fast 
rate until day 5, cells with reduced IGF-IR expression stopped proliferating completely after 
day 2. This suggests that the type I IGF receptor is one of the main receptors driving cell 
proliferation in this cell line. 
In MKN74 cells, reduction of IGF-IR expression by siRNA knockdown reduced the 
proliferation rate compared to cells transfected with scrambled oligonucleotide (Figure 5.9). 
Cell number was reduced significantly two days after transfection and remained low until day 
4. A similar effect was seen in NUGC3 cells. Reduced IGF-IR expression following 
transfection resulted in a significant reduction in cell number 3 days after transfection. The 
number of AGS cells was reduced significantly 2 days after transfection with the siRNA 
against the type I IGF receptor and remained low over the course of 4 days.  
Cell proliferation was reduced in all four cell lines tested after knockdown of the type I IGF 
receptor. This suggests that even in an environment with various growth factors and stimuli, 




Figure 5.9. The effect of knockdown of the IGF-IR with siRNA on proliferation of SNU-1, MKN74, 
NUGC3 and AGS cells in full medium. Transfection medium was prepared by mixing either scrambled (scr) or 
IGF-IR targeted (IGF-IR) siRNA duplexes at a final concentration of 50 nM (SNU-1) and 40 nM (MKN74, 
NUGC3 and AGS) and Lipofectamine RNAiMAX at a final concentration of 0.2% (v/v), in 0.1 ml DMEM 
without serum. The transfection medium was then incubated at room temperature for 30 minutes. SNU-1 cells 
were centrifuged and diluted in medium supplemented with 2% foetal calf serum at 10 x 10
4
 cells/ml. MKN74, 
NUGC3 and AGS cells grown in maintenance medium were detached using trypsin:EDTA and resuspended in 
medium supplememented with 10%, 2% and 10% foetal calf serum, respectively, at 12.5 x 10
4
 cells /ml. Four 
hundred µl of the cell suspension were mixed with 0.1 ml of the transfection medium, containing scrambled or 
IGF-IR targeted sequences, in 24 well tissue culture plates. After 24, 48, 72 and 96 hours, the cells were washed 
with 0.5 ml ice cold PBS and stored in -20
o
 C. The cells were lysed in SSC/SDS solution and the amount of 
DNA present in each well was quantified with the Quanti-iT picogreen fluorimetric assay. Bars are the mean 
±SEM. Asterisks show times at which there were significantly fewer cells after transfection with the si IGF-IR2 
than after transfection with the scrambled oligonucleotide (Two-way ANOVA; SNU-1, p<0.0001; MKN74, 
p<0.0001; NUGC3, p<0.0001; AGS, p<0.0001). 
 
5.2.6 Effect of siRNA knockdown of the type I IGF receptor on cell cycle progression in 
gastric cancer cells in a growth factor enriched environment 
To confirm that the reduction in cell number observed after knockdown of the type I IGF 
receptor is a result of decreased cell proliferation, as opposed to increased cell death, two 
markers of cell cycle progression were measured in gastric cancer cells that had been 
transfected with a siRNA against the type I IGF receptor.  
Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU) is a synthetic nucleoside that is an 
analogue of thymidine and was first described in the 1950s (Kit et al., 1958). BrdU can be 
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incorporated in the place of thymidine into the newly synthesized DNA of replicating cells, 
during the S phase of the cell cycle. It allows the detection of proliferating cells in living 
tissues. To test the effect of decreased IGF-IR expression on DNA synthesis, SNU-1, 
MKN74, NUGC3 and AGS cells were transfected with siRNA 2, which targets the type I IGF 
receptor or with a scrambled sequence and cultured in medium supplemented with 2-10% 
foetal calf serum for 72 hours. The cells were incubated with BrdU for 2 hours before fixation 
and incubation with an antibody that detects BrdU.  
Approximately 15% of SNU-1 cells transfected with scrambled oligonucleotide were actively 
synthesizing DNA (Figure 5.10). Reduction of IGF-IR expression by transfection with siRNA 
2 reduced significantly the above percentage to 7%. Similarly, reduced IGF-IR expression by 
siRNA knockdown reduced significantly the percentage of MKN74 cells in S phase from 
21% to 8%. In NUGC3 and AGS cells, the percentage of cells that were synthesizing DNA 





Figure 5.10.  The effect of knockdown of the IGF-IR with siRNA on DNA synthesis in SNU-1, MKN74, 
NUGC3 and AGS cells in full medium. Transfection medium was prepared by mixing either scrambled (scr) or 
IGF-IR targeted (IGF-IR) siRNA duplexes at a final concentration of 50 nM (SNU-1 cells) and 40 nM (MKN74, 
NUGC3 and AGS cells) and Lipofectamine RNAiMAX at a final concentration of 0.2% (v/v), in 0.5 ml DMEM 
without serum. The transfection medium was then incubated at room temperature for 30 minutes. SNU-1 cells 
were centrifuged and resuspended in medium supplemented with 2% foetal calf serum at 25x10
4 
cells/ml. 
MKN74, NUGC3 and AGS cells grown in maintenance medium were detached using trypsin:EDTA and 
resuspended in medium supplemented with 2%, 10% and 2% foetal calf serum at 25x10
4
 cells/ml. Two ml of the 
cell suspension were mixed with 0.5 ml of the transfection medium, containing
 
scrambled or IGF-IR targeted 
sequences, inside the wells of 6 well plates. After 72 hours, cells were incubated with 0.03 mg/ml 
bromodeoxyuridine for 2 hours. Then the cells were fixed in 4% paraformaldehyde. Fixed cells were incubated 
with a fluorescent antibody against BrdU (1:1400). The secondary antibody was Alexa-Fluor conjugated. Cells 
were mounted on top of slides in DAPI X mounting medium. Pictures of the cells were taken in a Leica 
fluorescent microscope (A). Quantification of the number of cells with positive staining was done in five fields 
of view for each treatment. The results are shown as a percentage of the total number of cells. Bars, SEM. 
Asterisks indicate that the proportion of cells in S phase is significantly lower after transfection with the si IGF-
IR2 than after transfection with the scrambled oligonucleotide. Unpaired t-test; S-phase: SNU-1, p=0.0078; 
MKN74, p=0.0001; NUGC3, p=0.0001; AGS, p=0.0004) (B). 
 
Phosphorylation of histone H3 at Ser10 is tightly correlated with chromosome condensation 
during mitosis (Goto et al., 1999). To test the effect of decreased IGF-IR expression on 
mitosis, SNU-1, MKN74, NUGC3 and AGS cells were transfected with siRNA 2, which 
targets the type I IGF receptor or with a scrambled sequence and cultured in medium 
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supplemented with 2-10% foetal calf serum for 72 hours. The cells were fixed and incubated 
with an antibody that detects phosphorylated histone H3 at Ser10. 
Approximately 4% of SNU-1 cells that had been transfected with a scrambled sequence were 
undergoing mitosis (Figure 5.11). Decreased IGF-IR expression resulted in a significant 
reduction of the percentage of the actively dividing cells to 1.5%. Similar results were 
obtained with the remaining three cell lines, with knockdown of the type I IGF receptor 
resulting in a significant reduction of the number of cells undergoing mitosis from 2.8 to 0.8% 
for MKN74 cells, from 6 to 2% for NUGC3 cells and from 2.4 to 1.1% for AGS cells.   
 
Figure 5.11. The effect of knockdown of the IGF-IR with siRNA on mitosis in SNU-1, MKN74, NUGC3 
and AGS cells in full medium. Transfection medium was prepared by mixing either scrambled (scr) or IGF-IR 
targeted (IGF-IR) siRNA duplexes at a final concentration of 50 nM (SNU-1 cells) and 40 nM (MKN74, 
NUGC3 and AGS cells) and Lipofectamine RNAiMAX at a final concentration of 0.2% (v/v), in 0.5 ml DMEM 
without serum. The transfection medium was then incubated at room temperature for 30 minutes. SNU-1 cells 
were centrifuged and resuspended in medium supplemented with 2% foetal calf serum at 25x10
4 
cells/ml. 
MKN74, NUGC3 and AGS cells grown in maintenance medium were detached using trypsin:EDTA and 
resuspended in medium supplemented with 2%, 10% and 2% foetal calf serum at 25x10
4
 cells/ml. Two ml of the 
cell suspension were mixed with 0.5 ml of the transfection medium, containing
 
scrambled or IGF-IR targeted 
sequences, inside the wells of 6 well plates. After 72 hours, cells were fixed in 4% paraformaldehyde. Fixed cells 
were incubated with a fluorescent antibody against phosphorylated histone H3 (1:100 dilution). The secondary 
antibody was Alexa-Fluor conjugated. Cells were mounted on top of slides in DAPI X mountant medium. 
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Pictures of the cells were taken in a Leica fluorescent microscope (A). Quantification of the number of cells with 
positive staining was done in five fields of view for each treatment. The results are shown as a percentage of the 
total number of cells. Bars, SEM. Asterisks indicate that the proportion of cells in mitosis is significantly lower 
after transfection with the si IGF-IR2 than after transfection with the scrambled oligonucleotide. (Unpaired t-test; 
SNU-1, p=0.0009; MKN74, p=0.0046; NUGC3, p=0.0023; AGS, p=0.017) (B). 
 
Decreased IGF-IR expression resulted in a reduction of the number of cells in S phase and in 
mitosis in all four cell lines tested here. This suggests that activation of the type I IGF 
receptor transmits signals that trigger both DNA synthesis and mitosis. 
 
5.2.7 Effect of IGF-IR/IR inhibition by BMS754807 on cell proliferation in a growth factor 
enriched environment 
As mentioned previously, reduction of IGF-IR expression with siRNA knockdown resulted in 
decreased proliferation rates in SNU-1, MKN74, NUGC3 and AGS cells. We, therefore, 
tested if the small molecule tyrosine kinase inhibitor, BMS754807, which targets both the 
type I IGF receptor and the insulin receptor would inhibit proliferation. SNU-1, MKN74, 
NUGC3 and AGS cells were cultured in medium supplemented with 10% foetal calf serum 
and various concentrations of BMS754807, ranging from 0 to 10 µM for 3 days. The cells 
were lysed and the amount of DNA present in each sample was measured with the PicoGreen 
fluorimetric assay. 
In SNU-1 cells, the amount of DNA was reduced by BMS754807 in a concentration 
dependent manner (Figure 5.12). Treatment with 10 μM BMS754807 reduced the number of 
cells by 60%. The concentration of BMS754807 required to reduce the number of cells by 
50% (IC50) was approximately 2 μM. A similar profile in response to BMS754807 was 
observed also in MKN74 and NUGC3 cells, with IC50 close to 2 μM. AGS cells were slightly 
more sensitive to BMS754807 compared to the other cells lines, as 10 μM of the inhibitor 
reduced the amount of cells by 80%. The IC50 of the BMS754807 in this cell line was 




Figure 5.12. The effect of treatment with different concentrations of BMS754807 on cell number. SNU-1, 
MKN74, NUGC3 and AGS cells were seeded into 24 well tissue culture plates at 1x10
4 
cells per well, in 0.5 ml 
maintenance medium. Adherent cells were incubated for 24 hours to allow attachment. Medium was replaced to 
maintenance medium which contained DMSO, 0.001, 0.01, 0.1, 1 or 10 µM BMS754807. After 3 days, medium 
was aspirated and the cells washed with 0.5 ml ice cold PBS. PBS was aspirated and the cells stored in -20
o
C. 
The cells were lysed in SSC/SDS solution and the amount of DNA in each well was quantified with the Quanti-
iT picogreen fluorimetric assay. Bars are the mean ±SEM. 
 
To test the effect of the BMS754807 inhibitor overtime, SNU-1, MKN74, NUGC3 and AGS 
cells were cultured in medium supplemented with 10% foetal calf serum in the presence or 
absence of 5 µM BMS754807 for 1 to 5 days (Figure 5.13). In the absence of BMS754807, 
SNU-1 cells proliferated quite fast and doubled their number from day 2 to day 3. In the 
presence of BMS754807, their growth rates were reduced significantly and there was a 60% 
reduction in cell number on day 3 compared to untreated cells. The growth of MKN74 cells 
was inhibited completely by BMS754807. In NUGC3 cells, treatment with 5 µM 
BMS754807 resulted in a reduction of cell number by 50% after 3 days. In AGS cells, growth 




Figure 5.13. The effect of BMS754807 on proliferation in SNU-1, MKN74 and NUGC3 cells cultured in 
maintenance medium. MKN74, NUGC3 and AGS cells were seeded into 24 well tissue culture plates at 1x10
4 
cells per well, in 0.5 ml maintenance medium. Cells were incubated for 24 hours to allow attachment. Medium 
was replaced to maintenance medium which contained DMSO, 0.5 µM or 5 µM BMS754807. SNU-1 cells were 
seeded into 24 well tissue culture plates at 1x10
4 
cells per well, in 0.5 ml maintenance medium which contained 
DMSO, 0.5 µM or 5 µM BMS754807. Medium was replaced every 3 days. After 0, 1, 2, and 3 days (SNU-1, 
NUGC3 and AGS cells) and 0, 1, 3 and 5 days (MKN74 cells) medium was aspirated and the cells washed with 
0.5 ml ice cold PBS. PBS was aspirated and the cells stored in -20
o
C. The cells were lysed in SSC/SDS solution 
and the amount of DNA in each well was quantified with the Quanti-iT picogreen fluorimetric assay. Bars are 
the mean ±SEM, * denotes statistically significantly lower DNA content in the presence of BMS754807 
compared with in the absence of BMS754807 (Two-way ANOVA; SNU-1, p<0.0001; MKN74, p<0.0001; 
NUGC3, p≤0.0002; AGS, p<0.0001).  
 
The above results suggest that BMS754807 effectively inhibits growth of gastric cancer cells, 
even in an environment enriched with growth factors. This underlines the importance of the 
type I IGF receptor and possibly the insulin receptor as mediators of mitogenic stimuli.  




The aim of the results reported in this chapter was to investigate the proliferative effect of the 
IGF signal transduction pathway and to evaluate the potential of blocking this proliferative 
effect in gastric cancer cells. IGF-1 increased effectively the proliferation of MKN74 and 
NUGC3 cells, in the absence of other growth factors. The proliferative effect of IGF-1 was 
reduced significantly in NUGC3 cells when expression of the type I IGF receptor was reduced 
and with an inhibitor against MEK1 and MEK2. Our demonstration that ERK1 and ERK2 
activation is essential for the induction of the IGF-1 proliferative effect suggests distinct roles 
for Akt and ERK1 and ERK2 activation in response to IGF-1. Activation of the PI3K/Akt, 
and not the Raf/MAPK pathway, is necessary for the induction of the IGF-1 survival effect 
(chapter 4), whereas ERK1 and ERK2 phosphorylation is necessary for mediating the IGF-1 
proliferative effect. Further, our results suggest that the type I IGF receptor is the main 
mediator of the IGF-1 proliferative effect. 
The importance of the type I IGF receptor in the growth of four gastric cancer cell lines 
without HER-2, FGFR2 and c-Met amplification, cultured in the presence of growth factors, 
was demonstrated by significant reduction in cell proliferation after knockdown of the type I 
IGF receptor. In particular, SNU-1 cells were dependent on the type I IGF receptor for 
proliferation, as knockdown of the receptor resulted in cessation of growth in those cells. 
Previously, reduced colony formation has been shown after inhibition of the type I IGF 
receptor with shRNA and the αIR3 antibody for MET-amplified MKN45 cells and tumour 
explants, respectively (Pavelic et al., 2003; Wang et al., 2010a). Infection with an adenovirus 
that expresses truncated IGF-IR reduced proliferation of MKN74 cells, as well as two other 
gastric cancer cell lines, NUGC4 and the MET-amplified cell line MKN45 (Min et al., 2005).  
We confirmed that the reduction in cell growth after knockdown of the type I IGF receptor in 
SNU-1, MKN74, NUGC3 and AGS cells was reflected in reduced proportion of cells in the 
S-phase and mitotic-phase of the cell cycle. Therefore, rather than inducing cell death, 
inhibition of IGF-IR expression resulted in reduced cell proliferation by inhibiting 
progression through the cell cycle. This is supported by a previous study in which induction 
of cyclin D1 synthesis, DNA synthesis and cell division was detected in MCF-7 breast cancer 
cells after treatment with IGF-1 (Dufourny et al., 1997).  
IGF-IR knockdown resulted in reduced phosphorylation of Akt in SNU-1 and MKN74 cells 
and reduced phosphorylation of ERK1 and ERK2 in SNU-1, MKN74 and NUGC3 cells. This 
suggests that even in the presence of other growth factors and activated receptors, the type I 
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IGF receptor is primarily important for stimulating Akt and ERK1 and ERK2 and, 
consequently, cell survival and proliferation. The reduction of phosphorylated Akt was 
accompanied by an accumulation of total Akt, in cells with decreased IGF-IR expression. On 
the contrary, reduction of phosphorylated ERK2 levels resulted in a reduction of total ERK2 
levels. In MKN74 cells, inhibition of ERK2 phosphorylation preceded the reduction of total 
ERK2 levels. This suggests that there is a negative feedback loop that reduces the expression 
of ERK2 in cells in which ERK2 phosphorylation is inhibited. There was a clear increase in 
IRS-1 levels in SNU-1 and MKN74 cells with reduced IGF-IR expression 96 hours after 
siRNA transfection. Due to the lack of good quality commercially available antibodies for 
phosphorylated IRS-1, it was not possible to investigate differences in IRS-1 phosphorylation 
after IGF-IR knockdown. It could be hypothesised that accumulation of total IRS-1 is a result 
of reduction in IRS-1 phosphorylation after loss of IGF-IR activation. 
Treatment with the BMS754807 inhibitor, which prevents phosphorylation of the type IGF 
and insulin receptors, inhibited the growth of SNU-1, MKN74, NUGC3 and AGS cells. 
Inhibition of cell growth with BMS754807, evaluated by 
3
H-thymidine incorporation into the 
newly synthesised DNA, has been reported in Ewing’s sarcoma, rhabdomyosarcoma, 
neuroblastoma, liposarcoma, breast, lung, pancreatic, colon cancer, multiple myeloma and 
leukaemia cell lines (Carboni et al., 2009).  
According to experts in the field, small-molecule tyrosine kinase inhibitors, such as 
BMS754807, that target both IGF1R and the insulin receptor would yield better results in the 
clinic compared to monoclonal antibodies against the type I IGF receptor, as they would 
prevent interaction of IGFs with the insulin receptor. However, Bristol-Myers Squibb stopped 
enrolment into trials of BMS754807 due to disappointing phase III trials (Guha, 2013). The 
negative results obtained from phase III trials suggest that the establishment of predictive 
biomarkers is essential to select patients more likely to respond to treatment. Also, the 
combination of IGF-IR and IR targeted inhibitors with inhibitors used in the clinic should be 
tested preclinically. Furthermore, some cancer cells are driven by other receptors to such an 
extent that insulin and IGF signalling become less relevant and these cells would also be 
predicted to be resistant (Pollak, 2012).  
In summary, the results reported in this chapter suggest that the type I IGF receptor is 
important for cell proliferation in “triple negative” gastric cancer cells. Mediation of the 
proliferative effect by the type I IGF receptor requires activation of the Raf/ERK pathway. 
Inhibition of the type I IGF receptor results in reduction of the number of cells in the S-phase 
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and mitotic-phase of the cell cycle. Finally, BMS754807 inhibits effectively the growth of 




Chapter 6. Responsiveness of Gastric Cancer Cells to IGF-2 and Insulin 




Activation of the type I IGF receptor by IGF-1 and IGF-2 has been considered the main 
mechanism of stimulation of downstream IGF signal transduction pathways involved in cell 
survival and proliferation, whereas signalling through the insulin receptor has been linked 
traditionally to regulation of metabolic processes. However, there is a considerable amount of 
preclinical data which indicate that signalling through the insulin receptor could be more 
involved in cancer progression than thought previously. 
Two isoforms of the insulin receptor are generated by alternative splicing of exon 11. The 
form that contains 12 amino acids encoded by exon 11 is called the B-isoform (IR-B) and the 
form that lacks the 12 amino acids encoded by exon 11 is called the A-isoform (IR-A) (Seino 
and Bell, 1989). IR-A binds insulin with the highest affinity (Kd=0.25 nM), followed by IGF-
2 (Kd=2 nM) and IGF-1 (Kd=10 nM)  (Westley and May, 2013). It is overexpressed in several 
human cancers and it has been proposed that its overexpression provides a mechanism for 
over-activation of the IGF signal transduction pathway in cancer (Belfiore, 2007). Another 
way in which the insulin receptor can contribute to IGF-1 and IGF-2 signal transduction is by 
the formation of hybrid receptors assembled with one α and β chain of the IGF-IR and one α 
and β chain of the IR-A or IR-B (Pandini et al., 1999; Frasca et al., 2003). These hybrid 
receptors bind IGF-1 and IGF-2 with very high affinity (Kd=0.3-0.7 nM) and insulin with 
lower affinity (Kd=70-80 nM). Hybrid receptors are thought to contribute to downstream 
signalling that leads to cell survival and proliferation.  
Insulin has been shown to stimulate effectively growth of breast, lung and prostate cancer 
cells (Sciacca et al., 2014). Both IGF-IR and isoform A of the insulin receptor mediated 
increased tumour growth in a mouse mammary model and it has been proposed that inhibition 
of both receptors may provide additional efficacy compared to inhibition of IGF-1R alone 
(Buck et al., 2010). Downregulation of the insulin receptor with shRNA reduced growth, 
angiogenesis, lymphangiogenesis and metastasis of LCC6 breast xenograft tumours in mice 
(Zhang et al., 2010). The above results from preclinical studies in combination with negative 
results from clinical studies of monoclonal antibodies which inhibit the IGF-IR selectively 
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(King and Wong, 2012; Langer et al., 2014), suggest that there is a rationale for co-targeting 
the type I IGF and insulin receptor in cancer.      
 
6.1.1 Aims 
The aim of the results reported in this chapter is to investigate the biological effect of 
interactions between IGF-2 and insulin with the type I IGF and insulin receptors in gastric 
cancer cells. Activation of the receptors and downstream molecules by IGF-2 and insulin was 
investigated. The effect of IGF-2 and insulin on cell survival and proliferation was also 
analysed. The importance of the type I IGF and insulin receptors in gastric cancer cell 
survival was investigated by transient silencing of the two receptors with a short interfering 
RNA sequence and by tyrosine kinase inhibition with the small molecule inhibitor 
BMS754807. Finally, expression of the two insulin receptor isoforms was measured in gastric 




6.2.1 The effect of IGF-2 on gastric cancer cells 
 
6.2.1.1 The effect of different concentrations of IGF-2 on activation of IGF-signal 
transduction pathway proteins 
IGF-2 is known to bind the type I IGF receptor with very high affinity (Kd=0.5 nM) but can 
also bind isoform A and isoform B of the insulin receptor with slightly lower affinities (Kd=2 
and 10 nM, respectively).    
To investigate the effect of stimulation with different concentrations of IGF-2 on downstream 
signalling, SNU-1 and NUGC3 cells were selected as representative cell lines. SNU-1 and 
NUGC3 cells have no HER-2, FGFR2 or c-Met amplification and they express relatively high 
amounts of the type I IGF and insulin receptors. Therefore, all possible interactions between 
the ligands and the receptors of the IGF signal transduction pathway may take place in those 
cells. SNU-1 and NUGC3 cells were withdrawn from the effects of growth factors by culture 
in withdrawal medium for 2 days and, then, treated with different concentrations of IGF-2 up 
to 50 ngml
-1
 for 15 minutes prior to protein lysis. 
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Induction of IGF-IR and IR phosphorylation was detected in SNU-1 cells, after stimulation 
with 20 ng/ml IGF-2 or higher (Figure 6.1). Maximal phosphorylation was achieved with 50 
ng/ml IGF-2. Phosphorylated IGF-IR and IR were detected in NUGC3 cells also after 
treatment with 20 ng/ml IGF-2 or higher. Again, the maximal levels of phosphorylation were 
achieved with 50 ng/ml IGF-2. The levels of total IGF-IR and IR remained unchanged after 
stimulation with IGF-2.  
Akt stimulation was detected in SNU-1 cells after treatment with 20 ng/ml IGF-2, whereas a 
higher IGF-2 concentration did not increase phosphorylated Akt levels (Figure 6.1). In 
NUGC3 cells some Akt phosphorylation was detected in the absence of IGF-2, but it 
increased after IGF-2 stimulation in a concentration-dependent manner. Maximal Akt 
phosphorylation was reached with 20 and 50 ng/ml IGF-2. Phosphorylated ERK1 and 2 was 
detected in both cell lines in the absence of IGF-2 and there was a concentration-dependent 
increase after stimulation with IGF-2, only in NUGC3 cells. Maximal phosphorylation was 
achieved with 50 ng/ml IGF-2 in NUGC3 cells. In SNU-1 cells, IGF-2 did not increase ERK1 
and 2 phosphorylation at any concentration. Total Akt and ERK1 and 2 levels were not 
affected by stimulation with IGF-2.  
Stimulation of SNU-1 and NUGC3 cells with IGF-2 resulted in phosphorylation of the type I 
IGF and/or insulin receptor and activation of downstream pathways. Detectable 
phosphorylation of the type I IGF and/or insulin receptor required higher IGF-2 
concentrations compared to IGF-1 concentrations in SNU-1 and NUGC3 cells (20 ng/ml vs 2-
5 ng/ml, see chapter 3). Also, in SNU-1 cells higher IGF-2 concentrations were required to 






Figure 6.1. The effect of stimulation with different concentrations of IGF-2 on phosphorylation of IGF 
signal transduction proteins in SNU-1 and NUGC3 cells. SNU-1 cells were centrifuged and resuspended in 
DCCS medium and seeded into a 75 cm
2 
flask at a concentration of 0.9 x 10
6 
cells per flask. After 24 hours, 
medium was replaced with 12 ml fresh DCCS medium for another 24 hours. Cells were centrifuged and 
resuspended in serum-free medium with 0.1% BSA for 2 hours. Cells were then centrifuged and resuspended in 
serum-free medium with 0.1% BSA and 0, 0.5, 2, 5, 20, 50 ng/ml IGF-2 for 15 minutes. Cells were collected in a 
15 ml Flacon tube and proteins were lysed with 50 µl RIPA buffer plus inhibitors. NUGC3 cells were seeded 
into 12 well tissue culture plates at 15x10
4 
cells/well, in 1 ml maintenance medium. Cells were incubated for 24 
hours to allow attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. Medium was replaced 
daily with 1 ml DCCS medium for two days. Cells were incubated with serum-free medium which contained 
0.1% BSA for two hours. Medium was changed to include IGF-2 at final concentrations of 0, 0.5, 2, 5, 20, 50 
ng/ml. After incubation for 15 minutes proteins were extracted with 80 µl per well RIPA buffer plus inhibitors. 
Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% polyacrylamide gels and 
transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with antibodies against 
phosphorylated IGF-IR/IR (1:1000 dilution), IGF-IR (1:2000 dilution), IR (1:1000 dilution), phosphorylated Akt 
(1:3000 dilution), Akt (1:3000 dilution), phosphorylated ERK1/2 (1:5000 dilution), ERK1/2 (1:5000 dilution) 
and GAPDH (1:10000 dilution). Images shown are representative of results from one triplicate experiment. 
Images obtained after incubation with antibodies against the total proteins are shown beneath those of the 
phosphorylated proteins. Total insulin receptor is shown below the total type I IGF receptor.     
 
6.2.1.2 The effect of IGF-2 on survival of gastric cancer cells 
To investigate whether IGF-2 can protect against staurosporine-induced apoptosis, SNU-1 
and NUGC3 cells were withdrawn from the effects of growth factors and treated with 
concentrations of IGF-2 ranging from 2 to 200 ng/ml in the presence of 0.5 µM staurosporine. 
Treatment with staurosporine resulted in PARP cleavage in SNU-1 cells. The amount of 
cleaved PARP was reduced by IGF-2 in a concentration-dependent manner (Figure 6.2). Best 
protection against cell death was achieved with 50 and 200 ng/ml IGF-2. In NUGC3 cells, 
treatment with staurosporine also resulted in PARP cleavage. IGF-2 reduced the amount of 
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cleaved PARP in a concentration-dependent manner with maximal protection achieved with 
200 ng/ml.  
Higher concentration of IGF-2 were required to reduce PARP cleavage in SNU-1 and 
NUGC3 cells compared to IGF-1 (SNU-1; 20 vs 5 ng/ml, NUGC3; 50 vs 20 ng/ml, see 
chapter 3). The above results suggest that IGF-2 can protect gastric cancer cells against cell 
death caused by tyrosine kinase inhibition.  
 
Figure 6.2. The protective effect of different concentrations of IGF-2 against staurosporine-induced 
apoptosis in SNU-1 and NUGC3 cells. SNU-1 cells were centrifuged and resuspended in DCCS medium and 
seeded into a 75 cm
2 
flask at a concentration of 0.9 x 10
6 
cells per flask. After 24 hours, medium was replaced 
with 12 ml fresh DCCS medium for another 24 hours. Cells were centrifuged and resuspended in DCCS medium 
supplemented or not with different concentrations of IGF-2 for 15 minutes. Cells were then incubated with 0.5 
µM staurosporine in the presence and absence of IGF-2 for 4 hours. Cells were collected in 15 ml Falcon tubes 
and lysed in 50 µl RIPA buffer plus inhibitors. NUGC3 cells were seeded into 12 well tissue culture plates at 15 
x 10
4 
cells per well, in 1 ml maintenance medium. Cells were incubated for 24 hours to allow attachment. 
Medium was aspirated and the cells washed with 0.5 ml PBS. Medium was replaced daily with 1 ml DCCS 
medium for two days. Cells were incubated with DCCS medium supplemented or not with different 
concentrations of IGF-2 for 15 minutes. Cells were then incubated with 0.5 µM staurosporine in the presence 
and absence of IGF-2 for 5 hours. Proteins were extracted with 80 µl of RIPA buffer plus inhibitors per well. 
Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% polyacrylamide gels and 
transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with antibodies against 
cleaved PARP (1:2000 dilution) and GAPDH (1:10000 dilution). Densitometry was with Labworks 4.0 software, 
adjusted for the background optical density of the X-ray film and normalised to GAPDH. 
 
6.2.2 The effect of insulin on gastric cancer cells 
 
6.2.2.1 The effect of different concentrations of insulin on activation of IGF-signal 
transduction pathway proteins 
Insulin binds the insulin receptor with very high affinity (Kd=0.25-0.5 nM) and it has a much 
lower affinity for the type I IGF receptor (Kd=100 nM). However, it has an intermediate 
affinity for hybrid receptors formed by the assembly of one α and β chain of the IGF-IR and 
one α and β chain of the IR-A or IR-B (Kd=70-80 nM) (Westley and May, 2013).   
The effect of stimulation with different concentrations of insulin on downstream signalling 
was investigated in SNU-1 and NUGC3 cells. SNU-1 and NUGC3 cells were withdrawn from 
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the effects of growth factors by culture in withdrawal medium for 2 days and, then, treated 
with different concentrations of insulin ranging from 2 to 50 ngml
-1
 for 15 minutes prior to 
protein lysis. 
Induction of IGF-IR and IR phosphorylation was detected in SNU-1 cells, after stimulation 
with 5 ng/ml insulin or higher (Figure 6.3). Maximal phosphorylation was achieved with 50 
ng/ml. Phosphorylated IGF-IR and IR were detected in NUGC3 cells after treatment with 2 
ng/ml insulin or higher. Again, the maximal levels of phosphorylation were achieved with 50 
ng/ml insulin. The levels of total IGF-IR and IR remained unchanged after stimulation with 
insulin.  
Akt phosphorylation was detected in SNU-1 cells after treatment with 5 ng/ml insulin, and 
maximal phosphorylation was achieved with 50 ng/ml (Figure 6.3). In NUGC3 cells, some 
levels of Akt phosphorylation were detected in the absence of insulin but increased after 
insulin stimulation in a concentration-dependent manner. Maximal Akt phosphorylation was 
reached with 20 and 50 ng/ml insulin. Phosphorylated ERK1 and 2 were detected in both cell 
lines in the absence of insulin and there was a concentration-dependent increase after 
stimulation with insulin, only in NUGC3 cells. Maximal phosphorylation was achieved with 
20 and 50 ng/ml in NUGC3 cells. In SNU-1 cells, insulin did not increase ERK1 and 2 
phosphorylation at any concentration. Total Akt and ERK1 and 2 levels were not affected by 





Figure 6.3. The effect of stimulation with different concentrations of insulin on phosphorylation of IGF 
signal transduction proteins in SNU-1 and NUGC3 cells. SNU-1 cells were centrifuged and resuspended in 
DCCS medium and seeded into a 75 cm
2 
flask at a concentration of 0.9x10
6 
cells per flask. After 24 hours, 
medium was replaced with 12 ml fresh DCCS medium for another 24 hours. Cells were centrifuged and 
resuspended in serum-free medium with 0.1% BSA for 2 hours. Cells were then centrifuged and resuspended in 
serum-free medium with 0.1% BSA and 0, 0.5, 2, 5, 20, 50 ng/ml insulin for 15 minutes. Cells were collected in 
a 15 ml Falcon tube and proteins were lysed with 50 µl RIPA buffer plus inhibitors. NUGC3 cells were seeded 
into 12 well tissue culture plates at 15x10
4 
cells/well, in 1 ml maintenance medium. Cells were incubated for 24 
hours to allow attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. Medium was replaced 
daily with 1 ml DCCS medium for two days. Cells were incubated with serum-free medium which contained 
0.1% BSA for two hours. Medium was changed to include insulin at final concentrations of 0, 0.5, 2, 5, 20, 50 
ng/ml. After incubation for 15 minutes proteins were extracted with 80 µl per well RIPA buffer plus inhibitors. 
Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% polyacrylamide gels and 
transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with antibodies against 
phosphorylated IGF-IR/IR (1:1000 dilution), IGF-IR (1:2000 dilution), phosphorylated Akt (1:3000 dilution), 
Akt (1:3000 dilution), phosphorylated ERK1/2 (1:5000 dilution), ERK1/2 (1:5000 dilution) and GAPDH 
(1:10000 dilution). Images shown are representative of results from one triplicate experiment. Images obtained 
after incubation with antibodies against the total proteins are shown beneath those of the phosphorylated 
proteins. Total insulin receptor is shown below the total type I IGF receptor.      
 
Stimulation of both SNU-1 and NUGC3 cells with insulin resulted in phosphorylation of the 
type I IGF and insulin receptors and activation of the PI3K/Akt pathway in SNU-1 and 
NUGC3 cells and the Ras/Raf/MAPK pathway in NUGC3 cells. Phosphorylation of the type I 
IGF and/or insulin receptor in SNU-1 and NUGC3 cells was detected with similar 
concentrations of insulin and IGF-1 (SNU-1 cells; 5 ng/ml, NUGC3 cells; 2 ng/ml, see 
chapter 3). Also, a slightly higher concentration of insulin was required to induce Akt 




6.2.2.2 The effect of insulin on survival of gastric cancer cells 
The effect of insulin on staurosporine-induced apoptosis was investigated. SNU-1 and 
NUGC3 cells were withdrawn from the effects of growth factors and treated with 
concentrations of insulin ranging from 2 to 200 ng/ml in the presence of 0.5 µM 
staurosporine. Cleaved PARP was detected in SNU-1 cells treated with staurosporine. The 
amount of cleaved PARP was reduced by insulin in a concentration-dependent manner 
(Figure 6.4). Highest protection against cell death was achieved with 200 ng/ml. In NUGC3 
cells, treatment with staurosporine also resulted in cleavage of PARP into its 89 kDa 
fragment. Insulin reduced the amount of cleaved PARP in a concentration-dependent manner 
with maximal protection achieved with 200 ng/ml.  
The above results suggest that, like IGF-1 and IGF-2, insulin can also afford protection 
against cell death induced by tyrosine kinase inhibition. 
 
Figure 6.4. The protective effect of different concentrations of insulin against staurosporine-induced 
apoptosis in SNU-1 and NUGC3 cells. SNU-1 cells were centrifuged and resuspended in DCCS medium and 
seeded into a 75 cm
2 
flask at a concentration of 0.9x10
6 
cells per flask. After 24 hours, medium was replaced 
with 12 ml fresh DCCS medium for another 24 hours. Cells were centrifuged and resuspended in DCCS medium 
supplemented or not with different concentrations of insulin for 15 minutes. Cells were then incubated with 0.5 
µM staurosporine in the presence and absence of insulin for 4 hours. Cells were collected in 15 ml Falcon tubes 
and lysed in 50 µl RIPA buffer plus inhibitors. NUGC3 cells were seeded into 12 well tissue culture plates at 
15x10
4 
cells per well, in 1 ml maintenance medium. Cells were incubated for 24 hours to allow attachment. 
Medium was aspirated and the cells washed with 0.5 ml PBS. Medium was replaced daily with 1 ml DCCS 
medium for two days. Cells were incubated with DCCS medium supplemented or not with different 
concentrations of insulin for 15 minutes. Cells were then incubated with 0.5 µM staurosporine in the presence 
and absence of insulin for 5 hours. Proteins were extracted with 80 µl of RIPA buffer plus inhibitors per well. 
Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% polyacrylamide gels and 
transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with antibodies against 
cleaved PARP (1:2000 dilution) and GAPDH (1:10000 dilution). Densitometry was with Labworks 4.0 software, 
adjusted for the background optical density of the X-ray film and normalised to GAPDH. 
 
6.2.3 The effect of siRNA knockdown of the type I IGF receptor on survival of gastric 
cancer cells in the presence of serum 
Our results suggest that all three growth factors, IGF-1, IGF-2 and insulin, promote survival 
of gastric cancer cells. To determine which of the two receptors of the IGF signal transduction 
pathway is involved in mediating survival signals, expression of the type I IGF receptor was 
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reduced in SNU-1 and NUGC3 cells and the effect on cell survival was investigated, in 
culture medium enriched with growth factors. The levels of cleaved PARP were measured in 
SNU-1 and NUGC3 cells that had been transfected with the siRNA oligonucleotide against 
the type I IGF receptor and compared to the levels detected after transfection with scrambled 
oligonucleotide.    
Expression of the type I IGF receptor was detected readily in SNU-1 cells transfected with the 
scrambled oligonucleotide (Figure 6.5). Following transfection with siRNA 2 against the type 
I IGF receptor, expression of the receptor was reduced to non-detectable levels. Low levels of 
cleaved PARP were detected in cells transfected with the scrambled oligonucleotide (Figure 
6.5). Knockdown of the type I IGF receptor with siRNA 2 did not alter significantly the 
amount of PARP cleavage. In NUGC3 cells, siRNA 2 against the type I IGF receptor reduced 
also receptor expression to non-detectable levels (Figure 6.5). Reduction of type I IGF 
receptor expression was followed by a very small induction of PARP cleavage. 
The above results suggest that signalling through the type I IGF receptor is not critical for the 
survival of SNU-1 cells when many ligands are available, whereas it might be slightly more 
important in mediation of survival in NUGC3 cells.  
 
Figure 6.5. The effect of inhibition of the type I IGF receptor with siRNA knockdown on apoptosis in 
SNU-1 and NUGC3 cells cultured in maintenance medium. Transfection medium was prepared by mixing 
either scrambled (scr) or IGF-IR targeted (siIGF-IR) siRNA duplex 2 at final concentrations of 50 and 40 nM for 
SNU-1 and NUGC3 cells, respectively, and Lipofectamine RNAiMAX at a final concentration of 0.2% (v/v), in 
0.25 ml DMEM without serum. The transfection medium was then incubated at room temperature for 30 
minutes. SNU-1 cells were centrifuged and diluted in medium supplemented with 10% foetal calf serum at 10 x 
10
4
 cells/ml. NUGC3 cells grown in maintenance medium were detached using trypsin:EDTA and resuspended 
in maintenance medium at 10 x 10
4
 cells /ml. One ml of the cell suspension was mixed with 0.25 ml of the 
transfection medium, containing scrambled or IGF-IR targeted sequences, in 12 well tissue culture plates. After 
incubation for 72 hours, protein extracts were prepared with 80 µl per well of RIPA buffer plus inhibitors. 
Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% polyacrylamide gels and 
transferred to nitrocellulose for at 100 mA for 45 minutes. Membranes were incubated with antibodies against 




6.2.4 The effect of siRNA knockdown of the insulin receptor on survival of gastric cancer 
cells in the presence of serum 
The importance of the insulin receptor in cell survival was investigated by transient 
knockdown of the insulin receptor, in culture medium enriched with growth factors. The 
levels of cleaved PARP were measured in SNU-1 and NUGC3 cells that had been transfected 
with the siRNA oligonucleotides against the insulin receptor and compared to the levels 
detected after transfection with scrambled oligonucleotide.  
Insulin receptor expression was detected readily in SNU-1 cells transfected with the 
scrambled oligonucleotide (Figure 6.6A). Following transfection with siRNA 2 against the 
insulin receptor, expression of the receptor was reduced to non-detectable levels. Transfection 
with siRNA 3 reduced insulin receptor expression by 60% (Figure 6.6B). Low levels of 
cleaved PARP were detected in cells transfected with the scrambled oligonucleotide (Figure 
6.6A). Knockdown of the insulin receptor with siRNA 2 induced significantly PARP 
cleavage. There was no increase in the levels of cleaved PARP after transfection with siRNA 
3 (Figure 6.6B), probably, due to inefficient knockdown of the insulin receptor with the above 
siRNA. 
In NUGC3 cells, both siRNAs against the insulin receptor reduced insulin receptor expression 
to non-detectable levels (Figure 6.6A and B). Reduction of insulin receptor expression was 





Figure 6.6. The effect of inhibition of the insulin receptor with siRNA knockdown on apoptosis in SNU-1 
and NUGC3 cells cultured in maintenance medium. Transfection medium was prepared by mixing either 
scrambled (scr) or IR targeted (InsR) siRNA duplexes 2 and 3 at a final concentration of 50, 20 and 50 nM, 
respectively, and Lipofectamine RNAiMAX at a final concentration of 0.2% (v/v), in 0.25 ml DMEM without 
serum. The transfection medium was then incubated at room temperature for 30 minutes. SNU-1 cells were 
centrifuged and diluted in medium supplemented with 10% foetal calf serum at 10 x 10
4
 cells/ml. NUGC3 cells 
grown in maintenance medium were detached using trypsin:EDTA and resuspended in maintenance medium at 
10 x 10
4
 cells /ml. One ml of the cell suspension was mixed with 0.25 ml of the transfection medium, containing 
scrambled or IR targeted sequences, in 12 well tissue culture plates. After incubation for 72 hours, protein 
extracts were prepared with 80 µl per well of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein 
were electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose for at 100 mA for 
45 minutes. Membranes were incubated with antibodies against the IR (1:1000 dilution), cleaved PARP (1:2000) 
and GAPDH (1:10000 dilution) (A). Densitometry was with Labworks 4.0 software, adjusted for the background 
optical density of the X-ray film and normalised to β-tubulin. Results are expressed as a percentage of the 
intensity of the cleaved PARP band observed after transfection with siRNA 2. Bars are the mean ±SEM, * 
denotes statistically significantly lower insulin receptor expression and higher amount of cleaved PARP after 
transfection with the siRNA against insulin receptor (One-way ANOVA; SNU-1, IR, p≤0.0005, cleaved PARP, 
p<0.0001; NUGC3, IR, p<0.0001, cleaved PARP, p≤0.0001) (B). 
 
The above results suggest that signalling through the insulin receptor is important for 
mediating survival signals and preventing apoptosis in SNU-1 and NUGC3 cells, even in the 




6.2.5 The effect of concomitant knockdown of the type I IGF receptor and insulin receptor 
on survival of gastric cancer cells in the presence of serum  
The relative importance of the type I IGF and insulin receptors in cell survival was 
investigated by reduction of the two receptors’ expression separately and concomitantly, in 
medium supplemented with growth factors. NUGC3 cells were transfected with scrambled 
siRNA, with siRNA-2 against the type I IGF receptor (si-IGF-IR), with siRNA-2 against the 
insulin receptor (si-IR) and with a combination of si-IGF-IR 2 and si-IR 2. Cells were 
incubated with the transfection mix, containing the siRNA sequences and lipofectamine and 
cultured for 72 hours before protein lysis. Expression of the two receptors and cleavage of 
PARP were analysed by western transfer. 
Both the type I IGF and insulin receptors were detected in cells that had been transfected with 
scrambled siRNA (Figure 6.7). No type I IGF receptor was detected in cells that had been 
transfected with si-IGF-IR 2. Very low levels of insulin receptor were detected in cells that 
had been transfected with si-IR 2. Combination of si-IGF-IR 2 and si-IR 2 resulted in 
effective knockdown of both receptors, simultaneously. Reduction in the expression of either 
receptor did not alter the expression levels of the other receptor.  
There was no cleaved PARP in cells that had been transfected with scrambled siRNA. 
Reduced IGF-IR expression resulted in appearance of a small amount of the 89 kDa fragment 
of PARP (Figure 6.7). Reduced IR expression induced 4x higher levels of cleaved PARP 
compared to reduced IGF-IR expression. Finally, combination of the two siRNAs did not 
induce a significant increase in cell death, compared to transfection with the si-IR alone. 
These results suggest that the insulin receptor might be more important for cell survival than 





Figure 6.7. The effect of concomitant inhibition of the type I IGF and insulin receptors with siRNA 
knockdown on apoptosis in NUGC3 cells cultured in maintenance medium. Transfection medium was 
prepared by mixing scrambled (60 nM), IGF-IR targeted (40 nM), IR targeted (20 nM), or IGF-IR targeted plus 
IR targeted (40+20 nM) siRNA duplexes and Lipofectamine RNAiMAX at a final concentration of 0.2% (v/v), 
in 0.25 ml DMEM without serum. The transfection medium was then incubated at room temperature for 30 
minutes. NUGC3 cells grown in maintenance medium were detached using trypsin:EDTA and resuspended in 
maintenance medium at 15 x 10
4
 cells /ml. One ml of the cell suspension was mixed with 0.25 ml of the 
transfection medium, containing scrambled, IR or IGF-IR targeted sequences, in 12 well tissue culture plates. 
After incubation for 72 hours, protein extracts were prepared with 80 µl per well of RIPA buffer plus inhibitors. 
Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% polyacrylamide gels and 
transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with antibodies against the 
IGF-IR (1:2000 dilution), IR (1:1000), cleaved PARP (1:2000) and GAPDH (1:10000 dilution). The results 
shown are from an experiment that has been duplicated (A). Densitometry was with Labworks 4.0 software, 
adjusted for the background optical density of the X-ray film and normalised to GAPDH. Results are expressed 
as a percentage of the intensity of the cleaved PARP band observed after transfection with si IR and si IGF-IR. 
Bars are the mean ±SEM, * denotes statistically significantly higher amount of cleaved PARP after transfection 
with si IR (One-way ANOVA; p≤0.0027) (B). 
 
6.2.6 The effect of treatment with BMS754807 in the presence of serum  
The effect of treatment with the BMS754807 inhibitor, which targets both the type I IGF and 
insulin receptor, was investigated in SNU-1 and NUGC3 cells in the presence of growth 
factors. SNU-1 and NUGC3 cells were cultured with and without 0.5 μM BMS754807 in 
maintenance medium supplemented with 10% foetal calf serum for 3 days. A small amount of 
cleaved PARP was detected in SNU-1 cells after 3 days of culture in maintenance medium 
(Figure 6.8). Treatment with BMS754807 increased significantly the amount of cleaved 
PARP (p=0.001). Similarly, a relatively small amount of cleaved PARP was detected in 
NUGC3 cells after culture in medium supplemented with 10% foetal calf serum for 3 days 
(Figure 6.8). Treatment of cells with the BMS754807 inhibitor increased significantly the 
amount of cleaved PARP (p=0.0002). 
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The above results suggest that treatment with the BMS754807 in the presence of other growth 
factors and functioning pathways can affect viability of SNU-1 and NUGC3 cells. This result 
is in agreement with the data obtained from siRNA knockdown of the type I IGF and insulin 
receptors (Figure 6.7).   
 
Figure 6.8. The effect of inhibition of IGF-IR/IR with BMS754807 on apoptosis in SNU-1 and NUGC3 
cells cultured in maintenance medium. SNU-1 and NUGC3 cells were seeded into 12 well tissue culture plates 
at a concentration of 150000 cells/well, in 1 ml maintenance medium which contained DMSO, 0.5 µM or 5 µM 
BMS754807. The cells were left for 72 hours and protein extracts were prepared with 90 µl per well RIPA buffer 
plus inhibitors. Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% polyacrylamide 
gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with antibodies 
against cleaved PARP (1:2000 dilution) and GAPDH (1:10000 dilution) (A). Densitometry was with Labworks 
4.0 software, adjusted for the background optical density of the X-ray film and normalised to GAPDH. Results 
are expressed as a percentage of the intensity of the cleaved PARP band observed in the presence of the 
BMS754807 inhibitor. Bars are the mean ±SEM, * denotes statistically significantly increased cleaved PARP 
levels in the presence of BMS54807 compared with in the absence of BMS754807 (Unpaired t-test; SNU-1, 
p=0.001; NUGC3, p=0.0002) (B).  
 
6.2.7 The effect of IGF-2 on proliferation 
So far our results suggest that IGF-2 and insulin mediate survival signals in SNU-1 and 
NUGC3 cells and the insulin receptor is more involved in mediation of survival signals than 
the type I IGF receptor. To investigate the effect of IGF-2 on gastric cancer cell growth, 
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NUGC3 cells were cultured in serum-free medium over several days, in the presence or 
absence of 50 ng/ml IGF-2. The amount of DNA in the presence and in the absence of IGF-2 
was measured with the PicoGreen fluorimetric assay. The amount of DNA increased 
progressively in NUGC3 cells cultured in serum-free medium over the course of 9 days, when 
IGF-2 was not present (Figure 6.9). This could be attributed to the lack of withdrawal of 
NUGC3 cells from the effects of growth factors prior to treatment. When IGF-2 was present 
in the medium, the amount of DNA was increased at all time-points tested and this increase 
was statistically significant after 6 and 9 days of treatment. Importantly, in NUGC3 cells 
grown in serum-free medium, there was no significant increase in cell number from day 3 to 
day 6 (Two-way ANOVA; p=0.2714). However, in the presence of IGF-2, the number of cells 
increased significantly from day 3 to day 6 (Two-way ANOVA; p=0.0002). There was no 
increase in cell number both in the presence and in the absence of IGF-2 from day 6 to day 9, 
which suggests that the cells were confluent.    
The above result suggests that IGF-2 can promote increased proliferation in NUGC3 cells. 
 
Figure 6.9. The effect of IGF-2 on cell proliferation in NUGC3 cells. NUGC3 cells were seeded into 24 well 
tissue culture plates at 1x10
4 
cells per well, in 0.5 ml maintenance medium. Cells were incubated for 24 hours to 
allow attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. Medium was replaced every 3 
days with 0.5 ml serum-free medium (NUGC3 cells) or 0.5 ml DCCS medium, supplemented or not with 50 
ng/ml IGF-2. At the end of each time point, medium was aspirated and the cells washed with 0.5 ml ice cold 
PBS. PBS was aspirated and the cells stored in -20
o
C. The cells were lysed in SSC/SDS solution and the amount 
of DNA in each well was quantified with the Quanti-iT picogreen fluorimetric assay. Bars are the mean ±SEM, * 
denotes statistically significantly higher DNA content in the presence of IGF-2 compared with in the absence of 




6.2.8 The effect of insulin on proliferation  
The effect of insulin on gastric cancer cell growth was investigated over time. NUGC3 cells 
were cultured in serum-free medium, in the presence or absence of 50 ng/ml insulin for 9 
days. The amount of DNA in the presence and in the absence of insulin was measured with 
the PicoGreen fluorimetric assay. The amount of DNA increased progressively in NUGC3 
cells cultured in serum-free medium over the course of 9 days, when insulin was not present 
(Figure 6.10). Again, increase in cell number could be attributed to the lack of withdrawal of 
the cells from the growth factors present in the serum prior to treatment. When insulin was 
present in the medium, the amount of DNA was increased at all time-points tested and the 
increase was statistically significant after 6 and 9 days of treatment. In the absence of insulin, 
there was no significant increase in cell number from day 3 to day 6 (Two-way ANOVA; 
p=0.5473), whereas when insulin was present cell number increased significantly (Two-way 
ANOVA; p=0.0002).  
This suggests that, apart from inducing cell survival, insulin can also promote increased 
proliferation in NUGC3 cells. 
 
Figure 6.10. The effect of insulin on cell proliferation in NUGC3 cells. NUGC3 cells were seeded into 24 
well tissue culture plates at 1x10
4 
cells per well, in 0.5 ml maintenance medium. Cells were incubated for 24 
hours to allow attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. Medium was replaced 
every 3 days with 0.5 ml serum-free medium (NUGC3 cells) or 0.5 ml DCCS medium, supplemented or not with 
50 ng/ml insulin. At the end of each time point, medium was aspirated and the cells washed with 0.5 ml ice cold 
PBS. PBS was aspirated and the cells stored in -20
o
C. The cells were lysed in SSC/SDS solution and the amount 
of DNA in each well was quantified with the Quanti-iT picogreen fluorimetric assay. Bars are the mean ±SEM, * 
denotes statistically significantly higher DNA content in the presence of insulin compared with in the absence of 




6.2.9 The effect of IGF-IR knockdown on the proliferative effect of IGF-2 and insulin 
To investigate whether the type I IGF receptor mediates the IGF-2 proliferative effect in 
NUGC3 cells, the effect of IGF-2 on cell proliferation was tested after transient knockdown of 
the type I IGF receptor with siRNA.  
NUGC3 cells were reverse transfected with siRNA 2, which targets the type I IGF receptor or 
with scrambled sequence and cultured in serum-free medium, in the presence or absence of 
IGF-2 for 9 days. In the absence of IGF-2, transfection with siRNA 2 resulted in a small 
reduction in cell growth, compared with transfection with scrambled sequence (Figure 6.11). 
This suggests that, as mentioned in section 6.2.7, NUGC3 cells were not completely 
withdrawn from the effects of growth factors prior to transfection, therefore, IGF-IR 
knockdown might have retarded their growth. The proliferative response of NUGC3 cells to 
IGF-2 was reduced significantly in cells in which endogenous expression of the type I IGF 
receptor had been lowered (Figure 6.11). This suggests that the type I IGF receptor mediates, 
at least in part, the IGF-2 proliferative effect in NUGC3 cells. 
 
Figure 6.11. The effect of inhibition of the type I IGF receptor on the IGF-2 proliferative effect. 
Transfection medium was prepared by mixing either scrambled (scr) or IGF-IR targeted (IGF-IR) siRNA 
duplexes at a final concentration of 40 nM and Lipofectamine RNAiMAX at a final concentration of 0.2% (v/v), 
in 0.1 ml DMEM without serum. The transfection medium was then incubated at room temperature for 30 
minutes. NUGC3 cells grown in maintenance medium were detached using trypsin:EDTA and resuspended in 
maintenance medium at 12.5x10
4
 cells /ml. Four hundred µl of the cell suspension were mixed with 0.1 ml of the 
transfection medium, containing scrambled or IGF-IR targeted sequences, in 24 well tissue culture plates. Cells 
were incubated for 24 hours to allow attachment. Medium was aspirated and the cells were washed with PBS. 
Medium was replaced every 3 days with serum-free medium supplemented or not with 50 ng/ml IGF-2. After 
treatment with IGF-2 for 9 days, medium was aspirated and cells were washed once with ice cold PBS. PBS was 
aspirated and the cells stored in -20
o
 C. The cells were lysed in SSC/SDS solution and the amount of DNA 
present in each well was quantified with the Quanti-iT picogreen fluorimetric assay. Bars are the mean ±SEM. 
Asterisks indicate significant reduction in IGF-2-stimulated proliferation after reduction in type I IGF receptor 
expression (Two-way ANOVA; p=0.0007). 
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The importance of the type I IGF receptor in transmission of the proliferative effect of insulin 
was investigated in NUGC3 cells, by testing the effect of insulin on cell proliferation after 
transient knockdown of the type I IGF receptor with siRNA.  
NUGC3 cells were reverse transfected with siRNA 2, which targets the type I IGF receptor or 
with scrambled sequence and cultured in serum-free medium, in the presence or absence of 
insulin for 9 days (Figure 6.12). In the absence of insulin, transfection with siRNA 2 resulted 
in a small reduction of cell growth, compared with transfection with scrambled sequence, due 
to the absence of withdrawal of the cells from growth factors prior to transfection. The 
proliferative response of NUGC3 cells to insulin was reduced significantly in cells in which 
endogenous expression of the type I IGF receptor had been lowered (Figure 6.11). This 
suggests that the type I IGF receptor mediates, at least in part, the proliferative effect of 
insulin in NUGC3 cells. 
 
Figure 6.12. The effect of inhibition of the type I IGF receptor on the insulin proliferative effect. 
Transfection medium was prepared by mixing either scrambled (scr) or IGF-IR targeted (IGF-IR) siRNA 
duplexes at a final concentration of 40 nM and Lipofectamine RNAiMAX at a final concentration of 0.2% (v/v), 
in 0.1 ml DMEM without serum. The transfection medium was then incubated at room temperature for 30 
minutes. NUGC3 cells grown in maintenance medium were detached using trypsin:EDTA and resuspended in 
maintenance medium at 12.5x10
4
 cells /ml. Four hundred µl of the cell suspension were mixed with 0.1 ml of the 
transfection medium, containing scrambled or IGF-IR targeted sequences, in 24 well tissue culture plates. Cells 
were incubated for 24 hours to allow attachment. Medium was aspirated and the cells were washed with PBS. 
Medium was replaced every 3 days with serum-free medium supplemented or not with 50 ng/ml insulin. After 
treatment with insulin for 9 days, medium was aspirated and cells were washed once with ice cold PBS. PBS was 
aspirated and the cells stored in -20
o
 C. The cells were lysed in SSC/SDS solution and the amount of DNA 
present in each well was quantified with the Quanti-iT picogreen fluorimetric assay. Bars are the mean ±SEM. 
Asterisks indicate significant reduction in insulin-stimulated proliferation after reduction in type I IGF receptor 




6.2.10 The effect of IGF-IR and IR knockdown on cell number in the presence of serum 
To compare the effect of reduced expression of the type I IGF and insulin receptor on cell 
number in the presence of growth factors, NUGC3 cells were reverse transfected with siRNA 
2 against the type I IGF receptor, siRNA 2 against the insulin receptor or scrambled sequence 
and the number of cells was measured three days after transfection.  
There was a significant reduction in the amount of DNA after knockdown of either the type I 
IGF receptor or the insulin receptor in NUGC3 cells (Figure 6.13). Knockdown of the type I 
IGF receptor did not induce significant levels of PARP cleavage (Figure 6.5) and as seen in 
chapter 5, loss of IGF-IR reduced the number of cells synthesizing DNA and undergoing 
mitosis (Figure 5.10 and Figure 5.11). Therefore, we can conclude that the reduction in cell 
number after IGF-IR knockdown is a result of reduced cell proliferation rather than increased 
cell death. On the contrary, reduction in IR expression induced significant amount of cell 
death (Figure 6.6), which has led to detachment of the cells from tissue culture plates (data 
not shown) and subsequent reduction in cell number. Therefore, it cannot be excluded that 
reduction in cell number after IR knockdown is a result of increased cell death rather than 





Figure 6.13. The effect of inhibition of the type I IGF and insulin receptor on cell number. Transfection 
medium was prepared by mixing scrambled (scr), IGF-IR targeted (si IGF-IR 2) or IR targeted (si IR 2) siRNA 
duplexes at a final concentration of 40, 40 and 20 nM, respectively, and Lipofectamine RNAiMAX at a final 
concentration of 0.2% (v/v), in 0.1 ml DMEM without serum. The transfection medium was then incubated at 
room temperature for 30 minutes. NUGC3 cells grown in maintenance medium were detached using 
trypsin:EDTA and resuspended in maintenance medium at 12.5x10
4
 cells /ml. Four hundred µl of the cell 
suspension were mixed with 0.1 ml of the transfection medium, containing scrambled or IGF-IR targeted 
sequences, in 24 well tissue culture plates. Cells were incubated for 72 hours. Medium was aspirated and cells 
were washed once with ice cold PBS. PBS was aspirated and the cells stored in -20
o
 C. The cells were lysed in 
SSC/SDS solution and the amount of DNA present in each well was quantified with the Quanti-iT picogreen 
fluorimetric assay. Bars are the mean ±SEM. Asterisks indicate significant reduction in cell number after 
reduction in type I IGF and insulin receptor expression (One-way ANOVA; p≤0.0057). 
 
6.2.11 Expression of insulin receptor isoforms in gastric cancer cells 
As mentioned previously, there are two insulin receptor isoforms, which are generated by 
alternative splicing of exon 11. The form that contains 12 amino acids encoded by exon 11 is 
called the B-isoform (IR-B) and the form that lacks the 12 amino acids encoded by exon 11 is 
called the A-isoform (IR-A). Isoform A of the insulin receptor has 2x higher affinity for 
insulin, 5x higher affinity for IGF-2 and 10x higher affinity for IGF-1 compared to isoform B 
(Westley and May, 2013). Given the observed importance of the insulin receptor in survival 
of SNU-1 and NUGC3 cells (sections 6.2.4 and 6.2.5), it is of interest to analyse expression of 
the two isoforms in gastric cancer cells.        
To determine the expression of the two insulin receptor isoforms in gastric cancer cells, 
polymerase chain reactions were designed to amplify specifically isoform A of the insulin 
receptor or isoform B. A relatively high number of PCR cycles was used to ensure detection 
of the two isoforms in gastric cancer cells. Isoform A of the insulin receptor was detected in 
all cell lines, with MKN74 cells expressing the lowest amount (Figure 6.14). Similarly, 
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isoform B of the insulin receptor was detected in all cell lines tested, with MKN74 cells 
expressing again the lowest levels.  
 
Figure 6.14. Expression of insulin receptor isoform A and insulin receptor isoform B in gastric cancer 
cells. KATO III, SNU-16, SNU-5, SNU-1, MKN74, NUGC3 and AGS cells were cultured in 25 cm
2 
tissue 
culture flasks in maintenance medium to ~80% confluence. Total RNA was extracted from the cells with the 
Direct-zol™ RNA MiniPrep, as described in the Materials and Methods section. Complementary DNA was 
synthesised from total RNA with the Moloney Murine Leukaemia Virus Reverse Transcriptase. Specific primer 
sequences were used to amplify isosoform A and isoform B of the insulin receptor and 18S rRNA. A high 
number of PCR cycles (35) was used for detection of the two isoforms. The amplified DNA was electrophoresed 
in a 3% agarose gel, stained with GelRed, and bands were visualised with a UV transilluminator. 
 
To determine the relative abundance of the two insulin receptor isoforms in gastric cancer 
cells, a specific polymerase chain reaction was designed to amplify both isoforms 
simultaneously. The amplicon corresponding to insulin receptor isoform B is 187 bp in 
length, whereas the one corresponding to isoform A is 151 bp. A lower number of PCR cycles 
was performed to detect any potential differences in the expression of the two isoforms. SNU-
16, NCI-N87 and MKN74 cells expressed lower levels of insulin receptor compared to KATO 
III, SNU-5, SNU-1, NUGC3 and AGS cells (Figure 6.15). The two isoforms were expressed 
equally in SNU-16, NCI-N87 and SNU-5 cells. The remaining cell lines, KATO III, SNU-1, 
MKN74, NUGC3 and AGS had higher IRA:IRB ratios compared to the previous cell lines. In 
the above four cell lines, isoform A of the insulin receptor was the predominantly expressed 
isoform.  
It is of interest that SNU-1 and NUGC3 cells, in which knockdown of the insulin receptor 
induced cell death, expressed considerably higher levels of isoform A of the insulin receptor 
than isoform B. It could, therefore, be concluded that isoform A is primarily responsible for 




Figure 6.15. Relative expression of insulin receptor isoforms A and B in gastric cancer cells. NCI-N87, 
KATO III, SNU-16, SNU-5, SNU-1, MKN74, NUGC3 and AGS cells were cultured in 25 cm
2 
tissue culture 
flasks in maintenance medium to ~80% confluence. Total RNA was extracted from the cells with the Direct-
zol™ RNA MiniPrep, as described in the Materials and Methods section. Complementary DNA was synthesised 
from total RNA with the Moloney Murine Leukaemia Virus Reverse Transcriptase. Specific primer sequences 
were used to amplify both insulin receptor isoforms and 18S rRNA. A relatively low number of PCR cycles was 
used (31). The amplified DNA was electrophoresed in a 3% agarose gel, stained with GelRed, and bands were 
visualised with a UV transilluminator. 
 
6.3 Discussion 
The aim of the experiments reported in this chapter was to investigate the responsiveness of 
gastric cancer cells to IGF-2 and insulin and the relative importance of the type I IGF and 
insulin receptor in cell survival and proliferation.  Both IGF-2 and insulin stimulated 
phosphorylation of the type I IGF and insulin receptors and activated the PI3K/Akt pathway 
in SNU-1 and NUGC3 cells and the Ras/MAPK pathway in NUGC3 cells. Consequently, 
apart from IGF-1 binding to the type I IGF receptor, it is evident that other ligand-receptor 
interactions may take place and contribute to IGF signal transduction and biological effects. 
Exogenous IGF-2 and insulin afforded protection against staurosporine-induced PARP 
cleavage in SNU-1 and NUGC3 cells. Also, both growth factors stimulated proliferation of 
NUGC3 cells. 
Previously, IGF-2 protected MKN74 and Met-amplified MKN45 gastric cancer cells against 
apoptosis which had been induced by treatment with 5% ethanol (Min et al., 2005). The same 
study has shown that IGF-2 stimulates proliferation of MKN45 gastric cancer cells. The role 
of IGF-2 in cell proliferation has been demonstrated in MCF-7 breast cancer cells (Stewart et 
al., 1990) and in colon cancer cells, in which an anti IGF-2 antibody reduced effectively cell 
growth (Singh et al., 1996). Furthermore, the mitogenic effect of 29 ng/ml insulin, lower to 
the concentration of 50 ng/ml used in the present study, has been shown in a variety of cancer 
cell lines, including breast, lung and prostate cancer cells (Sciacca et al., 2014).  
Transient knockdown of the insulin receptor with two different siRNA sequences, in an 
environment enriched with growth factors, resulted in increased levels of apoptosis in SNU-1 
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and NUGC3 cells. This suggests that gastric cancer cells depend on signalling through the 
insulin receptor in order to evade apoptosis and that other growth factors present in the serum 
are not sufficient to substitute its survival effects. A cell survival effect mediated by the 
insulin receptor has been shown previously in glioblastoma cells, in which, knockdown of the 
insulin receptor increased caspase 3/7 activity (Gong et al., 2015).  
The effect of reducing the expression of the insulin receptor was compared to the effect of 
reducing the expression of the type I IGF receptor on cell survival. Reduction of IGF-IR 
expression did not induce significant levels of cleaved PARP in NUGC3 cells, whereas 
reduction of IR expression increased cleaved PARP levels significantly. Targeting both 
receptors at the same time did not increase further the amount of cleaved PARP, which 
suggests that the insulin receptor is mainly responsible for evasion of apoptosis. It was not 
possible to investigate the role of insulin receptor on cell proliferation in this study, as 
knockdown of the insulin receptor resulted in increased detachment of the cells from tissue 
culture plates, due to cell death, which led to reduction of the amount of DNA. Consequently, 
quantification of the amount of DNA as a measure of cell proliferation would not have been 
applicable in this case. Detection of proliferation markers, such as BrdU incorporation or 
histone H3 phosphorylation could specify the role of insulin receptor in cell proliferation.  
Treatment of SNU-1 and NUGC3 cells with the tyrosine kinase inhibitor BMS754807, which 
targets both the type I IGF and insulin receptors, induced PARP cleavage in SNU-1 and 
NUGC3 cells grown in the presence of growth factors. Also, treatment with BMS754807 
reduced cell proliferation in SNU-1, MKN74, NUGC3 and AGS cells (section 5.2.7). This 
suggests that the BMS754807 inhibitor targets effectively both the proliferative effect 
mediated by the type I IGF receptor and the survival effect mediated by the insulin receptor.  
Several studies have reported apoptosis induction by BMS754807 alone or in combination 
with other drugs, in other cancer types. Treatment with BMS754807 increased PARP and 
caspase 3 cleavage in a rhabdomyosarcoma cell line, Rh41 (Carboni et al., 2009). 
Combination of the BMS754807 inhibitor with docetaxel in a tumourgraft model of human 
triple negative breast cancer, resulted in tumour regression associated with increased 
apoptosis (Litzenburger et al., 2011). Combined use of BMS754807 with gemcitabine 
increased caspase 3 and PARP cleavage in pancreatic ductal adenocarcinoma cell lines 
(Awasthi et al., 2012). 
Our results suggest that the type I IGF receptor mediates cell proliferation and the insulin 
receptor is important for cell survival. It is, therefore, expected that inhibition of both 
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receptors simultaneously might be a more effective therapeutic strategy than inhibition of 
either receptor alone. In prostate cancer cells, signalling through the insulin receptor 
compensated for and mediated IGF-1 mitogenic signals, following inhibition of the type I IGF 
receptor with cixutumumab, a monoclonal antibody against the type I IGF receptor 
(Weinstein et al., 2014). In a mouse mammary tumour model, inhibition of both the type I 
IGF receptor and insulin receptor with OSI-906, a small-molecule tyrosine kinase inhibitor, 
was more effective at reducing tumour volume compared to inhibition of the type I IGF 
receptor alone (Buck et al., 2010). Co-targeting of the type I IGF and insulin receptors with 
AZ12253801 and NVPAWD742 tyrosine kinase inhibitors was more effective at reducing 
non-small cell lung cancer cell proliferation than targeting the type I IGF receptor alone with 
the monoclonal antibody aIR3 (Vincent et al., 2013). Given the reported importance of the 
insulin receptor in survival and proliferation, it could be concluded that the lack of survival 
benefit in phase III clinical trials of figitumumab, an anti-IGF-IR antibody, in non-small cell 
lung cancer patients, could be attributed, partly, to insulin receptor signalling, which might 
have circumvented IGF-IR inhibition (Langer et al., 2014).  
Interestingly, knockdown of the type I IGF receptor resulted in significant reduction of the 
proliferative effect of IGF-2 and insulin in NUGC3 cells. This suggests that the type I IGF 
receptor is activated by IGF-2 and insulin and stimulates downstream pathways that result in 
cell growth. Previously, the proliferative effect of insulin in MCF-7 and 184B5 breast cancer 
cells was inhibited by 50-60%, after treatment with a monoclonal antibody which targets the 
type I IGF receptor (Milazzo et al., 1992). However, the same study showed that in two breast 
cancer cell lines, T-47D and ZR-75-1, the proliferative effect of insulin was not inhibited by 
the same monoclonal antibody against the type I IGF receptor, which suggests that in these 
cells insulin acts only through its own receptor.   
Expression of the two insulin receptor isoforms was detected in the gastric cancer cell lines, 
with 5 out of 8 cell lines expressing higher levels of isoform A than isoform B. This is 
consistent with the finding that isoform A of the insulin receptor is highly expressed in 
several human malignancies (Belfiore, 2007). KATO III, SNU-1, NUGC3 and AGS cells 
expressed highly isoform A of the insulin receptor and expressed very small amounts of the 
isoform B.   
In summary, the findings in this chapter have confirmed that apart from IGF-1-mediated 
activation of the type I IGF receptor, other ligand-receptor interactions take place and 
contribute to increased survival and proliferation. Both IGF-2 and insulin activated 
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downstream signal transduction pathways, protected cells against apoptosis induced by 
tyrosine kinase inhibition and increased cell proliferation. Also, the insulin receptor was more 
important than the type I IGF receptor in mediation of survival signals. Our results suggest 
that simultaneous inhibition of the type I IGF and insulin receptors might be a more effective 




Chapter 7. Combination of IGF signal transduction pathway inhibition 
with cytotoxic and targeted therapy in gastric cancer cells 
 
7.1 Introduction 
Preclinical analysis of the effects of combining a targeted inhibitor with cytotoxic drugs, helps 
to determine the effective drug combinations to be tested in the clinic. In the UK, the standard 
cytotoxic treatment for patients with advanced gastric cancer comprises a fluorouracil-based 
regimen, such as capecitabine or 5-fluorouracil, with cisplatin or oxaliplatin and epirubicin. It 
is, therefore, important to investigate the effect of combining anti-IGF-IR/IR targeted 
treatment to the above cytotoxic agents in a pre-clinical setting.    
As mentioned previously, inhibitors against FGFR2 and c-Met are currently being evaluated 
in clinical trials for patients with advanced gastric cancer. In preclinical models, it has already 
been demonstrated that activation of several receptor tyrosine kinases, including EGFR, 
HER3 and Met contributed to reduced sensitivity to AZD4547, a selective FGFR2 inhibitor, 
in FGFR2 amplified gastric cancer cells (Chang et al., 2015). The rescue effect exerted by the 
above tyrosine kinases was abrogated by inhibiting them with their targeted tyrosine kinase 
inhibitors. Concomitant inhibition of IGF-IR with FGFR2 or Met has not been investigated in 
gastric cancer cells. 
Advanced gastric cancer patients with HER2 positive cancer receive trastuzumab as well as 
cytotoxic drugs as part of their standard treatment. Approximately 50% of patients with HER-
2 positive advanced gastric cancer do not respond to trastuzumab treatment and 12% develop 
progressive disease within 18 months (Bang et al., 2010). The effect of IGF-IR/IR inhibition 
has yet to be investigated in HER2 amplified gastric cancer cells, which have acquired 
resistance to a HER2 targeted inhibitor. 
 
7.1.1 Aims 
The aim of the results reported in this chapter is to investigate the effect of combining 
cytotoxic agents currently used in the clinic for advanced gastric cancer patients with IGF-
IR/IR inhibition in gastric cancer cells. Furthermore, the potential of combining IGF-IR/IR 
inhibition with FGFR2 and Met inhibitors, which are currently in clinical trials for advanced 
gastric cancer, will be investigated in gastric cancer cells. Finally, inhibition of the IGF signal 
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transduction pathway will be investigated as a potential way of circumventing secondary 
resistance of HER-2 amplified gastric cancer cells to a HER-2 targeted inhibitor.     
 
7.2 Results 
7.2.1 The effect of treatment with oxaliplatin on viability of gastric cancer cells 
Oxaliplatin is a third-generation platinum-based drug with cytotoxic activity (Misset et al., 
2000). It is currently included in the chemotherapeutic regime administered to patients with 
advanced gastric cancer and other cancers. To investigate the effect of oxaliplatin on the 
viability of gastric cancer cells in vitro, SNU-1 and NUGC3 cells were treated with increasing 
concentrations of oxaliplatin and the amount of DNA in each sample was measured after 3 
days. 
Oxaliplatin reduced significantly the number of SNU-1 cells at concentrations equal to or 
higher than 1 µM (Figure 7.1). The IC50 of oxaliplatin in the above cell line was 
approximately 0.8 µM and the IC90 was approximately 10 µM. In NUGC3 cells, oxaliplatin 
reduced significantly the number of cells at concentrations equal to or higher that 0.1 µM. An 
IC50 of approximately 0.8 µM and an IC90 of 3 µM was detected in those cells. 
 
Figure 7.1. The effect of treatment with different concentrations of oxaliplatin on viability of SNU-1 and 
NUGC3 cells. SNU-1 and NUGC3 cells were seeded into 24 well tissue culture plates at 5x10
4 
cells per well, in 
0.5 ml maintenance medium. Adherent cells were incubated for 24 hours to allow attachment. Medium was 
replaced to maintenance medium which contained 0, 0.01, 0.1, 1, 10 or 100 µM oxaliplatin. After 3 days, 
medium was aspirated and the cells washed with 0.5 ml ice cold PBS. PBS was aspirated and the cells stored in -
20
o
C. The cells were lysed in SSC/SDS solution and the amount of DNA in each well was quantified with the 
Quanti-iT picogreen fluorimetric assay. Bars are the mean ±SEM, * denotes statistically significantly lower 
amount of DNA after treatment with oxaliplatin compared to untreated cells (One-way ANOVA; p<0.0001).  
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To investigate the effect of different concentrations of oxaliplatin on cell survival, NUGC3 
cells were treated with a range of concentrations of oxaliplatin for 24 hours and cell death was 
measured by detecting the amount of cleaved PARP. No cleaved PARP was detected in 
NUGC3 cells after culture in maintenance medium in the absence of oxaliplatin (Figure 7.2). 
Oxaliplatin increased the amount of cleaved PARP in a concentration dependent manner and 
maximum levels were achieved with 20 µM.   
 
Figure 7.2. The effect of treatment with oxaliplatin on survival of NUGC3 cells. NUGC3 cells were seeded 
into 12 well tissue culture plates at 1x10
5 
cells per well, in 1 ml maintenance medium. Cells were incubated for 
24 hours to allow attachment. Medium was replaced to maintenance medium which contained 0, 4, 8, or 20 µM 
oxaliplatin. After 24 hours, proteins were extracted with 80 µl of RIPA buffer plus inhibitors per well. Aliquots 
containing 10 µg of protein were electrophoresed on denaturing 12% polyacrylamide gels and transferred to 
nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with antibodies against cleaved PARP 
(1:2000 dilution) and GAPDH (1:10000 dilution).  
 
The above results suggest that oxaliplatin effectively reduces the number of SNU-1 and 
NUGC3 gastric cancer cells, in a concentration-dependent manner. Also, oxaliplatin 
effectively induces cell death in NUGC3 cells, as measured by the induction of cleaved 
PARP.    
 
7.2.2 The effect of IGF-1 on gastric cancer cells treated with oxaliplatin in the presence of 
serum 
Treatment with oxaliplatin reduced the number of SNU-1 and NUGC3 cells, in a 
concentration-dependent manner and induced apoptosis. To investigate whether IGF-1 can 
protect gastric cancer cells from the cytotoxic effects of oxaliplatin, SNU-1 and NUGC3 cells 
were treated with different concentrations of oxaliplatin in the presence or absence of 50 
ng/ml IGF-1 and the amount of DNA in the presence or absence of IGF-1 was measured. 
In SNU-1 cells, oxaliplatin reduced significantly the number of cells after three days of 
treatment, however, concomitant treatment with IGF-1 did not alter the amount of DNA at 
135 
 
any concentration of oxaliplatin tested (Figure 7.3). A similar result was obtained in NUGC3 
cells, with IGF-1 having no effect on the amount of DNA present after treatment with 
different concentrations of oxaliplatin. Since the cells were not withdrawn from the effects of 
growth factors prior to treatment, it is possible that some IGF-1 was already present in the 
serum and, therefore, the externally added IGF-1 did not induce an additional effect.  
 
Figure 7.3. The effect of IGF-1 on treatment with oxaliplatin in SNU-1 and NUGC3 cells. SNU-1 and 
NUGC3 cells were seeded into 24 well tissue culture plates at 5x10
4 
cells per well, in 0.5 ml maintenance 
medium. Adherent cells were incubated for 24 hours to allow attachment. Medium was replaced to maintenance 
medium which contained 0, 0.001, 0.01, 0.1, 1, 10 or 100 µM oxaliplatin, in the presence or absence of 50 ng/ml 
IGF-1. After 3 days, medium was aspirated and the cells washed with 0.5 ml ice cold PBS. PBS was aspirated 
and the cells stored in -20
o
C. The cells were lysed in SSC/SDS solution and the amount of DNA in each well 
was quantified with the Quanti-iT picogreen fluorimetric assay.  
 
7.2.3 The effect of inhibition of the IGF signal transduction pathway on cell death induced 
by oxaliplatin in gastric cancer cells 
To investigate whether inhibition of the IGF signal transduction pathway can intensify the 
amount of cell death induced by oxaliplatin, NUGC3 cells were transfected with a siRNA 
against the type I IGF receptor and treated with 8 µM oxaliplatin for 3 days and the amount of 
cleaved PARP was measured by western transfer analysis. 
No reduction of IGF-IR expression was detected in NUGC3 cells that had been transfected 
with the scrambled oligonucleotide (Figure 7.4). Transfection with the siRNA against the type 
I IGF receptor resulted in effective reduction of IGF-IR expression. No cleaved PARP was 
detected in cells that had been transfected with the scrambled oligonucleotide in the absence 
of oxaliplatin. Treatment with 8 µM oxaliplatin for three days induced cleaved PARP in 
NUGC3 cells. Transfection of NUGC3 cells with siRNA against the type I IGF receptor in the 
absence of oxaliplatin, also induced cleaved PARP. When treatment with oxaliplatin was 
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combined with inhibition of IGF-IR by siRNA knockdown, the amount of cleaved PARP was 
higher than in any of the above conditions alone (Figure 7.4A). Interestingly, the effect 
observed with the combined treatment was higher than the additive effect of the two 
treatments (Figure 7.4B). This suggests that inhibition of IGF-IR might potentiate induction 
of cell death by oxaliplatin in NUGC3 cells.  
 
Figure 7.4. The effect of treatment with oxaliplatin in combination with reduction of IGF-IR expression 
on survival of NUGC3 cells. Transfection medium was prepared by mixing either scrambled (scr) or IGF-IR 
targeted (IGF-IR) siRNA duplexes at a final concentration of 20 nM and Lipofectamine RNAiMAX at a final 
concentration of 0.2% (v/v), in 0.25 ml DMEM without serum. The transfection medium was then incubated at 
room temperature for 30 minutes. NUGC3 cells grown in maintenance medium were detached using 
trypsin:EDTA and resuspended in medium supplemented with 10% foetal calf serum at 10 x 10
4
 cells /ml. One 
ml of the cell suspension was mixed with 0.25 ml of the transfection medium, containing scrambled or IGF-IR 
targeted sequences, in 12 well tissue culture plates. After 24 hours the medium was replaced with maintenance 
medium, which contained 8 µM oxaliplatin. After 72 hours of treatment with oxaliplatin, protein extracts were 
prepared with 80 µl per well of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein were 
electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose for at 100 mA for 45 
minutes. Membranes were incubated with antibodies against cleaved PARP (1:2000 dilution), IGF-IR (1:2000 
dilution) and GAPDH (1:10000 dilution) (A). Densitometry was with Labworks 4.0 software, adjusted for the 
background optical density of the X-ray film and normalised to GAPDH. Results are expressed as a percentage 
of the intensity of the cleaved PARP band observed in cells transfected with siRNA against the IGF-IR and 
treated with oxaliplatin. Bars are the mean ±SEM, * denotes statistically significantly higher amount of cleaved 
PARP in the presence of oxaliplatin and in the absence of IGF-IR (One-way ANOVA; p<0.0001) (B). 
 
7.2.4 The effect of combining cytotoxic agents with BMS754807 on viability of gastric 
cancer cells 
To investigate the effect of combining cytotoxic agents currently used in the clinic for 
advanced gastric cancer patients, such as oxaliplatin and 5-fluorouracil with inhibition of the 
IGF signal transduction pathway, SNU-1 and NUGC3 cells were treated with different 
concentrations of the above cytotoxic agents, in the presence and absence of BMS754807. 
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In SNU-1 cells, treatment with oxaliplatin resulted in significant reduction of the number of 
cells at concentrations ranging from 1 to 100 µM, whereas concentrations ranging from 0 to 
0.1 µM did not have any significant cytotoxic effect (Figure 7.5). Treatment with 5 µM 
BMS754807 within the non-cytotoxic range of oxaliplatin concentrations (0 to 0.1 µM), 
reduced significantly the number of cells. However, at higher concentrations of oxaliplatin, 
which were cytotoxic for the cells, treatment with the BMS754807 did not confer any 
additional benefit. A similar result was observed in NUGC3 cells, in which BMS754807 
reduced significantly the number of cells within the non-cytotoxic range of oxaliplatin 
concentrations, but did not confer any additional benefit at higher cytotoxic concentrations 
(Figure 7.5). The above result suggests that inhibition of the IGF signal transduction pathway 
with BMS754807 does not aggravate the detrimental effect of oxaliplatin on cell viability.  
 
 
Figure 7.5. The effect of treatment of SNU-1 and NUGC3 cells with different concentrations of oxaliplatin 
in combination with the BMS754807 inhibitor. SNU-1 and NUGC3 cells were seeded into 24 well tissue 
culture plates at 5x10
4 
cells per well, in 0.5 ml maintenance medium. Adherent cells were incubated for 24 hours 
to allow attachment. Medium was replaced to maintenance medium which contained 0, 0.0001, 0.001, 0.01, 0.1, 
1, 10 or 100 µM oxaliplatin with 5 µM BMS754807 or DMSO. After 3 days, medium was aspirated and the cells 
washed with 0.5 ml ice cold PBS. PBS was aspirated and the cells stored in -20
o
C. The cells were lysed in 
SSC/SDS solution and the amount of DNA in each well was quantified with the Quanti-iT picogreen 
fluorimetric assay. Bars are the mean ±SEM, * denotes statistically significantly lower amount of DNA in the 
presence of BMS754807 inhibitor and oxaliplatin compared to treatment with oxaliplatin alone (Two-way 
ANOVA; SNU-1, p<0.0001, NUGC3, p≤0.0001).  
 
The fluoropyrimidine 5-fluorouracil (5-FU) is a uracil analogue, which enters the cell in a 
similar manner to uracil and leads to creation of DNA strand breaks, which eventually cause 
cell death (Lindahl, 1974). To investigate the effect of 5-fluorouracil on the viability of gastric 
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cancer cells in vitro, SNU-1 and NUGC3 cells were treated with increasing concentrations of 
the drug and the amount of DNA in each sample was measured after 3 days. 
In SNU-1 cells treatment with 5-fluorouracil reduced significantly the number of cells at 
concentrations ranging from 10 to 100 µM, whereas concentrations up to 1 µM did not have 
any significant cytotoxic effect (Figure 7.5). The IC50 of 5-fluorouracil in SNU-1 cells was 
close to 10 µM, which suggests that SNU-1 cells are less sensitive to 5-fluorouracil than to 
oxaliplatin. As seen with oxaliplatin, treatment with 5 µM BMS754807 within the non-
cytotoxic range of 5-fluorouracil concentrations (0 to 0.1 µM), reduced significantly the 
number of SNU-1 cells. Interestingly, treatment with BMS754807 reduced further the number 
of cells which had been treated with 10 and 100 µM 5-fluorouracil, concentrations which kill 
approximately 60% and 80% of SNU-1 cells, respectively. In NUGC3 cells, 5-fluorouracil 
was cytotoxic at concentrations starting from 1 µM and higher, with an IC50 of approximately 
2 µM. Treatment with 5 µM BMS754807 reduced even further the number of cells at all 
concentrations of 5-fluorouracil used, both in the non-cytotoxic and in the cytotoxic range 
(Figure 7.6).     
 
Figure 7.6. The effect of treatment of SNU-1 and NUGC3 cells with different concentrations of 5-
fluorouracil in combination with the BMS754807 inhibitor. SNU-1 and NUGC3 cells were seeded into 24 
well tissue culture plates at 5x10
4 
cells per well, in 0.5 ml maintenance medium. Adherent cells were incubated 
for 24 hours to allow attachment. Medium was replaced to maintenance medium which contained 0, 0.0001, 
0.001, 0.01, 0.1, 1, 10 or 100 µM 5-fluorouracil, with 5 µM BMS754807 or DMSO. After 3 days, medium was 
aspirated and the cells washed with 0.5 ml ice cold PBS. PBS was aspirated and the cells stored in -20
o
C. The 
cells were lysed in SSC/SDS solution and the amount of DNA in each well was quantified with the Quanti-iT 
picogreen fluorimetric assay. Bars are the mean ±SEM, * denotes statistically significantly lower amount of 
DNA in the presence of BMS754807 inhibitor and 5-fluorouracil compared to treatment with 5-fluorouracil 
alone (Two-way ANOVA; SNU-1, p≤0.0435, NUGC3, p≤0.0015).  
 
The above data suggests that there is a small potentiation of the cytotoxic effect of 5-




7.2.5 The effect of IGF-IR and IR inhibition on viability of FGFR2-amplified cells treated 
with AZD4547 
As mentioned previously, inhibitors that target FGFR2 and Met are currently in clinical trials 
for advanced gastric cancer. We tested whether or not such inhibitors inhibit effectively 
gastric cancer cell growth in vitro and whether IGF-1 might provide some protection against 
those inhibitors. 
AZD4547 is a selective inhibitor of the FGFR1, 2 and 3 tyrosine kinases (Gavine et al., 2012) 
and it is currently in clinical trials for advanced gastric cancer. To test the efficacy of 
AZD4547, FGFR-2 amplified cell lines KATO III and SNU-16 were treated with different 
concentrations of AZD4547 and the amount of DNA was measured after three days of 
treatment. In KATO III cells, treatment with 0.003 µM AZD4547 or higher, reduced 
significantly the amount of DNA, compared to untreated cells (Figure 7.7A). SNU-16 cells 
were even more sensitive to AZD4547; cell number was reduced significantly with 0.001 µM 
AZD4547 and was reduced even further with higher concentrations (Figure 7.7B).     
The effect of IGF-1 was tested in KATO III and SNU-16 cells which had been treated with 
AZD4547. KATO III cells were not protected against AZD4547 by IGF-1 (Figure 7.7C). 
However, in SNU-16 cells there was a small trend of IGF-1 protection against AZD4547, 
with a significant increase in cell number after treatment with IGF-1 in the presence of  0.3 




Figure 7.7. The effect of IGF-1 on treatment with AZD4547 in FGR-2 amplified cells. KATO III and SNU-
16 cells were seeded into 24 well tissue culture plates at 5x10
4 
cells per well, in 0.5 ml maintenance medium. 
Adherent cells were incubated for 24 hours to allow attachment. Medium was replaced to maintenance medium 
which contained 0, 0.001, 0.003, 0.01, 0.03, 0.1 or 0.3 µM AZD4547. After 3 days, medium was aspirated and 
the cells washed with 0.5 ml ice cold PBS. PBS was aspirated and the cells stored in -20
o
C. The cells were lysed 
in SSC/SDS solution and the amount of DNA in each well was quantified with the Quanti-iT picogreen 
fluorimetric assay. Bars are the mean ±SEM, * denotes statistically significantly lower levels of DNA in cells 
treated with AZD4547 compared with untreated cells (One-way ANOVA; p≤0.0003) (A, B). KATO III and 
SNU-16 cells were seeded into 24 well tissue culture plates at 5x10
4 
cells per well, in 0.5 ml maintenance 
medium. Adherent cells were incubated for 24 hours to allow attachment. Medium was replaced to maintenance 
medium which contained 0, 0.001, 0.003, 0.01, 0.03, 0.1 or 0.3 µM AZD4547 in the presence or absence of 50 
ng/ml IGF-1. After 3 days, medium was aspirated and the cells washed with 0.5 ml ice cold PBS. PBS was 
aspirated and the cells stored in -20
o
C. The cells were lysed in SSC/SDS solution and the amount of DNA in 
each well was quantified with the Quanti-iT picogreen fluorimetric assay. Bars are the mean ±SEM, * denotes 
statistically significantly higher levels of DNA in the presence of IGF-1 compared with in the absence of IGF-1 




To test whether inhibition of the IGF signal transduction pathway affects the response of 
SNU-16 cells to AZD4547, SNU-16 cells were treated with different concentrations of 
AZD4547 in the presence or absence of BMS754807 and the amount of DNA was measured. 
Treatment with 0.5 µM BMS754807 did not reduce the number of SNU-16 cells in the 
absence of AZD4547 (Figure 7.8A). Combination of BMS754807 with AZD4547 reduced the 
number of cells significantly at all concentrations of AZD4547 tested. Additionally, the IC50 
of AZD4547 was reduced from 0.01 µM to approximately 0.005 µM in the presence of 0.5 
µM BMS754807. Treatment with a higher concentration of BMS754807 (5 µM) reduced the 
number of cells to 15% in the absence of AZD4547 and combined treatment with AZD4547 
did not reduce further the number of cells (Figure 7.8B). This suggests that at lower 
concentrations, BMS754807 enhances the growth inhibitory effect of AZD4547 in SNU-16 
cells, whereas higher concentrations of BMS754807 overpower the growth inhibitory effect 
of AZD4547.  
 
Figure 7.8. The effect of combining BMS754807 with different concentrations of AZD4547 in SNU-16 
cells. SNU-16 cells were seeded into 24 well tissue culture plates at 5x10
4 
cells per well, in 0.5 ml maintenance 
medium, which contained 0, 0.001, 0.003, 0.01, 0.03, 0.1 or 0.3 µM AZD4547 in the presence or absence of 0.5 
µM (A) or 5 µM BMS754807 (B). After 3 days, medium was aspirated and the cells washed with 0.5 ml ice cold 
PBS. PBS was aspirated and the cells stored in -20
o
C. The cells were lysed in SSC/SDS solution and the amount 
of DNA in each well was quantified with the Quanti-iT picogreen fluorimetric assay. Bars are the mean ±SEM, * 
denotes statistically significantly lower levels of DNA in cells treated with BMS754807 and AZD4547 
compared to cells treated with AZD4547 alone. (Two-way ANOVA; (A) p≤0.0057, (B) p<0.0001).    
 
The above experiments suggest that SNU-16 cells are responsive to inhibition of the IGF 
signal transduction pathway and combination of IGF-IR/IR inhibition with FGFR2 inhibition 
may be more effective than inhibition of either receptor alone. However, optimal selection of 




7.2.6 The effect of IGF-IR and IR inhibition on viability of MET-amplified cells treated 
with crizotinib 
Crizotinib is a small-molecule tyrosine kinase inhibitor of MET, ALK and ROS1 kinases 
(Christensen et al., 2007). In Met-amplified SNU-5 cells, crizotinib reduced significantly cell 
number at 0.002 µM and higher (Figure 7.9A). There was a small but non-significant increase 
in the number of SNU-5 cells treated with IGF-1 in the presence of 0.002 and 0.06 µM 
crizotinib (Figure 7.9B). At higher concentrations of crizotinib, IGF-1 did not confer any 
protective effect (Figure 7.9B).  
 
Figure 7.9. The effect of IGF-1 on treatment with crizotinib in Met-amplified cells. SNU-5 cells were 
seeded into 24 well tissue culture plates at 5x10
4 
cells per well, in 0.5 ml maintenance medium, which contained 
0, 0.002, 0.006, 0.02, 0.06, 0.2 or 0.6 µM crizotinib. After 3 days, medium was aspirated and the cells washed 
with 0.5 ml ice cold PBS. PBS was aspirated and the cells stored in -20
o
C. The cells were lysed in SSC/SDS 
solution and the amount of DNA in each well was quantified with the Quanti-iT picogreen fluorimetric assay. 
Bars are the mean ±SEM, * denotes statistically significantly higher levels of DNA in cells treated with 
crizotinib compared to untreated cells (Two-way ANOVA; p<0.0001) (A). SNU-5 cells were seeded into 24 well 
tissue culture plates at 5x10
4 
cells per well, in 0.5 ml maintenance medium, which contained 0, 0.002, 0.006, 
0.02, 0.06, 0.2 or 0.6 µM crizotinib in the presence or absence of 50 ng/ml IGF-1. After 3 days, medium was 
aspirated and the cells washed with 0.5 ml ice cold PBS. PBS was aspirated and the cells stored in -20
o
C. The 
cells were lysed in SSC/SDS solution and the amount of DNA in each well was quantified with the Quanti-iT 
picogreen fluorimetric assay. Bars are the mean ±SEM (B).   
 
To test whether inhibition of the IGF signal transduction pathway affects the response of 
SNU-5 cells to crizotinib, SNU-5 cells were treated with different concentrations of crizotinib 
in the presence or absence of BMS754807 and the amount of DNA was measured. Treatment 
with 0.5 µM BMS754807 did not reduce the number of SNU-5 cells in the absence of 
crizotinib (Figure 7.10A). In the presence of different concentrations of crizotinib, treatment 
with 0.5 µM BMS754807 did not reduce further the amount of DNA (Figure 7.10A). 
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Treatment of SNU-5 cells with 5 µM BMS754807 reduced the number of SNU-5 cells to 35% 
in the absence of crizotinib (Figure 7.10B). Treatment with 5 µM BMS754807 in combination 
with low concentrations of crizotinib (up to 0.006 µM), reduced significantly the number of 
cells (Figure 7.10). At higher concentrations of crizotinib ranging from 0.02 to 0.6 µM, the 
above benefit was neutralised (Figure 7.10B). The above results suggest that addition of 
BMS754807 does not augment the growth inhibitory effect of high concentrations of 
crizotinib in SNU-5 cells. 
 
Figure 7.10. The effect of combining BMS754807 with different concentrations of crizotinib in SNU-5 
cells. SNU-5 cells were seeded into 24 well tissue culture plates at 5x10
4 
cells per well, in 0.5 ml maintenance 
medium, which contained 0, 0.002, 0.006, 0.02, 0.06, 0.2 or 0.6 µM crizotinib in the presence or absence of 0.5 
µM (A) or 5 µM (B) BMS754807. After 3 days, medium was aspirated and the cells washed with 0.5 ml ice cold 
PBS. PBS was aspirated and the cells stored in -20
o
C. The cells were lysed in SSC/SDS solution and the amount 
of DNA in each well was quantified with the Quanti-iT picogreen fluorimetric assay. Bars are the mean ±SEM, * 
denotes statistically significantly lower levels of DNA in cells treated with BMS754807 and crizotinib compared 
to cells treated with crizotinib alone. (Two-way ANOVA; (B) p<0.0001).    
 
7.2.7 The effect of EGF and IGF-1 on survival of HER-2 amplified cells 
As mentioned in chapter 4, HER-2-amplified NCI-N87 gastric cancer cells are protected by 
IGF-1 against cell death induced by protein kinase inhibition (Figure 4.3). To investigate the 
response of NCI-N87 cells to combined treatment with IGF-1 and epidermal growth factor, 
NCI-N87 cells were treated with staurosporine in the presence or absence of IGF-1 and EGF, 
separately and in combination.  
Cleavage of PARP was detected in NCI-N87 cells treated with staurosporine in the absence of 
IGF-1 and EGF (Figure 7.11). Treatment of the cells with EGF reduced significantly the 
amount of cleaved PARP to approximately 40% and a similar effect was observed with IGF-
1. Most effective protection against staurosporine-induced PARP cleavage was achieved after 
concomitant treatment with EGF and IGF-1 (Figure 7.11). Double treatment resulted in 
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reduction of cleaved PARP amount to 10% of the amount detected in the absence of the two 
growth factors.
 
Figure 7.11. The effect of EGF and IGF-1 on cell survival in HER-2-amplified NCI-N87 cells. NCI-N87 
cells were seeded into 12 well tissue culture plates at 15 x 10
4 
cells per well, in 1 ml maintenance medium. Cells 
were incubated for 24 hours to allow attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. 
Medium was replaced daily with 1 ml withdrawal medium for two days. Cells were incubated with withdrawal 
medium supplemented or not with 50 ng/ml EGF, 50 ng/ml IGF-1 or both, for 15 minutes. Cells were then 
incubated with 0.5 µM staurosporine in the presence and absence of 50 ng/ml EGF, 50 ng/ml IGF-1 or both for 4 
hours. Proteins were extracted with 80 µl of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein 
were electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 
minutes. Membranes were incubated with antibodies against cleaved PARP (1:2000 dilution) and GAPDH 
(1:10000 dilution) (A). Densitometry was with Labworks 4.0 software, adjusted for the background optical 
density of the X-ray film and normalised to GAPDH. Results are expressed as a percentage of the intensity of the 
cleaved PARP band observed in the absence of EGF and IGF-1. Bars are the mean ±SEM, * denotes statistically 
significantly less cleaved PARP in the presence of EGF, IGF-1 or both than in their absence (One-way ANOVA; 
p≤0.0002) (B). 
 
The above result suggests that despite the amplification of human epidermal growth factor 
receptor (HER-2) in NCI-N87 cells, they are still responsive to IGF-1. Also, treatment with 
both growth factors is more effective at inhibition of cell death than treatment with each 
growth factor alone. It would, therefore, be interesting to investigate the response of NCI-N87 
cells to inhibition of the IGF signal transduction pathway in the presence of a HER-2 
inhibitor.   
 
7.2.8 The effect of treatment with lapatinib on viability of HER-2 amplified cells with and 
without lapatinib resistance 
As mentioned previously, approximately 50% of patients with HER-2 positive advanced 
gastric cancer do not respond to trastuzumab treatment and approximately 12% develop 
progressive disease (Bang et al., 2010). Involvement of other signal transduction pathways, 
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such as Met, HER3 and the IGF pathways, in primary resistance to lapatinib, a dual tyrosine 
kinase inhibitor against HER2 and EGFR, has been reported previously (Zhang et al., 2014). 
We wanted to test whether the IGF signal transduction pathway is involved in acquired 
resistance of HER-2 amplified gastric cancer cells to lapatinib. 
Resistance to lapatinib was achieved by continuous treatment of NCI-N87 cells with 
increasing concentrations of lapatinib for 6 months. The sensitivity of non-resistant and 
resistant cells to lapatinib was analysed by quantification of the amount of DNA after 
treatment with different concentrations of lapatinib. In non-resistant NCI-N87 cells, treatment 
with lapatinib reduced the amount of DNA in a concentration dependent manner (Figure 
7.12). The IC50 of lapatinib for those cells was close to 90 nM. In NCI-N87/lapatinib resistant 
cells, the effectiveness of lapatinib in reduction of cell number was reduced significantly. In 
those cells, the IC50 of lapatinib was increased to approximately 9 µM. This suggests that the 
cells had lost their sensitivity to the drug and could therefore be used as models of resistant 
disease.  
 
Figure 7.12. Effect of treatment with different concentrations of lapatinib on parental NCI-N87 cells and 
on NCI-N87 cells which have developed a secondary resistance to lapatinib. NCI-N87 and NCI-
N87/lapatinib resistant cells were seeded into 24 well tissue culture plates at 5x10
4 
cells per well, in 0.5 ml 
maintenance medium. Cells were incubated for 24 hours to allow attachment. Medium was replaced to 
maintenance medium which contained 0, 0.001, 0.01, 0.1, 1 or 10 µM lapatinib. After 3 days, medium was 
aspirated and the cells washed with 0.5 ml ice cold PBS. PBS was aspirated and the cells stored in -20
o
C. The 
cells were lysed in SSC/SDS solution and the amount of DNA in each well was quantified with the Quanti-iT 
picogreen fluorimetric assay. Bars are the mean ±SEM, * denotes statistically significantly higher amount of 





7.2.9 The effect of treatment with lapatinib on signal transduction in HER-2 amplified cells 
with and without resistance to lapatinib 
To test the effect of lapatinib on lapatinib-resistant and non-resistant NCI-N87 cells, both cell 
lines were cultured in the presence or absence of lapatinib and phosphorylation of key 
proteins was analysed.  
In non-resistant NCI-N87 cells, treatment with lapatinib reduced effectively HER-2 
phosphorylation (Figure 7.13). In lapatinib-resistant NCI-N87 cells, the basal levels of HER-2 
phosphorylation were reduced compared to non-resistant cells. Moreover, treatment with 
lapatinib did not seem to affect the amount of phosphorylated HER-2. The amount of total 
HER-2 was not affected by acquisition of resistance to lapatinib or by treatment with 
lapatinib. 
To investigate potential involvement of the IGF signal transduction pathway in acquisition of 
resistance to lapatinib, phosphorylation of IGF-IR and IR was analysed in resistant and non-
resistant cells. There were no differences between IGF-IR and IR phosphorylation levels in 
resistant and non-resistant cells (Figure 7.13). Also, the amount of total IGF-IR was not 
affected by acquisition of resistance to lapatinib or by treatment with lapatinib.  
Activation of downstream signalling pathways in response to lapatinib treatment was also 
investigated. In non-resistant NCI-N87 cells, treatment with lapatinib reduced effectively the 
amount of phosphorylated Akt. However, in cells with resistance to lapatinib, Akt 
phosphorylation was not reduced after lapatinib treatment (Figure 7.13). A similar result was 
obtained with ERK1 and ERK2 phosphorylation. Both total Akt and total ERK1 and ERK2 




Figure 7.13. The effect of lapatinib on signal transduction in NCI-N87 cells and NCI-N87- lapatinib-
resistant cells. NCI-N87 and NCI-N87/lapatinib resistant cells were seeded into 12 well tissue culture plates at 
1.5 x 10
5 
cells per well, in 1 ml maintenance medium. Cells were incubated for 24 hours to allow attachment. 
Medium was replaced to maintenance medium which contained 0.2 µM lapatinib. After 24 hours, proteins were 
extracted with 80 µl of RIPA buffer plus inhibitors per well. Aliquots containing 10 µg of protein were 
electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 
minutes. Membranes were incubated with antibodies against phosphorylated HER-2 (1:1000 dilution), HER-2 
(1:1000 dilution), phosphorylated IGF-IR&IR (1:1000 dilution), IGF-IR (1:2000 dilution), phosphorylated Akt 
(1:2000 dilution), Akt (1:2000 dilution), phosphorylated ERK1&ERK2 (1:5000), ERK1&ERK2 (1:5000 
dilution) and GAPDH (1:10000 dilution). Images obtained after incubation with antibodies against the total 
proteins are shown beneath those of the phosphorylated proteins.   
 
The above results suggest that NCI-N87 cells with an acquired resistance to lapatinib have 
lost their dependency on the HER-2 receptor and are able to stimulate the PI3K/Akt and 
Ras/Raf/MAPK pathway independent of HER-2 activation. Resistance to lapatinib-induced 





7.2.10 The effect of treatment with BMS754807 on viability of HER-2 amplified cells with 
and without resistance to lapatinib 
To investigate if inhibition of the IGF-signal transduction pathway is effective in HER-2 
amplified cells, with and without secondary resistance to lapatinib, NCI-N87 and NCI-
N87/lapatinib-resistant cells were cultured with different concentrations of BMS754807 and 
the amount of DNA was measured. In NCI-N87 cells, treatment with BMS754807 reduced 
the number of cells in a concentration-dependent manner. Significant reduction in cell number 
was achieved with 1 and 10 µM BMS754807 (Figure 7.14). In NCI-N87/lapatinib-resistant 
cells, the cytotoxic effect of BMS754807 was identical to non-resistant cells, at 1 µM 
BMS754807. When the cells were treated with 10 µM BMS754807, the amount of DNA was 
reduced significantly in lapatinib-resistant cells compared to non-resistant cells (p=0.0029). 
This suggests that NCI-N87 cells with acquired resistance to lapatinib, are more sensitive to 
high concentrations of the BMS754807 inhibitor than non-resistant cells. 
 
Figure 7.14. Effect of treatment with different concentrations of BMS754807 on viability of NCI-N87 cells 
and NCI-N87 lapatinib resistant cells. NCI-N87 and NCI-N87/lapatinib-resistant cells were seeded into 24 
well tissue culture plates at 5x10
4 
cells per well, in 0.5 ml maintenance medium. Cells were incubated for 24 
hours to allow attachment. Medium was replaced to maintenance medium which contained 0, 0.001, 0.01, 0.1, 1 
or 10 µM BMS754807. After 3 days, medium was aspirated and the cells washed with 0.5 ml ice cold PBS. PBS 
was aspirated and the cells stored in -20
o
C. The cells were lysed in SSC/SDS solution and the amount of DNA in 
each well was quantified with the Quanti-iT picogreen fluorimetric assay. Bars are the mean ±SEM, * denotes 
statistically significantly lower amount of DNA in lapatinib-resistant cells that had been treated with 
BMS754807compared to non-resistant cells (Two-way ANOVA; p=0.0029). 
 
7.3 Discussion 
SNU-1 and NUGC3 cells were sensitive to treatment with oxaliplatin and 5-fluorouracil, as 
indicated by the reduction of cell number and induction of PARP cleavage. The IC50s for both 
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cell lines were higher for 5-fluorouracil than for oxaliplatin, which suggests that oxaliplatin 
had a more potent cytotoxic effect. Treatment with IGF-1 did not rescue the cells from the 
cytotoxic effect of oxaliplatin, in the presence of other growth factors found in the serum. It is 
possible that some IGF-1 was already present in the serum and the externally added IGF-1 did 
not confer any additional changes in cell growth. Alternatively, it could be concluded that 
IGF-1 is unable to rescue gastric cancer cells from the cytotoxic effects of oxaliplatin in a 
growth factor enriched environment. 
Combined inhibition of the type I IGF receptor by siRNA knockdown with oxaliplatin 
treatment resulted in higher amounts of cleaved PARP, compared to the additive effect of the 
two treatments. However, when SNU-1 and NUGC3 cells were treated with different 
concentrations of oxaliplatin, addition of BMS754807 did not reduce further the number of 
cells. There is, therefore, an inconsistency between the results obtained in the genetic level 
and the pharmacological level. It is possible that different time-frames are required for the 
treatments to show an effect at each level. For example, induction of PARP cleavage might 
precede the reduction in cell number which could be detectable at later time points. It would 
be useful to investigate different time-frames of treatment with oxaliplatin in combination 
with siRNA knockdown or BMS754807.  
Addition of BMS754807 to SNU-1 and NUGC3 cells treated with different concentrations of 
5-fluorouracil, reduced further the number of cells even at the higher range of 5-fluorouracil 
concentrations. Combined use of IGF-IR inhibition with cytotoxic drugs has proven beneficial 
in preclinical models of various cancer types. Combination of PQIP, a tyrosine kinase 
inhibitor which targets IGF-IR/IR, with oxaliplatin and fluorouracil, showed synergistic 
inhibition of colorectal cancer cell proliferation (Flanigan et al., 2010). Combination of 
robatumumab (SCH 717454), an IGF-IR targeted antibody, with cisplatin was significantly 
more effective than either agent alone at reducing the volume of paediatric tumour xenografts 
(Wang et al., 2010b). Downregulation of IGF-IR with antisense oligonucleotide treatment 
increased significantly chemosensitivity of central nervous system atypical teratoid/rhabdoid 
tumours cells to cisplatin (D'Cunja et al., 2007) and of human colon cancer cells to 5-
fluorouracil (Yavari et al., 2010).   
In gastric cancer, there is a very limited number of preclinical studies which have investigated 
the potential of combined inhibition of the IGF signal transduction pathway with 
chemotherapy. Wang et al., have shown that reduction of IGF-IR expression with a dominant 
negative adenovirus increases cisplatin-induced apoptosis in MKN45, Met-amplified, gastric 
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cancer cells (Wang et al., 2010a). Min et al., found that reduction of IGF-IR expression with a 
dominant negative adenovirus, increased 5-fluorouracil-induced apoptosis in MKN45 cells. 
Combination of the two treatments was more effective than either therapy alone, at inhibiting 
growth of tumours, which were induced by subcutaneous injection of MKN45 cells in mice 
(Min et al., 2005). Our results are, therefore, the first to investigate the potential of combining 
IGF signal transduction pathway inhibition with chemotherapy in un-amplified gastric cancer 
cells.  
FGFR2-amplified gastric cancer cell lines KATO III and SNU-16 were extremely sensitive to 
the AZD4547 inhibitor, with IC50 values lower than 10 nM. The effectiveness of AZD4547 in 
inhibition of KATO III and SNU-16 cell growth has been shown previously (Xie et al., 2013). 
The same group have reported a significant concentration-dependent tumour growth 
inhibition in FGFR2-amplified xenografts treated with AZD4547.  
Our results show that IGF-1 afforded a small protection against AZD4547 treatment in SNU-
16 cells, but not KATO III cells, even in the presence of other growth factors. Further, 
treatment of SNU-16 cells with low concentrations of BMS754807 equal to 0.5 µM, enhanced 
the growth inhibitory effects of AZD4547, which suggests that SNU-16 cells are more 
responsive to activation of the IGF signal transduction pathway compared to KATO III, 
possibly due to higher IGF-IR expression in those cells (Figure 3.1). Involvement of other 
tyrosine kinase receptors, such as EGFR, HER3 and MET in attenuation of the efficacy of 
AZD4547 on SNU-16 cells has been reported previously (Chang et al., 2015). However, our 
results are the first to suggest that combined inhibition of FGFR2 and IGF-IR/IR might be 
more effective in SNU-16 cells than either treatment alone.  
The growth inhibitory effect of crizotinib on Met-amplified, SNU-5 cells was potent. This is 
supported by a study in which treatment with crizotinib reduced the volume of tumour 
xenografts established by subcutaneous injection of SNU-5 cells (Okamoto et al., 2012). IGF-
1 did not protect SNU-5 cells against the growth inhibitory effect of crizotinib and treatment 
with the BMS754807 inhibitor did not enhance the effect of crizotinib. SNU-5 cells express 
very low amounts of the type I IGF receptor, which might explain the lack of their 
responsiveness to IGF pathway inhibition. 
Combined inhibition of IGF-IR and HER-2 has been shown previously to have synergistic 
effects in breast cancer cells. Combination of trastuzumab with NVP-AEW541, a tyrosine 
kinase inhibitor which targets IGF-IR and IR, was more effective at inhibiting BT474 cell 
proliferation than either agent alone (Esparis-Ogando et al., 2008). A bispecific antibody 
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which targeted both HER-2 and IGF-IR was more effective at inhibiting proliferation of 
breast cancer cells and tumour growth in mice compared to trastuzumab alone or trastuzumab 
in combination with  m590, a monoclonal antibody against the type I IGF receptor (Chen et 
al., 2014).  
In gastric cancer, the IGF signal transduction pathway has been reported to be involved in 
mediating primary resistance of HER-2-amplified-gastric cancer cells, NCI-N87, to lapatinib 
and combined treatment with lapatinib and AEW-541, a tyrosine kinase inhibitor against IGF-
IR and IR, resulted in reduced cell viability and reduced tumour volume in mice compared to 
either inhibitor alone (Zhang et al., 2014). In trastuzumab-resistant NCI-N87 cells, there was 
increased IGF-IR activation, which suggested that the type I IGF receptor might be involved 
in acquisition of resistance to trastuzumab (Zuo et al., 2015).  
In our study, acquisition of resistance to lapatinib was accompanied by a reduction in 
phosphorylated HER-2. Also, lapatinib had lost its ability to inhibit Akt and ERK1 and ERK2 
phosphorylation in resistant cells. Activation of the type I IGF and insulin receptors was not 
altered in NCI-N87/lapatinib-resistant cells. However, treatment with high concentrations of 
BMS754807 inhibitor, which targets the type I IGF and insulin receptors, was more effective 
at inhibiting growth of NCI-N87/lapatinib-resistant cells compared to non-resistant cells. This 
suggests that NCI-N87/lapatinib resistant cells are more susceptible to inhibition of the IGF 
signal transduction pathway, although IGF-IR/IR phosphorylated and total levels are not 
increased. Alterations in adaptor protein expression and activation e.g. IRS 1, 2, 4 in resistant 
cells, may have increased the dependency of the cells on the IGF signal transduction pathway. 
Investigation of expression and activation of adaptor proteins in resistant cells could clarify 
the above hypothesis. Also, loss of HER-2 phosphorylation in lapatinib resistant cells might 
have made more PI3K subunits or Ras molecules available to the IGF signal transduction 
pathway, resulting in increased sensitivity of the phosphorylated IGF-IR, although the levels 
of phosphorylation were not affected.   
In summary, the results reported in this chapter suggest that there may be potential for 
concomitant treatment of SNU-1 and NUGC3 cells with 5-fluorouracil and BMS754807, as 
demonstrated by the reduction of cell number after treatment with the combination of the two 
drugs. Also, the small molecule tyrosine kinase inhibitor BMS754807 improves the efficiency 
of the anti-FGFR2 inhibitor AZD4547, in FGFR2-amplified SNU-16 cells. Finally, NCI-




Chapter 8. Importance of the IGF signal transduction pathway in primary 
cultures of gastric cancer cells 
 
8.1 Introduction 
The term ascites describes the pathological accumulation of excessive fluid inside the 
peritoneal cavity (Parsons et al., 1996b). Approximately 10% of all ascites cases are caused 
by malignant disease. Malignant ascites presents as an end-stage event in a variety of cancers 
and is associated with significant morbidity (Saif et al., 2009). The most common cancer 
types that may result in development of ascites are ovarian, endometrial, breast, oesophageal, 
gastric, colorectal, lung, pancreatic, hepatobillary and primary peritoneal carcinomas 
(Runyon, 1994). Approximately 50% of patients with malignant ascites present with it at the 
initial diagnosis of their cancer (Garrison et al., 1986; Parsons et al., 1996a).  
Management of patients with ascites ranges from drainage procedures to chemotherapy. The 
quality of life and, sometimes, the survival of patients with malignant ascites can be improved 
with appropriate combination chemotherapy (Buckman et al., 1992).  
Established, immortalised cancer cell lines are an invaluable tool for the study of molecular 
and cellular biology underpinning cancer. However, it can be argued that established cell lines 
represent a simplified model for the study of cancer, as they comprise isolated cells, which are 
no longer in contact with their surrounding microenvironment and have been growing in 
culture indefinitely. In this sense, ex vivo primary cultures are one step closer to the organism 
level and could provide valuable models for testing the efficiency of targeted therapies. 
Previously, primary cultures of cancer cells have been established from ascites isolated from 
patients with ovarian cancer (Shepherd et al., 2006; Theriault et al., 2013).   
 
8.1.1 Aims 
The aim of the results reported in this chapter is the establishment of a model of advanced 
gastric cancer, based on the utilisation of primary cultures of gastric cancer cells derived from 
ascites of patients with advanced gastric adenocarcinoma. Expression and activation of 
receptors and downstream molecules of the IGF-signal transduction pathway was investigated 
in the above primary cultures. The role of IGF-1 and the type I IGF receptor in cell survival 
and proliferation was tested. The effectiveness of the small molecule tyrosine kinase inhibitor 





8.2.1 The relative expression of IGF-signal transduction pathway proteins in primary 
cultures of gastric cancer cells 
Four primary cultures of gastric cancer cells were established from the ascitic fluid collected 
from four patients diagnosed with advanced gastric adenocarcinoma. The appearance of cells 
in culture within two weeks of isolation from patients is shown in Figure 8.1. Tumour cells 
had varied morphology but most grew with a characteristic epithelial cell, pavement-like 
appearance as monolayers in culture. Their epithelial origin was confirmed by expression of 
total keratins 4, 5, 6, 8, 10, 13 and 18 (Figure 8.2). The epithelial cells proliferated until 
passage 5-6, with a doubling time of approximately 7 days. All experiments were performed 
with passage numbers lower than 6. 
 
Figure 8.1. Primary cultures of gastric cancer cells established from ascites of patients with gastric 
adenocarcinoma. Ascitic fluid was collected from patients with advanced gastric adenocarcinoma and was 
diluted 1:1 in medium supplemented with 20% foetal calf serum. After 5-7 days the medium was changed to 
maintenance medium with 20% foetal calf serum and the adherent cells were either kept in culture or frozen. 
Four primary cultures were established, GC, HC, NC and JW. The primary cells were seeded on top of 
coverslips in 6 well tissue culture plates at 30 x 10
4
 cells per well, in 2.5 ml maintenance medium. Cells were 
incubated for 7 days. Medium was replaced every two to three days. Cells were washed with 2 ml PBS and fixed 
in 2 ml ice-cold methanol. Fixed cells were incubated with a fluorescent pan-keratin antibody (1:50 dilution) and 
cleaved PARP (1:50 dilution). Cells were mounted on top of slides in 20 µl DAPI X mounting medium. Pictures 




Figure 8.2. Expression of keratins in primary cultures of gastric cancer cells. HC, NC and JW cells were 
seeded on top of coverslips in 6 well tissue culture plates at 15 x 10
4 
cells per well, in 2.5 ml maintenance 
medium. Cells were incubated for 5-7 days. Cells were washed with 2 ml PBS and fixed in 2 ml ice-cold 
methanol. Fixed cells were incubated with a fluorescent pan-keratin antibody that detects total keratins 4, 5, 6, 8, 
10, 13 and 18 (1:50 dilution). Cells were mounted on top of slides in 20 µl DAPI X mounting medium. Pictures 
of the cells were taken in a Leica fluorescent microscope. 
 
Expression of the receptors of the IGF-signal transduction pathway and of downstream 
molecules was measured in the four primary cultures by western transfer analysis. GC, HC, 
NC and JW cells were cultured until 80% confluence and protein extracts were prepared.  
Highest IGF-IR expression was detected in NC cells, followed by JW, GC and HC (Figure 
8.3). In general, the levels of IGF-IR expression in the primary cultures were similar to the 
levels detected in AGS cells. A small amount of insulin receptor was detected in all primary 
cultures; NC cells expressed the highest amount, followed by HC, JW and GC. HC cells 
expressed the highest amount of type II IGF receptor, whereas NC, JW and GC cells did not 
express much IGF-IIR (Figure 8.3). The receptors of the IGF signal transduction pathway 




Figure 8.3. Expression of IGF-signal transduction pathway proteins in primary cultures of gastric cancer 
cells. GC, HC, NC and JW cells were cultured in 75 cm
2
-tissue culture flasks in maintenance medium to ~80% 
confluence. Proteins were extracted with 1 ml per flask of RIPA buffer plus inhibitors, as described in the 
Materials and Methods section. Aliquots containing 10-20 µg of protein were electrophoresed on denaturing 
12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated 
with antibodies against the IGF-IR (1:2000), IR (1:1000), IGF-IIR (1:1000), and GAPDH (1:10000). All 
secondary antibodies were horseradish-peroxidase bound. Bands were visualised on Fuji X-ray film following 
incubation of membranes with Supersignal chemiluminescent solutions, as described in the Methods section. The 
images shown are representative of results from three separate experiments. The molecular masses of the 
proteins are indicated on the right hand side of the panels. 
 
To detect the amount of the two insulin receptor isoforms present in the primary cultures of 
gastric cancer cells, specific DNA primers were designed to amplify both the A and B isoform 
of the receptor. Both isoforms of the insulin receptor were detected in GC, HC and NC cells, 
and all three primary cultures expressed higher levels of the B isoform compared to the A 
isoform (Figure 8.4). Also, in comparison with SNU-16 and KATO III cells, the IRA:IRB 





Figure 8.4. Expression of insulin receptor isoforms in primary cultures of gastric cancer cells. SNU-16, 
KATO III, GC, HC and NC cells were cultured in 25 cm
2 
tissue culture flasks in maintenance medium to ~80% 
confluence. Total RNA was extracted from the cells with the Direct-zol™ RNA MiniPrep, as described in the 
Materials and Methods section. Complementary DNA was synthesised from total RNA with the Moloney 
Murine Leukaemia Virus Reverse Transcriptase. Specific primer sequences were used to amplify both insulin 
receptor isoforms and 18S rRNA. The amplified DNA was electrophoresed in a 3% agarose gel and bands were 
visualised with a UV transilluminator. 
 
There was lower expression of IRS-1 in GC, HC, NC and JW cells, compared to AGS and 
MKN74 cells (Figure 8.5). Akt, ERK1 and ERK2 were expressed in all four primary cultures 
in similar levels to those detected in the gastric cancer cell lines (Figure 8.5). Expression of 
IRS-1 mRNA was detected in all four primary cultures and was similar to the AGS cell line 
(Figure 8.6). This suggests that there are either differences between the mRNA and protein 
expression of IRS-1 in the primary cultures, possibly due to post-translational modifications 
in the IRS-1 protein, or there is a difference in the sensitivity of the two assays.  
Due to the lack of high quality commercially available antibodies against IRS-2 and IRS-4 
proteins, expression of the above genes was analysed by PCR (Figure 8.6). Expression of both 
IRS-2 and IRS-4 was detected in all primary cultures, with HC cells expressing slightly 






Figure 8.5. Expression of IGF-signal transduction pathway downstream proteins in primary cultures of 
gastric cancer cells. GC, HC, NC and JW cells were cultured in 75 cm
2
-tissue culture flasks in maintenance 
medium to ~80% confluence. Proteins were extracted with 1 ml per flask of RIPA buffer plus inhibitors, as 
described in the Materials and Methods section. Aliquots containing 10-20 µg of protein were electrophoresed 
on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes 
were incubated with antibodies against IRS-1 (1:2000), Akt (1:3000) ERK1/2 (1:5000) and GAPDH (1:10000). 
All secondary antibodies were horseradish-peroxidase bound. Bands were visualised on Fuji X-ray film 
following incubation of membranes with Supersignal chemiluminescent solutions, as described in the Methods 
section. The images shown are representative of results from three separate experiments. The molecular masses 
of the proteins are indicated on the right hand side of the panels.  
 
 
Figure 8.6. Expression of insulin-receptor substrate proteins (IRS) in primary cultures of gastric cancer 
cells. AGS, GC, HC, NC and JW cells were cultured in 25 cm
2 
tissue culture flasks in maintenance medium to 
~80% confluence. Total RNA was extracted from the cells with the Direct-zol™ RNA MiniPrep, as described in 
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the Materials and Methods section. Complementary DNA was synthesised from total RNA with the Moloney 
Murine Leukaemia Virus Reverse Transcriptase. Specific primer sequences were used to amplify IRS-1, IRS-2, 
IRS-4 and 18S rRNA. The amplified DNA was electrophoresed in a 3% agarose gel and bands were visualised 
with a UV transilluminator. 
 
8.2.2 The relative expression of HER-2, FGFR2 and c-Met in primary cultures of gastric 
cancer cells 
To identify potential amplification or overexpression that could affect responsiveness to IGF 
ligands, expression of the three most frequently amplified growth factor receptors in gastric 
cancer, HER-2, FGFR2 and c-Met, was measured in the four primary cultures of gastric 
cancer cells. None of those three receptors were detected by western transfer analysis in the 
four primary cultures (Figure 8.7). 
 
Figure 8.7. Expression of HER-2, FGFR2 and c-Met in primary cultures of gastric cancer cells.  GC, HC, 
NC and JW cells were cultured in 75 cm
2 
tissue culture flasks in maintenance medium to ~80% confluence. 
Proteins were extracted with 1 ml per flask of RIPA buffer plus inhibitors, as described in the Materials and 
Methods section. Aliquots containing 10-20 µg of protein were electrophoresed on denaturing 12% 
polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with 
antibodies against the HER-2 (1:2000), FGFR2 (1:1000) and c-Met (1:1000). All secondary antibodies were 
horseradish-peroxidase bound. Bands were visualised on Fuji X-ray film following incubation of membranes 
with Supersignal chemiluminescent solutions, as described in the Methods section. The molecular masses of the 
proteins are indicated on the right hand side of the panels.  
 
The four primary cultures expressed the type I IGF receptor but not HER-2, FGFR2 and c-
Met. This suggests that they could possibly be responsive to stimulation with IGF ligands and 
that the IGF-signal transduction pathway might be important for the survival and growth of 
these cells.   
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8.2.3 The effect of IGF-1 stimulation on the activity of IGF-signal transduction pathway 
proteins in primary cultures of gastric cancer cells 
The effect of stimulation with IGF-1 on activation and phosphorylation of components of the 
IGF signal transduction pathway was tested in GC, HC, NC and JW cells. The cells were 
withdrawn from the effects of growth factors present in the serum by culture in medium 
supplemented with dextran-coated charcoal stripped calf serum (DCCS). Phosphorylation of 
proteins in the IGF signal transduction pathway in cells that had been treated with 50 ng/ml 
IGF-1 was determined by western transfer. 
Phosphorylation of the type I IGF and/or insulin receptor was not detected in any of the 
primary cultures after culture in growth factor-depleted medium for 48 hours (Figure 8.8). 
Stimulation with IGF-1 resulted in IGF-IR/IR phosphorylation in all primary cultures. The 
amount of total IGF-IR was not altered by stimulation with IGF-1 for 15 minutes. 
Akt phosphorylation was detected only in JW cells after withdrawal of cells by culture in 
growth-factor-deprived culture medium. However, stimulation with IGF-1 increased Akt 
phosphorylation in those cells. GC, HC and NC cells had no detectable levels of Akt 
phosphorylation after withdrawal. IGF-1 stimulated Akt phosphorylation in all these cells. 
Total Akt levels were not affected by incubation with IGF-1 for 15 minutes. Phosphorylated 
ERK2 was detected in the absence of IGF-1 in all the primary cultures, except GC cells. 
There was no increase in ERK1 or ERK2 phosphorylation after stimulation with IGF-1 in JW 
cells. Most effective induction of ERK2 phosphorylation was observed in GC cells. The 






Figure 8.8. The effect of stimulation with IGF-1 on phosphorylation of IGF-signal transduction pathway 
proteins in primary cultures of gastric cancer cells. GC, HC, NC and JW cells were seeded into 12 well tissue 
culture plates at 15x10
4 
cells/well, in 1 ml maintenance medium. Cells were incubated for 24 hours to allow 
attachment. Medium was aspirated and the cells washed with 0.5 ml PBS. Medium was replaced daily with 1 ml 
withdrawal medium for two days. Cells were incubated with serum-free medium which contained 0.1% BSA for 
two hours. Cells were incubated with 50 ng/ml IGF-1 for 15 minutes. Proteins were extracted with 80 µl per well 
RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% 
polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with 
antibodies against phosphorylated IGF-IR/IR (1:1000 dilution), IGF-IR (1:2000 dilution), phosphorylated Akt 
(1:3000 dilution), Akt (1:3000 dilution), phosphorylated ERK1/2 (1:5000 dilution), ERK1/2 (1:5000 dilution) 
and GAPDH (1:10000 dilution). Images obtained after incubation with antibodies against the total proteins are 
shown beneath those of the phosphorylated proteins.   
 
8.2.4 The effect of IGF-1 on staurosporine-induced apoptosis in primary cultures of gastric 
cancer cells 
To investigate whether IGF-1 can promote survival in the primary cultures of gastric cancer 
cells, the ability of IGF-1 to inhibit staurosporine-induced cell death was assessed. GC, HC, 
NC and JW cells were withdrawn from the effects of growth factors for 2 days and treated 
with staurosporine in the presence and absence of IGF-1 for 5 hours.  
In GC cells, the 89 kDa PARP fragment was detected by western transfer analysis after 
culture in 0.5 µM staurosporine, in the absence of IGF-1 (Figure 8.9). Treatment with IGF-1 
completely inhibited cleavage of PARP to its 89 kDa fragment (p<0.0001), suggesting that 
IGF-1 rescued those cells from apoptosis. Identical results were obtained with HC and NC 
cells. In JW cells, IGF-1 reduced potently the amount of the 89 kDa fragment of PARP but 




Figure 8.9. The effect of IGF-1 on staurosporine-induced apoptosis in primary cultures of gastric cancer 
cells. GC , HC, NC and JW cells were seeded into 12 well tissue culture plates at 15x10
4 
cells per well, in 1 ml 
maintenance medium. Cells were incubated for 24 hours to allow attachment. Medium was aspirated and the 
cells washed with 0.5 ml PBS. Medium was replaced daily with 1 ml withdrawal medium for two days. Cells 
were incubated with withdrawal medium supplemented or not with 50 ng/ml IGF-1 for 15 minutes. Cells were 
then incubated with 0.5 µM staurosporine in the presence and absence of 50 ng/ml IGF-1 for 6 hours. Proteins 
were extracted with 80 µl of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein were 
electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 
minutes. Membranes were incubated with antibodies against cleaved PARP (1:1000 dilution) and GAPDH 
(1:10000 dilution) (A). Densitometry was with Labworks 4.0 software, adjusted for the background optical 
density of the X-ray film and normalised to GAPDH. Results are expressed as a percentage of the intensity of the 
cleaved PARP band observed in the presence of staurosporine and in the absence of IGF-1. Asterisks show 
cleaved PARP levels that are statistically significantly lower in the presence of IGF-1 than in its absence (One-
way ANOVA; GC, p<0.0001; HC, p<0.0001; NC, p<0.0001; JW, p<0.0001) (B).  
 
8.2.5 The effect of IGF-1 on cell death induced by anoikis in primary cultures of gastric 
cancer cells  
As mentioned previously, anoikis is a form of apoptosis induced by disruption of the 
interactions between normal epithelial cells and extracellular matrix.  Disruption of the 
interactions can be achieved in vitro by culture of cells in plates coated with 
polyhydroxyethylmethacrylate (poly-HEMA). 
To test the hypothesis that IGF-1 is important for resistance to anoikis, GC, HC, NC and JW 
cells were cultured in non-attached conditions in the presence or in the absence of IGF-1. The 
89 kDa PARP fragment was detected in cells cultured in poly-HEMA coated plates in the 
absence of IGF-1 (Figure 8.10). IGF-1 reduced the amount of cleaved PARP in all four 
primary cultures, suggesting that it promotes resistance to anoikis. In particular, cleaved 
PARP was completely inhibited in NC cells by IGF-1 (p=0.0008), whereas very low levels of 




Figure 8.10. The effect of IGF-1 on PARP cleavage in non-attached conditions in primary cultures of 
gastric cancer cells. GC, HC, NC and JW cells were seeded into poly-HEMA coated 12 well plates at 20x10
4 
cells per well in 1 ml serum-free medium, in the presence or not of 50 ng/ml IGF-1. After incubation for 6 hours, 
proteins were extracted with 50 µl per well of RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein 
were electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 
minutes. Membranes were incubated with antibodies against cleaved PARP (1:1000 dilution) and GAPDH 
(1:10000 dilution) (A). Densitometry was with Labworks 4.0 software, adjusted for the background optical 
density of the X-ray film and normalised to GAPDH. Results are expressed as a percentage of the intensity of the 
cleaved PARP band observed in non-attached conditions and in the absence of IGF-1. Asterisks show cleaved 
PARP levels that are statistically significantly lower in the presence of IGF-1 than in its absence (One-way 
ANOVA; GC, p=0.0470; HC, p=0.0003; NC, p=0.0008; JW, p=0.0004) (B).   
 
8.2.6 The effect of IGF-1 on activation of the PI3K/Akt and RAS/RAF/ERK signal 
transduction pathways in the context of apoptosis 
Activation of downstream signal transduction pathways in response to IGF-1 was investigated 
in the apoptosis assay. GC, HC and NC cells were withdrawn from the effects of growth 
factors by culture in withdrawal medium for 2 days. The cells were then treated with 
staurosporine in the presence or absence of 50 ngml
-1
 IGF-1.  
In GC, HC and NC cells, cultured in withdrawal medium, very low amount of phosphorylated 
Akt was detected. Staurosporine inhibited slightly phosphorylation of Akt, particularly in HC 
cells (Figure 8.11). Treatment with IGF-1 resulted in a significant increase in Akt 
phosphorylation in all three primary cultures (p≤0.0033) (Figure 8.11). ERK1 and ERK2 
phosphorylation was detected in GC, HC and NC cells cultured in withdrawal medium. 
Treatment with staurosporine reduced the amount of phosphorylated ERK1 and ERK2 in all 
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three primary cultures. However, IGF-1 did not increase ERK2 phosphorylation in any of the 
primary cultures (Figure 8.11).  
The above results corroborate the results obtained in established gastric cancer cell lines, in 
which increased Akt rather than ERK1 and ERK2 phosphorylation was detected after 
treatment with IGF-1 in the context of apoptosis (Figure 4.13).  
 
Figure 8.11. The effect of IGF-1 stimulation on activation of the PI3K/Akt and RAS/RAF/ERK signal 
transduction pathways in apoptosis. GC , HC and NC cells were seeded into 12 well tissue culture plates at 
15x104 cells per well, in 1 ml maintenance medium. Cells were incubated for 24 hours to allow attachment. 
Medium was aspirated and the cells washed with 0.5 ml PBS. Medium was replaced daily with 1 ml withdrawal 
medium for two days. Cells were incubated with withdrawal medium supplemented or not with 50 ng/ml IGF-1 
for 15 minutes. Cells were then incubated with 0.5 µM staurosporine in the presence and absence of 50 ng/ml 
IGF-1 for 6 hours. Proteins were extracted with 80 µl of RIPA buffer plus inhibitors. Aliquots containing 10 µg 
of protein were electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 
mA for 45 minutes. Membranes were incubated with antibodies against phosphorylated Akt (1:3000 dilution), 
phosphorylated ERK1/ERK2 (1:5000 dilution) and GAPDH (1:10000 dilution) (A). Densitometry was with 
Labworks 4.0 software, adjusted for the background optical density of the X-ray film and normalised to 
GAPDH. Results are expressed as a percentage of the intensity of the phosphorylated Akt band observed in the 
presence of IGF-1 or as percentage of the intensity of the phosphorylated ERK1 and 2 band observed in the 
absence of staurosporine and IGF-1. Asterisks show phosphorylated Akt levels that are statistically significantly 
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higher in the presence of IGF-1 than in its absence (One-way ANOVA; GC, p<0.001; HC, p<0.0001; NC, 
p=0.0033) (B).     
 
8.2.7 The effect of siRNA knockdown of the type I IGF receptor on survival of primary 
cultures of gastric cancer cells 
To investigate the importance of the type I IGF receptor in cell survival, expression of the 
receptor was lowered with transient knockdown, in an environment enriched with growth 
factors.  
The type I IGF receptor was detected in HC and NC cells that had been transfected with 
scrambled siRNA (Figure 8.12). Incubation for 72 hours with siRNA 2, designed to target the 
type I IGF receptor, inhibited completely IGF-IR expression.  The importance of type I IGF 
receptor on cell survival was investigated by measuring the levels of cleaved PARP in HC 
and NC cells that had been transfected with siRNA against the IGF-IR or with scrambled 
sequence, in medium supplemented with foetal calf serum. No cleaved PARP was detected in 
HC cells after transfection with the scrambled sequence. Furthermore, no cleavage of PARP 
into its 89 kDa fragment was induced after reduction of IGF-IR expression. Low levels of 
cleaved PARP were detected after transfection with the scrambled sequence in NC cells. 
Those levels were not increased when IGF-IR was absent. 
 
Figure 8.12. The effect of knockdown of the IGF-IR with siRNA on cell death in HC and NC cells in full 
medium. Transfection medium was prepared by mixing either scrambled (scr) or IGF-IR targeted (IGF-IR) 
siRNA duplexes at a final concentration of 40 nM and Lipofectamine RNAiMAX at a final concentration of 
0.2% (v/v), in 0.1 ml DMEM without serum. The transfection medium was then incubated at room temperature 
for 30 minutes. Cells grown in maintenance medium were detached using trypsin:EDTA and resuspended in 
maintenance medium at 10x10
4
 cells /ml. Four hundred µl of the cell suspension were mixed with 0.1 ml of the 
transfection medium, containing scrambled or IGF-IR targeted sequences, in 24 well tissue culture plates. After 
3 days, proteins were extracted with 50 µl per well of RIPA buffer plus inhibitors. Aliquots containing 10 µg of 
protein were electrophoresed on denaturing 12% polyacrylamide gels and transferred to nitrocellulose at 100 mA 
for 45 minutes. Membranes were incubated with antibodies against IGF-IR (1:2000), cleaved PARP (1:1000 




The above results suggest that knockdown of the type I IGF receptor in HC and NC cells, 
does not activate apoptotic pathways which lead to PARP cleavage. Either the cells do not 
depend on the type I IGF receptor for their survival, or they undergo cell death through a 
different mechanism, independent of PARP. 
 
8.2.8 The effect of siRNA knockdown of the type I IGF receptor on growth of primary 
cultures of gastric cancer cells 
Proliferation of primary cultures of gastric cancer cells that do or do not express the type I 
IGF receptor was investigated in a growth-factor-enriched-environment. GC, HC, NC and JW 
cells were transfected with siRNA 2 or siRNA 3, which target the type I IGF receptor or with 
a scrambled sequence and cultured in medium supplemented with 20% foetal calf serum for 
7-10 days. The number of cells at the end of each time point was measured by detecting the 
amount of DNA in each sample with the PicoGreen fluorimetric assay.  
In GC cells, there was a 20% growth inhibition after transfection with siRNA 2 against the 
type I IGF receptor, compared to transfection with the scrambled oligonucleotide (p=0.0322) 
(Figure 8.13). Transfection with siRNA 3 resulted in 10% reduction in cell growth, which was 
not statistically significant. In HC cells, both siRNAs reduced cell growth by 25%, and this 
reduction was statistically significant (siRNA 2; p=0.001, siRNA 3; p=0.008). There was a 
35% reduction in growth in NC cells after transfection with siRNA 2 (p=0.0001) and 25% 
reduction with siRNA 3 (p=0.0006). In JW cells, siRNA 2 reduced significantly cell growth 
by 20% (p=0.0411) and siRNA 3 by 45% (p=0.006).  
 
Figure 8.13. The effect of knockdown of the IGF-IR with siRNA on cell number in GC, HC, NC and JW 
cells in full medium. Transfection medium was prepared by mixing either scrambled (scr) or IGF-IR targeted 
(IGF-IR) siRNA duplexes at a final concentration of 40 nM and Lipofectamine RNAiMAX at a final 
concentration of 0.2% (v/v), in 0.1 ml DMEM without serum. The transfection medium was then incubated at 
room temperature for 30 minutes. Cells grown in maintenance medium were detached using trypsin:EDTA and 
resuspended in maintenance medium at 10x10
4
 cells /ml. Four hundred µl of the cell suspension were mixed 
with 0.1 ml of the transfection medium, containing scrambled or IGF-IR targeted sequences, in 24 well tissue 
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culture plates. After 7 days, the cells were washed with 0.5 ml ice cold PBS and stored in -20
o
 C. The cells were 
lysed in SSC/SDS solution and the amount of DNA present in each well was quantified with the Quanti-iT 
picogreen fluorimetric assay. Bars are the mean ±SEM. Asterisks indicate significant growth inhibition after 
reduction in type I IGF receptor expression (One-way ANOVA; GC, p=0.0322; HC, p=0.001, p=0.0008; NC, 
p=0.0001, p=0.0006; JW, p=0.0411, p=0.0006). 
 
Reduction of IGF-IR expression affects growth of the primary cultures, suggesting that the 
above receptor is important for cell proliferation.  
 
8.2.9 The effect of IGF-IR/IR inhibition by BMS754807 on cell survival in a growth factor-
enriched environment 
The effectiveness of the small molecule tyrosine kinase inhibitor BMS754807 on induction of 
cell death was tested by measuring the levels of cleaved PARP after treatment of the cells 
with the inhibitor, in the presence of 20% foetal calf serum.   
Low levels of cleaved PARP were detected in untreated HC and NC cells (Figure 8.14). 
Addition of 0.5 µM BMS754807 increased slightly the amount of cleaved PARP in both 
primary cultures but in a non-significant manner. A higher concentration of BMS (5 µM) 
induced a significant increase of the amount of cleaved PARP (p<0.0001). It is noteworthy 
that cell death was induced in the primary cultures after inhibition of the type I IGF and 
insulin receptors by BMS754807, even in the presence of a high concentration of foetal calf 
serum, which contains a variety of growth factors. This underlines the importance of these 




Figure 8.14. The effect of inhibition of IGF-IR/IR with BMS754807 on apoptosis in primary cultures of 
gastric cancer cells cultured in maintenance medium. HC and NC cells were seeded into 12 well tissue 
culture plates at a concentration of 150000 cells/well, in 1 ml maintenance medium which contained DMSO, 0.5 
µM or 5 µM BMS754807. The cells were left for 7 days and protein extracts were prepared with 80 µl per well 
RIPA buffer plus inhibitors. Aliquots containing 10 µg of protein were electrophoresed on denaturing 12% 
polyacrylamide gels and transferred to nitrocellulose at 100 mA for 45 minutes. Membranes were incubated with 
antibodies against cleaved PARP (1:2000 dilution) and GAPDH (1:10000 dilution) (A). Densitometry was with 
Labworks 4.0 software, adjusted for the background optical density of the X-ray film and normalised to 
GAPDH. Results are expressed as a percentage of the intensity of the cleaved PARP band observed after 
treatment with 5 µM BMS754807. Bars are the mean ±SEM. Asterisks indicate significant induction of cleaved 
PARP after treatment with the BMS754807 inhibitor (One-way ANOVA test; HC, p<0.0001; NC, p<0.0001). 
 
8.3 Discussion 
Four primary cultures of gastric cancer cells, GC, HC, NC and JW, were established from 
ascites removed from patients with advanced gastric adenocarcinoma. To our knowledge, this 
is the first study to establish primary cultures of gastric cancer cells from ascites. Primary 
cultures of ovarian cells derived from ascitic fluid have been described previously (Theriault 
et al., 2013).  
The gastric cancer cells in culture had a variable morphology but mostly had an epithelial 
appearance and were positive for keratin expression. The epithelial origin of ovarian cancer 
cells established from ascites has been reported previously by expression of cytokeratins and 
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EPCAM (ODonnell et al., 2014). In the molecular level, the four primary cultures did not 
express any of the three receptors, HER-2, FGFR2 and c-Met, which are currently targeted in 
the clinic in patients with gastric cancer. However, type I IGF receptor and low levels of 
insulin receptor expression were demonstrated readily in all primary cultures. 
IGF-1 treatment in a growth-factor-depleted environment induced IGF-IR/IR phosphorylation 
in the primary cultures. In GC gastric cancer cells, IGF-1 stimulated particularly strong 
activation of the PI3K/Akt and Ras/ERK pathways. In the other gastric cancer cells from 
patients, activation of the PI3K/Akt pathway was more marked than of the Ras/ERK pathway. 
The above results are in agreement with the data obtained from the established gastric cancer 
cell lines, in which IGF-IR/IR and Akt activation in response to IGF-1 were universal, 
whereas stimulation of ERK1 and ERK2 activation was not equally effective in all of the cell 
lines.  
It was noteworthy that cell death could be induced in gastric cancer cells isolated from 
patients with very advanced gastric cancer either by inhibition of kinase activity or by 
prevention of cell attachment. Remarkably, the survival effect of IGF-1 for these gastric 
cancer cells was more pronounced than for the established gastric cancer cell lines. The 
concomitant activation of the PI3K/Akt but not the Ras/ERK pathway indicates that the cell 
survival signal is transmitted via the former pathway and supports the data obtained from the 
established cell lines. The role of IGF-1 in protection against anoikis is of particular 
importance, as it suggests that circulating IGF-1 could promote the survival of cancer cells 
present in the ascitic fluid and increase their migratory and invasive potential.  
Reduction of IGF-IR expression with siRNA knockdown resulted in inhibition of cell growth 
in all four primary gastric cancer cultures. This confirms the result obtained in gastric cancer 
cell lines and strengthens the hypothesis that inhibition of IGF-IR could be a valid treatment 
option for patients with gastric cancer. The primary cultures of gastric cancer cells have a 
significantly slower growth rate compared to the immortalised cell lines, with a doubling time 
of approximately 5-7 days, versus 1-2 days for cell lines. It is, therefore, very encouraging 
that inhibition of the IGF-IR affected the growth rate of the primary cultures only 7 days after 
knockdown of the IGF-IR and it suggests that the receptor is important for their growth.  
The use of RNA interference methods in ovarian cancer cells derived from ascites has been 
described previously (Ingram et al., 2010). In the above study, primary cultures of ovarian 
cancer cells were transduced with a recombinant adenovirus and the level of transduction was 
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much higher than in the established cell lines. This suggests that it is possible to use RNA 
interference methods as a method of gene therapy in cells present in the ascitic fluid.  
In summary, the findings in this chapter suggest that epithelial cells present in the ascitic fluid 
of patients can be used as models of advanced gastric cancer. In the four primary cultures 
established here the importance of the IGF signal transduction pathway in cell survival was 
manifested by the protective effect of IGF-1 against apoptosis induced by tyrosine kinase 
inhibition and prevention of cell attachment. Also, knockdown of the type I IGF receptor and 
inhibition of the IGF-IR and IR by the small molecule inhibitor, BMS754807, reduced 
proliferation and increased cell death, respectively.      
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Chapter 9. Discussion 
 
The aim of the present study was to investigate the importance of the IGF signal transduction 
pathway in gastric cancer cells and to explore the potential of targeting the above pathway as 
a therapeutic option for advanced gastric cancer. 
Gastric cancer is the third-leading cause of cancer-related death, worldwide, with a median 
survival of 11.2 months (Cunningham et al., 2008; Ferlay et al., 2015). Standard therapy 
includes total or subtotal gastrectomy combined with removal of the perigastric lymph nodes 
and chemotherapeutic agents, such as 5-fluorouracil/capecitabine, cisplatin/oxaliplatin and 
epirubicin. The 5-year survival rate of patients diagnosed with gastric cancer is very low, 
close to 20%. Approximately 70% of advanced gastric cancer patients would be ineligible for 
the currently available targeted treatments, such as anti-HER-2, anti-c-Met and anti-FGFR-2 
treatment (Gravalos and Jimeno, 2008; Kawakami et al., 2013; Xie et al., 2013; Su et al., 
2014). There is, therefore, an urgent need for the introduction of new targeted agents into the 
existing therapeutic regime, to prolong survival and alleviate symptoms. 
A number of studies have reported the importance of the IGF signal transduction pathway in 
development and progression of several cancer types (reviewed by (Pollak, 2008)). Phase I 
and II trials of monoclonal antibodies against the type I IGF receptor or small molecule 
tyrosine kinase inhibitors against the type I IGF and insulin receptors have shown positive 
results for a variety of cancers (Karp et al., 2009; Haluska et al., 2010; Olmos et al., 2010). 
Very few preclinical studies have attempted to investigate the involvement of the IGF signal 
transduction pathway in the development and progression of advanced gastric cancer. 
Among the gastric cancer cell lines analysed here, NCI-N87 cells expressed high levels of 
HER2, KATO III and SNU-16 expressed high levels of FGFR2 and SNU-5 overexpressed c-
Met, consistent with reported amplification of the genes that encode these receptors (Liu et 
al., 2014). SNU-1, MKN74, NUGC3 and AGS cells represent the majority of gastric cancers 
that do not overexpress the three tyrosine kinase receptors against which drugs are licensed or 
in clinical trial (triple negative gastric cancer). Importantly, they expressed the type I IGF 
receptor and all but MKN74 expressed high levels of isoform A of the insulin receptor. 
IGF-1 stimulated phosphorylation of the type I IGF and/or insulin receptor and Akt in all the 
gastric cancer cell lines analysed which demonstrates that the IGF signal transduction 
pathway is active even in cells that overexpress HER2, FGFR2 or MET. In particular, NCI-
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N87 and SNU-16 cells, with amplification of HER-2 and FGFR2, respectively, were very 
responsive to IGF-1 stimulation with concomitant increase in Akt and ERK1 and ERK2 
phosphorylation. It is possible that despite the dependence of those cells on their amplified 
receptors, the IGF signal transduction pathway also contributes, to a certain extent, to their 
growth and survival mechanisms.    
Previously, IGF-1 protected MET-amplified MKN45 cells from ethanol-induced caspase 3 
activation (Min et al., 2005). Our study is the first to demonstrate a significant survival effect 
of IGF-1 against caspase-dependent apoptosis induced by protein kinase inhibition or 
anchorage deprivation in triple negative gastric cancer cells. That IGF-1 protects against 
apoptosis induced by the kinase inhibitor staurosporine, emphasizes the potency of IGF-1 as a 
pro-survival factor and suggests that it may protect gastric cancer cells from therapeutic 
kinase inhibitors. Also, IGF-1 protection against anoikis underlines the importance of IGF-1 
for the survival of cells grown in anchorage-independent conditions and suggests that it could 
facilitate the migration of cancer cells from their initial site to another location. Overall, that 
the survival effect of IGF-1 was manifested in two different survival assays strengthens the 
conclusion that it can promote survival in various settings and under different conditions. 
Inhibition of the type I IGF and insulin receptors with the small molecule tyrosine kinase 
inhibitor BMS754807 (Carboni et al., 2009), abrogated the IGF-1 survival effect, which 
suggests that in the absence of active type I IGF and insulin receptors, IGF-1 is no longer able 
to transduce survival signals. Furthermore, the protective effect of IGF-1 was associated with 
activation of the PI3-kinase/Akt pathway but not the Ras/MAP-kinase pathway, and was 
prevented by inhibitors of the former but not the latter pathway. Involvement of the PI3-
kinase/Akt pathway in mediation of the IGF-1 survival effect has been shown in MCF-7 
breast cancer cells against cell death induced by chemotherapy (Gooch et al., 1999).   
Proliferation of gastric cancer cells was stimulated by IGF-1 and the stimulation was 
decreased by inhibition of the Ras/MAP-kinase pathway. Our results demonstrate that the 
type I IGF receptor mediates the IGF-1 proliferative effect. The overall importance of the type 
I IGF receptor in gastric cancer cell proliferation was demonstrated by the significant 
reductions in cell-growth in serum-containing medium and in the proportion of cells in S- and 
mitotic-phases of the cell cycle after knockdown of receptor expression. In previous studies, 
inhibition of the type I IGF receptor with shRNA and the αIR3 antibody reduced colony 
formation in MET-amplified MKN45 cells and tumour explants, respectively (Pavelic et al., 
2003; Wang et al., 2010a). Further, infection with an adenovirus that expressed truncated 
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IGF-IR reduced proliferation of MKN74, NUGC4 and MET-amplified MKN45 cells (Min et 
al., 2005).  
IGF-2 and insulin protected SNU-1 and NUGC3 cells from apoptosis induced by the protein 
kinase inhibitor staurosporine and stimulated proliferation of NUGC3 cells. The overall 
importance of the insulin receptor in gastric cancer cell survival was demonstrated by a 
significant increase in cleaved PARP levels after knockdown of insulin receptor expression, in 
growth-factor-enriched medium. Importantly, when individual and concomitant knockdown 
of the type I IGF and insulin receptors was attempted, only loss of the insulin receptor 
resulted in significant induction of apoptosis. Our results suggest that the insulin receptor is 
primarily important for the mediation of cell survival. To elucidate the role of the insulin 
receptor in cell proliferation, markers of cell proliferation e.g. BrdU incorporation, could be 
measured in cells transfected with siRNA against the insulin receptor.  
Treatment of triple-negative gastric cancer cells with the small-molecule tyrosine kinase 
inhibitor BMS754807, which targets both the type I IGF and insulin receptors, induced 
apoptosis and inhibited effectively proliferation in serum-containing medium. It has been 
argued that inhibition of both receptors might be more beneficial in the clinic than inhibition 
of the type I IGF receptor alone. Several pre-clinical studies have reported that combined 
inhibition of the type I IGF and insulin receptors is more efficient than inhibition of either 
receptor alone (Buck et al., 2010; Vincent et al., 2013). In this respect, small molecule 
inhibitors which target both receptors might be superior to monoclonal antibodies which 
target the type I IGF receptor, selectively. 
Our results suggest that treatment of SNU-1 and NUGC3 cells with the cytotoxic agents 
oxaliplatin and 5-fluorouracil, at concentrations equal to or higher than 1μM, reduced their 
viability. Concomitant treatment with 5-fluorouracil and BMS754807 was more effective than 
treatment with either agent alone in triple-negative SNU-1 and NUGC3 cells. To date, a 
remarkably small number of preclinical studies have investigated the effect of combined 
treatment with cytotoxic agents and IGF-IR/IR inhibitors in gastric cancer cells. Inhibition of 
the type I IGF receptor enhanced chemotherapy-induced apoptosis in Met-amplified MKN45 
gastric cancer cells (Min et al., 2005; Wang et al., 2010a). Our study is the first to investigate 
the effect of concomitant inhibition of the type I IGF and insulin receptors with oxaliplatin 
and 5-fluorouracil treatment in triple-negative gastric cancer cells. It is encouraging that a 
small potentiation of the cytotoxic effect of 5-fluorouracil was detected after treatment with 
BMS754807 in SNU-1 and NUGC3 cells, however, an extensive concentration range for the 
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two drugs should be analysed and the effects of combined treatment with the two drugs 
should be investigated in in vivo models.     
Whether or not resistance to cytotoxic therapy can be subverted by inhibition of the IGF 
signal transduction pathway has not been determined here. Previously, it has been shown that 
colorectal cancer cells which have acquired resistance to 5-fluorouracil and oxaliplatin had 
increased phosphorylated and total levels of the type I IGF receptor (Dallas et al., 2009). The 
same study has shown that inhibition of the type I IGF receptor with a monoclonal antibody 
was more efficient at reduction of growth and induction of apoptosis in chemoresistant 
tumours than in non-resistant tumours. It would be useful to create gastric cancer cell lines 
with resistance to cytotoxic agents, currently used in the clinic, and measure the levels of 
phosphorylated and total type I IGF and insulin receptors.    
Consistent with previous studies, FGFR2-amplified KATO III and SNU-16 cells and c-Met-
amplified SNU-5 cells were highly sensitive to FGFR2 and c-Met inhibitors, AZD4547 and 
crizotinib, respectively (Okamoto et al., 2012; Xie et al., 2013). In FGFR2 amplified SNU-16 
cells, which express high levels of the type I IGF receptor, addition of external IGF-1 afforded 
a small protection against treatment with AZD4547. In addition, inhibition of the type I IGF 
and insulin receptors with BMS754807 aggravated the cytotoxic effect of AZD4547. On the 
contrary, no significant benefit was achieved after combined treatment of KATO III and 
SNU-5 cells with BMS754807 and AZD4547 or crizotinib, respectively. This study is the first 
to investigate the effect of combining a FGFR2 inhibitor with an IGF-IR/IR inhibitor in 
gastric cancer cells. Our results suggest that dual targeting may be a valid therapeutic option 
for a subset of gastric cancers. The effect of IGF-IR/IR inhibition on cells with resistance to 
FGFR2 and c-Met targeted inhibitors should also be investigated.       
In a previous study, signalling through both the type I IGF and insulin receptor was involved 
in primary resistance of NCI-N87 cells to lapatinib (Zhang et al., 2014). Lapatinib-resistant 
HER2-amplified NCI-N87 cells were established in this study. NCI-N87/lapatinib-resistant 
cells lost their sensitivity to the dual, anti-HER2 and anti-EGFR inhibitor lapatinib, 
suggesting that the cells had lost their dependency on HER2 signalling and relied more on 
other growth factor signal transduction pathways for sustaining their growth and survival. 
Involvement of the IGF signal transduction pathway in acquisition of lapatinib-resistance has 
not been demonstrated here, since there was no alteration in phosphorylated or total IGF-IR 
levels in resistant cells. Detection of expression and activation levels of downstream 
molecules of the IGF signal transduction pathway, as wells as other receptors of the HER 
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signalling pathway, e.g. HER3 and HER4, could shed some light on the mechanisms of 
resistance developed in these cells. 
This study is the first to report establishment of ex vivo cultures of gastric cancer cells from 
ascites removed from patients with advanced gastric cancer. The type I IGF receptor and 
insulin receptor were expressed in these cells. There was no expression of HER2, FGFR2 or 
c-Met, which suggests that the patients would not have benefited from targeted therapies 
currently in the clinic. Remarkably, the survival effect of IGF-1 against caspase-dependent 
apoptosis induced by anchorage deprivation or by protein kinase inhibition was more 
pronounced in patient-derived gastric cancer cells than in established cell lines, which 
indicates that IGF-dependence is characteristic of gastric cancer cells and not derived during 
culture. The role of IGF-1 in protection against anoikis is of particular importance because 
circulating IGFs could promote the survival of cancer cells present in serum or ascitic fluid 
and increase their migratory and invasive potential.  
Consistent with the findings from gastric cancer cell lines, knockdown of the type I IGF 
receptor in triple-negative gastric cancer cells isolated from patients inhibited their growth. 
Treatment with BMS754807 induced apoptosis even in the presence of a high concentration 
of growth-factor-containing serum. Confirmation of the results obtained from gastric cancer 
cell lines in ex vivo cultures corroborates the importance of the IGF signal transduction 
pathway in progression of gastric cancer and strengthens the idea that it should be considered 
as a potential therapeutic target in gastric tumours without known amplifications. 
 
Conclusions 
Our results suggest that the gastric cancer cells analysed in this study could be classified in 
two separate categories, cells with amplification of HER-2, FGFR2 or MET and cells without 
amplification or triple-negative cells. All triple-negative gastric cancer cells, apart from 
MKN74, were protected from apoptosis by IGF-1. Amongst the amplified cell lines, an IGF-1 
survival effect was detected in NCI-N87 cells; for the remaining amplified cells, either 
apoptosis was not induced or IGF-1 was not protective against apoptosis (Table 8.1).  
The proliferative effect of IGF-1, in controlled conditions, was demonstrated in MKN74 and 
NUGC3 triple-negative gastric cancer cells. All triple-negative gastric cancer cells responded 
with reduced proliferation upon IGF-IR/IR inhibition. The effect of IGF-IR/IR inhibition was 
not investigated directly in amplified cells. However, experiments in which SNU-16 and 
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SNU-5 cells were treated with the BMS754807 inhibitor showed that there was no effect on 
cell growth after treatment with 0.5 μM of the inhibitor, but that there was significant 
reduction in cell number after treatment with 5 μM of the inhibitor (Figure 7.8 and Figure 
7.10). Finally, IGF-IR/IR inhibition with BMS754807 induced apoptosis in SNU-1, NUGC3, 
HC and NC triple-negative gastric cancer cells (Table 8.1. 

















NCI-N87 HER-2 + Not tested Not tested Not tested 
KATO-III FGFR2 - Not tested Not tested Not tested 
SNU-16 FGFR2 No apoptosis Not tested Not tested Not tested 
SNU-5 MET No apoptosis Not tested Not tested Not tested 
SNU-1 - + Not tested + + 
MKN74 - No apoptosis + + Not tested 
NUGC3 - + + + + 
AGS - + Not tested + Not tested 
GC - + Not tested + Not tested 
HC - + Not tested + + 
NC - + Not tested + + 
JW - + Not tested + Not tested 
Table 8.1. Response of amplified and triple-negative gastric cancer cells to IGFs and IGF receptor-
targeted therapy.    
 
It could be concluded that triple-negative gastric cancer cells represent distinct gastric cancer 
populations which could potentially benefit from inhibition of the IGF signal transduction 
pathway in the clinic. The lack of alternative targeted treatments available currently for 
patients with these types of gastric cancer further supports the idea of investigating the effect 





Introduction of IGF-targeted inhibitors into the clinic would require the identification of 
effective biomarkers with which to select patients most likely to respond. Expression of the 
type I IGF and insulin receptors is not considered a sufficient predictor of IGF 
responsiveness. For instance, gastric cancer cells with amplified genes that encode tyrosine 
kinase receptors were shown in the present study to express receptors of the IGF signal 
transduction pathway. The presence of amplification of other tyrosine kinase receptor genes 
could provide a contraindication of response to IGF-targeted therapy because those tumour 
cells are likely to be driven by the amplified tyrosine kinase receptor pathways. Expression of 
IGF signal transduction pathway receptors in combination with downstream insulin receptor 
substrate proteins (IRS-1, 2 and 4) might be indicative of potential positive response to IGF-
targeted therapy.  
The standard cytotoxic chemotherapeutic regimen in the UK for advanced gastric cancer 
patients comprises cisplatin/oxaliplatin, epirubicin and capecitabine/5-fluorouracil. Combined 
efficacy of cytotoxic therapy with IGF-targeted inhibitors should be demonstrated 
preclinically prior to introduction into the clinic. Validation of results in in vivo models or in 
tumour explants could offer another level of validation of the above therapeutic combination. 
Similarly, combination of IGF-targeted drugs with HER2, FGFR2 and c-Met inhibitors could 
be tested pre-clinically, as a way of reducing onset of resistance. As shown in our results, 
NCI-N87 cells, which have HER2 amplification, were responsive to IGFs which suggests that 
some HER2-amplified gastric cancer cells might benefit from concomitant HER2 and IGF-
IR/IR inhibition.      
Acquisition of resistance to cytotoxic drugs or targeted inhibitors is a common problem in 
oncology that is encountered also in gastric cancer patients. It would be of value to test the 
involvement of the IGF signal transduction pathway in acquisition of resistance and the 






Saisana M., Griffin S.M., May F.E. (2015) Importance of the insulin-like growth factor (IGF) 
signal transduction pathway and the type I IGF receptor in gastric cancer cells without HER2, 
FGFR2 or MET amplification. In: National Cancer Research Institute (NCRI) Cancer 
Conference. Liverpool, UK   
Saisana M., Griffin S.M., May F.E. (2016) Importance of the type I insulin-like growth factor 
receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras 












Abuzzahab, M.J., Schneider, A., Goddard, A., Grigorescu, F., Lautier, C., Keller, E., Kiess, 
W., Klammt, J., Kratzsch, J., Osgood, D., Pfaffle, R., Raile, K., Seidel, B., Smith, R.J., 
Chernausek, S.D. and Intrauterine Growth Retardation Study, G. (2003) 'IGF-I receptor 
mutations resulting in intrauterine and postnatal growth retardation', N Engl J Med, 349(23), 
pp. 2211-22. 
 
Adams, J.M. and Cory, S. (2007) 'The Bcl-2 apoptotic switch in cancer development and 
therapy', Oncogene, 26(9), pp. 1324-37. 
 
Adams, T.E., Epa, V.C., Garrett, T.P. and Ward, C.W. (2000) 'Structure and function of the 
type 1 insulin-like growth factor receptor', Cell Mol Life Sci, 57(7), pp. 1050-93. 
 
Aherne, G.W., Hardcastle, A., Raynaud, F. and Jackman, A.L. (1996) 'Immunoreactive 
dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex 
(ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse 
leukaemia cells', Biochem Pharmacol, 51(10), pp. 1293-301. 
 
Allen, G.W., Saba, C., Armstrong, E.A., Huang, S.M., Benavente, S., Ludwig, D.L., Hicklin, 
D.J. and Harari, P.M. (2007) 'Insulin-like growth factor-I receptor signaling blockade 
combined with radiation', Cancer Res, 67(3), pp. 1155-62. 
 
Bang, Y.J., Kim, Y.W., Yang, H.K., Chung, H.C., Park, Y.K., Lee, K.H., Lee, K.W., Kim, 
Y.H., Noh, S.I., Cho, J.Y., Mok, Y.J., Kim, Y.H., Ji, J., Yeh, T.S., Button, P., Sirzen, F., Noh, 
S.H. and investigators, C.t. (2012) 'Adjuvant capecitabine and oxaliplatin for gastric cancer 
after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial', Lancet, 
379(9813), pp. 315-21. 
 
Bang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., Lordick, F., 
Ohtsu, A., Omuro, Y., Satoh, T., Aprile, G., Kulikov, E., Hill, J., Lehle, M., Ruschoff, J., 
Kang, Y.K. and To, G.A.T.I. (2010) 'Trastuzumab in combination with chemotherapy versus 
chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal 
junction cancer (ToGA): a phase 3, open-label, randomised controlled trial', Lancet, 
376(9742), pp. 687-97. 
 
Barr, S., Russo, S., Buck, E., Thomson, S., Haley, J., Ji, Q.S., Miglarese, M. and Iwata, K.K. 
(2007) 'The EGFR antagonist, erlotinib, combined with a small molecule inhibitor of IGF-1R 
acts synergistically to inhibit proliferation and induce apoptosis in ovarian and HNSCC cells', 
Molecular Cancer Therapeutics, 6(12), pp. 3377s-3377s. 
 
Bartek, J., Lukas, C. and Lukas, J. (2004) 'Checking on DNA damage in S phase', Nat Rev 
Mol Cell Biol, 5(10), pp. 792-804. 
 
Baserga, R., Peruzzi, F. and Reiss, K. (2003) 'The IGF-1 receptor in cancer biology', Int J 
Cancer, 107(6), pp. 873-7. 
 
Beattie, J., Phillips, K., Shand, J.H., Szymanowska, M., Flint, D.J. and Allan, G.J. (2008) 
'Molecular interactions in the insulin-like growth factor (IGF) axis: a surface plasmon 




Belfiore, A. (2007) 'The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors 
in human cancer', Curr Pharm Des, 13(7), pp. 671-86. 
 
Belmokhtar, C.A., Hillion, J. and Segal-Bendirdjian, E. (2001) 'Staurosporine induces 
apoptosis through both caspase-dependent and caspase-independent mechanisms', Oncogene, 
20(26), pp. 3354-62. 
 
Benyoucef, S., Surinya, K.H., Hadaschik, D. and Siddle, K. (2007) 'Characterization of 
insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and 
the alternatively spliced exon 11 sequence to ligand binding and receptor activation', Biochem 
J, 403(3), pp. 603-13. 
 
Bjornsti, M.A. and Houghton, P.J. (2004) 'The TOR pathway: a target for cancer therapy', Nat 
Rev Cancer, 4(5), pp. 335-48. 
 
Buck, E., Gokhale, P.C., Koujak, S., Brown, E., Eyzaguirre, A., Tao, N., Rosenfeld-Franklin, 
M., Lerner, L., Chiu, M.I., Wild, R., Epstein, D., Pachter, J.A. and Miglarese, M.R. (2010) 
'Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 
receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer', Mol Cancer Ther, 
9(10), pp. 2652-64. 
 
Buck, E. and Mulvihill, M. (2011) 'Small molecule inhibitors of the IGF-1R/IR axis for the 
treatment of cancer', Expert Opin Investig Drugs, 20(5), pp. 605-21. 
 
Buckman, R., De Angelis, C., Shaw, P., Covens, A., Osborne, R., Kerr, I., Reed, R., 
Michaels, H., Woo, M., Reilly, R. and et al. (1992) 'Intraperitoneal therapy of malignant 
ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal 
antibody 2G3', Gynecol Oncol, 47(1), pp. 102-9. 
 
Burz, C., Berindan-Neagoe, I., Balacescu, O. and Irimie, A. (2009) 'Apoptosis in cancer: key 
molecular signaling pathways and therapy targets', Acta Oncol, 48(6), pp. 811-21. 
Cancer Genome Atlas Research, N. (2014) 'Comprehensive molecular characterization of 
gastric adenocarcinoma', Nature, 513(7517), pp. 202-9. 
 
Carboni, J.M., Wittman, M., Yang, Z., Lee, F., Greer, A., Hurlburt, W., Hillerman, S., Cao, 
C., Cantor, G.H., Dell-John, J., Chen, C., Discenza, L., Menard, K., Li, A., Trainor, G., Vyas, 
D., Kramer, R., Attar, R.M. and Gottardis, M.M. (2009) 'BMS-754807, a small molecule 
inhibitor of insulin-like growth factor-1R/IR', Mol Cancer Ther, 8(12), pp. 3341-9. 
 
Chang, J., Wang, S., Zhang, Z., Liu, X., Wu, Z., Geng, R., Ge, X., Dai, C., Liu, R., Zhang, Q., 
Li, W. and Li, J. (2015) 'Multiple receptor tyrosine kinase activation attenuates therapeutic 
efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified 
gastric cancer', Oncotarget, 6(4), pp. 2009-22. 
 
Chappell, S.A., Walsh, T., Walker, R.A. and Shaw, J.A. (1997) 'Loss of heterozygosity at the 
mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor 
differentiation in early breast carcinomas', Br J Cancer, 76(12), pp. 1558-61. 
 
Chen, C., Zhang, Y., Zhang, Y., Li, J., Tsao, S.W. and Zhang, M.Y. (2014) 'Superior 
antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor 




Chen, Y., Liu, L., Wang, X., Wang, J., Yan, Z., Cheng, J., Gong, G. and Li, G. (2013) 'Body 
mass index and risk of gastric cancer: a meta-analysis of a population with more than ten 
million from 24 prospective studies', Cancer Epidemiol Biomarkers Prev, 22(8), pp. 1395-
408. 
 
Chitnis, M.M., Yuen, J.S., Protheroe, A.S., Pollak, M. and Macaulay, V.M. (2008) 'The type 1 
insulin-like growth factor receptor pathway', Clin Cancer Res, 14(20), pp. 6364-70. 
 
Christensen, J.G., Zou, H.Y., Arango, M.E., Li, Q., Lee, J.H., McDonnell, S.R., Yamazaki, S., 
Alton, G.R., Mroczkowski, B. and Los, G. (2007) 'Cytoreductive antitumor activity of PF-
2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models 
of anaplastic large-cell lymphoma', Mol Cancer Ther, 6(12 Pt 1), pp. 3314-22. 
 
Chung, H., Seo, S., Moon, M. and Park, S. (2007) 'IGF-I inhibition of apoptosis is associated 
with decreased expression of prostate apoptosis response-4', J Endocrinol, 194(1), pp. 77-85. 
Clemmons, D.R. (1998) 'Role of insulin-like growth factor binding proteins in controlling 
IGF actions', Mol Cell Endocrinol, 140(1-2), pp. 19-24. 
 
Correa, P. (1992) 'Human gastric carcinogenesis: a multistep and multifactorial process--First 
American Cancer Society Award Lecture on Cancer Epidemiology and Prevention', Cancer 
Res, 52(24), pp. 6735-40. 
 
Cossa, G., Gatti, L., Cassinelli, G., Lanzi, C., Zaffaroni, N. and Perego, P. (2013) 'Modulation 
of sensitivity to antitumor agents by targeting the MAPK survival pathway', Curr Pharm Des, 
19(5), pp. 883-94. 
 
Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M. and Hemmings, B.A. (1995) 
'Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B', Nature, 
378(6559), pp. 785-9. 
 
Cui, H. (2007) 'Loss of imprinting of IGF2 as an epigenetic marker for the risk of human 
cancer', Dis Markers, 23(1-2), pp. 105-12. 
 
Cui, M., Xing, J.D., Yang, W., Ma, Y.Y., Yao, Z.D., Zhang, N. and Su, X.Q. (2012) 'D2 
dissection in laparoscopic and open gastrectomy for gastric cancer', World J Gastroenterol, 
18(8), pp. 833-9. 
 
Cunningham, D., Allum, W.H., Stenning, S.P., Thompson, J.N., Van de Velde, C.J., 
Nicolson, M., Scarffe, J.H., Lofts, F.J., Falk, S.J., Iveson, T.J., Smith, D.B., Langley, R.E., 
Verma, M., Weeden, S., Chua, Y.J. and Participants, M.T. (2006) 'Perioperative 
chemotherapy versus surgery alone for resectable gastroesophageal cancer', N Engl J Med, 
355(1), pp. 11-20. 
 
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., 
Daniel, F., Oates, J., Norman, A.R. and Upper Gastrointestinal Clinical Studies Group of the 
National Cancer Research Institute of the United, K. (2008) 'Capecitabine and oxaliplatin for 
advanced esophagogastric cancer', N Engl J Med, 358(1), pp. 36-46. 
 
D'Cunja, J., Shalaby, T., Rivera, P., von Buren, A., Patti, R., Heppner, F.L., Arcaro, A., 
Rorke-Adams, L.B., Phillips, P.C. and Grotzer, M.A. (2007) 'Antisense treatment of IGF-IR 
induces apoptosis and enhances chemosensitivity in central nervous system atypical 
teratoid/rhabdoid tumours cells', Eur J Cancer, 43(10), pp. 1581-9. 
181 
 
D'Elia, L., Rossi, G., Ippolito, R., Cappuccio, F.P. and Strazzullo, P. (2012) 'Habitual salt 
intake and risk of gastric cancer: a meta-analysis of prospective studies', Clin Nutr, 31(4), pp. 
489-98. 
 
Dallas, N.A., Xia, L., Fan, F., Gray, M.J., Gaur, P., van Buren, G., 2nd, Samuel, S., Kim, 
M.P., Lim, S.J. and Ellis, L.M. (2009) 'Chemoresistant colorectal cancer cells, the cancer stem 
cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition', 
Cancer Res, 69(5), pp. 1951-7. 
 
Datta, S.R., Katsov, A., Hu, L., Petros, A., Fesik, S.W., Yaffe, M.B. and Greenberg, M.E. 
(2000) '14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain 
phosphorylation', Mol Cell, 6(1), pp. 41-51. 
 
Davison, Z., de Blacquière, G.E., Westley, B.R., May, F.E. (2011) 'Insulin-like growth factor 
dependent proliferation and survival of triple-negative breast cancer cells: implications for 
therapy', Neoplasia, 13(6), pp. 504-15. 
 
De Luca, A., Maiello, M.R., D'Alessio, A., Pergameno, M. and Normanno, N. (2012) 'The 
RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis 
and implications for therapeutic approaches', Expert Opin Ther Targets, 16 Suppl 2, pp. S17-
27. 
 
De Meyts, P. (1994) 'The structural basis of insulin and insulin-like growth factor-I receptor 
binding and negative co-operativity, and its relevance to mitogenic versus metabolic 
signalling', Diabetologia, 37 Suppl 2, pp. S135-48. 
 
de Vries, A.C., van Grieken, N.C., Looman, C.W., Casparie, M.K., de Vries, E., Meijer, G.A. 
and Kuipers, E.J. (2008) 'Gastric cancer risk in patients with premalignant gastric lesions: a 
nationwide cohort study in the Netherlands', Gastroenterology, 134(4), pp. 945-52. 
 
Delaney, C.L., Cheng, H.L. and Feldman, E.L. (1999) 'Insulin-like growth factor-I prevents 
caspase-mediated apoptosis in Schwann cells', J Neurobiol, 41(4), pp. 540-8. 
 
Dhanasekaran, N. and Premkumar Reddy, E. (1998) 'Signaling by dual specificity kinases', 
Oncogene, 17(11 Reviews), pp. 1447-55. 
 
Di Cola, G., Cool, M.H. and Accili, D. (1997) 'Hypoglycemic effect of insulin-like growth 
factor-1 in mice lacking insulin receptors', J Clin Invest, 99(10), pp. 2538-44. 
 
Dijkers, P.F., Birkenkamp, K.U., Lam, E.W., Thomas, N.S., Lammers, J.W., Koenderman, L. 
and Coffer, P.J. (2002) 'FKHR-L1 can act as a critical effector of cell death induced by 
cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of 
mitochondrial integrity', J Cell Biol, 156(3), pp. 531-42. 
 
Dinchuk, J.E., Cao, C., Huang, F., Reeves, K.A., Wang, J., Myers, F., Cantor, G.H., Zhou, X., 
Attar, R.M., Gottardis, M. and Carboni, J.M. (2010) 'Insulin receptor (IR) pathway 
hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the 
dual IGF-IR/IR inhibitor, BMS-754807', Endocrinology, 151(9), pp. 4123-32. 
 
Dufourny, B., Alblas, J., van Teeffelen, H.A., van Schaik, F.M., van der Burg, B., Steenbergh, 
P.H. and Sussenbach, J.S. (1997) 'Mitogenic signaling of insulin-like growth factor I in MCF-
182 
 
7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of 
mitogen-activated protein kinase', J Biol Chem, 272(49), pp. 31163-71. 
 
Dunn, S.E., Hardman, R.A., Kari, F.W. and Barrett, J.C. (1997) 'Insulin-like growth factor 1 
(IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of 
apoptosis induced by diverse anticancer drugs', Cancer Res, 57(13), pp. 2687-93. 
 
Esparis-Ogando, A., Ocana, A., Rodriguez-Barrueco, R., Ferreira, L., Borges, J. and 
Pandiella, A. (2008) 'Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on 
HER2-overexpressing breast cancer cells', Ann Oncol, 19(11), pp. 1860-9. 
 
Faivre, S., Chan, D., Salinas, R., Woynarowska, B. and Woynarowski, J.M. (2003) 'DNA 
strand breaks and apoptosis induced by oxaliplatin in cancer cells', Biochem Pharmacol, 
66(2), pp. 225-37. 
 
Favata, M.F., Horiuchi, K.Y., Manos, E.J., Daulerio, A.J., Stradley, D.A., Feeser, W.S., Van 
Dyk, D.E., Pitts, W.J., Earl, R.A., Hobbs, F., Copeland, R.A., Magolda, R.L., Scherle, P.A. 
and Trzaskos, J.M. (1998) 'Identification of a novel inhibitor of mitogen-activated protein 
kinase kinase', J Biol Chem, 273(29), pp. 18623-32. 
 
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., 
Forman, D. and Bray, F. (2015) 'Cancer incidence and mortality worldwide: sources, methods 
and major patterns in GLOBOCAN 2012', Int J Cancer, 136(5), pp. E359-86. 
 
Fernald, K. and Kurokawa, M. (2013) 'Evading apoptosis in cancer', Trends Cell Biol, 23(12), 
pp. 620-33. 
 
Fernandes-Alnemri, T., Litwack, G. and Alnemri, E.S. (1994) 'CPP32, a novel human 
apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and 
mammalian interleukin-1 beta-converting enzyme', J Biol Chem, 269(49), pp. 30761-4. 
 
Ferrara, N., Gerber, H.P. and LeCouter, J. (2003) 'The biology of VEGF and its receptors', 
Nat Med, 9(6), pp. 669-76. 
 
Flanigan, S.A., Pitts, T.M., Eckhardt, S.G., Tentler, J.J., Tan, A.C., Thorburn, A. and Leong, 
S. (2010) 'The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor 
PQIP exhibits enhanced antitumor effects in combination with chemotherapy against 
colorectal cancer models', Clin Cancer Res, 16(22), pp. 5436-46. 
 
Folkman, J. and Moscona, A. (1978) 'Role of cell shape in growth control', Nature, 
273(5661), pp. 345-9. 
 
Forbes, B.E., McCarthy, P. and Norton, R.S. (2012) 'Insulin-like growth factor binding 
proteins: a structural perspective', Front Endocrinol (Lausanne), 3, p. 38. 
 
Frasca, F., Pandini, G., Scalia, P., Sciacca, L., Mineo, R., Costantino, A., Goldfine, I.D., 
Belfiore, A. and Vigneri, R. (1999) 'Insulin receptor isoform A, a newly recognized, high-
affinity insulin-like growth factor II receptor in fetal and cancer cells', Mol Cell Biol, 19(5), 
pp. 3278-88. 
 
Frasca, F., Pandini, G., Vigneri, R. and Goldfine, I.D. (2003) 'Insulin and hybrid insulin/IGF 




Friedbichler, K., Hofmann, M.H., Kroez, M., Ostermann, E., Lamche, H.R., Koessl, C., 
Borges, E., Pollak, M.N., Adolf, G. and Adam, P.J. (2014) 'Pharmacodynamic and 
antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and 
mechanistic rationale for combination with rapamycin', Mol Cancer Ther, 13(2), pp. 399-409. 
 
Frisch, S.M. and Francis, H. (1994) 'Disruption of epithelial cell-matrix interactions induces 
apoptosis', J Cell Biol, 124(4), pp. 619-26. 
 
Frostad, S. and Bruserud, O. (1999) 'In vitro effects of insulin-like growth factor-1 (IGF-1) on 
proliferation and constitutive cytokine secretion by acute myelogenous leukemia blasts', Eur J 
Haematol, 62(3), pp. 191-8. 
 
Fuchs, C.S., Tomasek, J., Yong, C.J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., 
dos Santos, L.V., Aprile, G., Ferry, D.R., Melichar, B., Tehfe, M., Topuzov, E., Zalcberg, 
J.R., Chau, I., Campbell, W., Sivanandan, C., Pikiel, J., Koshiji, M., Hsu, Y., Liepa, A.M., 
Gao, L., Schwartz, J.D., Tabernero, J. and Investigators, R.T. (2014) 'Ramucirumab 
monotherapy for previously treated advanced gastric or gastro-oesophageal junction 
adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, 
phase 3 trial', Lancet, 383(9911), pp. 31-9. 
 
Furlanetto, R.W., Harwell, S.E. and Frick, K.K. (1994) 'Insulin-like growth factor-I induces 
cyclin-D1 expression in MG63 human osteosarcoma cells in vitro', Mol Endocrinol, 8(4), pp. 
510-7. 
 
Gagnon, A., Dods, P., Roustan-Delatour, N., Chen, C.S. and Sorisky, A. (2001) 
'Phosphatidylinositol-3,4,5-trisphosphate is required for insulin-like growth factor 1-mediated 
survival of 3T3-L1 preadipocytes', Endocrinology, 142(1), pp. 205-12. 
 
Gao, J., Chang, Y.S., Jallal, B. and Viner, J. (2012) 'Targeting the insulin-like growth factor 
axis for the development of novel therapeutics in oncology', Cancer Res, 72(1), pp. 3-12. 
 
Garrison, R.N., Kaelin, L.D., Galloway, R.H. and Heuser, L.S. (1986) 'Malignant ascites. 
Clinical and experimental observations', Ann Surg, 203(6), pp. 644-51. 
 
Gavine, P.R., Mooney, L., Kilgour, E., Thomas, A.P., Al-Kadhimi, K., Beck, S., Rooney, C., 
Coleman, T., Baker, D., Mellor, M.J., Brooks, A.N. and Klinowska, T. (2012) 'AZD4547: an 
orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor 
tyrosine kinase family', Cancer Res, 72(8), pp. 2045-56. 
 
Ge, J., Chen, Z., Wu, S., Chen, J., Li, X., Li, J., Yin, J. and Chen, Z. (2009) 'Expression levels 
of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor 
prognosis in patients with gastric cancer', Digestion, 80(3), pp. 148-58. 
 
Gil-Ad, I., Shtaif, B., Luria, D., Karp, L., Fridman, Y. and Weizman, A. (1999) 'Insulin-like-
growth-factor-I (IGF-I) antagonizes apoptosis induced by serum deficiency and doxorubicin 
in neuronal cell culture', Growth Horm IGF Res, 9(6), pp. 458-64. 
 




Gombos, A., Metzger-Filho, O., Dal Lago, L. and Awada-Hussein, A. (2012) 'Clinical 
development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?', 
Invest New Drugs, 30(6), pp. 2433-42. 
 
Gong, Y., Ma, Y., Sinyuk, M., Loganathan, S., Thompson, R.C., Sarkaria, J.N., Chen, W., 
Lathia, J.D., Mobley, B.C., Clark, S.W. and Wang, J. (2015) 'Insulin-mediated signaling 
promotes proliferation and survival of glioblastoma through Akt activation', Neuro Oncol. 
 
Gooch, J.L., Van Den Berg, C.L. and Yee, D. (1999) 'Insulin-like growth factor (IGF)-I 
rescues breast cancer cells from chemotherapy-induced cell death--proliferative and anti-
apoptotic effects', Breast Cancer Res Treat, 56(1), pp. 1-10. 
 
Goto, H., Tomono, Y., Ajiro, K., Kosako, H., Fujita, M., Sakurai, M., Okawa, K., Iwamatsu, 
A., Okigaki, T., Takahashi, T. and Inagaki, M. (1999) 'Identification of a novel 
phosphorylation site on histone H3 coupled with mitotic chromosome condensation', J Biol 
Chem, 274(36), pp. 25543-9. 
 
Gravalos, C. and Jimeno, A. (2008) 'HER2 in gastric cancer: a new prognostic factor and a 
novel therapeutic target', Ann Oncol, 19(9), pp. 1523-9. 
 
Grey, A., Chen, Q., Xu, X., Callon, K. and Cornish, J. (2003) 'Parallel phosphatidylinositol-3 
kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the 
mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells', 
Endocrinology, 144(11), pp. 4886-93. 
 
Group, G., Paoletti, X., Oba, K., Burzykowski, T., Michiels, S., Ohashi, Y., Pignon, J.P., 
Rougier, P., Sakamoto, J., Sargent, D., Sasako, M., Van Cutsem, E. and Buyse, M. (2010) 
'Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis', JAMA, 
303(17), pp. 1729-37. 
 
Gryko, M., Kisluk, J., Cepowicz, D., Zinczuk, J., Kamocki, Z., Guzinska-Ustymowicz, K., 
Pryczynicz, A., Czyzewska, J., Kemona, A. and Kedra, B. (2014) 'Expression of insulin-like 
growth factor receptor type 1 correlate with lymphatic metastases in human gastric cancer', 
Pol J Pathol, 65(2), pp. 135-40. 
 
Guha, M. (2013) 'Anticancer IGF1R classes take more knocks', Nat Rev Drug Discov, 12(4), 
p. 250. 
 
Gunderson, L.L. (2002) 'Gastric cancer--patterns of relapse after surgical resection', Semin 
Radiat Oncol, 12(2), pp. 150-61. 
 
Haisa, M. (2013) 'The type 1 insulin-like growth factor receptor signalling system and 
targeted tyrosine kinase inhibition in cancer', J Int Med Res, 41(2), pp. 253-64. 
 
Haluska, P., Menefee, M., Plimack, E.R., Rosenberg, J., Northfelt, D., LaVallee, T., Shi, L., 
Yu, X.Q., Burke, P., Huang, J., Viner, J., McDevitt, J. and LoRusso, P. (2014) 'Phase I dose-
escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and 
IGFII, in patients with advanced solid tumors', Clin Cancer Res, 20(18), pp. 4747-57. 
 
Haluska, P., Worden, F., Olmos, D., Yin, D., Schteingart, D., Batzel, G.N., Paccagnella, M.L., 
de Bono, J.S., Gualberto, A. and Hammer, G.D. (2010) 'Safety, tolerability, and 
185 
 
pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with 
refractory adrenocortical carcinoma', Cancer Chemother Pharmacol, 65(4), pp. 765-73. 
 
Hanahan, D. and Weinberg, R.A. (2000) 'The hallmarks of cancer', Cell, 100(1), pp. 57-70. 
 
Hanahan, D. and Weinberg, R.A. (2011) 'Hallmarks of cancer: the next generation', Cell, 
144(5), pp. 646-74. 
 
Harbour, J.W. and Dean, D.C. (2000) 'The Rb/E2F pathway: expanding roles and emerging 
paradigms', Genes Dev, 14(19), pp. 2393-409. 
 
Hartwell, L.H. and Weinert, T.A. (1989) 'Checkpoints: controls that ensure the order of cell 
cycle events', Science, 246(4930), pp. 629-34. 
 
Headey, S.J., Leeding, K.S., Norton, R.S. and Bach, L.A. (2004) 'Contributions of the N- and 
C-terminal domains of IGF binding protein-6 to IGF binding', J Mol Endocrinol, 33(2), pp. 
377-86. 
 
Hebert, E. (2006) 'Mannose-6-phosphate/insulin-like growth factor II receptor expression and 
tumor development', Biosci Rep, 26(1), pp. 7-17. 
 
Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y. and Mills, G.B. (2005) 'Exploiting the 
PI3K/AKT pathway for cancer drug discovery', Nat Rev Drug Discov, 4(12), pp. 988-1004. 
 
Houghton, J.A., Tillman, D.M. and Harwood, F.G. (1995) 'Ratio of 2'-deoxyadenosine-5'-
triphosphate/thymidine-5'-triphosphate influences the commitment of human colon carcinoma 
cells to thymineless death', Clin Cancer Res, 1(7), pp. 723-30. 
 
Hsieh, A.C. and Moasser, M.M. (2007) 'Targeting HER proteins in cancer therapy and the 
role of the non-target HER3', Br J Cancer, 97(4), pp. 453-7. 
 
Huang, F., Greer, A., Hurlburt, W., Han, X., Hafezi, R., Wittenberg, G.M., Reeves, K., Chen, 
J., Robinson, D., Li, A., Lee, F.Y., Gottardis, M.M., Clark, E., Helman, L., Attar, R.M., 
Dongre, A. and Carboni, J.M. (2009) 'The mechanisms of differential sensitivity to an insulin-
like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with 
EGFR/HER2 inhibitors', Cancer Res, 69(1), pp. 161-70. 
 
Ingram, N., MacCormac, L.P., Oxley, N.T., Burns, P.A. and Hall, G.D. (2010) 'Role of cell 
surface molecules and autologous ascitic fluid in determining efficiency of adenoviral 
transduction of ovarian cancer cells', Cancer Gene Ther, 17(10), pp. 684-93. 
 
Jiang, Y., Rom, W.N., Yie, T.A., Chi, C.X. and Tchou-Wong, K.M. (1999) 'Induction of 
tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-
negative IGF-I receptor', Oncogene, 18(44), pp. 6071-7. 
 
Johnson, G.L. and Lapadat, R. (2002) 'Mitogen-activated protein kinase pathways mediated 
by ERK, JNK, and p38 protein kinases', Science, 298(5600), pp. 1911-2. 
 
Jones, J.I. and Clemmons, D.R. (1995) 'Insulin-like growth factors and their binding proteins: 




Jones, R.A., Campbell, C.I., Gunther, E.J., Chodosh, L.A., Petrik, J.J., Khokha, R. and 
Moorehead, R.A. (2007) 'Transgenic overexpression of IGF-IR disrupts mammary ductal 
morphogenesis and induces tumor formation', Oncogene, 26(11), pp. 1636-44. 
 
Karp, D.D., Paz-Ares, L.G., Novello, S., Haluska, P., Garland, L., Cardenal, F., Blakely, L.J., 
Eisenberg, P.D., Langer, C.J., Blumenschein, G., Jr., Johnson, F.M., Green, S. and Gualberto, 
A. (2009) 'Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-
751,871 in combination with paclitaxel and carboplatin in previously untreated, locally 
advanced, or metastatic non-small-cell lung cancer', J Clin Oncol, 27(15), pp. 2516-22. 
 
Kato, S., Matsukura, N., Tsukada, K., Matsuda, N., Mizoshita, T., Tsukamoto, T., Tatematsu, 
M., Sugisaki, Y., Naito, Z. and Tajiri, T. (2007) 'Helicobacter pylori infection-negative gastric 
cancer in Japanese hospital patients: incidence and pathological characteristics', Cancer Sci, 
98(6), pp. 790-4. 
 
Kawakami, H., Okamoto, I., Arao, T., Okamoto, W., Matsumoto, K., Taniguchi, H., Kuwata, 
K., Yamaguchi, H., Nishio, K., Nakagawa, K. and Yamada, Y. (2013) 'MET amplification as 
a potential therapeutic target in gastric cancer', Oncotarget, 4(1), pp. 9-17. 
 
Kerr, J.F., Wyllie, A.H. and Currie, A.R. (1972) 'Apoptosis: a basic biological phenomenon 
with wide-ranging implications in tissue kinetics', Br J Cancer, 26(4), pp. 239-57. 
 
King, E.R. and Wong, K.K. (2012) 'Insulin-like growth factor: current concepts and new 
developments in cancer therapy', Recent Pat Anticancer Drug Discov, 7(1), pp. 14-30. 
King, H., Aleksic, T., Haluska, P. and Macaulay, V.M. (2014) 'Can we unlock the potential of 
IGF-1R inhibition in cancer therapy?', Cancer Treat Rev, 40(9), pp. 1096-105. 
 
Kit, S., Beck, C., Graham, O.L. and Gross, A. (1958) 'Effect of 5-bromodeoxyuridine on 
deoxyribonucleic acid-thymine synthesis and cell metabolism of lymphatic tissues and 
tumors', Cancer Res, 18(5), pp. 598-602. 
 
Klinakis, A., Szabolcs, M., Chen, G., Xuan, S., Hibshoosh, H. and Efstratiadis, A. (2009) 
'Igf1r as a therapeutic target in a mouse model of basal-like breast cancer', Proc Natl Acad Sci 
U S A, 106(7), pp. 2359-64. 
 
Kuhn, C., Hurwitz, S.A., Kumar, M.G., Cotton, J. and Spandau, D.F. (1999) 'Activation of the 
insulin-like growth factor-1 receptor promotes the survival of human keratinocytes following 
ultraviolet B irradiation', Int J Cancer, 80(3), pp. 431-8. 
 
La Torre, G., Chiaradia, G., Gianfagna, F., De Lauretis, A., Boccia, S., Mannocci, A. and 
Ricciardi, W. (2009) 'Smoking status and gastric cancer risk: an updated meta-analysis of 
case-control studies published in the past ten years', Tumori, 95(1), pp. 13-22. 
 
Langer, C.J., Novello, S., Park, K., Krzakowski, M., Karp, D.D., Mok, T., Benner, R.J., 
Scranton, J.R., Olszanski, A.J. and Jassem, J. (2014) 'Randomized, phase III trial of first-line 
figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin 
alone in patients with advanced non-small-cell lung cancer', J Clin Oncol, 32(19), pp. 2059-
66. 
 
Lauren, P. (1965) 'The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-
Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification', Acta Pathol 




Lauren, P.A. and Nevalainen, T.J. (1993) 'Epidemiology of intestinal and diffuse types of 
gastric carcinoma. A time-trend study in Finland with comparison between studies from high- 
and low-risk areas', Cancer, 71(10), pp. 2926-33. 
 
Lee, J., Lim do, H., Kim, S., Park, S.H., Park, J.O., Park, Y.S., Lim, H.Y., Choi, M.G., Sohn, 
T.S., Noh, J.H., Bae, J.M., Ahn, Y.C., Sohn, I., Jung, S.H., Park, C.K., Kim, K.M. and Kang, 
W.K. (2012) 'Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus 
cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with 
D2 lymph node dissection: the ARTIST trial', J Clin Oncol, 30(3), pp. 268-73. 
 
Lee, K.H., Lee, J.H., Cho, J.K., Kim, T.W., Kang, Y.K., Lee, J.S., Kim, W.K., Chung, J.G., 
Lee, I.C. and Sun, H.S. (2001) 'A prospective correlation of Lauren's histological 
classification of stomach cancer with clinicopathological findings including DNA flow 
cytometry', Pathol Res Pract, 197(4), pp. 223-9. 
 
Li, H., Adachi, Y., Yamamoto, H., Min, Y., Ohashi, H., Ii, M., Arimura, Y., Endo, T., Lee, 
C.T., Carbone, D.P., Imai, K. and Shinomura, Y. (2011) 'Insulin-like growth factor-I receptor 
blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human 
gastric cancer cell line, MKN45', Cancer, 117(14), pp. 3135-47. 
 
Lindahl, T. (1974) 'An N-glycosidase from Escherichia coli that releases free uracil from 
DNA containing deaminated cytosine residues', Proc Natl Acad Sci U S A, 71(9), pp. 3649-
53. 
 
Liu, J.P., Baker, J., Perkins, A.S., Robertson, E.J. and Efstratiadis, A. (1993) 'Mice carrying 
null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF 
receptor (Igf1r)', Cell, 75(1), pp. 59-72. 
 
Liu, W., Chin-Chance, C., Lee, E.J. and Lowe, W.L., Jr. (2002) 'Activation of 
phosphatidylinositol 3-kinase contributes to insulin-like growth factor I-mediated inhibition 
of pancreatic beta-cell death', Endocrinology, 143(10), pp. 3802-12. 
 
Liu, W.D., Yu, R. and Zhou, G.R. (2009) '[Expression and significance of IGF-1R and VEGF 
in gastric carcinoma]', Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 25(6), pp. 529-30. 
 
Liu, Y.J., Shen, D., Yin, X., Gavine, P., Zhang, T., Su, X., Zhan, P., Xu, Y., Lv, J., Qian, J., 
Liu, C., Sun, Y., Qian, Z., Zhang, J., Gu, Y. and Ni, X. (2014) 'HER2, MET and FGFR2 
oncogenic driver alterations define distinct molecular segments for targeted therapies in 
gastric carcinoma', Br J Cancer, 110(5), pp. 1169-78. 
 
Longley, D.B., Harkin, D.P. and Johnston, P.G. (2003) '5-fluorouracil: mechanisms of action 
and clinical strategies', Nat Rev Cancer, 3(5), pp. 330-8. 
 
Lopez, T. and Hanahan, D. (2002) 'Elevated levels of IGF-1 receptor convey invasive and 
metastatic capability in a mouse model of pancreatic islet tumorigenesis', Cancer Cell, 1(4), 
pp. 339-53. 
 
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. and Pollak, M. (2001) 'Insulin-like growth factor-I 





Ludwig, T., Eggenschwiler, J., Fisher, P., D'Ercole, A.J., Davenport, M.L. and Efstratiadis, A. 
(1996) 'Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal 
lethality in Igf2 and Igf1r null backgrounds', Dev Biol, 177(2), pp. 517-35. 
 
Macdonald, J.S., Smalley, S.R., Benedetti, J., Hundahl, S.A., Estes, N.C., Stemmermann, 
G.N., Haller, D.G., Ajani, J.A., Gunderson, L.L., Jessup, J.M. and Martenson, J.A. (2001) 
'Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the 
stomach or gastroesophageal junction', N Engl J Med, 345(10), pp. 725-30. 
 
MacDonald, R.G., Pfeffer, S.R., Coussens, L., Tepper, M.A., Brocklebank, C.M., Mole, J.E., 
Anderson, J.K., Chen, E., Czech, M.P. and Ullrich, A. (1988) 'A single receptor binds both 
insulin-like growth factor II and mannose-6-phosphate', Science, 239(4844), pp. 1134-7. 
 
Malumbres, M. and Barbacid, M. (2006) 'Is Cyclin D1-CDK4 kinase a bona fide cancer 
target?', Cancer Cell, 9(1), pp. 2-4. 
 
Malumbres, M. and Barbacid, M. (2009) 'Cell cycle, CDKs and cancer: a changing paradigm', 
Nat Rev Cancer, 9(3), pp. 153-66. 
 
Marcelli, M., Cunningham, G.R., Walkup, M., He, Z., Sturgis, L., Kagan, C., Mannucci, R., 
Nicoletti, I., Teng, B. and Denner, L. (1999) 'Signaling pathway activated during apoptosis of 
the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy 
strategy for prostate cancer', Cancer Res, 59(2), pp. 382-90. 
 
Martin, M.J., Melnyk, N., Pollard, M., Bowden, M., Leong, H., Podor, T.J., Gleave, M. and 
Sorensen, P.H. (2006) 'The insulin-like growth factor I receptor is required for Akt activation 
and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine 
kinase', Mol Cell Biol, 26(5), pp. 1754-69. 
 
Matsumoto, K., Arao, T., Hamaguchi, T., Shimada, Y., Kato, K., Oda, I., Taniguchi, H., 
Koizumi, F., Yanagihara, K., Sasaki, H., Nishio, K. and Yamada, Y. (2012) 'FGFR2 gene 
amplification and clinicopathological features in gastric cancer', Br J Cancer, 106(4), pp. 727-
32. 
 
Mayo, L.D. and Donner, D.B. (2001) 'A phosphatidylinositol 3-kinase/Akt pathway promotes 
translocation of Mdm2 from the cytoplasm to the nucleus', Proc Natl Acad Sci U S A, 98(20), 
pp. 11598-603. 
 
Meggio, F., Donella Deana, A., Ruzzene, M., Brunati, A.M., Cesaro, L., Guerra, B., Meyer, 
T., Mett, H., Fabbro, D., Furet, P. and et al. (1995) 'Different susceptibility of protein kinases 
to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein 
kinase CK2', Eur J Biochem, 234(1), pp. 317-22. 
 
Meloche, S. and Pouyssegur, J. (2007) 'The ERK1/2 mitogen-activated protein kinase 
pathway as a master regulator of the G1- to S-phase transition', Oncogene, 26(22), pp. 3227-
39. 
 
Milazzo, G., Giorgino, F., Damante, G., Sung, C., Stampfer, M.R., Vigneri, R., Goldfine, I.D. 
and Belfiore, A. (1992) 'Insulin receptor expression and function in human breast cancer cell 




Min, Y., Adachi, Y., Yamamoto, H., Imsumran, A., Arimura, Y., Endo, T., Hinoda, Y., Lee, 
C.T., Nadaf, S., Carbone, D.P. and Imai, K. (2005) 'Insulin-like growth factor I receptor 
blockade enhances chemotherapy and radiation responses and inhibits tumour growth in 
human gastric cancer xenografts', Gut, 54(5), pp. 591-600. 
 
Minshall, C., Arkins, S., Straza, J., Conners, J., Dantzer, R., Freund, G.G. and Kelley, K.W. 
(1997) 'IL-4 and insulin-like growth factor-I inhibit the decline in Bcl-2 and promote the 
survival of IL-3-deprived myeloid progenitors', J Immunol, 159(3), pp. 1225-32. 
 
Misset, J.L., Bleiberg, H., Sutherland, W., Bekradda, M. and Cvitkovic, E. (2000) 'Oxaliplatin 
clinical activity: a review', Crit Rev Oncol Hematol, 35(2), pp. 75-93. 
 
Mitrovski, B., Pressacco, J., Mandelbaum, S. and Erlichman, C. (1994) 'Biochemical effects 
of folate-based inhibitors of thymidylate synthase in MGH-U1 cells', Cancer Chemother 
Pharmacol, 35(2), pp. 109-14. 
 
Mooney, L.M., Al-Sakkaf, K.A., Brown, B.L. and Dobson, P.R. (2002) 'Apoptotic 
mechanisms in T47D and MCF-7 human breast cancer cells', Br J Cancer, 87(8), pp. 909-17. 
 
Munoz, N. and Connelly, R. (1971) 'Time trends of intestinal and diffuse types of gastric 
cancer in the United States', Int J Cancer, 8(1), pp. 158-64. 
 
Murray, A.W. (1993) 'Cell-cycle control: turning on mitosis', Curr Biol, 3(5), pp. 291-3. 
 
Musacchio, A. and Salmon, E.D. (2007) 'The spindle-assembly checkpoint in space and time', 
Nat Rev Mol Cell Biol, 8(5), pp. 379-93. 
 
Navarro, P., Valverde, A.M., Benito, M. and Lorenzo, M. (1998) 'Insulin/IGF-I rescues 
immortalized brown adipocytes from apoptosis down-regulating Bcl-xS expression, in a PI 3-
kinase- and map kinase-dependent manner', Exp Cell Res, 243(2), pp. 213-21. 
 
Neuenschwander, S., Roberts, C.T., Jr. and LeRoith, D. (1995) 'Growth inhibition of MCF-7 
breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense 
ribonucleic acid', Endocrinology, 136(10), pp. 4298-303. 
 
Nicholson, D.W., Ali, A., Thornberry, N.A., Vaillancourt, J.P., Ding, C.K., Gallant, M., 
Gareau, Y., Griffin, P.R., Labelle, M., Lazebnik, Y.A. and et al. (1995) 'Identification and 
inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis', Nature, 
376(6535), pp. 37-43. 
 
Nigg, E.A. (2001) 'Mitotic kinases as regulators of cell division and its checkpoints', Nat Rev 
Mol Cell Biol, 2(1), pp. 21-32. 
 
Nissley, S.P., Haskell, J.F., Sasaki, N., De Vroede, M.A. and Rechler, M.M. (1985) 'Insulin-
like growth factor receptors', J Cell Sci Suppl, 3, pp. 39-51. 
 
Oates, A.J., Schumaker, L.M., Jenkins, S.B., Pearce, A.A., DaCosta, S.A., Arun, B. and Ellis, 
M.J. (1998) 'The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a 
putative breast tumor suppressor gene', Breast Cancer Res Treat, 47(3), pp. 269-81. 
 
ODonnell, R.L., McCormick, A., Mukhopadhyay, A., Woodhouse, L.C., Moat, M., Grundy, 
A., Dixon, M., Kaufman, A., Soohoo, S., Elattar, A., Curtin, N.J. and Edmondson, R.J. (2014) 
190 
 
'The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary 
Cultures Capable of Undergoing Functional Analysis', Plos One, 9(3). 
 
Ohtsu, A., Ajani, J.A., Bai, Y.X., Bang, Y.J., Chung, H.C., Pan, H.M., Sahmoud, T., Shen, L., 
Yeh, K.H., Chin, K., Muro, K., Kim, Y.H., Ferry, D., Tebbutt, N.C., Al-Batran, S.E., Smith, 
H., Costantini, C., Rizvi, S., Lebwohl, D. and Van Cutsem, E. (2013) 'Everolimus for 
previously treated advanced gastric cancer: results of the randomized, double-blind, phase III 
GRANITE-1 study', J Clin Oncol, 31(31), pp. 3935-43. 
 
Ohtsu, A., Shah, M.A., Van Cutsem, E., Rha, S.Y., Sawaki, A., Park, S.R., Lim, H.Y., 
Yamada, Y., Wu, J., Langer, B., Starnawski, M. and Kang, Y.K. (2011) 'Bevacizumab in 
combination with chemotherapy as first-line therapy in advanced gastric cancer: a 
randomized, double-blind, placebo-controlled phase III study', J Clin Oncol, 29(30), pp. 
3968-76. 
 
Okamoto, W., Okamoto, I., Arao, T., Kuwata, K., Hatashita, E., Yamaguchi, H., Sakai, K., 
Yanagihara, K., Nishio, K. and Nakagawa, K. (2012) 'Antitumor action of the MET tyrosine 
kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification', 
Mol Cancer Ther, 11(7), pp. 1557-64. 
 
Oku, K., Tanaka, A., Yamanishi, H., Nishizawa, Y., Matsumoto, K., Shiozaki, H. and Mori, 
T. (1991) 'Effects of various growth factors on growth of a cloned human esophageal 
squamous cancer cell line in a protein-free medium', Anticancer Res, 11(4), pp. 1591-5. 
 
Olmos, D., Postel-Vinay, S., Molife, L.R., Okuno, S.H., Schuetze, S.M., Paccagnella, M.L., 
Batzel, G.N., Yin, D., Pritchard-Jones, K., Judson, I., Worden, F.P., Gualberto, A., Scurr, M., 
de Bono, J.S. and Haluska, P. (2010) 'Safety, pharmacokinetics, and preliminary activity of 
the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's 
sarcoma: a phase 1 expansion cohort study', Lancet Oncol, 11(2), pp. 129-35. 
 
Omura, S., Sasaki, Y., Iwai, Y. and Takeshima, H. (1995) 'Staurosporine, a potentially 
important gift from a microorganism', J Antibiot (Tokyo), 48(7), pp. 535-48. 
 
Organ, S.L. and Tsao, M.S. (2011) 'An overview of the c-MET signaling pathway', Ther Adv 
Med Oncol, 3(1 Suppl), pp. S7-S19. 
 
Pandini, G., Vigneri, R., Costantino, A., Frasca, F., Ippolito, A., Fujita-Yamaguchi, Y., 
Siddle, K., Goldfine, I.D. and Belfiore, A. (1999) 'Insulin and insulin-like growth factor-I 
(IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor 
overexpression: evidence for a second mechanism of IGF-I signaling', Clin Cancer Res, 5(7), 
pp. 1935-44. 
 
Pappo, A.S., Patel, S.R., Crowley, J., Reinke, D.K., Kuenkele, K.P., Chawla, S.P., Toner, 
G.C., Maki, R.G., Meyers, P.A., Chugh, R., Ganjoo, K.N., Schuetze, S.M., Juergens, H., 
Leahy, M.G., Geoerger, B., Benjamin, R.S., Helman, L.J. and Baker, L.H. (2011) 'R1507, a 
monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or 
refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for 
Research through Collaboration study', J Clin Oncol, 29(34), pp. 4541-7. 
 
Parrizas, M. and LeRoith, D. (1997) 'Insulin-like growth factor-1 inhibition of apoptosis is 





Parsons, S.L., Lang, M.W. and Steele, R.J. (1996a) 'Malignant ascites: a 2-year review from a 
teaching hospital', Eur J Surg Oncol, 22(3), pp. 237-9. 
 
Parsons, S.L., Watson, S.A. and Steele, R.J. (1996b) 'Malignant ascites', Br J Surg, 83(1), pp. 
6-14. 
 
Pavelic, K., Kolak, T., Kapitanovic, S., Radosevic, S., Spaventi, S., Kruslin, B. and Pavelic, J. 
(2003) 'Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 
1R and M6-P/IGF 2R)', J Pathol, 201(3), pp. 430-8. 
 
Pietrzkowski, Z., Mulholland, G., Gomella, L., Jameson, B.A., Wernicke, D. and Baserga, R. 
(1993) 'Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like 
growth factor 1', Cancer Res, 53(5), pp. 1102-6. 
 
Planas-Silva, M.D. and Weinberg, R.A. (1997) 'The restriction point and control of cell 
proliferation', Curr Opin Cell Biol, 9(6), pp. 768-72. 
 
Pollak, M. (2008) 'Insulin and insulin-like growth factor signalling in neoplasia', Nat Rev 
Cancer, 8(12), pp. 915-28. 
 
Pollak, M. (2012) 'The insulin and insulin-like growth factor receptor family in neoplasia: an 
update', Nat Rev Cancer, 12(3), pp. 159-69. 
 
Pollak, M., Blouin, M.J., Zhang, J.C. and Kopchick, J.J. (2001) 'Reduced mammary gland 
carcinogenesis in transgenic mice expressing a growth hormone antagonist', Br J Cancer, 
85(3), pp. 428-30. 
 
Pollak, M.N., Schernhammer, E.S. and Hankinson, S.E. (2004) 'Insulin-like growth factors 
and neoplasia', Nat Rev Cancer, 4(7), pp. 505-18. 
 
Qiu, M.Z. and Xu, R.H. (2013) 'The progress of targeted therapy in advanced gastric cancer', 
Biomark Res, 1(1), p. 32. 
 
Resnicoff, M., Coppola, D., Sell, C., Rubin, R., Ferrone, S. and Baserga, R. (1994) 'Growth 
inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-
like growth factor receptor', Cancer Res, 54(18), pp. 4848-50. 
 
Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K. and Fojo, T. (1996) 
'Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell 
lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel', 
Biochem Pharmacol, 52(12), pp. 1855-65. 
 
Robinson, M.J. and Cobb, M.H. (1997) 'Mitogen-activated protein kinase pathways', Curr 
Opin Cell Biol, 9(2), pp. 180-6. 
 
Roukos, D., Lorenz, M. and Hottenrott, C. (1989) '[Prognostic significance of the Lauren 
classification of patients with stomach carcinoma. A statistical analysis of long-term results 
following gastrectomy]', Schweiz Med Wochenschr, 119(21), pp. 755-9. 
 




Saif, M.W., Siddiqui, I.A. and Sohail, M.A. (2009) 'Management of ascites due to 
gastrointestinal malignancy', Ann Saudi Med, 29(5), pp. 369-77. 
 
Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., 
Furukawa, H., Nakajima, T., Ohashi, Y., Imamura, H., Higashino, M., Yamamura, Y., Kurita, 
A., Arai, K. and Group, A.-G. (2007) 'Adjuvant chemotherapy for gastric cancer with S-1, an 
oral fluoropyrimidine', N Engl J Med, 357(18), pp. 1810-20. 
 
Samani, A.A., Yakar, S., LeRoith, D. and Brodt, P. (2007) 'The role of the IGF system in 
cancer growth and metastasis: overview and recent insights', Endocr Rev, 28(1), pp. 20-47. 
 
Savage, M.O., Attie, K.M., David, A., Metherell, L.A., Clark, A.J. and Camacho-Hubner, C. 
(2006) 'Endocrine assessment, molecular characterization and treatment of growth hormone 
insensitivity disorders', Nat Clin Pract Endocrinol Metab, 2(7), pp. 395-407. 
 
Schmidt, W. and Chaney, S.G. (1993) 'Role of carrier ligand in platinum resistance of human 
carcinoma cell lines', Cancer Res, 53(4), pp. 799-805. 
 
Schwarz, R.E. (2015) 'Current status of management of malignant disease: current 
management of gastric cancer', J Gastrointest Surg, 19(4), pp. 782-8. 
 
Sciacca, L., Cassarino, M.F., Genua, M., Vigneri, P., Giovanna Pennisi, M., Malandrino, P., 
Squatrito, S., Pezzino, V. and Vigneri, R. (2014) 'Biological effects of insulin and its analogs 
on cancer cells with different insulin family receptor expression', J Cell Physiol, 229(11), pp. 
1817-21. 
 
Scorrano, L. and Korsmeyer, S.J. (2003) 'Mechanisms of cytochrome c release by 
proapoptotic BCL-2 family members', Biochem Biophys Res Commun, 304(3), pp. 437-44. 
 
Scotlandi, K., Maini, C., Manara, M.C., Benini, S., Serra, M., Cerisano, V., Strammiello, R., 
Baldini, N., Lollini, P.L., Nanni, P., Nicoletti, G. and Picci, P. (2002) 'Effectiveness of 
insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells', Cancer 
Gene Ther, 9(3), pp. 296-307. 
 
Scotlandi, K., Manara, M.C., Nicoletti, G., Lollini, P.L., Lukas, S., Benini, S., Croci, S., 
Perdichizzi, S., Zambelli, D., Serra, M., Garcia-Echeverria, C., Hofmann, F. and Picci, P. 
(2005) 'Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-
AEW541 in musculoskeletal tumors', Cancer Res, 65(9), pp. 3868-76. 
 
Seino, S. and Bell, G.I. (1989) 'Alternative splicing of human insulin receptor messenger 
RNA', Biochem Biophys Res Commun, 159(1), pp. 312-6. 
 
Sell, C., Dumenil, G., Deveaud, C., Miura, M., Coppola, D., DeAngelis, T., Rubin, R., 
Efstratiadis, A. and Baserga, R. (1994) 'Effect of a null mutation of the insulin-like growth 
factor I receptor gene on growth and transformation of mouse embryo fibroblasts', Mol Cell 
Biol, 14(6), pp. 3604-12. 
 
Sell, C., Rubini, M., Rubin, R., Liu, J.P., Efstratiadis, A. and Baserga, R. (1993) 'Simian virus 
40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 




Shepherd, T.G., Theriault, B.L., Campbell, E.J. and Nachtigal, M.W. (2006) 'Primary culture 
of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients', Nat 
Protoc, 1(6), pp. 2643-9. 
 
Singh, P., Dai, B., Yallampalli, U., Lu, X. and Schroy, P.C. (1996) 'Proliferation and 
differentiation of a human colon cancer cell line (CaCo2) is associated with significant 
changes in the expression and secretion of insulin-like growth factor (IGF) IGF-II and IGF 
binding protein-4: role of IGF-II', Endocrinology, 137(5), pp. 1764-74. 
 
Sitar, T., Popowicz, G.M., Siwanowicz, I., Huber, R. and Holak, T.A. (2006) 'Structural basis 
for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins', 
Proc Natl Acad Sci U S A, 103(35), pp. 13028-33. 
 
Smalley, S.R., Benedetti, J.K., Haller, D.G., Hundahl, S.A., Estes, N.C., Ajani, J.A., 
Gunderson, L.L., Goldman, B., Martenson, J.A., Jessup, J.M., Stemmermann, G.N., Blanke, 
C.D. and Macdonald, J.S. (2012) 'Updated analysis of SWOG-directed intergroup study 0116: 
a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric 
cancer resection', J Clin Oncol, 30(19), pp. 2327-33. 
 
Smolen, G.A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., Kim, 
W.J., Okimoto, R.A., Bell, D.W., Sgroi, D.C., Christensen, J.G., Settleman, J. and Haber, 
D.A. (2006) 'Amplification of MET may identify a subset of cancers with extreme sensitivity 
to the selective tyrosine kinase inhibitor PHA-665752', Proc Natl Acad Sci U S A, 103(7), pp. 
2316-21. 
 
Son, D., Na, Y.R., Hwang, E.S. and Seok, S.H. (2014) 'Platelet-derived growth factor-C 
(PDGF-C) induces anti-apoptotic effects on macrophages through Akt and Bad 
phosphorylation', J Biol Chem, 289(9), pp. 6225-35. 
 
Stewart, A.J., Johnson, M.D., May, F.E. and Westley, B.R. (1990) 'Role of insulin-like 
growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated 
proliferation of human breast cancer cells', J Biol Chem, 265(34), pp. 21172-8. 
 
Su, X., Zhan, P., Gavine, P.R., Morgan, S., Womack, C., Ni, X., Shen, D., Bang, Y.J., Im, 
S.A., Ho Kim, W., Jung, E.J., Grabsch, H.I. and Kilgour, E. (2014) 'FGFR2 amplification has 
prognostic significance in gastric cancer: results from a large international multicentre study', 
Br J Cancer, 110(4), pp. 967-75. 
 
Theriault, B.L., Portelance, L., Mes-Masson, A.M. and Nachtigal, M.W. (2013) 
'Establishment of primary cultures from ovarian tumor tissue and ascites fluid', Methods Mol 
Biol, 1049, pp. 323-36. 
 
Tramacere, I., Negri, E., Pelucchi, C., Bagnardi, V., Rota, M., Scotti, L., Islami, F., Corrao, 
G., La Vecchia, C. and Boffetta, P. (2012) 'A meta-analysis on alcohol drinking and gastric 
cancer risk', Ann Oncol, 23(1), pp. 28-36. 
 
Ullrich, A., Gray, A., Tam, A.W., Yang-Feng, T., Tsubokawa, M., Collins, C., Henzel, W., Le 
Bon, T., Kathuria, S., Chen, E. and et al. (1986) 'Insulin-like growth factor I receptor primary 
structure: comparison with insulin receptor suggests structural determinants that define 




Valentinis, B., Reiss, K. and Baserga, R. (1998) 'Insulin-like growth factor-I-mediated 
survival from anoikis: role of cell aggregation and focal adhesion kinase', J Cell Physiol, 
176(3), pp. 648-57. 
 
Vauhkonen, M., Vauhkonen, H. and Sipponen, P. (2006) 'Pathology and molecular biology of 
gastric cancer', Best Pract Res Clin Gastroenterol, 20(4), pp. 651-74. 
 
Vincent, E.E., Elder, D.J., Curwen, J., Kilgour, E., Hers, I. and Tavare, J.M. (2013) 'Targeting 
non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like 
growth factor-1 receptor', PLoS One, 8(6), p. e66963. 
 
Vlahos, C.J., Matter, W.F., Hui, K.Y. and Brown, R.F. (1994) 'A specific inhibitor of 
phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 
(LY294002)', J Biol Chem, 269(7), pp. 5241-8. 
 
Wadhwa, R., Song, S., Lee, J.S., Yao, Y., Wei, Q. and Ajani, J.A. (2013) 'Gastric cancer-
molecular and clinical dimensions', Nat Rev Clin Oncol, 10(11), pp. 643-55. 
 
Wang, Y., Adachi, Y., Imsumran, A., Yamamoto, H., Piao, W., Li, H., Ii, M., Arimura, Y., 
Park, M.Y., Kim, D., Lee, C.T., Carbone, D.P., Imai, K. and Shinomura, Y. (2010a) 
'Targeting for insulin-like growth factor-I receptor with short hairpin RNA for human 
digestive/gastrointestinal cancers', J Gastroenterol, 45(2), pp. 159-70. 
 
Wang, Y., Lipari, P., Wang, X., Hailey, J., Liang, L., Ramos, R., Liu, M., Pachter, J.A., 
Bishop, W.R. and Wang, Y. (2010b) 'A fully human insulin-like growth factor-I receptor 
antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in 
combination with cytotoxics in pediatric tumor xenografts', Mol Cancer Ther, 9(2), pp. 410-8. 
 
Weinstein, D., Sarfstein, R., Laron, Z. and Werner, H. (2014) 'Insulin receptor compensates 
for IGF1R inhibition and directly induces mitogenic activity in prostate cancer cells', Endocr 
Connect, 3(1), pp. 24-35. 
 
Westley, R.L. and May, F.E. (2013) 'A twenty-first century cancer epidemic caused by 
obesity: the involvement of insulin, diabetes, and insulin-like growth factors', Int J 
Endocrinol, 2013, p. 632461. 
 
Wiseman, L.R., Johnson, M.D., Wakeling, A.E., Lykkesfeldt, A.E., May, F.E. and Westley, 
B.R. (1993) 'Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive 
human breast cancer cells', Eur J Cancer, 29A(16), pp. 2256-64. 
 
Wu, J.D., Haugk, K., Coleman, I., Woodke, L., Vessella, R., Nelson, P., Montgomery, R.B., 
Ludwig, D.L. and Plymate, S.R. (2006) 'Combined in vivo effect of A12, a type 1 insulin-like 
growth factor receptor antibody, and docetaxel against prostate cancer tumors', Clin Cancer 
Res, 12(20 Pt 1), pp. 6153-60. 
 
Wu, Y., Cui, K., Miyoshi, K., Hennighausen, L., Green, J.E., Setser, J., LeRoith, D. and 
Yakar, S. (2003) 'Reduced circulating insulin-like growth factor I levels delay the onset of 
chemically and genetically induced mammary tumors', Cancer Res, 63(15), pp. 4384-8. 
 
Xie, L., Su, X., Zhang, L., Yin, X., Tang, L., Zhang, X., Xu, Y., Gao, Z., Liu, K., Zhou, M., 
Gao, B., Shen, D., Zhang, L., Ji, J., Gavine, P.R., Zhang, J., Kilgour, E., Zhang, X. and Ji, Q. 
195 
 
(2013) 'FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR 
inhibitor AZD4547', Clin Cancer Res, 19(9), pp. 2572-83. 
 
Xue, F.B., Xu, Y.Y., Wan, Y., Pan, B.R., Ren, J. and Fan, D.M. (2001) 'Association of H. 
pylori infection with gastric carcinoma: a Meta analysis', World J Gastroenterol, 7(6), pp. 
801-4. 
 
Yang, S.Y., Hoy, M., Fuller, B., Sales, K.M., Seifalian, A.M. and Winslet, M.C. (2010) 
'Pretreatment with insulin-like growth factor I protects skeletal muscle cells against oxidative 
damage via PI3K/Akt and ERK1/2 MAPK pathways', Lab Invest, 90(3), pp. 391-401. 
 
Yang, X., Wei, A., Liu, Y., He, G., Zhou, Z. and Yu, Z. (2013) 'IGF-1 protects retinal 
ganglion cells from hypoxia-induced apoptosis by activating the Erk-1/2 and Akt pathways', 
Mol Vis, 19, pp. 1901-12. 
 
Yavari, K., Taghikhani, M., Ghannadi Maragheh, M., Mesbah-Namin, S.A. and Babaei, M.H. 
(2010) 'Downregulation of IGF-IR expression by RNAi inhibits proliferation and enhances 
chemosensitization of human colon cancer cells', Int J Colorectal Dis, 25(1), pp. 9-16. 
 
Ychou, M., Boige, V., Pignon, J.P., Conroy, T., Bouche, O., Lebreton, G., Ducourtieux, M., 
Bedenne, L., Fabre, J.M., Saint-Aubert, B., Geneve, J., Lasser, P. and Rougier, P. (2011) 
'Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal 
adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial', J Clin Oncol, 29(13), pp. 
1715-21. 
 
Yoon, H., Kim, N., Lee, H.S., Shin, C.M., Park, Y.S., Lee, D.H., Jung, H.C. and Song, I.S. 
(2011) 'Helicobacter pylori-negative gastric cancer in South Korea: incidence and 
clinicopathologic characteristics', Helicobacter, 16(5), pp. 382-8. 
 
Yoshioka, A., Tanaka, S., Hiraoka, O., Koyama, Y., Hirota, Y. and Wataya, Y. (1987) 
'Deoxyribonucleoside-triphosphate imbalance death: deoxyadenosine-induced dNTP 
imbalance and DNA double strand breaks in mouse FM3A cells and the mechanism of cell 
death', Biochem Biophys Res Commun, 146(1), pp. 258-64. 
 
Youle, R.J. and Strasser, A. (2008) 'The BCL-2 protein family: opposing activities that 
mediate cell death', Nat Rev Mol Cell Biol, 9(1), pp. 47-59. 
 
Yuen, J.S. and Macaulay, V.M. (2008) 'Targeting the type 1 insulin-like growth factor 
receptor as a treatment for cancer', Expert Opin Ther Targets, 12(5), pp. 589-603. 
 
Zetterberg, A. and Larsson, O. (1985) 'Kinetic analysis of regulatory events in G1 leading to 
proliferation or quiescence of Swiss 3T3 cells', Proc Natl Acad Sci U S A, 82(16), pp. 5365-9. 
 
Zhang, H., Fagan, D.H., Zeng, X., Freeman, K.T., Sachdev, D. and Yee, D. (2010) 'Inhibition 
of cancer cell proliferation and metastasis by insulin receptor downregulation', Oncogene, 
29(17), pp. 2517-27. 
 
Zhang, Z., Wang, J., Ji, D., Wang, C., Liu, R., Wu, Z., Liu, L., Zhu, D., Chang, J., Geng, R., 
Xiong, L., Fang, Q. and Li, J. (2014) 'Functional genetic approach identifies MET, HER3, 
IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive 




Zuo, Q., Liu, J., Zhang, J., Wu, M., Guo, L. and Liao, W. (2015) 'Development of 
trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance', 







Han, H.S. and Lauwers, G.Y. (2010) ‘Gastric Carcinoma’, Connection pp. 20-27. 
Jackson, R. C. and Grindley, G. B. (1984) ‘The Biochemical Basis for Methotrexate 
Cytotoxicity’, Academic, New York, pp. 289–315. 
Kumar, V., Abbas, A.K., Fausto, N. and Aster, J. (2010) ‘Pathologic Basis of Disease’ (8th 
ed.), Saunders Elsevier, pp. 784. 
Roukos, D.H., Agnantis, N.J., Fatouros, M. and Kappas, A.M. (2002) ‘Gastric Cancer: 
Introduction, Pathology, Epidemiology’, Gastric Breast Cancer, 1, pp. 1-3. 
 
